id	sid	tid	token	lemma	pos
ajlm-2394	1	1	abstract	abstract	ADJ
ajlm-2394	1	2	introduction	introduction	NOUN
ajlm-2394	1	3	methods	method	NOUN
ajlm-2394	1	4	results	result	VERB
ajlm-2394	1	5	discussion	discussion	NOUN
ajlm-2394	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2394	1	7	references	reference	NOUN
ajlm-2394	1	8	about	about	ADP
ajlm-2394	1	9	the	the	DET
ajlm-2394	1	10	author(s	author(s	NOUN
ajlm-2394	1	11	)	)	PUNCT
ajlm-2394	1	12	jemal	jemal	ADJ
ajlm-2394	1	13	alemu	alemu	PROPN
ajlm-2394	1	14	department	department	PROPN
ajlm-2394	1	15	of	of	ADP
ajlm-2394	1	16	medical	medical	PROPN
ajlm-2394	1	17	laboratory	laboratory	NOUN
ajlm-2394	1	18	sciences	sciences	PROPN
ajlm-2394	1	19	,	,	PUNCT
ajlm-2394	1	20	college	college	NOUN
ajlm-2394	1	21	of	of	ADP
ajlm-2394	1	22	health	health	PROPN
ajlm-2394	1	23	sciences	sciences	PROPN
ajlm-2394	1	24	,	,	PUNCT
ajlm-2394	1	25	addis	addis	PROPN
ajlm-2394	1	26	ababa	ababa	PROPN
ajlm-2394	1	27	university	university	PROPN
ajlm-2394	1	28	,	,	PUNCT
ajlm-2394	1	29	addis	addis	PROPN
ajlm-2394	1	30	ababa	ababa	PROPN
ajlm-2394	1	31	,	,	PUNCT
ajlm-2394	1	32	ethiopia	ethiopia	PROPN
ajlm-2394	1	33	armauer	armauer	PROPN
ajlm-2394	1	34	hansen	hansen	PROPN
ajlm-2394	1	35	research	research	PROPN
ajlm-2394	1	36	institute	institute	PROPN
ajlm-2394	1	37	,	,	PUNCT
ajlm-2394	1	38	addis	addis	PROPN
ajlm-2394	1	39	ababa	ababa	PROPN
ajlm-2394	1	40	,	,	PUNCT
ajlm-2394	1	41	ethiopia	ethiopia	PROPN
ajlm-2394	1	42	aklilu	aklilu	PROPN
ajlm-2394	1	43	lemma	lemma	PROPN
ajlm-2394	1	44	institute	institute	PROPN
ajlm-2394	1	45	of	of	ADP
ajlm-2394	1	46	pathobiology	pathobiology	NOUN
ajlm-2394	1	47	,	,	PUNCT
ajlm-2394	1	48	addis	addis	PROPN
ajlm-2394	1	49	ababa	ababa	PROPN
ajlm-2394	1	50	university	university	PROPN
ajlm-2394	1	51	,	,	PUNCT
ajlm-2394	1	52	addis	addis	PROPN
ajlm-2394	1	53	ababa	ababa	PROPN
ajlm-2394	1	54	,	,	PUNCT
ajlm-2394	1	55	ethiopia	ethiopia	PROPN
ajlm-2394	1	56	balako	balako	PROPN
ajlm-2394	1	57	gumi	gumi	PROPN
ajlm-2394	1	58	aklilu	aklilu	PROPN
ajlm-2394	1	59	lemma	lemma	PROPN
ajlm-2394	1	60	institute	institute	PROPN
ajlm-2394	1	61	of	of	ADP
ajlm-2394	1	62	pathobiology	pathobiology	NOUN
ajlm-2394	1	63	,	,	PUNCT
ajlm-2394	1	64	addis	addis	PROPN
ajlm-2394	1	65	ababa	ababa	PROPN
ajlm-2394	1	66	university	university	PROPN
ajlm-2394	1	67	,	,	PUNCT
ajlm-2394	1	68	addis	addis	PROPN
ajlm-2394	1	69	ababa	ababa	PROPN
ajlm-2394	1	70	,	,	PUNCT
ajlm-2394	1	71	ethiopia	ethiopia	PROPN
ajlm-2394	1	72	aster	aster	NOUN
ajlm-2394	1	73	tsegaye	tsegaye	VERB
ajlm-2394	1	74	department	department	PROPN
ajlm-2394	1	75	of	of	ADP
ajlm-2394	1	76	medical	medical	PROPN
ajlm-2394	1	77	laboratory	laboratory	NOUN
ajlm-2394	1	78	sciences	sciences	PROPN
ajlm-2394	1	79	,	,	PUNCT
ajlm-2394	1	80	college	college	NOUN
ajlm-2394	1	81	of	of	ADP
ajlm-2394	1	82	health	health	PROPN
ajlm-2394	1	83	sciences	sciences	PROPN
ajlm-2394	1	84	,	,	PUNCT
ajlm-2394	1	85	addis	addis	PROPN
ajlm-2394	1	86	ababa	ababa	PROPN
ajlm-2394	1	87	university	university	PROPN
ajlm-2394	1	88	,	,	PUNCT
ajlm-2394	1	89	addis	addis	PROPN
ajlm-2394	1	90	ababa	ababa	PROPN
ajlm-2394	1	91	,	,	PUNCT
ajlm-2394	1	92	ethiopia	ethiopia	PROPN
ajlm-2394	1	93	abdulaziz	abdulaziz	PROPN
ajlm-2394	1	94	sherif	sherif	PROPN
ajlm-2394	1	95	department	department	PROPN
ajlm-2394	1	96	of	of	ADP
ajlm-2394	1	97	internal	internal	ADJ
ajlm-2394	1	98	medicine	medicine	NOUN
ajlm-2394	1	99	,	,	PUNCT
ajlm-2394	1	100	college	college	NOUN
ajlm-2394	1	101	of	of	ADP
ajlm-2394	1	102	health	health	PROPN
ajlm-2394	1	103	sciences	sciences	PROPN
ajlm-2394	1	104	,	,	PUNCT
ajlm-2394	1	105	addis	addis	PROPN
ajlm-2394	1	106	ababa	ababa	PROPN
ajlm-2394	1	107	university	university	PROPN
ajlm-2394	1	108	,	,	PUNCT
ajlm-2394	1	109	addis	addis	PROPN
ajlm-2394	1	110	ababa	ababa	PROPN
ajlm-2394	1	111	,	,	PUNCT
ajlm-2394	1	112	ethiopia	ethiopia	PROPN
ajlm-2394	1	113	fisihatsion	fisihatsion	PROPN
ajlm-2394	1	114	tadesse	tadesse	PROPN
ajlm-2394	1	115	department	department	PROPN
ajlm-2394	1	116	of	of	ADP
ajlm-2394	1	117	internal	internal	ADJ
ajlm-2394	1	118	medicine	medicine	NOUN
ajlm-2394	1	119	,	,	PUNCT
ajlm-2394	1	120	college	college	NOUN
ajlm-2394	1	121	of	of	ADP
ajlm-2394	1	122	health	health	PROPN
ajlm-2394	1	123	sciences	sciences	PROPN
ajlm-2394	1	124	,	,	PUNCT
ajlm-2394	1	125	addis	addis	PROPN
ajlm-2394	1	126	ababa	ababa	PROPN
ajlm-2394	1	127	university	university	PROPN
ajlm-2394	1	128	,	,	PUNCT
ajlm-2394	1	129	addis	addis	PROPN
ajlm-2394	1	130	ababa	ababa	PROPN
ajlm-2394	1	131	,	,	PUNCT
ajlm-2394	1	132	ethiopia	ethiopia	PROPN
ajlm-2394	1	133	amha	amha	PROPN
ajlm-2394	1	134	gebremedhin	gebremedhin	PROPN
ajlm-2394	1	135	department	department	PROPN
ajlm-2394	1	136	of	of	ADP
ajlm-2394	1	137	internal	internal	ADJ
ajlm-2394	1	138	medicine	medicine	NOUN
ajlm-2394	1	139	,	,	PUNCT
ajlm-2394	1	140	college	college	NOUN
ajlm-2394	1	141	of	of	ADP
ajlm-2394	1	142	health	health	PROPN
ajlm-2394	1	143	sciences	sciences	PROPN
ajlm-2394	1	144	,	,	PUNCT
ajlm-2394	1	145	addis	addis	PROPN
ajlm-2394	1	146	ababa	ababa	PROPN
ajlm-2394	1	147	university	university	PROPN
ajlm-2394	1	148	,	,	PUNCT
ajlm-2394	1	149	addis	addis	PROPN
ajlm-2394	1	150	ababa	ababa	PROPN
ajlm-2394	1	151	,	,	PUNCT
ajlm-2394	1	152	ethiopia	ethiopia	PROPN
ajlm-2394	1	153	rawleigh	rawleigh	PROPN
ajlm-2394	1	154	howe	howe	PROPN
ajlm-2394	1	155	armauer	armauer	PROPN
ajlm-2394	1	156	hansen	hansen	PROPN
ajlm-2394	1	157	research	research	PROPN
ajlm-2394	1	158	institute	institute	PROPN
ajlm-2394	1	159	,	,	PUNCT
ajlm-2394	1	160	addis	addis	PROPN
ajlm-2394	1	161	ababa	ababa	PROPN
ajlm-2394	1	162	,	,	PUNCT
ajlm-2394	1	163	ethiopia	ethiopia	PROPN
ajlm-2394	1	164	citation	citation	PROPN
ajlm-2394	1	165	alemu	alemu	PROPN
ajlm-2394	1	166	j	j	PROPN
ajlm-2394	1	167	,	,	PUNCT
ajlm-2394	1	168	gumi	gumi	PROPN
ajlm-2394	1	169	b	b	PROPN
ajlm-2394	1	170	,	,	PUNCT
ajlm-2394	1	171	tsegaye	tsegaye	VERB
ajlm-2394	1	172	a	a	PRON
ajlm-2394	1	173	,	,	PUNCT
ajlm-2394	1	174	et	et	PROPN
ajlm-2394	1	175	al	al	PROPN
ajlm-2394	1	176	.	.	PROPN
ajlm-2394	2	1	flow	flow	VERB
ajlm-2394	2	2	cytometric	cytometric	ADJ
ajlm-2394	2	3	characterisation	characterisation	NOUN
ajlm-2394	2	4	of	of	ADP
ajlm-2394	2	5	acute	acute	ADJ
ajlm-2394	2	6	leukaemia	leukaemia	NOUN
ajlm-2394	2	7	in	in	ADP
ajlm-2394	2	8	adolescent	adolescent	ADJ
ajlm-2394	2	9	and	and	CCONJ
ajlm-2394	2	10	adult	adult	NOUN
ajlm-2394	2	11	ethiopians	ethiopians	PROPN
ajlm-2394	2	12	.	.	PUNCT
ajlm-2394	3	1	afr	afr	PROPN
ajlm-2394	3	2	j	j	PROPN
ajlm-2394	3	3	lab	lab	PROPN
ajlm-2394	3	4	med	med	PROPN
ajlm-2394	3	5	.	.	PUNCT
ajlm-2394	4	1	2025;14(1	2025;14(1	NUM
ajlm-2394	4	2	)	)	PUNCT
ajlm-2394	4	3	,	,	PUNCT
ajlm-2394	4	4	a2394	a2394	NOUN
ajlm-2394	4	5	.	.	PUNCT
ajlm-2394	4	6	https://doi.org/10.4102/ajlm.v14i1.2394	https://doi.org/10.4102/ajlm.v14i1.2394	X
ajlm-2394	5	1	note	note	NOUN
ajlm-2394	5	2	:	:	PUNCT
ajlm-2394	5	3	additional	additional	ADJ
ajlm-2394	5	4	supporting	support	VERB
ajlm-2394	5	5	information	information	NOUN
ajlm-2394	5	6	is	be	AUX
ajlm-2394	5	7	available	available	ADJ
ajlm-2394	5	8	for	for	ADP
ajlm-2394	5	9	download	download	NOUN
ajlm-2394	5	10	alongside	alongside	ADP
ajlm-2394	5	11	the	the	DET
ajlm-2394	5	12	online	online	ADJ
ajlm-2394	5	13	version	version	NOUN
ajlm-2394	5	14	of	of	ADP
ajlm-2394	5	15	this	this	DET
ajlm-2394	5	16	article	article	NOUN
ajlm-2394	5	17	as	as	ADP
ajlm-2394	5	18	online	online	ADJ
ajlm-2394	5	19	supplementary	supplementary	ADJ
ajlm-2394	5	20	document	document	NOUN
ajlm-2394	5	21	1	1	NUM
ajlm-2394	5	22	.	.	PUNCT
ajlm-2394	5	23	original	original	ADJ
ajlm-2394	5	24	research	research	NOUN
ajlm-2394	5	25	flow	flow	NOUN
ajlm-2394	5	26	cytometric	cytometric	ADJ
ajlm-2394	5	27	characterisation	characterisation	NOUN
ajlm-2394	5	28	of	of	ADP
ajlm-2394	5	29	acute	acute	ADJ
ajlm-2394	5	30	leukaemia	leukaemia	NOUN
ajlm-2394	5	31	in	in	ADP
ajlm-2394	5	32	adolescent	adolescent	ADJ
ajlm-2394	5	33	and	and	CCONJ
ajlm-2394	5	34	adult	adult	NOUN
ajlm-2394	5	35	ethiopians	ethiopians	PROPN
ajlm-2394	5	36	jemal	jemal	ADJ
ajlm-2394	5	37	alemu	alemu	PROPN
ajlm-2394	5	38	,	,	PUNCT
ajlm-2394	5	39	balako	balako	PROPN
ajlm-2394	5	40	gumi	gumi	PROPN
ajlm-2394	5	41	,	,	PUNCT
ajlm-2394	5	42	aster	aster	NOUN
ajlm-2394	5	43	tsegaye	tsegaye	NOUN
ajlm-2394	5	44	,	,	PUNCT
ajlm-2394	5	45	abdulaziz	abdulaziz	PROPN
ajlm-2394	5	46	sherif	sherif	PROPN
ajlm-2394	5	47	,	,	PUNCT
ajlm-2394	5	48	fisihatsion	fisihatsion	PROPN
ajlm-2394	5	49	tadesse	tadesse	ADV
ajlm-2394	5	50	,	,	PUNCT
ajlm-2394	5	51	amha	amha	PROPN
ajlm-2394	5	52	gebremedhin	gebremedhin	PROPN
ajlm-2394	5	53	,	,	PUNCT
ajlm-2394	5	54	rawleigh	rawleigh	PROPN
ajlm-2394	5	55	howe	howe	NOUN
ajlm-2394	5	56	received	receive	VERB
ajlm-2394	5	57	:	:	PUNCT
ajlm-2394	5	58	28	28	NUM
ajlm-2394	5	59	dec	dec	PROPN
ajlm-2394	5	60	.	.	PROPN
ajlm-2394	5	61	2023	2023	NUM
ajlm-2394	5	62	;	;	PUNCT
ajlm-2394	5	63	accepted	accept	VERB
ajlm-2394	5	64	:	:	PUNCT
ajlm-2394	5	65	28	28	NUM
ajlm-2394	5	66	oct	oct	PROPN
ajlm-2394	5	67	.	.	PROPN
ajlm-2394	5	68	2024	2024	NUM
ajlm-2394	5	69	;	;	PUNCT
ajlm-2394	5	70	published	publish	VERB
ajlm-2394	5	71	:	:	PUNCT
ajlm-2394	5	72	23	23	NUM
ajlm-2394	5	73	jan	jan	PROPN
ajlm-2394	5	74	.	.	PROPN
ajlm-2394	5	75	2025	2025	NUM
ajlm-2394	5	76	copyright	copyright	NOUN
ajlm-2394	5	77	:	:	PUNCT
ajlm-2394	5	78	©	©	PROPN
ajlm-2394	5	79	2025	2025	NUM
ajlm-2394	5	80	.	.	PUNCT
ajlm-2394	6	1	the	the	DET
ajlm-2394	6	2	author(s	author(s	PROPN
ajlm-2394	6	3	)	)	PUNCT
ajlm-2394	6	4	.	.	PUNCT
ajlm-2394	7	1	licensee	licensee	NOUN
ajlm-2394	7	2	:	:	PUNCT
ajlm-2394	7	3	aosis	aosis	NOUN
ajlm-2394	7	4	.	.	PUNCT
ajlm-2394	8	1	this	this	PRON
ajlm-2394	8	2	is	be	AUX
ajlm-2394	8	3	an	an	DET
ajlm-2394	8	4	open	open	ADJ
ajlm-2394	8	5	access	access	NOUN
ajlm-2394	8	6	article	article	NOUN
ajlm-2394	8	7	distributed	distribute	VERB
ajlm-2394	8	8	under	under	ADP
ajlm-2394	8	9	the	the	DET
ajlm-2394	8	10	terms	term	NOUN
ajlm-2394	8	11	of	of	ADP
ajlm-2394	8	12	the	the	DET
ajlm-2394	8	13	creative	creative	ADJ
ajlm-2394	8	14	commons	common	NOUN
ajlm-2394	8	15	attribution	attribution	NOUN
ajlm-2394	8	16	license	license	NOUN
ajlm-2394	8	17	,	,	PUNCT
ajlm-2394	8	18	which	which	PRON
ajlm-2394	8	19	permits	permit	VERB
ajlm-2394	8	20	unrestricted	unrestricted	ADJ
ajlm-2394	8	21	use	use	NOUN
ajlm-2394	8	22	,	,	PUNCT
ajlm-2394	8	23	distribution	distribution	NOUN
ajlm-2394	8	24	,	,	PUNCT
ajlm-2394	8	25	and	and	CCONJ
ajlm-2394	8	26	reproduction	reproduction	NOUN
ajlm-2394	8	27	in	in	ADP
ajlm-2394	8	28	any	any	DET
ajlm-2394	8	29	medium	medium	NOUN
ajlm-2394	8	30	,	,	PUNCT
ajlm-2394	8	31	provided	provide	VERB
ajlm-2394	8	32	the	the	DET
ajlm-2394	8	33	original	original	ADJ
ajlm-2394	8	34	work	work	NOUN
ajlm-2394	8	35	is	be	AUX
ajlm-2394	8	36	properly	properly	ADV
ajlm-2394	8	37	cited	cite	VERB
ajlm-2394	8	38	.	.	PUNCT
ajlm-2394	9	1	abstract	abstract	ADJ
ajlm-2394	9	2	background	background	NOUN
ajlm-2394	9	3	:	:	PUNCT
ajlm-2394	9	4	flow	flow	VERB
ajlm-2394	9	5	cytometric	cytometric	ADJ
ajlm-2394	9	6	characterisation	characterisation	NOUN
ajlm-2394	9	7	of	of	ADP
ajlm-2394	9	8	acute	acute	ADJ
ajlm-2394	9	9	leukaemia	leukaemia	NOUN
ajlm-2394	9	10	is	be	AUX
ajlm-2394	9	11	a	a	DET
ajlm-2394	9	12	key	key	ADJ
ajlm-2394	9	13	diagnostic	diagnostic	ADJ
ajlm-2394	9	14	approach	approach	NOUN
ajlm-2394	9	15	for	for	ADP
ajlm-2394	9	16	clinical	clinical	ADJ
ajlm-2394	9	17	management	management	NOUN
ajlm-2394	9	18	of	of	ADP
ajlm-2394	9	19	patients	patient	NOUN
ajlm-2394	9	20	,	,	PUNCT
ajlm-2394	9	21	but	but	CCONJ
ajlm-2394	9	22	is	be	AUX
ajlm-2394	9	23	minimally	minimally	ADV
ajlm-2394	9	24	practised	practise	VERB
ajlm-2394	9	25	in	in	ADP
ajlm-2394	9	26	resource	resource	NOUN
ajlm-2394	9	27	-	-	PUNCT
ajlm-2394	9	28	constrained	constrain	VERB
ajlm-2394	9	29	settings	setting	NOUN
ajlm-2394	9	30	like	like	ADP
ajlm-2394	9	31	ethiopia	ethiopia	PROPN
ajlm-2394	9	32	.	.	PUNCT
ajlm-2394	10	1	objective	objective	NOUN
ajlm-2394	10	2	:	:	PUNCT
ajlm-2394	10	3	this	this	DET
ajlm-2394	10	4	study	study	NOUN
ajlm-2394	10	5	aimed	aim	VERB
ajlm-2394	10	6	to	to	PART
ajlm-2394	10	7	determine	determine	VERB
ajlm-2394	10	8	the	the	DET
ajlm-2394	10	9	immunophenotypes	immunophenotype	NOUN
ajlm-2394	10	10	of	of	ADP
ajlm-2394	10	11	acute	acute	ADJ
ajlm-2394	10	12	leukaemia	leukaemia	NOUN
ajlm-2394	10	13	by	by	ADP
ajlm-2394	10	14	flow	flow	NOUN
ajlm-2394	10	15	cytometry	cytometry	NOUN
ajlm-2394	10	16	at	at	ADP
ajlm-2394	10	17	tikur	tikur	PROPN
ajlm-2394	10	18	anbessa	anbessa	ADJ
ajlm-2394	10	19	specialised	specialised	ADJ
ajlm-2394	10	20	hospital	hospital	NOUN
ajlm-2394	10	21	,	,	PUNCT
ajlm-2394	10	22	addis	addis	PROPN
ajlm-2394	10	23	ababa	ababa	PROPN
ajlm-2394	10	24	,	,	PUNCT
ajlm-2394	10	25	ethiopia	ethiopia	PROPN
ajlm-2394	10	26	.	.	PUNCT
ajlm-2394	11	1	methods	method	NOUN
ajlm-2394	11	2	:	:	PUNCT
ajlm-2394	11	3	a	a	DET
ajlm-2394	11	4	cross	cross	ADJ
ajlm-2394	11	5	-	-	ADJ
ajlm-2394	11	6	sectional	sectional	ADJ
ajlm-2394	11	7	study	study	NOUN
ajlm-2394	11	8	was	be	AUX
ajlm-2394	11	9	conducted	conduct	VERB
ajlm-2394	11	10	on	on	ADP
ajlm-2394	11	11	adolescent	adolescent	ADJ
ajlm-2394	11	12	and	and	CCONJ
ajlm-2394	11	13	adult	adult	NOUN
ajlm-2394	11	14	inpatients	inpatient	NOUN
ajlm-2394	11	15	consecutively	consecutively	ADV
ajlm-2394	11	16	admitted	admit	VERB
ajlm-2394	11	17	from	from	ADP
ajlm-2394	11	18	april	april	PROPN
ajlm-2394	11	19	2019	2019	NUM
ajlm-2394	11	20	to	to	ADP
ajlm-2394	11	21	june	june	PROPN
ajlm-2394	11	22	2021	2021	NUM
ajlm-2394	11	23	.	.	PUNCT
ajlm-2394	12	1	peripheral	peripheral	ADJ
ajlm-2394	12	2	blood	blood	NOUN
ajlm-2394	12	3	samples	sample	NOUN
ajlm-2394	12	4	were	be	AUX
ajlm-2394	12	5	stained	stain	VERB
ajlm-2394	12	6	for	for	ADP
ajlm-2394	12	7	surface	surface	NOUN
ajlm-2394	12	8	and	and	CCONJ
ajlm-2394	12	9	cytoplasmic	cytoplasmic	ADJ
ajlm-2394	12	10	markers	marker	NOUN
ajlm-2394	12	11	,	,	PUNCT
ajlm-2394	12	12	and	and	CCONJ
ajlm-2394	12	13	analysed	analyse	VERB
ajlm-2394	12	14	by	by	ADP
ajlm-2394	12	15	four	four	NUM
ajlm-2394	12	16	-	-	PUNCT
ajlm-2394	12	17	colour	colour	NOUN
ajlm-2394	12	18	flow	flow	NOUN
ajlm-2394	12	19	cytometry	cytometry	NOUN
ajlm-2394	12	20	.	.	PUNCT
ajlm-2394	13	1	results	result	NOUN
ajlm-2394	13	2	:	:	PUNCT
ajlm-2394	13	3	of	of	ADP
ajlm-2394	13	4	140	140	NUM
ajlm-2394	13	5	cases	case	NOUN
ajlm-2394	13	6	aged	age	VERB
ajlm-2394	13	7	13	13	NUM
ajlm-2394	13	8	years	year	NOUN
ajlm-2394	13	9	to	to	ADP
ajlm-2394	13	10	76	76	NUM
ajlm-2394	13	11	years	year	NOUN
ajlm-2394	13	12	,	,	PUNCT
ajlm-2394	13	13	74	74	NUM
ajlm-2394	13	14	(	(	PUNCT
ajlm-2394	13	15	53	53	NUM
ajlm-2394	13	16	%	%	NOUN
ajlm-2394	13	17	)	)	PUNCT
ajlm-2394	13	18	were	be	AUX
ajlm-2394	13	19	men	man	NOUN
ajlm-2394	13	20	and	and	CCONJ
ajlm-2394	13	21	66	66	NUM
ajlm-2394	13	22	(	(	PUNCT
ajlm-2394	13	23	47	47	NUM
ajlm-2394	13	24	%	%	NOUN
ajlm-2394	13	25	)	)	PUNCT
ajlm-2394	13	26	were	be	AUX
ajlm-2394	13	27	women	woman	NOUN
ajlm-2394	13	28	,	,	PUNCT
ajlm-2394	13	29	68	68	NUM
ajlm-2394	13	30	(	(	PUNCT
ajlm-2394	13	31	49	49	NUM
ajlm-2394	13	32	%	%	NOUN
ajlm-2394	13	33	)	)	PUNCT
ajlm-2394	14	1	had	have	AUX
ajlm-2394	14	2	acute	acute	ADJ
ajlm-2394	14	3	lymphocytic	lymphocytic	ADJ
ajlm-2394	14	4	leukaemia	leukaemia	NOUN
ajlm-2394	14	5	(	(	PUNCT
ajlm-2394	14	6	all	all	ADV
ajlm-2394	14	7	)	)	PUNCT
ajlm-2394	14	8	,	,	PUNCT
ajlm-2394	14	9	65	65	NUM
ajlm-2394	14	10	(	(	PUNCT
ajlm-2394	14	11	46	46	NUM
ajlm-2394	14	12	%	%	NOUN
ajlm-2394	14	13	)	)	PUNCT
ajlm-2394	14	14	had	have	VERB
ajlm-2394	14	15	acute	acute	ADJ
ajlm-2394	14	16	myelogenous	myelogenous	ADJ
ajlm-2394	14	17	leukaemia	leukaemia	NOUN
ajlm-2394	14	18	(	(	PUNCT
ajlm-2394	14	19	aml	aml	PROPN
ajlm-2394	14	20	)	)	PUNCT
ajlm-2394	14	21	,	,	PUNCT
ajlm-2394	14	22	and	and	CCONJ
ajlm-2394	14	23	7	7	NUM
ajlm-2394	14	24	(	(	PUNCT
ajlm-2394	14	25	5.0	5.0	NUM
ajlm-2394	14	26	%	%	NOUN
ajlm-2394	14	27	)	)	PUNCT
ajlm-2394	14	28	had	have	VERB
ajlm-2394	14	29	acute	acute	ADJ
ajlm-2394	14	30	leukaemia	leukaemia	NOUN
ajlm-2394	14	31	non	non	ADJ
ajlm-2394	14	32	-	-	ADJ
ajlm-2394	14	33	otherwise	otherwise	ADV
ajlm-2394	14	34	specified	specify	VERB
ajlm-2394	14	35	.	.	PUNCT
ajlm-2394	15	1	acute	acute	ADJ
ajlm-2394	15	2	lymphocytic	lymphocytic	ADJ
ajlm-2394	15	3	leukaemia	leukaemia	NOUN
ajlm-2394	15	4	was	be	AUX
ajlm-2394	15	5	more	more	ADV
ajlm-2394	15	6	common	common	ADJ
ajlm-2394	15	7	among	among	ADP
ajlm-2394	15	8	adolescent	adolescent	ADJ
ajlm-2394	15	9	and	and	CCONJ
ajlm-2394	15	10	male	male	ADJ
ajlm-2394	15	11	cases	case	NOUN
ajlm-2394	15	12	;	;	PUNCT
ajlm-2394	15	13	aml	aml	PROPN
ajlm-2394	15	14	was	be	AUX
ajlm-2394	15	15	more	more	ADV
ajlm-2394	15	16	common	common	ADJ
ajlm-2394	15	17	among	among	ADP
ajlm-2394	15	18	adult	adult	NOUN
ajlm-2394	15	19	and	and	CCONJ
ajlm-2394	15	20	female	female	ADJ
ajlm-2394	15	21	cases	case	NOUN
ajlm-2394	15	22	.	.	PUNCT
ajlm-2394	16	1	among	among	ADP
ajlm-2394	16	2	all	all	DET
ajlm-2394	16	3	subtypes	subtype	NOUN
ajlm-2394	16	4	,	,	PUNCT
ajlm-2394	16	5	b	b	X
ajlm-2394	16	6	-	-	PUNCT
ajlm-2394	16	7	cell	cell	NOUN
ajlm-2394	16	8	acute	acute	ADJ
ajlm-2394	16	9	lymphocytic	lymphocytic	ADJ
ajlm-2394	16	10	leukaemia	leukaemia	NOUN
ajlm-2394	16	11	cases	case	NOUN
ajlm-2394	16	12	(	(	PUNCT
ajlm-2394	16	13	73.5	73.5	NUM
ajlm-2394	16	14	%	%	NOUN
ajlm-2394	16	15	)	)	PUNCT
ajlm-2394	16	16	were	be	AUX
ajlm-2394	16	17	more	more	ADV
ajlm-2394	16	18	common	common	ADJ
ajlm-2394	16	19	than	than	ADP
ajlm-2394	16	20	t	t	NOUN
ajlm-2394	16	21	-	-	PUNCT
ajlm-2394	16	22	cell	cell	NOUN
ajlm-2394	16	23	acute	acute	ADJ
ajlm-2394	16	24	lymphocytic	lymphocytic	ADJ
ajlm-2394	16	25	leukaemia	leukaemia	NOUN
ajlm-2394	16	26	(	(	PUNCT
ajlm-2394	16	27	26.5	26.5	NUM
ajlm-2394	16	28	%	%	NOUN
ajlm-2394	16	29	)	)	PUNCT
ajlm-2394	16	30	.	.	PUNCT
ajlm-2394	17	1	a	a	DET
ajlm-2394	17	2	subset	subset	NOUN
ajlm-2394	17	3	of	of	ADP
ajlm-2394	17	4	acute	acute	ADJ
ajlm-2394	17	5	leukaemia	leukaemia	NOUN
ajlm-2394	17	6	,	,	PUNCT
ajlm-2394	17	7	cd19+/cd56	cd19+/cd56	PRON
ajlm-2394	17	8	+	+	NUM
ajlm-2394	17	9	aml	aml	NOUN
ajlm-2394	17	10	was	be	AUX
ajlm-2394	17	11	identified	identify	VERB
ajlm-2394	17	12	in	in	ADP
ajlm-2394	17	13	3	3	NUM
ajlm-2394	17	14	cases	case	NOUN
ajlm-2394	17	15	(	(	PUNCT
ajlm-2394	17	16	6	6	NUM
ajlm-2394	17	17	%	%	NOUN
ajlm-2394	17	18	of	of	ADP
ajlm-2394	17	19	aml	aml	PROPN
ajlm-2394	17	20	)	)	PUNCT
ajlm-2394	17	21	.	.	PUNCT
ajlm-2394	18	1	of	of	ADP
ajlm-2394	18	2	the	the	DET
ajlm-2394	18	3	b	b	NOUN
ajlm-2394	18	4	-	-	PUNCT
ajlm-2394	18	5	cell	cell	NOUN
ajlm-2394	18	6	all	all	DET
ajlm-2394	18	7	cases	case	NOUN
ajlm-2394	18	8	,	,	PUNCT
ajlm-2394	18	9	21	21	NUM
ajlm-2394	18	10	(	(	PUNCT
ajlm-2394	18	11	42	42	NUM
ajlm-2394	18	12	%	%	NOUN
ajlm-2394	18	13	)	)	PUNCT
ajlm-2394	18	14	were	be	AUX
ajlm-2394	18	15	cd34+/cd10+/cd66c+	cd34+/cd10+/cd66c+	ADJ
ajlm-2394	18	16	,	,	PUNCT
ajlm-2394	18	17	10	10	NUM
ajlm-2394	18	18	%	%	NOUN
ajlm-2394	18	19	were	be	AUX
ajlm-2394	18	20	cd34+/cd10+/cd66c	cd34+/cd10+/cd66c	ADJ
ajlm-2394	18	21	–	–	PUNCT
ajlm-2394	18	22	,	,	PUNCT
ajlm-2394	18	23	32	32	NUM
ajlm-2394	18	24	%	%	NOUN
ajlm-2394	18	25	were	be	AUX
ajlm-2394	18	26	cd34-/cd10	cd34-/cd10	PROPN
ajlm-2394	18	27	+	+	PROPN
ajlm-2394	18	28	,	,	PUNCT
ajlm-2394	18	29	and	and	CCONJ
ajlm-2394	18	30	6	6	NUM
ajlm-2394	18	31	%	%	NOUN
ajlm-2394	18	32	were	be	AUX
ajlm-2394	18	33	cd34+/cd10–.	cd34+/cd10–.	PRON
ajlm-2394	18	34	an	an	DET
ajlm-2394	18	35	unexpectedly	unexpectedly	ADV
ajlm-2394	18	36	high	high	ADJ
ajlm-2394	18	37	number	number	NOUN
ajlm-2394	18	38	of	of	ADP
ajlm-2394	18	39	t	t	PROPN
ajlm-2394	18	40	-	-	PUNCT
ajlm-2394	18	41	cell	cell	NOUN
ajlm-2394	18	42	all	all	DET
ajlm-2394	18	43	cases	case	NOUN
ajlm-2394	18	44	that	that	PRON
ajlm-2394	18	45	lacked	lack	VERB
ajlm-2394	18	46	surface	surface	NOUN
ajlm-2394	18	47	cd3	cd3	PROPN
ajlm-2394	18	48	were	be	AUX
ajlm-2394	18	49	observed	observe	VERB
ajlm-2394	18	50	to	to	PART
ajlm-2394	18	51	have	have	VERB
ajlm-2394	18	52	significantly	significantly	ADV
ajlm-2394	18	53	higher	high	ADJ
ajlm-2394	18	54	levels	level	NOUN
ajlm-2394	18	55	of	of	ADP
ajlm-2394	18	56	aberrantly	aberrantly	ADV
ajlm-2394	18	57	expressed	express	VERB
ajlm-2394	18	58	myeloid	myeloid	ADJ
ajlm-2394	18	59	markers	marker	NOUN
ajlm-2394	18	60	.	.	PUNCT
ajlm-2394	19	1	conclusion	conclusion	NOUN
ajlm-2394	19	2	:	:	PUNCT
ajlm-2394	19	3	we	we	PRON
ajlm-2394	19	4	observed	observe	VERB
ajlm-2394	19	5	multiple	multiple	ADJ
ajlm-2394	19	6	phenotypes	phenotype	NOUN
ajlm-2394	19	7	identifying	identify	VERB
ajlm-2394	19	8	subtypes	subtype	NOUN
ajlm-2394	19	9	of	of	ADP
ajlm-2394	19	10	acute	acute	ADJ
ajlm-2394	19	11	leukaemia	leukaemia	NOUN
ajlm-2394	19	12	cases	case	NOUN
ajlm-2394	19	13	,	,	PUNCT
ajlm-2394	19	14	extending	extend	VERB
ajlm-2394	19	15	our	our	PRON
ajlm-2394	19	16	previous	previous	ADJ
ajlm-2394	19	17	studies	study	NOUN
ajlm-2394	19	18	in	in	ADP
ajlm-2394	19	19	ethiopia	ethiopia	PROPN
ajlm-2394	19	20	.	.	PUNCT
ajlm-2394	20	1	what	what	PRON
ajlm-2394	20	2	this	this	DET
ajlm-2394	20	3	study	study	NOUN
ajlm-2394	20	4	adds	add	VERB
ajlm-2394	20	5	:	:	PUNCT
ajlm-2394	20	6	this	this	DET
ajlm-2394	20	7	study	study	NOUN
ajlm-2394	20	8	extends	extend	VERB
ajlm-2394	20	9	previous	previous	ADJ
ajlm-2394	20	10	studies	study	NOUN
ajlm-2394	20	11	by	by	ADP
ajlm-2394	20	12	describing	describe	VERB
ajlm-2394	20	13	phenotypically	phenotypically	ADV
ajlm-2394	20	14	defined	define	VERB
ajlm-2394	20	15	subsets	subset	NOUN
ajlm-2394	20	16	of	of	ADP
ajlm-2394	20	17	all	all	DET
ajlm-2394	20	18	and	and	CCONJ
ajlm-2394	20	19	aml	aml	PROPN
ajlm-2394	20	20	which	which	PRON
ajlm-2394	20	21	,	,	PUNCT
ajlm-2394	20	22	in	in	ADP
ajlm-2394	20	23	addition	addition	NOUN
ajlm-2394	20	24	to	to	ADP
ajlm-2394	20	25	diagnosis	diagnosis	NOUN
ajlm-2394	20	26	,	,	PUNCT
ajlm-2394	20	27	may	may	AUX
ajlm-2394	20	28	have	have	VERB
ajlm-2394	20	29	useful	useful	ADJ
ajlm-2394	20	30	prognostic	prognostic	ADJ
ajlm-2394	20	31	value	value	NOUN
ajlm-2394	20	32	for	for	ADP
ajlm-2394	20	33	clinicians	clinician	NOUN
ajlm-2394	20	34	.	.	PUNCT
ajlm-2394	21	1	keywords	keyword	NOUN
ajlm-2394	21	2	:	:	PUNCT
ajlm-2394	21	3	flow	flow	NOUN
ajlm-2394	21	4	cytometry	cytometry	NOUN
ajlm-2394	21	5	;	;	PUNCT
ajlm-2394	21	6	acute	acute	NOUN
ajlm-2394	21	7	leukaemia	leukaemia	NOUN
ajlm-2394	21	8	;	;	PUNCT
ajlm-2394	21	9	ethiopia	ethiopia	PROPN
ajlm-2394	21	10	;	;	PUNCT
ajlm-2394	21	11	phenotype	phenotype	NOUN
ajlm-2394	21	12	;	;	PUNCT
ajlm-2394	21	13	cell	cell	NOUN
ajlm-2394	21	14	surface	surface	NOUN
ajlm-2394	21	15	biomarker	biomarker	NOUN
ajlm-2394	21	16	;	;	PUNCT
ajlm-2394	21	17	cytoplasmic	cytoplasmic	ADJ
ajlm-2394	21	18	biomarker	biomarker	NOUN
ajlm-2394	21	19	.	.	PUNCT
ajlm-2394	22	1	introduction	introduction	NOUN
ajlm-2394	22	2	acute	acute	PROPN
ajlm-2394	22	3	leukaemias	leukaemia	NOUN
ajlm-2394	22	4	are	be	AUX
ajlm-2394	22	5	malignant	malignant	ADJ
ajlm-2394	22	6	disorders	disorder	NOUN
ajlm-2394	22	7	of	of	ADP
ajlm-2394	22	8	precursor	precursor	NOUN
ajlm-2394	22	9	cells	cell	NOUN
ajlm-2394	22	10	because	because	SCONJ
ajlm-2394	22	11	of	of	ADP
ajlm-2394	22	12	chromosomal	chromosomal	ADJ
ajlm-2394	22	13	rearrangements	rearrangement	NOUN
ajlm-2394	22	14	and	and	CCONJ
ajlm-2394	22	15	multiple	multiple	ADJ
ajlm-2394	22	16	gene	gene	NOUN
ajlm-2394	22	17	mutations	mutation	NOUN
ajlm-2394	22	18	,	,	PUNCT
ajlm-2394	22	19	resulting	result	VERB
ajlm-2394	22	20	in	in	ADP
ajlm-2394	22	21	a	a	DET
ajlm-2394	22	22	high	high	ADJ
ajlm-2394	22	23	number	number	NOUN
ajlm-2394	22	24	of	of	ADP
ajlm-2394	22	25	transformed	transform	VERB
ajlm-2394	22	26	cells	cell	NOUN
ajlm-2394	22	27	within	within	ADP
ajlm-2394	22	28	the	the	DET
ajlm-2394	22	29	bone	bone	NOUN
ajlm-2394	22	30	marrow.1,2	marrow.1,2	ADJ
ajlm-2394	22	31	leukaemia	leukaemia	NOUN
ajlm-2394	22	32	is	be	AUX
ajlm-2394	22	33	diagnosed	diagnose	VERB
ajlm-2394	22	34	according	accord	VERB
ajlm-2394	22	35	to	to	ADP
ajlm-2394	22	36	clinical	clinical	ADJ
ajlm-2394	22	37	features	feature	NOUN
ajlm-2394	22	38	,	,	PUNCT
ajlm-2394	22	39	laboratory	laboratory	NOUN
ajlm-2394	22	40	tests	test	NOUN
ajlm-2394	22	41	including	include	VERB
ajlm-2394	22	42	morphological	morphological	ADJ
ajlm-2394	22	43	examination	examination	NOUN
ajlm-2394	22	44	of	of	ADP
ajlm-2394	22	45	blood	blood	NOUN
ajlm-2394	22	46	smears	smear	NOUN
ajlm-2394	22	47	,	,	PUNCT
ajlm-2394	22	48	flow	flow	NOUN
ajlm-2394	22	49	cytometry	cytometry	NOUN
ajlm-2394	22	50	immunophenotyping	immunophenotyping	NOUN
ajlm-2394	22	51	,	,	PUNCT
ajlm-2394	22	52	and	and	CCONJ
ajlm-2394	22	53	cytogenetic	cytogenetic	ADJ
ajlm-2394	22	54	and	and	CCONJ
ajlm-2394	22	55	molecular	molecular	ADJ
ajlm-2394	22	56	analysis.3,4	analysis.3,4	ADJ
ajlm-2394	22	57	flow	flow	NOUN
ajlm-2394	22	58	cytometry	cytometry	NOUN
ajlm-2394	22	59	contributes	contribute	VERB
ajlm-2394	22	60	important	important	ADJ
ajlm-2394	22	61	information	information	NOUN
ajlm-2394	22	62	to	to	ADP
ajlm-2394	22	63	the	the	DET
ajlm-2394	22	64	assigning	assigning	NOUN
ajlm-2394	22	65	of	of	ADP
ajlm-2394	22	66	leukaemic	leukaemic	ADJ
ajlm-2394	22	67	cell	cell	NOUN
ajlm-2394	22	68	lineages	lineage	NOUN
ajlm-2394	22	69	,	,	PUNCT
ajlm-2394	22	70	subtypes	subtype	NOUN
ajlm-2394	22	71	,	,	PUNCT
ajlm-2394	22	72	and	and	CCONJ
ajlm-2394	22	73	subsets	subset	NOUN
ajlm-2394	22	74	in	in	ADP
ajlm-2394	22	75	the	the	DET
ajlm-2394	22	76	diagnosis	diagnosis	NOUN
ajlm-2394	22	77	of	of	ADP
ajlm-2394	22	78	and	and	CCONJ
ajlm-2394	22	79	optimal	optimal	ADJ
ajlm-2394	22	80	therapy	therapy	NOUN
ajlm-2394	22	81	for	for	ADP
ajlm-2394	22	82	acute	acute	PROPN
ajlm-2394	22	83	leukaemia.5	leukaemia.5	PROPN
ajlm-2394	22	84	flow	flow	NOUN
ajlm-2394	22	85	cytometric	cytometric	ADJ
ajlm-2394	22	86	analysis	analysis	NOUN
ajlm-2394	22	87	determines	determine	VERB
ajlm-2394	22	88	expression	expression	NOUN
ajlm-2394	22	89	patterns	pattern	NOUN
ajlm-2394	22	90	for	for	ADP
ajlm-2394	22	91	cell	cell	NOUN
ajlm-2394	22	92	surface	surface	NOUN
ajlm-2394	22	93	and	and	CCONJ
ajlm-2394	22	94	cytoplasmic	cytoplasmic	ADJ
ajlm-2394	22	95	molecules	molecule	NOUN
ajlm-2394	22	96	defining	define	VERB
ajlm-2394	22	97	maturation	maturation	NOUN
ajlm-2394	22	98	stages	stage	NOUN
ajlm-2394	22	99	,	,	PUNCT
ajlm-2394	22	100	lineage	lineage	NOUN
ajlm-2394	22	101	,	,	PUNCT
ajlm-2394	22	102	and	and	CCONJ
ajlm-2394	22	103	subtype	subtype	NOUN
ajlm-2394	22	104	differentiation	differentiation	NOUN
ajlm-2394	22	105	,	,	PUNCT
ajlm-2394	22	106	as	as	ADV
ajlm-2394	22	107	well	well	ADV
ajlm-2394	22	108	as	as	ADP
ajlm-2394	22	109	aberrantly	aberrantly	ADV
ajlm-2394	22	110	expressed	express	VERB
ajlm-2394	22	111	markers.6	markers.6	PROPN
ajlm-2394	22	112	while	while	SCONJ
ajlm-2394	22	113	numerous	numerous	ADJ
ajlm-2394	22	114	studies	study	NOUN
ajlm-2394	22	115	have	have	AUX
ajlm-2394	22	116	been	be	AUX
ajlm-2394	22	117	conducted	conduct	VERB
ajlm-2394	22	118	in	in	ADP
ajlm-2394	22	119	developed	develop	VERB
ajlm-2394	22	120	countries	country	NOUN
ajlm-2394	22	121	on	on	ADP
ajlm-2394	22	122	flow	flow	NOUN
ajlm-2394	22	123	cytometric	cytometric	ADJ
ajlm-2394	22	124	phenotyping	phenotyping	NOUN
ajlm-2394	22	125	of	of	ADP
ajlm-2394	22	126	acute	acute	PROPN
ajlm-2394	22	127	leukaemias	leukaemia	NOUN
ajlm-2394	22	128	,	,	PUNCT
ajlm-2394	22	129	far	far	ADV
ajlm-2394	22	130	less	less	ADV
ajlm-2394	22	131	is	be	AUX
ajlm-2394	22	132	known	know	VERB
ajlm-2394	22	133	in	in	ADP
ajlm-2394	22	134	resource	resource	NOUN
ajlm-2394	22	135	-	-	PUNCT
ajlm-2394	22	136	limited	limit	VERB
ajlm-2394	22	137	settings	setting	NOUN
ajlm-2394	22	138	in	in	ADP
ajlm-2394	22	139	east	east	PROPN
ajlm-2394	22	140	africa	africa	PROPN
ajlm-2394	22	141	,	,	PUNCT
ajlm-2394	22	142	such	such	ADJ
ajlm-2394	22	143	as	as	ADP
ajlm-2394	22	144	ethiopia	ethiopia	PROPN
ajlm-2394	22	145	.	.	PUNCT
ajlm-2394	23	1	moreover	moreover	ADV
ajlm-2394	23	2	,	,	PUNCT
ajlm-2394	23	3	the	the	DET
ajlm-2394	23	4	method	method	NOUN
ajlm-2394	23	5	is	be	AUX
ajlm-2394	23	6	not	not	PART
ajlm-2394	23	7	well	well	ADV
ajlm-2394	23	8	established	establish	VERB
ajlm-2394	23	9	for	for	ADP
ajlm-2394	23	10	routine	routine	ADJ
ajlm-2394	23	11	care	care	NOUN
ajlm-2394	23	12	at	at	ADP
ajlm-2394	23	13	the	the	DET
ajlm-2394	23	14	main	main	ADJ
ajlm-2394	23	15	tertiary	tertiary	ADJ
ajlm-2394	23	16	care	care	NOUN
ajlm-2394	23	17	referral	referral	ADJ
ajlm-2394	23	18	hospital	hospital	NOUN
ajlm-2394	23	19	of	of	ADP
ajlm-2394	23	20	ethiopia	ethiopia	PROPN
ajlm-2394	23	21	.	.	PUNCT
ajlm-2394	24	1	using	use	VERB
ajlm-2394	24	2	this	this	DET
ajlm-2394	24	3	technology	technology	NOUN
ajlm-2394	24	4	,	,	PUNCT
ajlm-2394	24	5	we	we	PRON
ajlm-2394	24	6	are	be	AUX
ajlm-2394	24	7	continuing	continue	VERB
ajlm-2394	24	8	our	our	PRON
ajlm-2394	24	9	efforts	effort	NOUN
ajlm-2394	24	10	to	to	PART
ajlm-2394	24	11	integrate	integrate	VERB
ajlm-2394	24	12	patient	patient	ADJ
ajlm-2394	24	13	care	care	NOUN
ajlm-2394	24	14	with	with	ADP
ajlm-2394	24	15	research	research	NOUN
ajlm-2394	24	16	and	and	CCONJ
ajlm-2394	24	17	teaching	teaching	NOUN
ajlm-2394	24	18	.	.	PUNCT
ajlm-2394	25	1	we	we	PRON
ajlm-2394	25	2	previously	previously	ADV
ajlm-2394	25	3	conducted	conduct	VERB
ajlm-2394	25	4	an	an	DET
ajlm-2394	25	5	initial	initial	ADJ
ajlm-2394	25	6	research	research	NOUN
ajlm-2394	25	7	study7	study7	NOUN
ajlm-2394	25	8	showing	show	VERB
ajlm-2394	25	9	the	the	DET
ajlm-2394	25	10	feasibility	feasibility	NOUN
ajlm-2394	25	11	of	of	ADP
ajlm-2394	25	12	this	this	DET
ajlm-2394	25	13	approach	approach	NOUN
ajlm-2394	25	14	in	in	ADP
ajlm-2394	25	15	this	this	DET
ajlm-2394	25	16	resource	resource	NOUN
ajlm-2394	25	17	-	-	PUNCT
ajlm-2394	25	18	limited	limit	VERB
ajlm-2394	25	19	setting.8	setting.8	NOUN
ajlm-2394	25	20	our	our	PRON
ajlm-2394	25	21	current	current	ADJ
ajlm-2394	25	22	work	work	NOUN
ajlm-2394	25	23	was	be	AUX
ajlm-2394	25	24	aimed	aim	VERB
ajlm-2394	25	25	to	to	PART
ajlm-2394	25	26	determine	determine	VERB
ajlm-2394	25	27	the	the	DET
ajlm-2394	25	28	immunophenotypes	immunophenotype	NOUN
ajlm-2394	25	29	of	of	ADP
ajlm-2394	25	30	acute	acute	ADJ
ajlm-2394	25	31	leukaemia	leukaemia	NOUN
ajlm-2394	25	32	by	by	ADP
ajlm-2394	25	33	flow	flow	NOUN
ajlm-2394	25	34	cytometry	cytometry	NOUN
ajlm-2394	25	35	at	at	ADP
ajlm-2394	25	36	tikur	tikur	PROPN
ajlm-2394	25	37	anbessa	anbessa	ADJ
ajlm-2394	25	38	specialised	specialised	ADJ
ajlm-2394	25	39	hospital	hospital	NOUN
ajlm-2394	25	40	,	,	PUNCT
ajlm-2394	25	41	addis	addis	PROPN
ajlm-2394	25	42	ababa	ababa	PROPN
ajlm-2394	25	43	,	,	PUNCT
ajlm-2394	25	44	ethiopia	ethiopia	PROPN
ajlm-2394	25	45	.	.	PUNCT
ajlm-2394	26	1	methods	method	NOUN
ajlm-2394	26	2	ethical	ethical	ADJ
ajlm-2394	26	3	considerations	consideration	NOUN
ajlm-2394	26	4	our	our	PRON
ajlm-2394	26	5	study	study	NOUN
ajlm-2394	26	6	received	receive	VERB
ajlm-2394	26	7	approval	approval	NOUN
ajlm-2394	26	8	from	from	ADP
ajlm-2394	26	9	the	the	DET
ajlm-2394	26	10	institutional	institutional	ADJ
ajlm-2394	26	11	research	research	NOUN
ajlm-2394	26	12	board	board	NOUN
ajlm-2394	26	13	of	of	ADP
ajlm-2394	26	14	aklilu	aklilu	NOUN
ajlm-2394	26	15	lemma	lemma	PROPN
ajlm-2394	26	16	institute	institute	PROPN
ajlm-2394	26	17	of	of	ADP
ajlm-2394	26	18	pathobiology	pathobiology	NOUN
ajlm-2394	26	19	,	,	PUNCT
ajlm-2394	26	20	addis	addis	PROPN
ajlm-2394	26	21	ababa	ababa	PROPN
ajlm-2394	26	22	university	university	PROPN
ajlm-2394	26	23	(	(	PUNCT
ajlm-2394	26	24	reference	reference	NOUN
ajlm-2394	26	25	no	no	INTJ
ajlm-2394	26	26	.	.	PUNCT
ajlm-2394	26	27	:	:	PUNCT
ajlm-2394	27	1	alipb	alipb	PROPN
ajlm-2394	27	2	irb/009/2011/2018	irb/009/2011/2018	PROPN
ajlm-2394	27	3	)	)	PUNCT
ajlm-2394	27	4	,	,	PUNCT
ajlm-2394	27	5	the	the	DET
ajlm-2394	27	6	college	college	PROPN
ajlm-2394	27	7	of	of	ADP
ajlm-2394	27	8	health	health	PROPN
ajlm-2394	27	9	science	science	PROPN
ajlm-2394	27	10	,	,	PUNCT
ajlm-2394	27	11	addis	addis	PROPN
ajlm-2394	27	12	ababa	ababa	PROPN
ajlm-2394	27	13	university	university	PROPN
ajlm-2394	27	14	(	(	PUNCT
ajlm-2394	27	15	protocol	protocol	INTJ
ajlm-2394	27	16	no	no	INTJ
ajlm-2394	27	17	.	.	PUNCT
ajlm-2394	27	18	:	:	PUNCT
ajlm-2394	28	1	001/19	001/19	NUM
ajlm-2394	28	2	/	/	SYM
ajlm-2394	28	3	im	im	NOUN
ajlm-2394	28	4	)	)	PUNCT
ajlm-2394	28	5	,	,	PUNCT
ajlm-2394	28	6	and	and	CCONJ
ajlm-2394	28	7	the	the	DET
ajlm-2394	28	8	armauer	armauer	PROPN
ajlm-2394	28	9	hansen	hansen	PROPN
ajlm-2394	28	10	research	research	PROPN
ajlm-2394	28	11	institute	institute	PROPN
ajlm-2394	28	12	(	(	PUNCT
ajlm-2394	28	13	ahri)/all	ahri)/all	PROPN
ajlm-2394	28	14	africa	africa	PROPN
ajlm-2394	28	15	leprosy	leprosy	NOUN
ajlm-2394	28	16	,	,	PUNCT
ajlm-2394	28	17	tuberculosis	tuberculosis	NOUN
ajlm-2394	28	18	and	and	CCONJ
ajlm-2394	28	19	rehabilitation	rehabilitation	NOUN
ajlm-2394	28	20	training	training	NOUN
ajlm-2394	28	21	center	center	NOUN
ajlm-2394	28	22	(	(	PUNCT
ajlm-2394	28	23	alert	alert	NOUN
ajlm-2394	28	24	)	)	PUNCT
ajlm-2394	28	25	ethics	ethic	NOUN
ajlm-2394	28	26	review	review	PROPN
ajlm-2394	28	27	committee	committee	NOUN
ajlm-2394	28	28	(	(	PUNCT
ajlm-2394	28	29	protocol	protocol	INTJ
ajlm-2394	28	30	no	no	INTJ
ajlm-2394	28	31	.	.	PUNCT
ajlm-2394	28	32	:	:	PUNCT
ajlm-2394	28	33	po34/18	po34/18	NOUN
ajlm-2394	28	34	)	)	PUNCT
ajlm-2394	28	35	.	.	PUNCT
ajlm-2394	29	1	written	write	VERB
ajlm-2394	29	2	consent	consent	NOUN
ajlm-2394	29	3	was	be	AUX
ajlm-2394	29	4	obtained	obtain	VERB
ajlm-2394	29	5	from	from	ADP
ajlm-2394	29	6	adult	adult	NOUN
ajlm-2394	29	7	participants	participant	NOUN
ajlm-2394	29	8	,	,	PUNCT
ajlm-2394	29	9	whereas	whereas	SCONJ
ajlm-2394	29	10	written	write	VERB
ajlm-2394	29	11	assent	assent	NOUN
ajlm-2394	29	12	was	be	AUX
ajlm-2394	29	13	obtained	obtain	VERB
ajlm-2394	29	14	from	from	ADP
ajlm-2394	29	15	adolescent	adolescent	ADJ
ajlm-2394	29	16	cases	case	NOUN
ajlm-2394	29	17	or	or	CCONJ
ajlm-2394	29	18	their	their	PRON
ajlm-2394	29	19	families	family	NOUN
ajlm-2394	29	20	/	/	SYM
ajlm-2394	29	21	caregiver	caregiver	NOUN
ajlm-2394	29	22	.	.	PUNCT
ajlm-2394	30	1	consent	consent	NOUN
ajlm-2394	30	2	was	be	AUX
ajlm-2394	30	3	also	also	ADV
ajlm-2394	30	4	obtained	obtain	VERB
ajlm-2394	30	5	from	from	ADP
ajlm-2394	30	6	control	control	NOUN
ajlm-2394	30	7	participants	participant	NOUN
ajlm-2394	30	8	.	.	PUNCT
ajlm-2394	31	1	all	all	DET
ajlm-2394	31	2	personal	personal	ADJ
ajlm-2394	31	3	information	information	NOUN
ajlm-2394	31	4	obtained	obtain	VERB
ajlm-2394	31	5	from	from	ADP
ajlm-2394	31	6	the	the	DET
ajlm-2394	31	7	study	study	NOUN
ajlm-2394	31	8	was	be	AUX
ajlm-2394	31	9	coded	code	VERB
ajlm-2394	31	10	to	to	PART
ajlm-2394	31	11	maintain	maintain	VERB
ajlm-2394	31	12	complete	complete	ADJ
ajlm-2394	31	13	confidentiality	confidentiality	NOUN
ajlm-2394	31	14	throughout	throughout	ADP
ajlm-2394	31	15	the	the	DET
ajlm-2394	31	16	study	study	NOUN
ajlm-2394	31	17	period	period	NOUN
ajlm-2394	31	18	.	.	PUNCT
ajlm-2394	32	1	study	study	NOUN
ajlm-2394	32	2	design	design	NOUN
ajlm-2394	32	3	and	and	CCONJ
ajlm-2394	32	4	setting	set	VERB
ajlm-2394	32	5	the	the	DET
ajlm-2394	32	6	present	present	ADJ
ajlm-2394	32	7	study	study	NOUN
ajlm-2394	32	8	was	be	AUX
ajlm-2394	32	9	a	a	DET
ajlm-2394	32	10	cross	cross	ADJ
ajlm-2394	32	11	-	-	ADJ
ajlm-2394	32	12	sectional	sectional	ADJ
ajlm-2394	32	13	study	study	NOUN
ajlm-2394	32	14	done	do	VERB
ajlm-2394	32	15	at	at	ADP
ajlm-2394	32	16	the	the	DET
ajlm-2394	32	17	haematology	haematology	NOUN
ajlm-2394	32	18	wards	ward	NOUN
ajlm-2394	32	19	of	of	ADP
ajlm-2394	32	20	tikur	tikur	NOUN
ajlm-2394	32	21	anbessa	anbessa	ADJ
ajlm-2394	32	22	specialised	specialised	ADJ
ajlm-2394	32	23	hospital	hospital	NOUN
ajlm-2394	32	24	in	in	ADP
ajlm-2394	32	25	addis	addis	PROPN
ajlm-2394	32	26	ababa	ababa	PROPN
ajlm-2394	32	27	,	,	PUNCT
ajlm-2394	32	28	ethiopia	ethiopia	PROPN
ajlm-2394	32	29	,	,	PUNCT
ajlm-2394	32	30	between	between	ADP
ajlm-2394	32	31	april	april	PROPN
ajlm-2394	32	32	2019	2019	NUM
ajlm-2394	32	33	and	and	CCONJ
ajlm-2394	32	34	june	june	PROPN
ajlm-2394	32	35	2021	2021	NUM
ajlm-2394	32	36	.	.	PUNCT
ajlm-2394	33	1	tikur	tikur	PROPN
ajlm-2394	33	2	anbessa	anbessa	ADJ
ajlm-2394	33	3	specialised	specialised	ADJ
ajlm-2394	33	4	hospital	hospital	NOUN
ajlm-2394	33	5	is	be	AUX
ajlm-2394	33	6	the	the	DET
ajlm-2394	33	7	largest	large	ADJ
ajlm-2394	33	8	referral	referral	ADJ
ajlm-2394	33	9	hospital	hospital	NOUN
ajlm-2394	33	10	in	in	ADP
ajlm-2394	33	11	the	the	DET
ajlm-2394	33	12	country	country	NOUN
ajlm-2394	33	13	for	for	ADP
ajlm-2394	33	14	the	the	DET
ajlm-2394	33	15	diagnosis	diagnosis	NOUN
ajlm-2394	33	16	and	and	CCONJ
ajlm-2394	33	17	treatment	treatment	NOUN
ajlm-2394	33	18	of	of	ADP
ajlm-2394	33	19	malignancies	malignancy	NOUN
ajlm-2394	33	20	.	.	PUNCT
ajlm-2394	34	1	study	study	NOUN
ajlm-2394	34	2	population	population	NOUN
ajlm-2394	34	3	and	and	CCONJ
ajlm-2394	34	4	sampling	sample	VERB
ajlm-2394	34	5	strategy	strategy	NOUN
ajlm-2394	34	6	the	the	DET
ajlm-2394	34	7	study	study	NOUN
ajlm-2394	34	8	includes	include	VERB
ajlm-2394	34	9	140	140	NUM
ajlm-2394	34	10	adult	adult	NOUN
ajlm-2394	34	11	and	and	CCONJ
ajlm-2394	34	12	adolescent	adolescent	ADJ
ajlm-2394	34	13	(	(	PUNCT
ajlm-2394	34	14	aged	aged	ADJ
ajlm-2394	34	15	13–17	13–17	NUM
ajlm-2394	34	16	years	year	NOUN
ajlm-2394	34	17	)	)	PUNCT
ajlm-2394	34	18	inpatients	inpatient	NOUN
ajlm-2394	34	19	,	,	PUNCT
ajlm-2394	34	20	consecutively	consecutively	ADV
ajlm-2394	34	21	diagnosed	diagnose	VERB
ajlm-2394	34	22	with	with	ADP
ajlm-2394	34	23	acute	acute	ADJ
ajlm-2394	34	24	leukaemia	leukaemia	NOUN
ajlm-2394	34	25	and	and	CCONJ
ajlm-2394	34	26	admitted	admit	VERB
ajlm-2394	34	27	to	to	ADP
ajlm-2394	34	28	the	the	DET
ajlm-2394	34	29	adult	adult	NOUN
ajlm-2394	34	30	haematology	haematology	NOUN
ajlm-2394	34	31	ward	ward	NOUN
ajlm-2394	34	32	,	,	PUNCT
ajlm-2394	34	33	who	who	PRON
ajlm-2394	34	34	had	have	AUX
ajlm-2394	34	35	not	not	PART
ajlm-2394	34	36	yet	yet	ADV
ajlm-2394	34	37	started	start	VERB
ajlm-2394	34	38	chemotherapy	chemotherapy	NOUN
ajlm-2394	34	39	and	and	CCONJ
ajlm-2394	34	40	who	who	PRON
ajlm-2394	34	41	were	be	AUX
ajlm-2394	34	42	recruited	recruit	VERB
ajlm-2394	34	43	for	for	ADP
ajlm-2394	34	44	the	the	DET
ajlm-2394	34	45	study	study	NOUN
ajlm-2394	34	46	.	.	PUNCT
ajlm-2394	35	1	bone	bone	NOUN
ajlm-2394	35	2	marrow	marrow	NOUN
ajlm-2394	35	3	samples	sample	NOUN
ajlm-2394	35	4	from	from	ADP
ajlm-2394	35	5	each	each	DET
ajlm-2394	35	6	patient	patient	NOUN
ajlm-2394	35	7	had	have	AUX
ajlm-2394	35	8	been	be	AUX
ajlm-2394	35	9	obtained	obtain	VERB
ajlm-2394	35	10	,	,	PUNCT
ajlm-2394	35	11	and	and	CCONJ
ajlm-2394	35	12	smears	smear	NOUN
ajlm-2394	35	13	stained	stain	VERB
ajlm-2394	35	14	with	with	ADP
ajlm-2394	35	15	haematoxylin	haematoxylin	NOUN
ajlm-2394	35	16	and	and	CCONJ
ajlm-2394	35	17	eosin	eosin	NOUN
ajlm-2394	35	18	were	be	AUX
ajlm-2394	35	19	confirmed	confirm	VERB
ajlm-2394	35	20	and	and	CCONJ
ajlm-2394	35	21	classified	classify	VERB
ajlm-2394	35	22	as	as	ADP
ajlm-2394	35	23	acute	acute	ADJ
ajlm-2394	35	24	myelogenous	myelogenous	ADJ
ajlm-2394	35	25	leukaemia	leukaemia	NOUN
ajlm-2394	35	26	(	(	PUNCT
ajlm-2394	35	27	aml	aml	NOUN
ajlm-2394	35	28	)	)	PUNCT
ajlm-2394	35	29	or	or	CCONJ
ajlm-2394	35	30	acute	acute	ADJ
ajlm-2394	35	31	lymphocytic	lymphocytic	ADJ
ajlm-2394	35	32	leukaemia	leukaemia	NOUN
ajlm-2394	35	33	(	(	PUNCT
ajlm-2394	35	34	all	all	ADV
ajlm-2394	35	35	)	)	PUNCT
ajlm-2394	35	36	.	.	PUNCT
ajlm-2394	36	1	the	the	DET
ajlm-2394	36	2	sample	sample	NOUN
ajlm-2394	36	3	size	size	NOUN
ajlm-2394	36	4	of	of	ADP
ajlm-2394	36	5	140	140	NUM
ajlm-2394	36	6	was	be	AUX
ajlm-2394	36	7	calculated	calculate	VERB
ajlm-2394	36	8	by	by	ADP
ajlm-2394	36	9	using	use	VERB
ajlm-2394	36	10	the	the	DET
ajlm-2394	36	11	percentage	percentage	NOUN
ajlm-2394	36	12	of	of	ADP
ajlm-2394	36	13	acute	acute	ADJ
ajlm-2394	36	14	leukaemia	leukaemia	NOUN
ajlm-2394	36	15	cases	case	NOUN
ajlm-2394	36	16	(	(	PUNCT
ajlm-2394	36	17	among	among	ADP
ajlm-2394	36	18	total	total	ADJ
ajlm-2394	36	19	patients	patient	NOUN
ajlm-2394	36	20	within	within	ADP
ajlm-2394	36	21	a	a	DET
ajlm-2394	36	22	typical	typical	ADJ
ajlm-2394	36	23	a	a	DET
ajlm-2394	36	24	36	36	NUM
ajlm-2394	36	25	-	-	PUNCT
ajlm-2394	36	26	month	month	NOUN
ajlm-2394	36	27	period	period	NOUN
ajlm-2394	36	28	in	in	ADP
ajlm-2394	36	29	the	the	DET
ajlm-2394	36	30	haematology	haematology	NOUN
ajlm-2394	36	31	ward	ward	NOUN
ajlm-2394	36	32	)	)	PUNCT
ajlm-2394	36	33	and	and	CCONJ
ajlm-2394	36	34	the	the	DET
ajlm-2394	36	35	margin	margin	NOUN
ajlm-2394	36	36	of	of	ADP
ajlm-2394	36	37	error	error	NOUN
ajlm-2394	36	38	set	set	VERB
ajlm-2394	36	39	at	at	ADP
ajlm-2394	36	40	5	5	NUM
ajlm-2394	36	41	%	%	NOUN
ajlm-2394	36	42	,	,	PUNCT
ajlm-2394	36	43	with	with	ADP
ajlm-2394	36	44	level	level	NOUN
ajlm-2394	36	45	of	of	ADP
ajlm-2394	36	46	confidence	confidence	NOUN
ajlm-2394	36	47	at	at	ADP
ajlm-2394	36	48	95	95	NUM
ajlm-2394	36	49	%	%	NOUN
ajlm-2394	36	50	(	(	PUNCT
ajlm-2394	36	51	zα/2	zα/2	NOUN
ajlm-2394	36	52	=	=	SYM
ajlm-2394	36	53	1.96	1.96	NUM
ajlm-2394	36	54	)	)	PUNCT
ajlm-2394	36	55	.	.	PUNCT
ajlm-2394	37	1	sample	sample	NOUN
ajlm-2394	37	2	and	and	CCONJ
ajlm-2394	37	3	data	datum	NOUN
ajlm-2394	37	4	collection	collection	NOUN
ajlm-2394	37	5	important	important	ADJ
ajlm-2394	37	6	socio	socio	NOUN
ajlm-2394	37	7	-	-	ADJ
ajlm-2394	37	8	demographic	demographic	ADJ
ajlm-2394	37	9	as	as	ADV
ajlm-2394	37	10	well	well	ADV
ajlm-2394	37	11	as	as	ADP
ajlm-2394	37	12	related	relate	VERB
ajlm-2394	37	13	clinical	clinical	ADJ
ajlm-2394	37	14	information	information	NOUN
ajlm-2394	37	15	was	be	AUX
ajlm-2394	37	16	collected	collect	VERB
ajlm-2394	37	17	using	use	VERB
ajlm-2394	37	18	a	a	DET
ajlm-2394	37	19	standardised	standardised	ADJ
ajlm-2394	37	20	form	form	NOUN
ajlm-2394	37	21	.	.	PUNCT
ajlm-2394	38	1	cases	case	NOUN
ajlm-2394	38	2	/	/	SYM
ajlm-2394	38	3	families	family	NOUN
ajlm-2394	38	4	/	/	SYM
ajlm-2394	38	5	caregivers	caregiver	NOUN
ajlm-2394	38	6	were	be	AUX
ajlm-2394	38	7	interviewed	interview	VERB
ajlm-2394	38	8	for	for	ADP
ajlm-2394	38	9	demographic	demographic	ADJ
ajlm-2394	38	10	characteristics	characteristic	NOUN
ajlm-2394	38	11	and	and	CCONJ
ajlm-2394	38	12	clinical	clinical	ADJ
ajlm-2394	38	13	data	datum	NOUN
ajlm-2394	38	14	were	be	AUX
ajlm-2394	38	15	extracted	extract	VERB
ajlm-2394	38	16	from	from	ADP
ajlm-2394	38	17	patient	patient	ADJ
ajlm-2394	38	18	cards	card	NOUN
ajlm-2394	38	19	by	by	ADP
ajlm-2394	38	20	haematology	haematology	NOUN
ajlm-2394	38	21	fellows	fellow	NOUN
ajlm-2394	38	22	as	as	ADV
ajlm-2394	38	23	well	well	ADV
ajlm-2394	38	24	as	as	ADP
ajlm-2394	38	25	internal	internal	ADJ
ajlm-2394	38	26	medicine	medicine	NOUN
ajlm-2394	38	27	residents	resident	NOUN
ajlm-2394	38	28	under	under	ADP
ajlm-2394	38	29	the	the	DET
ajlm-2394	38	30	supervision	supervision	NOUN
ajlm-2394	38	31	of	of	ADP
ajlm-2394	38	32	the	the	DET
ajlm-2394	38	33	principal	principal	ADJ
ajlm-2394	38	34	investigator	investigator	NOUN
ajlm-2394	38	35	and	and	CCONJ
ajlm-2394	38	36	senior	senior	ADJ
ajlm-2394	38	37	advisers	adviser	NOUN
ajlm-2394	38	38	.	.	PUNCT
ajlm-2394	39	1	in	in	ADP
ajlm-2394	39	2	addition	addition	NOUN
ajlm-2394	39	3	,	,	PUNCT
ajlm-2394	39	4	we	we	PRON
ajlm-2394	39	5	used	use	VERB
ajlm-2394	39	6	test	test	NOUN
ajlm-2394	39	7	results	result	NOUN
ajlm-2394	39	8	from	from	ADP
ajlm-2394	39	9	healthy	healthy	ADJ
ajlm-2394	39	10	individuals	individual	NOUN
ajlm-2394	39	11	as	as	ADP
ajlm-2394	39	12	positive	positive	ADJ
ajlm-2394	39	13	controls	control	NOUN
ajlm-2394	39	14	for	for	ADP
ajlm-2394	39	15	some	some	PRON
ajlm-2394	39	16	of	of	ADP
ajlm-2394	39	17	the	the	DET
ajlm-2394	39	18	markers	marker	NOUN
ajlm-2394	39	19	as	as	ADP
ajlm-2394	39	20	a	a	DET
ajlm-2394	39	21	quality	quality	NOUN
ajlm-2394	39	22	control	control	NOUN
ajlm-2394	39	23	.	.	PUNCT
ajlm-2394	40	1	over	over	ADP
ajlm-2394	40	2	80	80	NUM
ajlm-2394	40	3	tikur	tikur	NOUN
ajlm-2394	40	4	anbessa	anbessa	ADJ
ajlm-2394	40	5	specialised	specialised	ADJ
ajlm-2394	40	6	hospital	hospital	NOUN
ajlm-2394	40	7	laboratory	laboratory	NOUN
ajlm-2394	40	8	staff	staff	NOUN
ajlm-2394	40	9	members	member	NOUN
ajlm-2394	40	10	,	,	PUNCT
ajlm-2394	40	11	ahri	ahri	PROPN
ajlm-2394	40	12	research	research	NOUN
ajlm-2394	40	13	staff	staff	NOUN
ajlm-2394	40	14	,	,	PUNCT
ajlm-2394	40	15	or	or	CCONJ
ajlm-2394	40	16	alert	alert	ADJ
ajlm-2394	40	17	hospital	hospital	NOUN
ajlm-2394	40	18	laboratory	laboratory	NOUN
ajlm-2394	40	19	staff	staff	NOUN
ajlm-2394	40	20	volunteered	volunteer	VERB
ajlm-2394	40	21	a	a	DET
ajlm-2394	40	22	whole	whole	ADJ
ajlm-2394	40	23	blood	blood	NOUN
ajlm-2394	40	24	sample	sample	NOUN
ajlm-2394	40	25	.	.	PUNCT
ajlm-2394	41	1	we	we	PRON
ajlm-2394	41	2	selected	select	VERB
ajlm-2394	41	3	apparently	apparently	ADV
ajlm-2394	41	4	healthy	healthy	ADJ
ajlm-2394	41	5	professionals	professional	NOUN
ajlm-2394	41	6	by	by	ADP
ajlm-2394	41	7	checking	check	VERB
ajlm-2394	41	8	their	their	PRON
ajlm-2394	41	9	complete	complete	ADJ
ajlm-2394	41	10	blood	blood	NOUN
ajlm-2394	41	11	count	count	NOUN
ajlm-2394	41	12	result	result	NOUN
ajlm-2394	41	13	with	with	ADP
ajlm-2394	41	14	five	five	NUM
ajlm-2394	41	15	differential	differential	ADJ
ajlm-2394	41	16	count	count	NOUN
ajlm-2394	41	17	analysers	analyser	NOUN
ajlm-2394	41	18	and	and	CCONJ
ajlm-2394	41	19	for	for	ADP
ajlm-2394	41	20	the	the	DET
ajlm-2394	41	21	presence	presence	NOUN
ajlm-2394	41	22	of	of	ADP
ajlm-2394	41	23	abnormal	abnormal	ADJ
ajlm-2394	41	24	results	result	NOUN
ajlm-2394	41	25	,	,	PUNCT
ajlm-2394	41	26	including	include	VERB
ajlm-2394	41	27	detection	detection	NOUN
ajlm-2394	41	28	of	of	ADP
ajlm-2394	41	29	immature	immature	ADJ
ajlm-2394	41	30	cells	cell	NOUN
ajlm-2394	41	31	.	.	PUNCT
ajlm-2394	42	1	a	a	DET
ajlm-2394	42	2	total	total	NOUN
ajlm-2394	42	3	of	of	ADP
ajlm-2394	42	4	three	three	NUM
ajlm-2394	42	5	samples	sample	NOUN
ajlm-2394	42	6	were	be	AUX
ajlm-2394	42	7	rejected	reject	VERB
ajlm-2394	42	8	.	.	PUNCT
ajlm-2394	43	1	a	a	DET
ajlm-2394	43	2	peripheral	peripheral	ADJ
ajlm-2394	43	3	blood	blood	NOUN
ajlm-2394	43	4	sample	sample	NOUN
ajlm-2394	43	5	of	of	ADP
ajlm-2394	43	6	about	about	ADV
ajlm-2394	43	7	2	2	NUM
ajlm-2394	43	8	ml	ml	NOUN
ajlm-2394	43	9	was	be	AUX
ajlm-2394	43	10	collected	collect	VERB
ajlm-2394	43	11	from	from	ADP
ajlm-2394	43	12	each	each	DET
ajlm-2394	43	13	patient	patient	NOUN
ajlm-2394	43	14	by	by	ADP
ajlm-2394	43	15	experienced	experienced	ADJ
ajlm-2394	43	16	and	and	CCONJ
ajlm-2394	43	17	trained	train	VERB
ajlm-2394	43	18	nurses	nurse	NOUN
ajlm-2394	43	19	,	,	PUNCT
ajlm-2394	43	20	and	and	CCONJ
ajlm-2394	43	21	transferred	transfer	VERB
ajlm-2394	43	22	to	to	ADP
ajlm-2394	43	23	tripotassium	tripotassium	PROPN
ajlm-2394	43	24	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-2394	43	25	acid	acid	NOUN
ajlm-2394	43	26	vacutainer	vacutainer	ADJ
ajlm-2394	43	27	tubes	tube	NOUN
ajlm-2394	43	28	(	(	PUNCT
ajlm-2394	43	29	becton	becton	PROPN
ajlm-2394	43	30	dickinson	dickinson	PROPN
ajlm-2394	43	31	,	,	PUNCT
ajlm-2394	43	32	pont	pont	NOUN
ajlm-2394	43	33	-	-	PUNCT
ajlm-2394	43	34	da	da	NOUN
ajlm-2394	43	35	-	-	PUNCT
ajlm-2394	43	36	claix	claix	ADJ
ajlm-2394	43	37	,	,	PUNCT
ajlm-2394	43	38	france	france	PROPN
ajlm-2394	43	39	)	)	PUNCT
ajlm-2394	43	40	.	.	PUNCT
ajlm-2394	44	1	the	the	DET
ajlm-2394	44	2	blood	blood	NOUN
ajlm-2394	44	3	samples	sample	NOUN
ajlm-2394	44	4	were	be	AUX
ajlm-2394	44	5	sent	send	VERB
ajlm-2394	44	6	to	to	ADP
ajlm-2394	44	7	tikur	tikur	PROPN
ajlm-2394	44	8	anbessa	anbessa	ADJ
ajlm-2394	44	9	specialised	specialised	ADJ
ajlm-2394	44	10	hospital	hospital	NOUN
ajlm-2394	44	11	main	main	ADJ
ajlm-2394	44	12	laboratory	laboratory	NOUN
ajlm-2394	44	13	for	for	ADP
ajlm-2394	44	14	complete	complete	ADJ
ajlm-2394	44	15	blood	blood	NOUN
ajlm-2394	44	16	count	count	NOUN
ajlm-2394	44	17	testing	testing	NOUN
ajlm-2394	44	18	on	on	ADP
ajlm-2394	44	19	an	an	DET
ajlm-2394	44	20	automated	automate	VERB
ajlm-2394	44	21	haematological	haematological	ADJ
ajlm-2394	44	22	analyser	analyser	NOUN
ajlm-2394	44	23	(	(	PUNCT
ajlm-2394	44	24	sysmex	sysmex	NOUN
ajlm-2394	44	25	2000i	2000i	NUM
ajlm-2394	44	26	;	;	PUNCT
ajlm-2394	44	27	sysmex	sysmex	NOUN
ajlm-2394	44	28	corporation	corporation	NOUN
ajlm-2394	44	29	,	,	PUNCT
ajlm-2394	44	30	kobe	kobe	PROPN
ajlm-2394	44	31	,	,	PUNCT
ajlm-2394	44	32	japan	japan	PROPN
ajlm-2394	44	33	)	)	PUNCT
ajlm-2394	44	34	and	and	CCONJ
ajlm-2394	44	35	retested	reteste	VERB
ajlm-2394	44	36	for	for	ADP
ajlm-2394	44	37	complete	complete	ADJ
ajlm-2394	44	38	blood	blood	NOUN
ajlm-2394	44	39	count	count	NOUN
ajlm-2394	44	40	(	(	PUNCT
ajlm-2394	44	41	by	by	ADP
ajlm-2394	44	42	sysmex	sysmex	NOUN
ajlm-2394	44	43	kh	kh	PROPN
ajlm-2394	44	44	21n	21n	NUM
ajlm-2394	44	45	;	;	PUNCT
ajlm-2394	44	46	sysmex	sysmex	NOUN
ajlm-2394	44	47	corporation	corporation	NOUN
ajlm-2394	44	48	,	,	PUNCT
ajlm-2394	44	49	kobe	kobe	PROPN
ajlm-2394	44	50	,	,	PUNCT
ajlm-2394	44	51	japan	japan	PROPN
ajlm-2394	44	52	,	,	PUNCT
ajlm-2394	44	53	or	or	CCONJ
ajlm-2394	44	54	coulter	coulter	PROPN
ajlm-2394	44	55	dxh	dxh	PROPN
ajlm-2394	44	56	800	800	NUM
ajlm-2394	44	57	;	;	PUNCT
ajlm-2394	44	58	beckman	beckman	PROPN
ajlm-2394	44	59	coulter	coulter	PROPN
ajlm-2394	44	60	,	,	PUNCT
ajlm-2394	44	61	shirley	shirley	PROPN
ajlm-2394	44	62	,	,	PUNCT
ajlm-2394	44	63	new	new	PROPN
ajlm-2394	44	64	york	york	PROPN
ajlm-2394	44	65	,	,	PUNCT
ajlm-2394	44	66	united	united	PROPN
ajlm-2394	44	67	states	states	PROPN
ajlm-2394	44	68	)	)	PUNCT
ajlm-2394	44	69	at	at	ADP
ajlm-2394	44	70	the	the	DET
ajlm-2394	44	71	alert	alert	ADJ
ajlm-2394	44	72	hospital	hospital	NOUN
ajlm-2394	44	73	,	,	PUNCT
ajlm-2394	44	74	and	and	CCONJ
ajlm-2394	44	75	the	the	DET
ajlm-2394	44	76	average	average	ADJ
ajlm-2394	44	77	values	value	NOUN
ajlm-2394	44	78	were	be	AUX
ajlm-2394	44	79	taken	take	VERB
ajlm-2394	44	80	.	.	PUNCT
ajlm-2394	45	1	samples	sample	NOUN
ajlm-2394	45	2	were	be	AUX
ajlm-2394	45	3	transported	transport	VERB
ajlm-2394	45	4	on	on	ADP
ajlm-2394	45	5	the	the	DET
ajlm-2394	45	6	same	same	ADJ
ajlm-2394	45	7	day	day	NOUN
ajlm-2394	45	8	to	to	ADP
ajlm-2394	45	9	the	the	DET
ajlm-2394	45	10	ahri	ahri	PROPN
ajlm-2394	45	11	immunology	immunology	NOUN
ajlm-2394	45	12	laboratory	laboratory	NOUN
ajlm-2394	45	13	for	for	ADP
ajlm-2394	45	14	flow	flow	NOUN
ajlm-2394	45	15	cytometry	cytometry	NOUN
ajlm-2394	45	16	analysis	analysis	NOUN
ajlm-2394	45	17	.	.	PUNCT
ajlm-2394	46	1	laboratory	laboratory	NOUN
ajlm-2394	46	2	analyses	analysis	NOUN
ajlm-2394	46	3	flow	flow	VERB
ajlm-2394	46	4	cytometry	cytometry	NOUN
ajlm-2394	46	5	we	we	PRON
ajlm-2394	46	6	used	use	VERB
ajlm-2394	46	7	a	a	DET
ajlm-2394	46	8	previously	previously	ADV
ajlm-2394	46	9	published	publish	VERB
ajlm-2394	46	10	procedure	procedure	NOUN
ajlm-2394	46	11	for	for	ADP
ajlm-2394	46	12	flow	flow	NOUN
ajlm-2394	46	13	phenotyping.7	phenotyping.7	PRON
ajlm-2394	46	14	briefly	briefly	NOUN
ajlm-2394	46	15	,	,	PUNCT
ajlm-2394	46	16	for	for	ADP
ajlm-2394	46	17	cell	cell	NOUN
ajlm-2394	46	18	surface	surface	NOUN
ajlm-2394	46	19	staining	stain	VERB
ajlm-2394	46	20	,	,	PUNCT
ajlm-2394	46	21	100	100	NUM
ajlm-2394	46	22	ml	ml	NOUN
ajlm-2394	46	23	of	of	ADP
ajlm-2394	46	24	blood	blood	NOUN
ajlm-2394	46	25	was	be	AUX
ajlm-2394	46	26	added	add	VERB
ajlm-2394	46	27	to	to	ADP
ajlm-2394	46	28	5	5	NUM
ajlm-2394	46	29	ml	ml	NOUN
ajlm-2394	46	30	polystyrene	polystyrene	VERB
ajlm-2394	46	31	tubes	tube	NOUN
ajlm-2394	46	32	to	to	PART
ajlm-2394	46	33	which	which	PRON
ajlm-2394	46	34	various	various	ADJ
ajlm-2394	46	35	combinations	combination	NOUN
ajlm-2394	46	36	of	of	ADP
ajlm-2394	46	37	fluorescent	fluorescent	NOUN
ajlm-2394	46	38	-	-	PUNCT
ajlm-2394	46	39	conjugated	conjugate	VERB
ajlm-2394	46	40	antibodies	antibody	NOUN
ajlm-2394	46	41	were	be	AUX
ajlm-2394	46	42	added.8	added.8	PROPN
ajlm-2394	46	43	the	the	DET
ajlm-2394	46	44	antibody	antibody	NOUN
ajlm-2394	46	45	target	target	NOUN
ajlm-2394	46	46	molecules	molecule	NOUN
ajlm-2394	46	47	and	and	CCONJ
ajlm-2394	46	48	fluorochromes	fluorochrome	NOUN
ajlm-2394	46	49	included	include	VERB
ajlm-2394	46	50	:	:	PUNCT
ajlm-2394	46	51	cd8	cd8	PROPN
ajlm-2394	46	52	-	-	PROPN
ajlm-2394	46	53	fitc	fitc	PROPN
ajlm-2394	46	54	,	,	PUNCT
ajlm-2394	46	55	cd4	cd4	PROPN
ajlm-2394	46	56	-	-	PUNCT
ajlm-2394	46	57	pe	pe	PROPN
ajlm-2394	46	58	,	,	PUNCT
ajlm-2394	46	59	cd45	cd45	PROPN
ajlm-2394	46	60	-	-	PUNCT
ajlm-2394	46	61	percp	percp	NOUN
ajlm-2394	46	62	-	-	PUNCT
ajlm-2394	46	63	cy5.5	cy5.5	NOUN
ajlm-2394	46	64	,	,	PUNCT
ajlm-2394	46	65	cd3	cd3	PROPN
ajlm-2394	46	66	-	-	PUNCT
ajlm-2394	46	67	apc	apc	PROPN
ajlm-2394	46	68	,	,	PUNCT
ajlm-2394	46	69	cd19	cd19	PROPN
ajlm-2394	46	70	-	-	PUNCT
ajlm-2394	46	71	fitc	fitc	PROPN
ajlm-2394	46	72	,	,	PUNCT
ajlm-2394	46	73	cd56	cd56	PROPN
ajlm-2394	46	74	-	-	PUNCT
ajlm-2394	46	75	pe	pe	PROPN
ajlm-2394	46	76	,	,	PUNCT
ajlm-2394	46	77	cd33	cd33	PROPN
ajlm-2394	46	78	-	-	PUNCT
ajlm-2394	46	79	fitc	fitc	PROPN
ajlm-2394	46	80	,	,	PUNCT
ajlm-2394	46	81	cd34	cd34	PROPN
ajlm-2394	46	82	-	-	PUNCT
ajlm-2394	46	83	pe	pe	PROPN
ajlm-2394	46	84	,	,	PUNCT
ajlm-2394	46	85	cd117	cd117	PROPN
ajlm-2394	46	86	-	-	PUNCT
ajlm-2394	46	87	apc	apc	PROPN
ajlm-2394	46	88	,	,	PUNCT
ajlm-2394	46	89	cd13	cd13	PROPN
ajlm-2394	46	90	-	-	PUNCT
ajlm-2394	46	91	fitc	fitc	PROPN
ajlm-2394	46	92	,	,	PUNCT
ajlm-2394	46	93	cd10	cd10	PROPN
ajlm-2394	46	94	-	-	PUNCT
ajlm-2394	46	95	pe	pe	PROPN
ajlm-2394	46	96	,	,	PUNCT
ajlm-2394	46	97	hla	hla	PROPN
ajlm-2394	46	98	-	-	PUNCT
ajlm-2394	46	99	dr	dr	PROPN
ajlm-2394	46	100	-	-	PUNCT
ajlm-2394	46	101	apc	apc	PROPN
ajlm-2394	46	102	,	,	PUNCT
ajlm-2394	46	103	isotype	isotype	NOUN
ajlm-2394	46	104	control	control	NOUN
ajlm-2394	46	105	igg1	igg1	PROPN
ajlm-2394	46	106	-	-	PUNCT
ajlm-2394	46	107	fitc	fitc	NOUN
ajlm-2394	46	108	,	,	PUNCT
ajlm-2394	46	109	isotype	isotype	NOUN
ajlm-2394	46	110	control	control	NOUN
ajlm-2394	46	111	igg1	igg1	PROPN
ajlm-2394	46	112	-	-	PUNCT
ajlm-2394	46	113	pe	pe	PROPN
ajlm-2394	46	114	,	,	PUNCT
ajlm-2394	46	115	isotype	isotype	NOUN
ajlm-2394	46	116	control	control	NOUN
ajlm-2394	46	117	igg1	igg1	PROPN
ajlm-2394	46	118	-	-	PUNCT
ajlm-2394	46	119	apc	apc	PROPN
ajlm-2394	46	120	,	,	PUNCT
ajlm-2394	46	121	cd66c	cd66c	NOUN
ajlm-2394	46	122	-	-	PUNCT
ajlm-2394	46	123	pe	pe	PROPN
ajlm-2394	46	124	,	,	PUNCT
ajlm-2394	46	125	cd15	cd15	PROPN
ajlm-2394	46	126	-	-	PUNCT
ajlm-2394	46	127	fitc	fitc	NOUN
ajlm-2394	46	128	,	,	PUNCT
ajlm-2394	46	129	cd14	cd14	PROPN
ajlm-2394	46	130	-	-	PUNCT
ajlm-2394	46	131	fitc	fitc	PROPN
ajlm-2394	46	132	,	,	PUNCT
ajlm-2394	46	133	cd7	cd7	PROPN
ajlm-2394	46	134	-	-	PUNCT
ajlm-2394	46	135	pe	pe	PROPN
ajlm-2394	46	136	,	,	PUNCT
ajlm-2394	46	137	cd22	cd22	PROPN
ajlm-2394	46	138	-	-	PUNCT
ajlm-2394	46	139	apc	apc	PROPN
ajlm-2394	46	140	,	,	PUNCT
ajlm-2394	46	141	and	and	CCONJ
ajlm-2394	46	142	cd64	cd64	PROPN
ajlm-2394	46	143	-	-	PUNCT
ajlm-2394	46	144	apc	apc	PROPN
ajlm-2394	46	145	.	.	PUNCT
ajlm-2394	47	1	mixtures	mixture	NOUN
ajlm-2394	47	2	containing	contain	VERB
ajlm-2394	47	3	cd8	cd8	PROPN
ajlm-2394	47	4	/	/	SYM
ajlm-2394	47	5	cd4	cd4	PROPN
ajlm-2394	47	6	/	/	SYM
ajlm-2394	47	7	cd3	cd3	PROPN
ajlm-2394	47	8	and	and	CCONJ
ajlm-2394	47	9	cd33	cd33	PROPN
ajlm-2394	47	10	/	/	SYM
ajlm-2394	47	11	cd34	cd34	PROPN
ajlm-2394	47	12	/	/	SYM
ajlm-2394	47	13	cd117	cd117	PROPN
ajlm-2394	47	14	antibodies	antibodie	VERB
ajlm-2394	47	15	,	,	PUNCT
ajlm-2394	47	16	and	and	CCONJ
ajlm-2394	47	17	cd3	cd3	PROPN
ajlm-2394	47	18	,	,	PUNCT
ajlm-2394	47	19	cd15	cd15	PROPN
ajlm-2394	47	20	,	,	PUNCT
ajlm-2394	47	21	cd19	cd19	PROPN
ajlm-2394	47	22	,	,	PUNCT
ajlm-2394	47	23	cd10	cd10	PROPN
ajlm-2394	47	24	,	,	PUNCT
ajlm-2394	47	25	cd56	cd56	PROPN
ajlm-2394	47	26	individual	individual	ADJ
ajlm-2394	47	27	antibodies	antibody	NOUN
ajlm-2394	47	28	were	be	AUX
ajlm-2394	47	29	obtained	obtain	VERB
ajlm-2394	47	30	from	from	ADP
ajlm-2394	47	31	agilent	agilent	PROPN
ajlm-2394	47	32	technologies	technology	NOUN
ajlm-2394	47	33	(	(	PUNCT
ajlm-2394	47	34	glostrup	glostrup	NOUN
ajlm-2394	47	35	,	,	PUNCT
ajlm-2394	47	36	denmark	denmark	PROPN
ajlm-2394	47	37	)	)	PUNCT
ajlm-2394	47	38	;	;	PUNCT
ajlm-2394	47	39	the	the	DET
ajlm-2394	47	40	remaining	remain	VERB
ajlm-2394	47	41	monoclonal	monoclonal	NOUN
ajlm-2394	47	42	antibodies	antibody	NOUN
ajlm-2394	47	43	were	be	AUX
ajlm-2394	47	44	received	receive	VERB
ajlm-2394	47	45	from	from	ADP
ajlm-2394	47	46	becton	becton	PROPN
ajlm-2394	47	47	dickinson	dickinson	PROPN
ajlm-2394	47	48	(	(	PUNCT
ajlm-2394	47	49	san	san	PROPN
ajlm-2394	47	50	jose	jose	PROPN
ajlm-2394	47	51	,	,	PUNCT
ajlm-2394	47	52	california	california	PROPN
ajlm-2394	47	53	,	,	PUNCT
ajlm-2394	47	54	united	united	PROPN
ajlm-2394	47	55	states	states	PROPN
ajlm-2394	47	56	)	)	PUNCT
ajlm-2394	47	57	.	.	PUNCT
ajlm-2394	48	1	antibodies	antibody	NOUN
ajlm-2394	48	2	were	be	AUX
ajlm-2394	48	3	organised	organise	VERB
ajlm-2394	48	4	into	into	ADP
ajlm-2394	48	5	10	10	NUM
ajlm-2394	48	6	panels	panel	NOUN
ajlm-2394	48	7	,	,	PUNCT
ajlm-2394	48	8	typically	typically	ADV
ajlm-2394	48	9	using	use	VERB
ajlm-2394	48	10	4	4	NUM
ajlm-2394	48	11	antibody	antibody	NOUN
ajlm-2394	48	12	colours	colour	NOUN
ajlm-2394	48	13	per	per	ADP
ajlm-2394	48	14	panel	panel	NOUN
ajlm-2394	48	15	.	.	PUNCT
ajlm-2394	49	1	the	the	DET
ajlm-2394	49	2	same	same	ADJ
ajlm-2394	49	3	panel	panel	NOUN
ajlm-2394	49	4	design	design	NOUN
ajlm-2394	49	5	was	be	AUX
ajlm-2394	49	6	used	use	VERB
ajlm-2394	49	7	for	for	ADP
ajlm-2394	49	8	all	all	DET
ajlm-2394	49	9	leukaemia	leukaemia	NOUN
ajlm-2394	49	10	cases	case	NOUN
ajlm-2394	49	11	.	.	PUNCT
ajlm-2394	50	1	this	this	PRON
ajlm-2394	50	2	was	be	AUX
ajlm-2394	50	3	done	do	VERB
ajlm-2394	50	4	to	to	PART
ajlm-2394	50	5	assure	assure	VERB
ajlm-2394	50	6	uniformity	uniformity	NOUN
ajlm-2394	50	7	among	among	ADP
ajlm-2394	50	8	all	all	DET
ajlm-2394	50	9	subjects	subject	NOUN
ajlm-2394	50	10	within	within	ADP
ajlm-2394	50	11	the	the	DET
ajlm-2394	50	12	study	study	NOUN
ajlm-2394	50	13	as	as	ADV
ajlm-2394	50	14	well	well	ADV
ajlm-2394	50	15	as	as	ADP
ajlm-2394	50	16	to	to	PART
ajlm-2394	50	17	ascertain	ascertain	VERB
ajlm-2394	50	18	potential	potential	ADJ
ajlm-2394	50	19	aberrant	aberrant	ADJ
ajlm-2394	50	20	expression	expression	NOUN
ajlm-2394	50	21	of	of	ADP
ajlm-2394	50	22	lineage	lineage	NOUN
ajlm-2394	50	23	-	-	PUNCT
ajlm-2394	50	24	specific	specific	ADJ
ajlm-2394	50	25	markers	marker	NOUN
ajlm-2394	50	26	on	on	ADP
ajlm-2394	50	27	some	some	DET
ajlm-2394	50	28	leukaemias	leukaemia	NOUN
ajlm-2394	50	29	,	,	PUNCT
ajlm-2394	50	30	for	for	ADP
ajlm-2394	50	31	example	example	NOUN
ajlm-2394	50	32	myeloid	myeloid	NOUN
ajlm-2394	50	33	markers	marker	NOUN
ajlm-2394	50	34	cd13	cd13	PROPN
ajlm-2394	50	35	,	,	PUNCT
ajlm-2394	50	36	cd33	cd33	PROPN
ajlm-2394	50	37	,	,	PUNCT
ajlm-2394	50	38	mpo	mpo	PROPN
ajlm-2394	50	39	,	,	PUNCT
ajlm-2394	50	40	and	and	CCONJ
ajlm-2394	50	41	cd66c	cd66c	NOUN
ajlm-2394	50	42	on	on	ADP
ajlm-2394	50	43	b	b	NOUN
ajlm-2394	50	44	-	-	PUNCT
ajlm-2394	50	45	cell	cell	NOUN
ajlm-2394	50	46	all	all	DET
ajlm-2394	50	47	(	(	PUNCT
ajlm-2394	50	48	b	b	X
ajlm-2394	50	49	-	-	PUNCT
ajlm-2394	50	50	all).8,9	all).8,9	ADJ
ajlm-2394	50	51	cytoplasmic	cytoplasmic	ADJ
ajlm-2394	50	52	staining	staining	NOUN
ajlm-2394	50	53	was	be	AUX
ajlm-2394	50	54	performed	perform	VERB
ajlm-2394	50	55	with	with	ADP
ajlm-2394	50	56	the	the	DET
ajlm-2394	50	57	following	follow	VERB
ajlm-2394	50	58	antibodies	antibodie	VERB
ajlm-2394	50	59	:	:	PUNCT
ajlm-2394	50	60	cd45	cd45	PROPN
ajlm-2394	50	61	-	-	PUNCT
ajlm-2394	50	62	percp	percp	NOUN
ajlm-2394	50	63	-	-	PUNCT
ajlm-2394	50	64	cy5.5	cy5.5	ADJ
ajlm-2394	50	65	,	,	PUNCT
ajlm-2394	50	66	terminal	terminal	ADJ
ajlm-2394	50	67	deoxynucleotidal	deoxynucleotidal	NOUN
ajlm-2394	50	68	transferase	transferase	NOUN
ajlm-2394	50	69	-	-	PUNCT
ajlm-2394	50	70	fitc	fitc	NOUN
ajlm-2394	50	71	,	,	PUNCT
ajlm-2394	50	72	cmyeloperoxidase	cmyeloperoxidase	NOUN
ajlm-2394	50	73	(	(	PUNCT
ajlm-2394	50	74	cmpo)-fitc	cmpo)-fitc	NOUN
ajlm-2394	50	75	,	,	PUNCT
ajlm-2394	50	76	cd79a	cd79a	X
ajlm-2394	50	77	-	-	PUNCT
ajlm-2394	50	78	pe	pe	ADJ
ajlm-2394	50	79	,	,	PUNCT
ajlm-2394	50	80	cd3	cd3	PROPN
ajlm-2394	50	81	-	-	PUNCT
ajlm-2394	50	82	apc	apc	PROPN
ajlm-2394	50	83	,	,	PUNCT
ajlm-2394	50	84	igg1	igg1	NOUN
ajlm-2394	50	85	-	-	PUNCT
ajlm-2394	50	86	fitc	fitc	NOUN
ajlm-2394	50	87	,	,	PUNCT
ajlm-2394	50	88	igg1	igg1	PROPN
ajlm-2394	50	89	-	-	PUNCT
ajlm-2394	50	90	pe	pe	PROPN
ajlm-2394	50	91	,	,	PUNCT
ajlm-2394	50	92	igg1	igg1	NOUN
ajlm-2394	50	93	-	-	PUNCT
ajlm-2394	50	94	apc	apc	PROPN
ajlm-2394	50	95	.	.	PUNCT
ajlm-2394	51	1	the	the	DET
ajlm-2394	51	2	cmpo	cmpo	NOUN
ajlm-2394	51	3	/	/	SYM
ajlm-2394	51	4	cd79a	cd79a	NOUN
ajlm-2394	51	5	/	/	SYM
ajlm-2394	51	6	cd3	cd3	VERB
ajlm-2394	51	7	mixture	mixture	NOUN
ajlm-2394	51	8	and	and	CCONJ
ajlm-2394	51	9	terminal	terminal	ADJ
ajlm-2394	51	10	deoxynucleotidal	deoxynucleotidal	NOUN
ajlm-2394	51	11	transferase	transferase	NOUN
ajlm-2394	51	12	antibodies	antibody	NOUN
ajlm-2394	51	13	were	be	AUX
ajlm-2394	51	14	obtained	obtain	VERB
ajlm-2394	51	15	from	from	ADP
ajlm-2394	51	16	agilent	agilent	PROPN
ajlm-2394	51	17	technologies	technology	NOUN
ajlm-2394	51	18	(	(	PUNCT
ajlm-2394	51	19	glostrup	glostrup	NOUN
ajlm-2394	51	20	,	,	PUNCT
ajlm-2394	51	21	denmark	denmark	PROPN
ajlm-2394	51	22	)	)	PUNCT
ajlm-2394	51	23	;	;	PUNCT
ajlm-2394	51	24	the	the	DET
ajlm-2394	51	25	remaining	remain	VERB
ajlm-2394	51	26	antibodies	antibody	NOUN
ajlm-2394	51	27	were	be	AUX
ajlm-2394	51	28	from	from	ADP
ajlm-2394	51	29	becton	becton	PROPN
ajlm-2394	51	30	dickinson	dickinson	PROPN
ajlm-2394	51	31	(	(	PUNCT
ajlm-2394	51	32	san	san	PROPN
ajlm-2394	51	33	jose	jose	PROPN
ajlm-2394	51	34	,	,	PUNCT
ajlm-2394	51	35	california	california	PROPN
ajlm-2394	51	36	,	,	PUNCT
ajlm-2394	51	37	united	united	PROPN
ajlm-2394	51	38	states	states	PROPN
ajlm-2394	51	39	)	)	PUNCT
ajlm-2394	51	40	.	.	PUNCT
ajlm-2394	52	1	staining	stain	VERB
ajlm-2394	52	2	was	be	AUX
ajlm-2394	52	3	performed	perform	VERB
ajlm-2394	52	4	as	as	SCONJ
ajlm-2394	52	5	described	describe	VERB
ajlm-2394	52	6	for	for	ADP
ajlm-2394	52	7	phenotyping.7	phenotyping.7	ADJ
ajlm-2394	52	8	acquisition	acquisition	NOUN
ajlm-2394	52	9	was	be	AUX
ajlm-2394	52	10	performed	perform	VERB
ajlm-2394	52	11	with	with	ADP
ajlm-2394	52	12	a	a	DET
ajlm-2394	52	13	facs	fac	NOUN
ajlm-2394	52	14	calibur	calibur	PROPN
ajlm-2394	52	15	four	four	NUM
ajlm-2394	52	16	-	-	PUNCT
ajlm-2394	52	17	colour	colour	NOUN
ajlm-2394	52	18	flow	flow	NOUN
ajlm-2394	52	19	cytometer	cytometer	NOUN
ajlm-2394	52	20	(	(	PUNCT
ajlm-2394	52	21	becton	becton	PROPN
ajlm-2394	52	22	-	-	PUNCT
ajlm-2394	52	23	dickinson	dickinson	PROPN
ajlm-2394	52	24	,	,	PUNCT
ajlm-2394	52	25	durham	durham	PROPN
ajlm-2394	52	26	,	,	PUNCT
ajlm-2394	52	27	new	new	ADJ
ajlm-2394	52	28	hamshire	hamshire	NOUN
ajlm-2394	52	29	,	,	PUNCT
ajlm-2394	52	30	united	united	PROPN
ajlm-2394	52	31	states	states	PROPN
ajlm-2394	52	32	;	;	PUNCT
ajlm-2394	52	33	an	an	DET
ajlm-2394	52	34	instrument	instrument	NOUN
ajlm-2394	52	35	that	that	PRON
ajlm-2394	52	36	measures	measure	VERB
ajlm-2394	52	37	six	six	NUM
ajlm-2394	52	38	parameters	parameter	NOUN
ajlm-2394	52	39	such	such	ADJ
ajlm-2394	52	40	as	as	ADP
ajlm-2394	52	41	side	side	NOUN
ajlm-2394	52	42	scatter	scatter	NOUN
ajlm-2394	52	43	,	,	PUNCT
ajlm-2394	52	44	forward	forward	ADV
ajlm-2394	52	45	scatter	scatter	NOUN
ajlm-2394	52	46	,	,	PUNCT
ajlm-2394	52	47	and	and	CCONJ
ajlm-2394	52	48	four	four	NUM
ajlm-2394	52	49	types	type	NOUN
ajlm-2394	52	50	of	of	ADP
ajlm-2394	52	51	fluorochrome	fluorochrome	NOUN
ajlm-2394	52	52	-	-	PUNCT
ajlm-2394	52	53	coated	coat	VERB
ajlm-2394	52	54	antibodies	antibody	NOUN
ajlm-2394	52	55	)	)	PUNCT
ajlm-2394	52	56	using	use	VERB
ajlm-2394	52	57	cell	cell	NOUN
ajlm-2394	52	58	quest	quest	NOUN
ajlm-2394	52	59	software	software	NOUN
ajlm-2394	52	60	(	(	PUNCT
ajlm-2394	52	61	bd	bd	PROPN
ajlm-2394	52	62	biosciences	bioscience	NOUN
ajlm-2394	52	63	,	,	PUNCT
ajlm-2394	52	64	san	san	PROPN
ajlm-2394	52	65	jose	jose	PROPN
ajlm-2394	52	66	,	,	PUNCT
ajlm-2394	52	67	california	california	PROPN
ajlm-2394	52	68	,	,	PUNCT
ajlm-2394	52	69	united	united	PROPN
ajlm-2394	52	70	states	states	PROPN
ajlm-2394	52	71	)	)	PUNCT
ajlm-2394	52	72	,	,	PUNCT
ajlm-2394	52	73	with	with	ADP
ajlm-2394	52	74	typically	typically	ADV
ajlm-2394	52	75	30	30	NUM
ajlm-2394	52	76	000	000	NUM
ajlm-2394	52	77	to	to	PART
ajlm-2394	52	78	100	100	NUM
ajlm-2394	52	79	000	000	NUM
ajlm-2394	52	80	events	event	NOUN
ajlm-2394	52	81	acquired	acquire	VERB
ajlm-2394	52	82	.	.	PUNCT
ajlm-2394	53	1	data	datum	NOUN
ajlm-2394	53	2	analysis	analysis	NOUN
ajlm-2394	53	3	data	datum	NOUN
ajlm-2394	53	4	were	be	AUX
ajlm-2394	53	5	imported	import	VERB
ajlm-2394	53	6	into	into	ADP
ajlm-2394	53	7	an	an	DET
ajlm-2394	53	8	ms	ms	PROPN
ajlm-2394	53	9	excel	excel	PROPN
ajlm-2394	53	10	(	(	PUNCT
ajlm-2394	53	11	microsoft	microsoft	PROPN
ajlm-2394	53	12	,	,	PUNCT
ajlm-2394	53	13	redmond	redmond	PROPN
ajlm-2394	53	14	,	,	PUNCT
ajlm-2394	53	15	washington	washington	PROPN
ajlm-2394	53	16	,	,	PUNCT
ajlm-2394	53	17	united	united	PROPN
ajlm-2394	53	18	states	states	PROPN
ajlm-2394	53	19	)	)	PUNCT
ajlm-2394	53	20	spreadsheet	spreadsheet	NOUN
ajlm-2394	53	21	and	and	CCONJ
ajlm-2394	53	22	thereafter	thereafter	ADV
ajlm-2394	53	23	exported	export	VERB
ajlm-2394	53	24	to	to	ADP
ajlm-2394	53	25	an	an	DET
ajlm-2394	53	26	ms	ms	NOUN
ajlm-2394	53	27	access	access	NOUN
ajlm-2394	53	28	(	(	PUNCT
ajlm-2394	53	29	microsoft	microsoft	PROPN
ajlm-2394	53	30	,	,	PUNCT
ajlm-2394	53	31	redmond	redmond	PROPN
ajlm-2394	53	32	,	,	PUNCT
ajlm-2394	53	33	washington	washington	PROPN
ajlm-2394	53	34	,	,	PUNCT
ajlm-2394	53	35	united	united	PROPN
ajlm-2394	53	36	states	states	PROPN
ajlm-2394	53	37	)	)	PUNCT
ajlm-2394	53	38	database	database	NOUN
ajlm-2394	53	39	where	where	SCONJ
ajlm-2394	53	40	the	the	DET
ajlm-2394	53	41	data	datum	NOUN
ajlm-2394	53	42	were	be	AUX
ajlm-2394	53	43	reviewed	review	VERB
ajlm-2394	53	44	,	,	PUNCT
ajlm-2394	53	45	cleaned	clean	VERB
ajlm-2394	53	46	,	,	PUNCT
ajlm-2394	53	47	and	and	CCONJ
ajlm-2394	53	48	analysed	analyse	VERB
ajlm-2394	53	49	with	with	ADP
ajlm-2394	53	50	spss	spss	PROPN
ajlm-2394	53	51	version	version	NOUN
ajlm-2394	53	52	25	25	NUM
ajlm-2394	53	53	statistical	statistical	ADJ
ajlm-2394	53	54	software	software	NOUN
ajlm-2394	53	55	(	(	PUNCT
ajlm-2394	53	56	ibm	ibm	PROPN
ajlm-2394	53	57	corp	corp	PROPN
ajlm-2394	53	58	,	,	PUNCT
ajlm-2394	53	59	armonk	armonk	PROPN
ajlm-2394	53	60	,	,	PUNCT
ajlm-2394	53	61	new	new	PROPN
ajlm-2394	53	62	york	york	PROPN
ajlm-2394	53	63	,	,	PUNCT
ajlm-2394	53	64	united	united	PROPN
ajlm-2394	53	65	states	states	PROPN
ajlm-2394	53	66	)	)	PUNCT
ajlm-2394	53	67	.	.	PUNCT
ajlm-2394	54	1	a	a	DET
ajlm-2394	54	2	given	give	VERB
ajlm-2394	54	3	marker	marker	NOUN
ajlm-2394	54	4	was	be	AUX
ajlm-2394	54	5	considered	consider	VERB
ajlm-2394	54	6	positive	positive	ADJ
ajlm-2394	54	7	if	if	SCONJ
ajlm-2394	54	8	>	>	X
ajlm-2394	54	9	20	20	NUM
ajlm-2394	54	10	%	%	NOUN
ajlm-2394	54	11	of	of	ADP
ajlm-2394	54	12	the	the	DET
ajlm-2394	54	13	leukaemia	leukaemia	NOUN
ajlm-2394	54	14	gated	gate	VERB
ajlm-2394	54	15	cells	cell	NOUN
ajlm-2394	54	16	were	be	AUX
ajlm-2394	54	17	above	above	ADP
ajlm-2394	54	18	the	the	DET
ajlm-2394	54	19	cutoff	cutoff	NOUN
ajlm-2394	54	20	threshold	threshold	NOUN
ajlm-2394	54	21	established	establish	VERB
ajlm-2394	54	22	by	by	ADP
ajlm-2394	54	23	isotype	isotype	NOUN
ajlm-2394	54	24	controls	control	NOUN
ajlm-2394	54	25	separately	separately	ADV
ajlm-2394	54	26	for	for	ADP
ajlm-2394	54	27	surface	surface	NOUN
ajlm-2394	54	28	and	and	CCONJ
ajlm-2394	54	29	cytoplasmic	cytoplasmic	ADJ
ajlm-2394	54	30	staining11	staining11	NOUN
ajlm-2394	54	31	;	;	PUNCT
ajlm-2394	54	32	a	a	DET
ajlm-2394	54	33	representative	representative	ADJ
ajlm-2394	54	34	gating	gating	NOUN
ajlm-2394	54	35	example	example	NOUN
ajlm-2394	54	36	is	be	AUX
ajlm-2394	54	37	depicted	depict	VERB
ajlm-2394	54	38	in	in	ADP
ajlm-2394	54	39	online	online	ADJ
ajlm-2394	54	40	supplementary	supplementary	ADJ
ajlm-2394	54	41	figure	figure	NOUN
ajlm-2394	54	42	1	1	NUM
ajlm-2394	54	43	.	.	PUNCT
ajlm-2394	55	1	in	in	ADP
ajlm-2394	55	2	some	some	DET
ajlm-2394	55	3	instances	instance	NOUN
ajlm-2394	55	4	,	,	PUNCT
ajlm-2394	55	5	marker	marker	NOUN
ajlm-2394	55	6	-	-	PUNCT
ajlm-2394	55	7	positive	positive	ADJ
ajlm-2394	55	8	cells	cell	NOUN
ajlm-2394	55	9	were	be	AUX
ajlm-2394	55	10	expressed	express	VERB
ajlm-2394	55	11	as	as	ADP
ajlm-2394	55	12	a	a	DET
ajlm-2394	55	13	percentage	percentage	NOUN
ajlm-2394	55	14	of	of	ADP
ajlm-2394	55	15	gated	gate	VERB
ajlm-2394	55	16	leukaemia	leukaemia	NOUN
ajlm-2394	55	17	cells	cell	NOUN
ajlm-2394	55	18	.	.	PUNCT
ajlm-2394	56	1	in	in	ADP
ajlm-2394	56	2	addition	addition	NOUN
ajlm-2394	56	3	,	,	PUNCT
ajlm-2394	56	4	for	for	ADP
ajlm-2394	56	5	selected	select	VERB
ajlm-2394	56	6	samples	sample	NOUN
ajlm-2394	56	7	,	,	PUNCT
ajlm-2394	56	8	marker	marker	NOUN
ajlm-2394	56	9	density	density	NOUN
ajlm-2394	56	10	was	be	AUX
ajlm-2394	56	11	calculated	calculate	VERB
ajlm-2394	56	12	by	by	ADP
ajlm-2394	56	13	dividing	divide	VERB
ajlm-2394	56	14	the	the	DET
ajlm-2394	56	15	mean	mean	ADJ
ajlm-2394	56	16	fluorescence	fluorescence	NOUN
ajlm-2394	56	17	of	of	ADP
ajlm-2394	56	18	marker	marker	NOUN
ajlm-2394	56	19	-	-	PUNCT
ajlm-2394	56	20	positive	positive	ADJ
ajlm-2394	56	21	cells	cell	NOUN
ajlm-2394	56	22	by	by	ADP
ajlm-2394	56	23	that	that	PRON
ajlm-2394	56	24	of	of	ADP
ajlm-2394	56	25	marker	marker	NOUN
ajlm-2394	56	26	-	-	PUNCT
ajlm-2394	56	27	negative	negative	ADJ
ajlm-2394	56	28	cells	cell	NOUN
ajlm-2394	56	29	.	.	PUNCT
ajlm-2394	57	1	the	the	DET
ajlm-2394	57	2	chi	chi	ADJ
ajlm-2394	57	3	-	-	PUNCT
ajlm-2394	57	4	square	square	ADJ
ajlm-2394	57	5	test	test	NOUN
ajlm-2394	57	6	was	be	AUX
ajlm-2394	57	7	used	use	VERB
ajlm-2394	57	8	to	to	PART
ajlm-2394	57	9	determine	determine	VERB
ajlm-2394	57	10	associations	association	NOUN
ajlm-2394	57	11	between	between	ADP
ajlm-2394	57	12	variables	variable	NOUN
ajlm-2394	57	13	,	,	PUNCT
ajlm-2394	57	14	and	and	CCONJ
ajlm-2394	57	15	p	p	X
ajlm-2394	57	16	<	<	X
ajlm-2394	57	17	0.05	0.05	NUM
ajlm-2394	57	18	indicates	indicate	VERB
ajlm-2394	57	19	statistical	statistical	ADJ
ajlm-2394	57	20	significance	significance	NOUN
ajlm-2394	57	21	;	;	PUNCT
ajlm-2394	57	22	the	the	DET
ajlm-2394	57	23	mann	mann	PROPN
ajlm-2394	57	24	-	-	PUNCT
ajlm-2394	57	25	whitney	whitney	PROPN
ajlm-2394	57	26	u	u	PROPN
ajlm-2394	57	27	parametric	parametric	PROPN
ajlm-2394	57	28	test	test	NOUN
ajlm-2394	57	29	was	be	AUX
ajlm-2394	57	30	used	use	VERB
ajlm-2394	57	31	for	for	ADP
ajlm-2394	57	32	continuous	continuous	ADJ
ajlm-2394	57	33	data	datum	NOUN
ajlm-2394	57	34	.	.	PUNCT
ajlm-2394	58	1	interpretation	interpretation	NOUN
ajlm-2394	58	2	and	and	CCONJ
ajlm-2394	58	3	grouping	grouping	NOUN
ajlm-2394	58	4	of	of	ADP
ajlm-2394	58	5	acute	acute	ADJ
ajlm-2394	58	6	leukaemia	leukaemia	NOUN
ajlm-2394	58	7	types	type	NOUN
ajlm-2394	58	8	and	and	CCONJ
ajlm-2394	58	9	subtypes	subtype	NOUN
ajlm-2394	58	10	leukaemic	leukaemic	ADJ
ajlm-2394	58	11	cells	cell	NOUN
ajlm-2394	58	12	were	be	AUX
ajlm-2394	58	13	identified	identify	VERB
ajlm-2394	58	14	,	,	PUNCT
ajlm-2394	58	15	typically	typically	ADV
ajlm-2394	58	16	(	(	PUNCT
ajlm-2394	58	17	but	but	CCONJ
ajlm-2394	58	18	not	not	PART
ajlm-2394	58	19	always	always	ADV
ajlm-2394	58	20	)	)	PUNCT
ajlm-2394	58	21	on	on	ADP
ajlm-2394	58	22	the	the	DET
ajlm-2394	58	23	basis	basis	NOUN
ajlm-2394	58	24	of	of	ADP
ajlm-2394	58	25	reduced	reduced	ADJ
ajlm-2394	58	26	expression	expression	NOUN
ajlm-2394	58	27	of	of	ADP
ajlm-2394	58	28	cd45	cd45	PROPN
ajlm-2394	58	29	and	and	CCONJ
ajlm-2394	58	30	side	side	NOUN
ajlm-2394	58	31	scatter	scatter	NOUN
ajlm-2394	58	32	.	.	PUNCT
ajlm-2394	59	1	gated	gate	VERB
ajlm-2394	59	2	cells	cell	NOUN
ajlm-2394	59	3	were	be	AUX
ajlm-2394	59	4	then	then	ADV
ajlm-2394	59	5	evaluated	evaluate	VERB
ajlm-2394	59	6	for	for	ADP
ajlm-2394	59	7	expression	expression	NOUN
ajlm-2394	59	8	of	of	ADP
ajlm-2394	59	9	different	different	ADJ
ajlm-2394	59	10	markers	marker	NOUN
ajlm-2394	59	11	.	.	PUNCT
ajlm-2394	60	1	the	the	DET
ajlm-2394	60	2	threshold	threshold	NOUN
ajlm-2394	60	3	for	for	ADP
ajlm-2394	60	4	marker	marker	NOUN
ajlm-2394	60	5	positivity	positivity	NOUN
ajlm-2394	60	6	was	be	AUX
ajlm-2394	60	7	determined	determine	VERB
ajlm-2394	60	8	by	by	ADP
ajlm-2394	60	9	parallel	parallel	ADJ
ajlm-2394	60	10	samples	sample	NOUN
ajlm-2394	60	11	stained	stain	VERB
ajlm-2394	60	12	with	with	ADP
ajlm-2394	60	13	control	control	NOUN
ajlm-2394	60	14	isotype	isotype	NOUN
ajlm-2394	60	15	markers	marker	NOUN
ajlm-2394	60	16	as	as	ADP
ajlm-2394	60	17	described.7	described.7	PROPN
ajlm-2394	60	18	since	since	SCONJ
ajlm-2394	60	19	markers	marker	NOUN
ajlm-2394	60	20	typically	typically	ADV
ajlm-2394	60	21	were	be	AUX
ajlm-2394	60	22	not	not	PART
ajlm-2394	60	23	entirely	entirely	ADV
ajlm-2394	60	24	specific	specific	ADJ
ajlm-2394	60	25	for	for	ADP
ajlm-2394	60	26	a	a	DET
ajlm-2394	60	27	given	give	VERB
ajlm-2394	60	28	lineage	lineage	NOUN
ajlm-2394	60	29	,	,	PUNCT
ajlm-2394	60	30	we	we	PRON
ajlm-2394	60	31	used	use	VERB
ajlm-2394	60	32	world	world	NOUN
ajlm-2394	60	33	health	health	NOUN
ajlm-2394	60	34	organization	organization	NOUN
ajlm-2394	60	35	(	(	PUNCT
ajlm-2394	60	36	who)10	who)10	PROPN
ajlm-2394	60	37	and	and	CCONJ
ajlm-2394	60	38	associazone	associazone	NOUN
ajlm-2394	60	39	italiana	italiana	PROPN
ajlm-2394	60	40	ematologia	ematologia	PROPN
ajlm-2394	60	41	oncologia	oncologia	PROPN
ajlm-2394	60	42	pediatrica	pediatrica	PROPN
ajlm-2394	60	43	and	and	CCONJ
ajlm-2394	60	44	the	the	DET
ajlm-2394	60	45	berlin	berlin	PROPN
ajlm-2394	60	46	-	-	PUNCT
ajlm-2394	60	47	frankfurt	frankfurt	ADJ
ajlm-2394	60	48	-	-	PUNCT
ajlm-2394	60	49	münster11	münster11	NOUN
ajlm-2394	60	50	guidelines	guideline	NOUN
ajlm-2394	60	51	for	for	ADP
ajlm-2394	60	52	aml	aml	PROPN
ajlm-2394	60	53	,	,	PUNCT
ajlm-2394	60	54	b	b	X
ajlm-2394	60	55	-	-	PUNCT
ajlm-2394	60	56	all	all	PRON
ajlm-2394	60	57	,	,	PUNCT
ajlm-2394	60	58	and	and	CCONJ
ajlm-2394	60	59	t	t	NOUN
ajlm-2394	60	60	-	-	PUNCT
ajlm-2394	60	61	cell	cell	NOUN
ajlm-2394	60	62	all	all	PRON
ajlm-2394	60	63	(	(	PUNCT
ajlm-2394	60	64	t	t	NOUN
ajlm-2394	60	65	-	-	PUNCT
ajlm-2394	60	66	all	all	PRON
ajlm-2394	60	67	)	)	PUNCT
ajlm-2394	60	68	classifications	classification	NOUN
ajlm-2394	60	69	,	,	PUNCT
ajlm-2394	60	70	and	and	CCONJ
ajlm-2394	60	71	additional	additional	ADJ
ajlm-2394	60	72	references	reference	NOUN
ajlm-2394	60	73	for	for	ADP
ajlm-2394	60	74	aml	aml	NOUN
ajlm-2394	60	75	subtyping	subtyping	NOUN
ajlm-2394	60	76	by	by	ADP
ajlm-2394	60	77	flow	flow	NOUN
ajlm-2394	60	78	cytometry.12	cytometry.12	NOUN
ajlm-2394	60	79	there	there	PRON
ajlm-2394	60	80	are	be	VERB
ajlm-2394	60	81	no	no	DET
ajlm-2394	60	82	generally	generally	ADV
ajlm-2394	60	83	accepted	accept	VERB
ajlm-2394	60	84	guidelines	guideline	NOUN
ajlm-2394	60	85	for	for	ADP
ajlm-2394	60	86	the	the	DET
ajlm-2394	60	87	sub	sub	NOUN
ajlm-2394	60	88	-	-	NOUN
ajlm-2394	60	89	classification	classification	NOUN
ajlm-2394	60	90	of	of	ADP
ajlm-2394	60	91	aml	aml	NOUN
ajlm-2394	60	92	by	by	ADP
ajlm-2394	60	93	flow	flow	NOUN
ajlm-2394	60	94	cytometry	cytometry	NOUN
ajlm-2394	60	95	aligned	align	VERB
ajlm-2394	60	96	with	with	ADP
ajlm-2394	60	97	the	the	DET
ajlm-2394	60	98	french	french	ADJ
ajlm-2394	60	99	-	-	PUNCT
ajlm-2394	60	100	american	american	ADJ
ajlm-2394	60	101	-	-	PUNCT
ajlm-2394	60	102	british	british	ADJ
ajlm-2394	60	103	categories	category	NOUN
ajlm-2394	60	104	,	,	PUNCT
ajlm-2394	60	105	but	but	CCONJ
ajlm-2394	60	106	we	we	PRON
ajlm-2394	60	107	arbitrarily	arbitrarily	ADV
ajlm-2394	60	108	subdivided	subdivide	VERB
ajlm-2394	60	109	them	they	PRON
ajlm-2394	60	110	into	into	ADP
ajlm-2394	60	111	categories	category	NOUN
ajlm-2394	60	112	of	of	ADP
ajlm-2394	60	113	aml	aml	PROPN
ajlm-2394	60	114	‘	'	PUNCT
ajlm-2394	60	115	m0	m0	NOUN
ajlm-2394	60	116	-	-	PUNCT
ajlm-2394	60	117	2	2	NUM
ajlm-2394	60	118	-	-	PUNCT
ajlm-2394	60	119	like	like	ADJ
ajlm-2394	60	120	’	'	PUNCT
ajlm-2394	60	121	leukaemias	leukaemia	VERB
ajlm-2394	60	122	(	(	PUNCT
ajlm-2394	60	123	with	with	ADP
ajlm-2394	60	124	phenotypes	phenotype	NOUN
ajlm-2394	60	125	of	of	ADP
ajlm-2394	60	126	either	either	CCONJ
ajlm-2394	60	127	aml	aml	PROPN
ajlm-2394	60	128	m0	m0	PROPN
ajlm-2394	60	129	,	,	PUNCT
ajlm-2394	60	130	m1	m1	PROPN
ajlm-2394	60	131	or	or	CCONJ
ajlm-2394	60	132	m2	m2	PROPN
ajlm-2394	60	133	)	)	PUNCT
ajlm-2394	60	134	,	,	PUNCT
ajlm-2394	60	135	‘	'	PUNCT
ajlm-2394	60	136	m3	m3	X
ajlm-2394	60	137	-	-	PUNCT
ajlm-2394	60	138	like	like	ADJ
ajlm-2394	60	139	’	'	PUNCT
ajlm-2394	60	140	,	,	PUNCT
ajlm-2394	60	141	‘	'	PUNCT
ajlm-2394	60	142	m4	m4	VERB
ajlm-2394	60	143	-	-	PUNCT
ajlm-2394	60	144	like	like	ADJ
ajlm-2394	60	145	’	'	PUNCT
ajlm-2394	60	146	and	and	CCONJ
ajlm-2394	60	147	‘	'	PUNCT
ajlm-2394	60	148	m5	m5	NOUN
ajlm-2394	60	149	-	-	PUNCT
ajlm-2394	60	150	like	like	ADJ
ajlm-2394	60	151	’	'	PUNCT
ajlm-2394	60	152	,	,	PUNCT
ajlm-2394	60	153	based	base	VERB
ajlm-2394	60	154	on	on	ADP
ajlm-2394	60	155	the	the	DET
ajlm-2394	60	156	percentage	percentage	NOUN
ajlm-2394	60	157	of	of	ADP
ajlm-2394	60	158	cases	case	NOUN
ajlm-2394	60	159	with	with	ADP
ajlm-2394	60	160	positive	positive	ADJ
ajlm-2394	60	161	(	(	PUNCT
ajlm-2394	60	162	>	>	SYM
ajlm-2394	60	163	20	20	NUM
ajlm-2394	60	164	%	%	NOUN
ajlm-2394	60	165	)	)	PUNCT
ajlm-2394	60	166	leukaemia	leukaemia	NOUN
ajlm-2394	60	167	cells	cell	NOUN
ajlm-2394	60	168	and/or	and/or	CCONJ
ajlm-2394	60	169	the	the	DET
ajlm-2394	60	170	percentage	percentage	NOUN
ajlm-2394	60	171	of	of	ADP
ajlm-2394	60	172	leukaemia	leukaemia	NOUN
ajlm-2394	60	173	cells	cell	NOUN
ajlm-2394	60	174	positive	positive	ADJ
ajlm-2394	60	175	across	across	ADP
ajlm-2394	60	176	those	those	DET
ajlm-2394	60	177	patients	patient	NOUN
ajlm-2394	60	178	.	.	PUNCT
ajlm-2394	61	1	moreover	moreover	ADV
ajlm-2394	61	2	,	,	PUNCT
ajlm-2394	61	3	we	we	PRON
ajlm-2394	61	4	provisionally	provisionally	ADV
ajlm-2394	61	5	defined	define	VERB
ajlm-2394	61	6	cases	case	NOUN
ajlm-2394	61	7	that	that	PRON
ajlm-2394	61	8	did	do	AUX
ajlm-2394	61	9	not	not	PART
ajlm-2394	61	10	exhibit	exhibit	VERB
ajlm-2394	61	11	a	a	DET
ajlm-2394	61	12	straightforward	straightforward	ADJ
ajlm-2394	61	13	lineage	lineage	NOUN
ajlm-2394	61	14	commitment	commitment	NOUN
ajlm-2394	61	15	,	,	PUNCT
ajlm-2394	61	16	as	as	ADP
ajlm-2394	61	17	acute	acute	PROPN
ajlm-2394	61	18	leukaemia	leukaemia	NOUN
ajlm-2394	61	19	non	non	ADJ
ajlm-2394	61	20	-	-	ADJ
ajlm-2394	61	21	otherwise	otherwise	ADV
ajlm-2394	61	22	specified.13	specified.13	NOUN
ajlm-2394	61	23	results	result	NOUN
ajlm-2394	61	24	demographic	demographic	ADJ
ajlm-2394	61	25	,	,	PUNCT
ajlm-2394	61	26	clinical	clinical	ADJ
ajlm-2394	61	27	and	and	CCONJ
ajlm-2394	61	28	flow	flow	NOUN
ajlm-2394	61	29	cytometry	cytometry	ADJ
ajlm-2394	61	30	characteristics	characteristic	NOUN
ajlm-2394	61	31	out	out	ADP
ajlm-2394	61	32	of	of	ADP
ajlm-2394	61	33	a	a	DET
ajlm-2394	61	34	total	total	NOUN
ajlm-2394	61	35	of	of	ADP
ajlm-2394	61	36	140	140	NUM
ajlm-2394	61	37	patients	patient	NOUN
ajlm-2394	61	38	,	,	PUNCT
ajlm-2394	61	39	the	the	DET
ajlm-2394	61	40	ages	age	NOUN
ajlm-2394	61	41	ranged	range	VERB
ajlm-2394	61	42	from	from	ADP
ajlm-2394	61	43	13	13	NUM
ajlm-2394	61	44	to	to	PART
ajlm-2394	61	45	76	76	NUM
ajlm-2394	61	46	years	year	NOUN
ajlm-2394	61	47	,	,	PUNCT
ajlm-2394	61	48	with	with	ADP
ajlm-2394	61	49	a	a	DET
ajlm-2394	61	50	median	median	NOUN
ajlm-2394	61	51	of	of	ADP
ajlm-2394	61	52	25	25	NUM
ajlm-2394	61	53	(	(	PUNCT
ajlm-2394	61	54	interquartile	interquartile	NOUN
ajlm-2394	61	55	range	range	NOUN
ajlm-2394	61	56	:	:	PUNCT
ajlm-2394	61	57	18–35	18–35	NUM
ajlm-2394	61	58	)	)	PUNCT
ajlm-2394	61	59	(	(	PUNCT
ajlm-2394	61	60	table	table	NOUN
ajlm-2394	61	61	1	1	NUM
ajlm-2394	61	62	)	)	PUNCT
ajlm-2394	61	63	.	.	PUNCT
ajlm-2394	62	1	sixty	sixty	NUM
ajlm-2394	62	2	-	-	PUNCT
ajlm-2394	62	3	two	two	NUM
ajlm-2394	62	4	per	per	ADP
ajlm-2394	62	5	cent	cent	NOUN
ajlm-2394	62	6	(	(	PUNCT
ajlm-2394	62	7	46/74	46/74	NUM
ajlm-2394	62	8	)	)	PUNCT
ajlm-2394	62	9	of	of	ADP
ajlm-2394	62	10	male	male	ADJ
ajlm-2394	62	11	patients	patient	NOUN
ajlm-2394	62	12	and	and	CCONJ
ajlm-2394	62	13	54.5	54.5	NUM
ajlm-2394	62	14	%	%	NOUN
ajlm-2394	62	15	(	(	PUNCT
ajlm-2394	62	16	36/66	36/66	NUM
ajlm-2394	62	17	)	)	PUNCT
ajlm-2394	62	18	of	of	ADP
ajlm-2394	62	19	female	female	ADJ
ajlm-2394	62	20	patients	patient	NOUN
ajlm-2394	62	21	were	be	AUX
ajlm-2394	62	22	within	within	ADP
ajlm-2394	62	23	the	the	DET
ajlm-2394	62	24	age	age	NOUN
ajlm-2394	62	25	group	group	NOUN
ajlm-2394	62	26	of	of	ADP
ajlm-2394	62	27	18	18	NUM
ajlm-2394	62	28	years	year	NOUN
ajlm-2394	62	29	–	–	PUNCT
ajlm-2394	62	30	39	39	NUM
ajlm-2394	62	31	years	year	NOUN
ajlm-2394	62	32	(	(	PUNCT
ajlm-2394	62	33	data	datum	NOUN
ajlm-2394	62	34	not	not	PART
ajlm-2394	62	35	shown	show	VERB
ajlm-2394	62	36	in	in	ADP
ajlm-2394	62	37	table	table	NOUN
ajlm-2394	62	38	)	)	PUNCT
ajlm-2394	62	39	.	.	PUNCT
ajlm-2394	63	1	no	no	DET
ajlm-2394	63	2	statistically	statistically	ADV
ajlm-2394	63	3	significance	significance	NOUN
ajlm-2394	63	4	associations	association	NOUN
ajlm-2394	63	5	were	be	AUX
ajlm-2394	63	6	found	find	VERB
ajlm-2394	63	7	between	between	ADP
ajlm-2394	63	8	gender	gender	NOUN
ajlm-2394	63	9	and	and	CCONJ
ajlm-2394	63	10	acute	acute	ADJ
ajlm-2394	63	11	leukaemia	leukaemia	NOUN
ajlm-2394	63	12	types	type	NOUN
ajlm-2394	63	13	or	or	CCONJ
ajlm-2394	63	14	subtypes	subtype	NOUN
ajlm-2394	63	15	.	.	PUNCT
ajlm-2394	64	1	the	the	DET
ajlm-2394	64	2	majority	majority	NOUN
ajlm-2394	64	3	of	of	ADP
ajlm-2394	64	4	patients	patient	NOUN
ajlm-2394	64	5	clinically	clinically	ADV
ajlm-2394	64	6	presented	present	VERB
ajlm-2394	64	7	with	with	ADP
ajlm-2394	64	8	anaemia	anaemia	NOUN
ajlm-2394	64	9	(	(	PUNCT
ajlm-2394	64	10	71.4	71.4	NUM
ajlm-2394	64	11	%	%	NOUN
ajlm-2394	64	12	)	)	PUNCT
ajlm-2394	64	13	.	.	PUNCT
ajlm-2394	65	1	based	base	VERB
ajlm-2394	65	2	on	on	ADP
ajlm-2394	65	3	flow	flow	NOUN
ajlm-2394	65	4	cytometry	cytometry	NOUN
ajlm-2394	65	5	analysis	analysis	NOUN
ajlm-2394	65	6	,	,	PUNCT
ajlm-2394	65	7	out	out	ADP
ajlm-2394	65	8	of	of	ADP
ajlm-2394	65	9	140	140	NUM
ajlm-2394	65	10	cases	case	NOUN
ajlm-2394	65	11	,	,	PUNCT
ajlm-2394	65	12	68	68	NUM
ajlm-2394	65	13	(	(	PUNCT
ajlm-2394	65	14	49	49	NUM
ajlm-2394	65	15	%	%	NOUN
ajlm-2394	65	16	)	)	PUNCT
ajlm-2394	65	17	were	be	AUX
ajlm-2394	65	18	identified	identify	VERB
ajlm-2394	65	19	as	as	ADP
ajlm-2394	65	20	all	all	PRON
ajlm-2394	65	21	(	(	PUNCT
ajlm-2394	65	22	b	b	NOUN
ajlm-2394	65	23	-	-	PUNCT
ajlm-2394	65	24	cell	cell	NOUN
ajlm-2394	65	25	and	and	CCONJ
ajlm-2394	65	26	t	t	NOUN
ajlm-2394	65	27	-	-	PUNCT
ajlm-2394	65	28	cell	cell	NOUN
ajlm-2394	65	29	)	)	PUNCT
ajlm-2394	65	30	,	,	PUNCT
ajlm-2394	65	31	and	and	CCONJ
ajlm-2394	65	32	65	65	NUM
ajlm-2394	65	33	(	(	PUNCT
ajlm-2394	65	34	46	46	NUM
ajlm-2394	65	35	%	%	NOUN
ajlm-2394	65	36	)	)	PUNCT
ajlm-2394	65	37	as	as	ADP
ajlm-2394	65	38	aml	aml	PROPN
ajlm-2394	65	39	.	.	PUNCT
ajlm-2394	66	1	seven	seven	NUM
ajlm-2394	66	2	(	(	PUNCT
ajlm-2394	66	3	5	5	NUM
ajlm-2394	66	4	%	%	NOUN
ajlm-2394	66	5	)	)	PUNCT
ajlm-2394	66	6	cases	case	NOUN
ajlm-2394	66	7	were	be	AUX
ajlm-2394	66	8	acute	acute	ADJ
ajlm-2394	66	9	leukaemia	leukaemia	NOUN
ajlm-2394	66	10	non	non	ADJ
ajlm-2394	66	11	-	-	ADJ
ajlm-2394	66	12	otherwise	otherwise	ADV
ajlm-2394	66	13	specified	specify	VERB
ajlm-2394	66	14	,	,	PUNCT
ajlm-2394	66	15	although	although	SCONJ
ajlm-2394	66	16	two	two	NUM
ajlm-2394	66	17	cases	case	NOUN
ajlm-2394	66	18	appeared	appear	VERB
ajlm-2394	66	19	to	to	PART
ajlm-2394	66	20	meet	meet	VERB
ajlm-2394	66	21	requirements	requirement	NOUN
ajlm-2394	66	22	for	for	ADP
ajlm-2394	66	23	mixed	mixed	ADJ
ajlm-2394	66	24	lineage	lineage	NOUN
ajlm-2394	66	25	(	(	PUNCT
ajlm-2394	66	26	table	table	NOUN
ajlm-2394	66	27	1	1	NUM
ajlm-2394	66	28	)	)	PUNCT
ajlm-2394	66	29	.	.	PUNCT
ajlm-2394	67	1	comparison	comparison	NOUN
ajlm-2394	67	2	of	of	ADP
ajlm-2394	67	3	flow	flow	NOUN
ajlm-2394	67	4	cytometry	cytometry	NOUN
ajlm-2394	67	5	classification	classification	NOUN
ajlm-2394	67	6	with	with	ADP
ajlm-2394	67	7	independent	independent	ADJ
ajlm-2394	67	8	classification	classification	NOUN
ajlm-2394	67	9	into	into	ADP
ajlm-2394	67	10	aml	aml	NOUN
ajlm-2394	67	11	and	and	CCONJ
ajlm-2394	67	12	all	all	PRON
ajlm-2394	67	13	,	,	PUNCT
ajlm-2394	67	14	using	use	VERB
ajlm-2394	67	15	morphology	morphology	NOUN
ajlm-2394	67	16	of	of	ADP
ajlm-2394	67	17	bone	bone	NOUN
ajlm-2394	67	18	marrow	marrow	NOUN
ajlm-2394	67	19	smears	smear	NOUN
ajlm-2394	67	20	,	,	PUNCT
ajlm-2394	67	21	gave	give	VERB
ajlm-2394	67	22	a	a	DET
ajlm-2394	67	23	concordance	concordance	NOUN
ajlm-2394	67	24	of	of	ADP
ajlm-2394	67	25	72	72	NUM
ajlm-2394	67	26	%	%	NOUN
ajlm-2394	67	27	.	.	PUNCT
ajlm-2394	68	1	leukaemia	leukaemia	NOUN
ajlm-2394	68	2	and	and	CCONJ
ajlm-2394	68	3	age	age	NOUN
ajlm-2394	68	4	were	be	AUX
ajlm-2394	68	5	significantly	significantly	ADV
ajlm-2394	68	6	associated	associate	VERB
ajlm-2394	68	7	(	(	PUNCT
ajlm-2394	68	8	p	p	X
ajlm-2394	68	9	<	<	X
ajlm-2394	68	10	0.001	0.001	NUM
ajlm-2394	68	11	)	)	PUNCT
ajlm-2394	68	12	.	.	PUNCT
ajlm-2394	69	1	low	low	ADJ
ajlm-2394	69	2	haemoglobin	haemoglobin	PROPN
ajlm-2394	69	3	and	and	CCONJ
ajlm-2394	69	4	high	high	ADJ
ajlm-2394	69	5	white	white	ADJ
ajlm-2394	69	6	blood	blood	NOUN
ajlm-2394	69	7	count	count	NOUN
ajlm-2394	69	8	levels	level	NOUN
ajlm-2394	69	9	were	be	AUX
ajlm-2394	69	10	detected	detect	VERB
ajlm-2394	69	11	across	across	ADP
ajlm-2394	69	12	all	all	DET
ajlm-2394	69	13	leukaemia	leukaemia	NOUN
ajlm-2394	69	14	types	type	NOUN
ajlm-2394	69	15	,	,	PUNCT
ajlm-2394	69	16	without	without	ADP
ajlm-2394	69	17	statistically	statistically	ADV
ajlm-2394	69	18	significant	significant	ADJ
ajlm-2394	69	19	differences	difference	NOUN
ajlm-2394	69	20	.	.	PUNCT
ajlm-2394	70	1	the	the	DET
ajlm-2394	70	2	highest	high	ADJ
ajlm-2394	70	3	platelet	platelet	NOUN
ajlm-2394	70	4	counts	count	NOUN
ajlm-2394	70	5	were	be	AUX
ajlm-2394	70	6	found	find	VERB
ajlm-2394	70	7	among	among	ADP
ajlm-2394	70	8	t	t	PROPN
ajlm-2394	70	9	-	-	PUNCT
ajlm-2394	70	10	all	all	DET
ajlm-2394	70	11	cases	case	NOUN
ajlm-2394	70	12	.	.	PUNCT
ajlm-2394	71	1	table	table	NOUN
ajlm-2394	71	2	1	1	NUM
ajlm-2394	71	3	:	:	PUNCT
ajlm-2394	71	4	 	 	SPACE
ajlm-2394	71	5	demographic	demographic	ADJ
ajlm-2394	71	6	,	,	PUNCT
ajlm-2394	71	7	complete	complete	ADJ
ajlm-2394	71	8	blood	blood	NOUN
ajlm-2394	71	9	counts	count	NOUN
ajlm-2394	71	10	(	(	PUNCT
ajlm-2394	71	11	haemoglobin	haemoglobin	PROPN
ajlm-2394	71	12	,	,	PUNCT
ajlm-2394	71	13	white	white	ADJ
ajlm-2394	71	14	blood	blood	NOUN
ajlm-2394	71	15	count	count	NOUN
ajlm-2394	71	16	,	,	PUNCT
ajlm-2394	71	17	and	and	CCONJ
ajlm-2394	71	18	platelet	platelet	NOUN
ajlm-2394	71	19	count	count	NOUN
ajlm-2394	71	20	)	)	PUNCT
ajlm-2394	71	21	and	and	CCONJ
ajlm-2394	71	22	acute	acute	ADJ
ajlm-2394	71	23	leukaemia	leukaemia	NOUN
ajlm-2394	71	24	types	type	NOUN
ajlm-2394	71	25	among	among	ADP
ajlm-2394	71	26	adolescent	adolescent	ADJ
ajlm-2394	71	27	and	and	CCONJ
ajlm-2394	71	28	adult	adult	NOUN
ajlm-2394	71	29	acute	acute	NOUN
ajlm-2394	71	30	leukaemia	leukaemia	NOUN
ajlm-2394	71	31	patients	patient	NOUN
ajlm-2394	71	32	before	before	ADP
ajlm-2394	71	33	chemotherapy	chemotherapy	VERB
ajlm-2394	71	34	at	at	ADP
ajlm-2394	71	35	tikur	tikur	PROPN
ajlm-2394	71	36	anbessa	anbessa	ADJ
ajlm-2394	71	37	specialised	specialised	ADJ
ajlm-2394	71	38	hospital	hospital	NOUN
ajlm-2394	71	39	,	,	PUNCT
ajlm-2394	71	40	addis	addis	PROPN
ajlm-2394	71	41	ababa	ababa	PROPN
ajlm-2394	71	42	,	,	PUNCT
ajlm-2394	71	43	ethiopia	ethiopia	PROPN
ajlm-2394	71	44	,	,	PUNCT
ajlm-2394	71	45	april	april	PROPN
ajlm-2394	71	46	2019	2019	NUM
ajlm-2394	71	47	to	to	ADP
ajlm-2394	71	48	june	june	PROPN
ajlm-2394	71	49	2021	2021	NUM
ajlm-2394	71	50	.	.	PUNCT
ajlm-2394	72	1	expression	expression	NOUN
ajlm-2394	72	2	of	of	ADP
ajlm-2394	72	3	markers	marker	NOUN
ajlm-2394	72	4	in	in	ADP
ajlm-2394	72	5	acute	acute	ADJ
ajlm-2394	72	6	leukaemia	leukaemia	NOUN
ajlm-2394	72	7	types	type	NOUN
ajlm-2394	72	8	,	,	PUNCT
ajlm-2394	72	9	subtypes	subtype	NOUN
ajlm-2394	72	10	and	and	CCONJ
ajlm-2394	72	11	subsets	subset	NOUN
ajlm-2394	72	12	nearly	nearly	ADV
ajlm-2394	72	13	all	all	ADV
ajlm-2394	72	14	(	(	PUNCT
ajlm-2394	72	15	96	96	NUM
ajlm-2394	72	16	%	%	NOUN
ajlm-2394	72	17	)	)	PUNCT
ajlm-2394	73	1	b	b	X
ajlm-2394	73	2	-	-	PUNCT
ajlm-2394	73	3	all	all	DET
ajlm-2394	73	4	patients	patient	NOUN
ajlm-2394	73	5	were	be	AUX
ajlm-2394	73	6	positive	positive	ADJ
ajlm-2394	73	7	for	for	ADP
ajlm-2394	73	8	all	all	DET
ajlm-2394	73	9	three	three	NUM
ajlm-2394	73	10	b	b	NOUN
ajlm-2394	73	11	lineage	lineage	NOUN
ajlm-2394	73	12	markers	marker	NOUN
ajlm-2394	73	13	(	(	PUNCT
ajlm-2394	73	14	cd19	cd19	PROPN
ajlm-2394	73	15	,	,	PUNCT
ajlm-2394	73	16	ccd79a	ccd79a	NOUN
ajlm-2394	73	17	,	,	PUNCT
ajlm-2394	73	18	cd22	cd22	PROPN
ajlm-2394	73	19	)	)	PUNCT
ajlm-2394	73	20	.	.	PUNCT
ajlm-2394	74	1	importantly	importantly	ADV
ajlm-2394	74	2	,	,	PUNCT
ajlm-2394	74	3	none	none	NOUN
ajlm-2394	74	4	of	of	ADP
ajlm-2394	74	5	the	the	DET
ajlm-2394	74	6	‘	'	PUNCT
ajlm-2394	74	7	b	b	X
ajlm-2394	74	8	-	-	PUNCT
ajlm-2394	74	9	cell	cell	NOUN
ajlm-2394	74	10	specific	specific	ADJ
ajlm-2394	74	11	’	'	PUNCT
ajlm-2394	74	12	markers	marker	NOUN
ajlm-2394	74	13	was	be	AUX
ajlm-2394	74	14	uniquely	uniquely	ADV
ajlm-2394	74	15	specific	specific	ADJ
ajlm-2394	74	16	to	to	ADP
ajlm-2394	74	17	b	b	X
ajlm-2394	74	18	-	-	PUNCT
ajlm-2394	74	19	all	all	PRON
ajlm-2394	74	20	.	.	PUNCT
ajlm-2394	75	1	a	a	DET
ajlm-2394	75	2	number	number	NOUN
ajlm-2394	75	3	of	of	ADP
ajlm-2394	75	4	cases	case	NOUN
ajlm-2394	75	5	of	of	ADP
ajlm-2394	75	6	t	t	PROPN
ajlm-2394	75	7	-	-	PUNCT
ajlm-2394	75	8	all	all	PRON
ajlm-2394	75	9	expressed	express	VERB
ajlm-2394	75	10	myeloid	myeloid	ADJ
ajlm-2394	75	11	markers	marker	NOUN
ajlm-2394	75	12	.	.	PUNCT
ajlm-2394	76	1	acute	acute	ADJ
ajlm-2394	76	2	myelogenous	myelogenous	ADJ
ajlm-2394	76	3	leukaemia	leukaemia	NOUN
ajlm-2394	76	4	was	be	AUX
ajlm-2394	76	5	observed	observe	VERB
ajlm-2394	76	6	to	to	PART
ajlm-2394	76	7	be	be	AUX
ajlm-2394	76	8	positive	positive	ADJ
ajlm-2394	76	9	for	for	ADP
ajlm-2394	76	10	cd117	cd117	PROPN
ajlm-2394	76	11	,	,	PUNCT
ajlm-2394	76	12	cd34	cd34	PROPN
ajlm-2394	76	13	and	and	CCONJ
ajlm-2394	76	14	cmpo	cmpo	NOUN
ajlm-2394	76	15	(	(	PUNCT
ajlm-2394	76	16	table	table	NOUN
ajlm-2394	76	17	2	2	NUM
ajlm-2394	76	18	)	)	PUNCT
ajlm-2394	76	19	.	.	PUNCT
ajlm-2394	77	1	among	among	ADP
ajlm-2394	77	2	b	b	X
ajlm-2394	77	3	-	-	PUNCT
ajlm-2394	77	4	all	all	PRON
ajlm-2394	77	5	,	,	PUNCT
ajlm-2394	77	6	42	42	NUM
ajlm-2394	77	7	%	%	NOUN
ajlm-2394	77	8	were	be	AUX
ajlm-2394	77	9	positive	positive	ADJ
ajlm-2394	77	10	for	for	SCONJ
ajlm-2394	77	11	the	the	DET
ajlm-2394	77	12	aberrantly	aberrantly	ADV
ajlm-2394	77	13	expressed	express	VERB
ajlm-2394	77	14	myeloid	myeloid	ADJ
ajlm-2394	77	15	marker	marker	NOUN
ajlm-2394	77	16	,	,	PUNCT
ajlm-2394	77	17	cd66c	cd66c	NOUN
ajlm-2394	77	18	,	,	PUNCT
ajlm-2394	77	19	together	together	ADV
ajlm-2394	77	20	with	with	ADP
ajlm-2394	77	21	cd34	cd34	PROPN
ajlm-2394	77	22	and	and	CCONJ
ajlm-2394	77	23	cd10	cd10	PROPN
ajlm-2394	77	24	(	(	PUNCT
ajlm-2394	77	25	21/50	21/50	NUM
ajlm-2394	77	26	)	)	PUNCT
ajlm-2394	77	27	,	,	PUNCT
ajlm-2394	77	28	10	10	NUM
ajlm-2394	77	29	%	%	NOUN
ajlm-2394	77	30	with	with	ADP
ajlm-2394	77	31	cd34+/cd10+/cd66c	cd34+/cd10+/cd66c	PROPN
ajlm-2394	77	32	–	–	PUNCT
ajlm-2394	77	33	(	(	PUNCT
ajlm-2394	77	34	5/50	5/50	NUM
ajlm-2394	77	35	)	)	PUNCT
ajlm-2394	77	36	,	,	PUNCT
ajlm-2394	77	37	6	6	NUM
ajlm-2394	77	38	%	%	NOUN
ajlm-2394	77	39	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	77	40	–	–	PUNCT
ajlm-2394	77	41	(	(	PUNCT
ajlm-2394	77	42	3/50	3/50	NUM
ajlm-2394	77	43	)	)	PUNCT
ajlm-2394	77	44	and	and	CCONJ
ajlm-2394	77	45	32	32	NUM
ajlm-2394	77	46	%	%	NOUN
ajlm-2394	77	47	cd34–/cd10	cd34–/cd10	NOUN
ajlm-2394	77	48	+	+	X
ajlm-2394	77	49	(	(	PUNCT
ajlm-2394	77	50	16/50	16/50	NUM
ajlm-2394	77	51	)	)	PUNCT
ajlm-2394	77	52	.	.	PUNCT
ajlm-2394	78	1	one	one	NUM
ajlm-2394	78	2	of	of	ADP
ajlm-2394	78	3	the	the	DET
ajlm-2394	78	4	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	78	5	–	–	PUNCT
ajlm-2394	78	6	cases	case	NOUN
ajlm-2394	78	7	was	be	AUX
ajlm-2394	78	8	cd66c	cd66c	ADV
ajlm-2394	78	9	positive	positive	ADJ
ajlm-2394	78	10	,	,	PUNCT
ajlm-2394	78	11	while	while	SCONJ
ajlm-2394	78	12	of	of	ADP
ajlm-2394	78	13	the	the	DET
ajlm-2394	78	14	cd34–/cd10	cd34–/cd10	PROPN
ajlm-2394	78	15	+	+	PROPN
ajlm-2394	78	16	subset	subset	NOUN
ajlm-2394	78	17	,	,	PUNCT
ajlm-2394	78	18	29	29	NUM
ajlm-2394	78	19	%	%	NOUN
ajlm-2394	78	20	were	be	AUX
ajlm-2394	78	21	cd66c	cd66c	ADV
ajlm-2394	78	22	positive	positive	ADJ
ajlm-2394	78	23	(	(	PUNCT
ajlm-2394	78	24	table	table	NOUN
ajlm-2394	78	25	3	3	NUM
ajlm-2394	78	26	)	)	PUNCT
ajlm-2394	78	27	.	.	PUNCT
ajlm-2394	79	1	among	among	ADP
ajlm-2394	79	2	scd3	scd3	PROPN
ajlm-2394	79	3	positive	positive	PROPN
ajlm-2394	79	4	t	t	PROPN
ajlm-2394	79	5	-	-	PUNCT
ajlm-2394	79	6	all	all	PRON
ajlm-2394	79	7	,	,	PUNCT
ajlm-2394	79	8	the	the	DET
ajlm-2394	79	9	average	average	ADJ
ajlm-2394	79	10	percentage	percentage	NOUN
ajlm-2394	79	11	of	of	ADP
ajlm-2394	79	12	scd3	scd3	ADJ
ajlm-2394	79	13	positive	positive	ADJ
ajlm-2394	79	14	cells	cell	NOUN
ajlm-2394	79	15	(	(	PUNCT
ajlm-2394	79	16	79.4	79.4	NUM
ajlm-2394	79	17	%	%	NOUN
ajlm-2394	79	18	)	)	PUNCT
ajlm-2394	79	19	was	be	AUX
ajlm-2394	79	20	less	less	ADJ
ajlm-2394	79	21	than	than	SCONJ
ajlm-2394	79	22	the	the	DET
ajlm-2394	79	23	average	average	ADJ
ajlm-2394	79	24	ccd3	ccd3	VERB
ajlm-2394	79	25	positive	positive	ADJ
ajlm-2394	79	26	cells	cell	NOUN
ajlm-2394	79	27	(	(	PUNCT
ajlm-2394	79	28	99	99	NUM
ajlm-2394	79	29	%	%	NOUN
ajlm-2394	79	30	)	)	PUNCT
ajlm-2394	79	31	,	,	PUNCT
ajlm-2394	79	32	and	and	CCONJ
ajlm-2394	79	33	scd3	scd3	PROPN
ajlm-2394	79	34	was	be	AUX
ajlm-2394	79	35	an	an	DET
ajlm-2394	79	36	average	average	NOUN
ajlm-2394	79	37	of	of	ADP
ajlm-2394	79	38	2.8	2.8	NUM
ajlm-2394	79	39	-	-	NUM
ajlm-2394	79	40	fold	fold	VERB
ajlm-2394	79	41	lower	lower	ADV
ajlm-2394	79	42	in	in	ADP
ajlm-2394	79	43	density	density	NOUN
ajlm-2394	79	44	than	than	ADP
ajlm-2394	79	45	that	that	PRON
ajlm-2394	79	46	of	of	ADP
ajlm-2394	79	47	ccd3	ccd3	PROPN
ajlm-2394	79	48	;	;	PUNCT
ajlm-2394	79	49	this	this	DET
ajlm-2394	79	50	difference	difference	NOUN
ajlm-2394	79	51	was	be	AUX
ajlm-2394	79	52	not	not	PART
ajlm-2394	79	53	observed	observe	VERB
ajlm-2394	79	54	among	among	ADP
ajlm-2394	79	55	mature	mature	ADJ
ajlm-2394	79	56	t	t	PROPN
ajlm-2394	79	57	-	-	PUNCT
ajlm-2394	79	58	cells	cell	NOUN
ajlm-2394	79	59	in	in	ADP
ajlm-2394	79	60	the	the	DET
ajlm-2394	79	61	same	same	ADJ
ajlm-2394	79	62	samples	sample	NOUN
ajlm-2394	79	63	(	(	PUNCT
ajlm-2394	79	64	data	datum	NOUN
ajlm-2394	79	65	not	not	PART
ajlm-2394	79	66	shown	show	VERB
ajlm-2394	79	67	)	)	PUNCT
ajlm-2394	79	68	.	.	PUNCT
ajlm-2394	80	1	notably	notably	ADV
ajlm-2394	80	2	,	,	PUNCT
ajlm-2394	80	3	cmpo	cmpo	VERB
ajlm-2394	80	4	density	density	NOUN
ajlm-2394	80	5	among	among	ADP
ajlm-2394	80	6	cmpo	cmpo	NOUN
ajlm-2394	80	7	-	-	PUNCT
ajlm-2394	80	8	positive	positive	ADJ
ajlm-2394	80	9	t	t	NOUN
ajlm-2394	80	10	-	-	PUNCT
ajlm-2394	80	11	all	all	DET
ajlm-2394	80	12	leukaemias	leukaemia	NOUN
ajlm-2394	80	13	was	be	AUX
ajlm-2394	80	14	substantially	substantially	ADV
ajlm-2394	80	15	5.4	5.4	NUM
ajlm-2394	80	16	times	time	NOUN
ajlm-2394	80	17	less	less	ADJ
ajlm-2394	80	18	than	than	ADP
ajlm-2394	80	19	that	that	PRON
ajlm-2394	80	20	of	of	ADP
ajlm-2394	80	21	cmpo	cmpo	NOUN
ajlm-2394	80	22	-	-	PUNCT
ajlm-2394	80	23	positive	positive	ADJ
ajlm-2394	80	24	aml	aml	NOUN
ajlm-2394	80	25	cases	case	NOUN
ajlm-2394	80	26	(	(	PUNCT
ajlm-2394	80	27	p	p	X
ajlm-2394	80	28	<	<	X
ajlm-2394	80	29	0.001	0.001	NUM
ajlm-2394	80	30	)	)	PUNCT
ajlm-2394	80	31	(	(	PUNCT
ajlm-2394	80	32	table	table	NOUN
ajlm-2394	80	33	2	2	NUM
ajlm-2394	80	34	)	)	PUNCT
ajlm-2394	80	35	.	.	PUNCT
ajlm-2394	81	1	table	table	NOUN
ajlm-2394	81	2	2	2	NUM
ajlm-2394	81	3	:	:	PUNCT
ajlm-2394	81	4	 	 	SPACE
ajlm-2394	81	5	percentage	percentage	NOUN
ajlm-2394	81	6	of	of	ADP
ajlm-2394	81	7	patients	patient	NOUN
ajlm-2394	81	8	who	who	PRON
ajlm-2394	81	9	tested	test	VERB
ajlm-2394	81	10	positive	positive	ADJ
ajlm-2394	81	11	for	for	ADP
ajlm-2394	81	12	indicated	indicate	VERB
ajlm-2394	81	13	markers	marker	NOUN
ajlm-2394	81	14	among	among	ADP
ajlm-2394	81	15	acute	acute	ADJ
ajlm-2394	81	16	leukaemia	leukaemia	NOUN
ajlm-2394	81	17	cases	case	NOUN
ajlm-2394	81	18	,	,	PUNCT
ajlm-2394	81	19	tikur	tikur	NOUN
ajlm-2394	81	20	anbessa	anbessa	ADJ
ajlm-2394	81	21	specialised	specialised	ADJ
ajlm-2394	81	22	hospital	hospital	NOUN
ajlm-2394	81	23	,	,	PUNCT
ajlm-2394	81	24	addis	addis	PROPN
ajlm-2394	81	25	ababa	ababa	PROPN
ajlm-2394	81	26	,	,	PUNCT
ajlm-2394	81	27	ethiopia	ethiopia	PROPN
ajlm-2394	81	28	,	,	PUNCT
ajlm-2394	81	29	april	april	PROPN
ajlm-2394	81	30	2019	2019	NUM
ajlm-2394	81	31	to	to	ADP
ajlm-2394	81	32	june	june	PROPN
ajlm-2394	81	33	2021	2021	NUM
ajlm-2394	81	34	.	.	PUNCT
ajlm-2394	82	1	table	table	NOUN
ajlm-2394	82	2	3	3	NUM
ajlm-2394	82	3	:	:	PUNCT
ajlm-2394	82	4	 	 	SPACE
ajlm-2394	82	5	percentage	percentage	NOUN
ajlm-2394	82	6	of	of	ADP
ajlm-2394	82	7	patients	patient	NOUN
ajlm-2394	82	8	positive	positive	ADJ
ajlm-2394	82	9	for	for	ADP
ajlm-2394	82	10	indicated	indicate	VERB
ajlm-2394	82	11	markers	marker	NOUN
ajlm-2394	82	12	among	among	ADP
ajlm-2394	82	13	b	b	NOUN
ajlm-2394	82	14	-	-	PUNCT
ajlm-2394	82	15	cell	cell	NOUN
ajlm-2394	82	16	acute	acute	ADJ
ajlm-2394	82	17	lymphocytic	lymphocytic	ADJ
ajlm-2394	82	18	leukaemia	leukaemia	NOUN
ajlm-2394	82	19	subsets	subset	NOUN
ajlm-2394	82	20	at	at	ADP
ajlm-2394	82	21	tikur	tikur	PROPN
ajlm-2394	82	22	anbessa	anbessa	ADJ
ajlm-2394	82	23	specialised	specialised	ADJ
ajlm-2394	82	24	hospital	hospital	NOUN
ajlm-2394	82	25	,	,	PUNCT
ajlm-2394	82	26	addis	addis	PROPN
ajlm-2394	82	27	ababa	ababa	PROPN
ajlm-2394	82	28	,	,	PUNCT
ajlm-2394	82	29	ethiopia	ethiopia	PROPN
ajlm-2394	82	30	,	,	PUNCT
ajlm-2394	82	31	april	april	PROPN
ajlm-2394	82	32	2019	2019	NUM
ajlm-2394	82	33	to	to	ADP
ajlm-2394	82	34	june	june	PROPN
ajlm-2394	82	35	2021	2021	NUM
ajlm-2394	82	36	.	.	PUNCT
ajlm-2394	83	1	distribution	distribution	NOUN
ajlm-2394	83	2	of	of	ADP
ajlm-2394	83	3	b	b	NOUN
ajlm-2394	83	4	-	-	PUNCT
ajlm-2394	83	5	cell	cell	NOUN
ajlm-2394	83	6	acute	acute	ADJ
ajlm-2394	83	7	lymphocytic	lymphocytic	ADJ
ajlm-2394	83	8	leukaemia	leukaemia	NOUN
ajlm-2394	83	9	subsets	subset	NOUN
ajlm-2394	83	10	in	in	ADP
ajlm-2394	83	11	age	age	NOUN
ajlm-2394	83	12	when	when	SCONJ
ajlm-2394	83	13	b	b	X
ajlm-2394	83	14	-	-	PUNCT
ajlm-2394	83	15	all	all	DET
ajlm-2394	83	16	subsets	subset	NOUN
ajlm-2394	83	17	were	be	AUX
ajlm-2394	83	18	stratified	stratify	VERB
ajlm-2394	83	19	according	accord	VERB
ajlm-2394	83	20	to	to	ADP
ajlm-2394	83	21	age	age	NOUN
ajlm-2394	83	22	,	,	PUNCT
ajlm-2394	83	23	among	among	ADP
ajlm-2394	83	24	b	b	X
ajlm-2394	83	25	-	-	PUNCT
ajlm-2394	83	26	all	all	DET
ajlm-2394	83	27	cases	case	NOUN
ajlm-2394	83	28	as	as	SCONJ
ajlm-2394	83	29	characterised	characterise	VERB
ajlm-2394	83	30	by	by	ADP
ajlm-2394	83	31	cd34	cd34	PROPN
ajlm-2394	83	32	,	,	PUNCT
ajlm-2394	83	33	cd10	cd10	PROPN
ajlm-2394	83	34	and	and	CCONJ
ajlm-2394	83	35	cd66	cd66	PROPN
ajlm-2394	83	36	markers	marker	NOUN
ajlm-2394	83	37	,	,	PUNCT
ajlm-2394	83	38	46	46	NUM
ajlm-2394	83	39	%	%	NOUN
ajlm-2394	83	40	(	(	PUNCT
ajlm-2394	83	41	6/13	6/13	NUM
ajlm-2394	83	42	)	)	PUNCT
ajlm-2394	83	43	of	of	ADP
ajlm-2394	83	44	adolescents	adolescent	NOUN
ajlm-2394	83	45	had	have	VERB
ajlm-2394	83	46	a	a	DET
ajlm-2394	83	47	cd34+/cd10+/cd66	cd34+/cd10+/cd66	NOUN
ajlm-2394	83	48	+	+	CCONJ
ajlm-2394	83	49	phenotype	phenotype	NOUN
ajlm-2394	83	50	and	and	CCONJ
ajlm-2394	83	51	8	8	NUM
ajlm-2394	83	52	%	%	NOUN
ajlm-2394	83	53	(	(	PUNCT
ajlm-2394	83	54	1/13	1/13	NUM
ajlm-2394	83	55	)	)	PUNCT
ajlm-2394	83	56	had	have	VERB
ajlm-2394	83	57	a	a	DET
ajlm-2394	83	58	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	83	59	–	–	PUNCT
ajlm-2394	83	60	phenotype	phenotype	NOUN
ajlm-2394	83	61	(	(	PUNCT
ajlm-2394	83	62	table	table	NOUN
ajlm-2394	83	63	4	4	NUM
ajlm-2394	83	64	)	)	PUNCT
ajlm-2394	83	65	.	.	PUNCT
ajlm-2394	84	1	moreover	moreover	ADV
ajlm-2394	84	2	,	,	PUNCT
ajlm-2394	84	3	41	41	NUM
ajlm-2394	84	4	%	%	NOUN
ajlm-2394	84	5	(	(	PUNCT
ajlm-2394	84	6	15/37	15/37	NUM
ajlm-2394	84	7	)	)	PUNCT
ajlm-2394	84	8	of	of	ADP
ajlm-2394	84	9	adult	adult	NOUN
ajlm-2394	84	10	cases	case	NOUN
ajlm-2394	84	11	had	have	VERB
ajlm-2394	84	12	a	a	DET
ajlm-2394	84	13	cd34+/cd10+/cd66	cd34+/cd10+/cd66	NOUN
ajlm-2394	84	14	+	+	CCONJ
ajlm-2394	84	15	phenotype	phenotype	NOUN
ajlm-2394	84	16	,	,	PUNCT
ajlm-2394	84	17	while	while	SCONJ
ajlm-2394	84	18	5	5	NUM
ajlm-2394	84	19	%	%	NOUN
ajlm-2394	84	20	(	(	PUNCT
ajlm-2394	84	21	2/37	2/37	NUM
ajlm-2394	84	22	)	)	PUNCT
ajlm-2394	84	23	were	be	AUX
ajlm-2394	84	24	cd34+/cd10–.	cd34+/cd10–.	VERB
ajlm-2394	84	25	importantly	importantly	ADV
ajlm-2394	84	26	,	,	PUNCT
ajlm-2394	84	27	there	there	PRON
ajlm-2394	84	28	were	be	VERB
ajlm-2394	84	29	no	no	DET
ajlm-2394	84	30	statistically	statistically	ADV
ajlm-2394	84	31	significant	significant	ADJ
ajlm-2394	84	32	differences	difference	NOUN
ajlm-2394	84	33	in	in	ADP
ajlm-2394	84	34	the	the	DET
ajlm-2394	84	35	distribution	distribution	NOUN
ajlm-2394	84	36	of	of	ADP
ajlm-2394	84	37	b	b	NOUN
ajlm-2394	84	38	-	-	PUNCT
ajlm-2394	84	39	all	all	DET
ajlm-2394	84	40	subsets	subset	NOUN
ajlm-2394	84	41	according	accord	VERB
ajlm-2394	84	42	to	to	ADP
ajlm-2394	84	43	age	age	NOUN
ajlm-2394	84	44	(	(	PUNCT
ajlm-2394	84	45	p	p	X
ajlm-2394	84	46	=	=	NOUN
ajlm-2394	84	47	0.93	0.93	NUM
ajlm-2394	84	48	)	)	PUNCT
ajlm-2394	84	49	.	.	PUNCT
ajlm-2394	85	1	table	table	NOUN
ajlm-2394	85	2	4	4	NUM
ajlm-2394	85	3	:	:	PUNCT
ajlm-2394	85	4	 	 	SPACE
ajlm-2394	85	5	distribution	distribution	NOUN
ajlm-2394	85	6	of	of	ADP
ajlm-2394	85	7	b	b	NOUN
ajlm-2394	85	8	-	-	PUNCT
ajlm-2394	85	9	cell	cell	NOUN
ajlm-2394	85	10	acute	acute	ADJ
ajlm-2394	85	11	lymphocytic	lymphocytic	ADJ
ajlm-2394	85	12	leukaemia	leukaemia	NOUN
ajlm-2394	85	13	subsets	subset	NOUN
ajlm-2394	85	14	and	and	CCONJ
ajlm-2394	85	15	acute	acute	ADJ
ajlm-2394	85	16	myelogenous	myelogenous	ADJ
ajlm-2394	85	17	leukaemia	leukaemia	NOUN
ajlm-2394	85	18	subtypes	subtype	NOUN
ajlm-2394	85	19	among	among	ADP
ajlm-2394	85	20	acute	acute	ADJ
ajlm-2394	85	21	leukaemia	leukaemia	NOUN
ajlm-2394	85	22	patients	patient	NOUN
ajlm-2394	85	23	by	by	ADP
ajlm-2394	85	24	age	age	NOUN
ajlm-2394	85	25	group	group	NOUN
ajlm-2394	85	26	,	,	PUNCT
ajlm-2394	85	27	tikur	tikur	PROPN
ajlm-2394	85	28	anbessa	anbessa	ADJ
ajlm-2394	85	29	specialized	specialized	ADJ
ajlm-2394	85	30	hospital	hospital	NOUN
ajlm-2394	85	31	,	,	PUNCT
ajlm-2394	85	32	addis	addis	PROPN
ajlm-2394	85	33	ababa	ababa	PROPN
ajlm-2394	85	34	,	,	PUNCT
ajlm-2394	85	35	ethiopia	ethiopia	PROPN
ajlm-2394	85	36	,	,	PUNCT
ajlm-2394	85	37	april	april	PROPN
ajlm-2394	85	38	2019	2019	NUM
ajlm-2394	85	39	to	to	ADP
ajlm-2394	85	40	june	june	PROPN
ajlm-2394	85	41	2021	2021	NUM
ajlm-2394	85	42	.	.	PUNCT
ajlm-2394	86	1	when	when	SCONJ
ajlm-2394	86	2	comparing	compare	VERB
ajlm-2394	86	3	scd3	scd3	ADJ
ajlm-2394	86	4	negative	negative	ADJ
ajlm-2394	86	5	and	and	CCONJ
ajlm-2394	86	6	t	t	NOUN
ajlm-2394	86	7	-	-	PUNCT
ajlm-2394	86	8	all	all	DET
ajlm-2394	86	9	positive	positive	ADJ
ajlm-2394	86	10	phenotypes	phenotype	NOUN
ajlm-2394	86	11	,	,	PUNCT
ajlm-2394	86	12	20	20	NUM
ajlm-2394	86	13	%	%	NOUN
ajlm-2394	86	14	of	of	ADP
ajlm-2394	86	15	t	t	PROPN
ajlm-2394	86	16	-	-	PUNCT
ajlm-2394	86	17	all	all	DET
ajlm-2394	86	18	cases	case	NOUN
ajlm-2394	86	19	without	without	ADP
ajlm-2394	86	20	surface	surface	NOUN
ajlm-2394	86	21	cd3	cd3	PROPN
ajlm-2394	86	22	were	be	AUX
ajlm-2394	86	23	positive	positive	ADJ
ajlm-2394	86	24	for	for	ADP
ajlm-2394	86	25	cd13	cd13	PROPN
ajlm-2394	86	26	,	,	PUNCT
ajlm-2394	86	27	30	30	NUM
ajlm-2394	86	28	%	%	NOUN
ajlm-2394	86	29	were	be	AUX
ajlm-2394	86	30	positive	positive	ADJ
ajlm-2394	86	31	for	for	ADP
ajlm-2394	86	32	cd33	cd33	PROPN
ajlm-2394	86	33	,	,	PUNCT
ajlm-2394	86	34	and	and	CCONJ
ajlm-2394	86	35	42	42	NUM
ajlm-2394	86	36	%	%	NOUN
ajlm-2394	86	37	were	be	AUX
ajlm-2394	86	38	positive	positive	ADJ
ajlm-2394	86	39	for	for	ADP
ajlm-2394	86	40	mpo	mpo	PROPN
ajlm-2394	86	41	(	(	PUNCT
ajlm-2394	86	42	table	table	NOUN
ajlm-2394	86	43	5	5	NUM
ajlm-2394	86	44	)	)	PUNCT
ajlm-2394	86	45	.	.	PUNCT
ajlm-2394	87	1	among	among	ADP
ajlm-2394	87	2	cases	case	NOUN
ajlm-2394	87	3	with	with	ADP
ajlm-2394	87	4	scd3	scd3	PROPN
ajlm-2394	87	5	expressed	express	VERB
ajlm-2394	87	6	,	,	PUNCT
ajlm-2394	87	7	8	8	NUM
ajlm-2394	87	8	%	%	NOUN
ajlm-2394	87	9	were	be	AUX
ajlm-2394	87	10	positive	positive	ADJ
ajlm-2394	87	11	for	for	ADP
ajlm-2394	87	12	cd13	cd13	PROPN
ajlm-2394	87	13	,	,	PUNCT
ajlm-2394	87	14	0	0	NUM
ajlm-2394	87	15	%	%	NOUN
ajlm-2394	87	16	were	be	AUX
ajlm-2394	87	17	positive	positive	ADJ
ajlm-2394	87	18	for	for	ADP
ajlm-2394	87	19	cd33	cd33	PROPN
ajlm-2394	87	20	,	,	PUNCT
ajlm-2394	87	21	and	and	CCONJ
ajlm-2394	87	22	20	20	NUM
ajlm-2394	87	23	%	%	NOUN
ajlm-2394	87	24	were	be	AUX
ajlm-2394	87	25	positive	positive	ADJ
ajlm-2394	87	26	for	for	ADP
ajlm-2394	87	27	mpo	mpo	PROPN
ajlm-2394	87	28	.	.	PUNCT
ajlm-2394	87	29	table	table	NOUN
ajlm-2394	87	30	5	5	NUM
ajlm-2394	87	31	:	:	PUNCT
ajlm-2394	87	32	 	 	SPACE
ajlm-2394	87	33	differential	differential	ADJ
ajlm-2394	87	34	expression	expression	NOUN
ajlm-2394	87	35	of	of	ADP
ajlm-2394	87	36	cell	cell	NOUN
ajlm-2394	87	37	surface	surface	NOUN
ajlm-2394	87	38	markers	marker	NOUN
ajlm-2394	87	39	cd3	cd3	VERB
ajlm-2394	87	40	positive	positive	ADJ
ajlm-2394	87	41	and	and	CCONJ
ajlm-2394	87	42	negative	negative	ADJ
ajlm-2394	87	43	t	t	NOUN
ajlm-2394	87	44	-	-	PUNCT
ajlm-2394	87	45	cell	cell	NOUN
ajlm-2394	87	46	acute	acute	ADJ
ajlm-2394	87	47	lymphocytic	lymphocytic	ADJ
ajlm-2394	87	48	leukaemia	leukaemia	NOUN
ajlm-2394	87	49	at	at	ADP
ajlm-2394	87	50	tikur	tikur	PROPN
ajlm-2394	87	51	anbessa	anbessa	ADJ
ajlm-2394	87	52	specialised	specialised	ADJ
ajlm-2394	87	53	hospital	hospital	NOUN
ajlm-2394	87	54	,	,	PUNCT
ajlm-2394	87	55	addis	addis	PROPN
ajlm-2394	87	56	ababa	ababa	PROPN
ajlm-2394	87	57	,	,	PUNCT
ajlm-2394	87	58	ethiopia	ethiopia	PROPN
ajlm-2394	87	59	,	,	PUNCT
ajlm-2394	87	60	april	april	PROPN
ajlm-2394	87	61	2019	2019	NUM
ajlm-2394	87	62	to	to	ADP
ajlm-2394	87	63	june	june	PROPN
ajlm-2394	87	64	2021	2021	NUM
ajlm-2394	87	65	.	.	PUNCT
ajlm-2394	88	1	expression	expression	NOUN
ajlm-2394	88	2	of	of	ADP
ajlm-2394	88	3	markers	marker	NOUN
ajlm-2394	88	4	in	in	ADP
ajlm-2394	88	5	acute	acute	ADJ
ajlm-2394	88	6	myelogenous	myelogenous	ADJ
ajlm-2394	88	7	leukaemia	leukaemia	NOUN
ajlm-2394	88	8	subtypes	subtype	NOUN
ajlm-2394	88	9	among	among	ADP
ajlm-2394	88	10	the	the	DET
ajlm-2394	88	11	65	65	NUM
ajlm-2394	88	12	aml	aml	NOUN
ajlm-2394	88	13	-	-	PUNCT
ajlm-2394	88	14	like	like	ADJ
ajlm-2394	88	15	cases	case	NOUN
ajlm-2394	88	16	,	,	PUNCT
ajlm-2394	88	17	46	46	NUM
ajlm-2394	88	18	were	be	AUX
ajlm-2394	88	19	thus	thus	ADV
ajlm-2394	88	20	arbitrarily	arbitrarily	ADV
ajlm-2394	88	21	classified	classify	VERB
ajlm-2394	88	22	as	as	ADP
ajlm-2394	88	23	aml	aml	PROPN
ajlm-2394	88	24	m0	m0	PROPN
ajlm-2394	88	25	-	-	PUNCT
ajlm-2394	88	26	2	2	NUM
ajlm-2394	88	27	-	-	PUNCT
ajlm-2394	88	28	like	like	ADJ
ajlm-2394	88	29	(	(	PUNCT
ajlm-2394	88	30	71	71	NUM
ajlm-2394	88	31	%	%	NOUN
ajlm-2394	88	32	)	)	PUNCT
ajlm-2394	88	33	,	,	PUNCT
ajlm-2394	88	34	10	10	NUM
ajlm-2394	88	35	as	as	ADP
ajlm-2394	88	36	m3	m3	NOUN
ajlm-2394	88	37	-	-	PUNCT
ajlm-2394	88	38	like	like	ADJ
ajlm-2394	88	39	(	(	PUNCT
ajlm-2394	88	40	15	15	NUM
ajlm-2394	88	41	%	%	NOUN
ajlm-2394	88	42	)	)	PUNCT
ajlm-2394	88	43	,	,	PUNCT
ajlm-2394	88	44	6	6	NUM
ajlm-2394	88	45	as	as	ADP
ajlm-2394	88	46	m4	m4	PROPN
ajlm-2394	88	47	-	-	PUNCT
ajlm-2394	88	48	like	like	ADJ
ajlm-2394	88	49	(	(	PUNCT
ajlm-2394	88	50	9	9	NUM
ajlm-2394	88	51	%	%	NOUN
ajlm-2394	88	52	)	)	PUNCT
ajlm-2394	88	53	and	and	CCONJ
ajlm-2394	88	54	3	3	NUM
ajlm-2394	88	55	as	as	ADP
ajlm-2394	88	56	m5	m5	NOUN
ajlm-2394	88	57	-	-	PUNCT
ajlm-2394	88	58	like	like	ADJ
ajlm-2394	88	59	(	(	PUNCT
ajlm-2394	88	60	5	5	NUM
ajlm-2394	88	61	%	%	NOUN
ajlm-2394	88	62	)	)	PUNCT
ajlm-2394	88	63	.	.	PUNCT
ajlm-2394	89	1	acute	acute	ADJ
ajlm-2394	89	2	myelogenous	myelogenous	ADJ
ajlm-2394	89	3	leukaemia	leukaemia	NOUN
ajlm-2394	89	4	m0	m0	NOUN
ajlm-2394	89	5	-	-	PUNCT
ajlm-2394	89	6	2	2	NUM
ajlm-2394	89	7	-	-	PUNCT
ajlm-2394	89	8	like	like	NOUN
ajlm-2394	89	9	expressed	express	VERB
ajlm-2394	89	10	markers	marker	NOUN
ajlm-2394	89	11	of	of	ADP
ajlm-2394	89	12	immaturity	immaturity	NOUN
ajlm-2394	89	13	,	,	PUNCT
ajlm-2394	89	14	93	93	NUM
ajlm-2394	89	15	%	%	NOUN
ajlm-2394	89	16	cd34	cd34	PROPN
ajlm-2394	89	17	,	,	PUNCT
ajlm-2394	89	18	100	100	NUM
ajlm-2394	89	19	%	%	NOUN
ajlm-2394	89	20	cd117	cd117	PROPN
ajlm-2394	89	21	and	and	CCONJ
ajlm-2394	89	22	93	93	NUM
ajlm-2394	89	23	%	%	NOUN
ajlm-2394	89	24	hla	hla	PROPN
ajlm-2394	89	25	-	-	PUNCT
ajlm-2394	89	26	dr	dr	PROPN
ajlm-2394	89	27	positive	positive	NOUN
ajlm-2394	89	28	,	,	PUNCT
ajlm-2394	89	29	as	as	ADV
ajlm-2394	89	30	well	well	ADV
ajlm-2394	89	31	as	as	ADP
ajlm-2394	89	32	other	other	ADJ
ajlm-2394	89	33	myeloid	myeloid	ADJ
ajlm-2394	89	34	markers	marker	NOUN
ajlm-2394	89	35	.	.	PUNCT
ajlm-2394	90	1	of	of	ADP
ajlm-2394	90	2	note	note	VERB
ajlm-2394	90	3	cd19	cd19	PROPN
ajlm-2394	90	4	and	and	CCONJ
ajlm-2394	90	5	cd56	cd56	PROPN
ajlm-2394	90	6	were	be	AUX
ajlm-2394	90	7	co	co	VERB
ajlm-2394	90	8	-	-	VERB
ajlm-2394	90	9	expressed	express	VERB
ajlm-2394	90	10	in	in	ADP
ajlm-2394	90	11	three	three	NUM
ajlm-2394	90	12	cases	case	NOUN
ajlm-2394	90	13	(	(	PUNCT
ajlm-2394	90	14	5	5	NUM
ajlm-2394	90	15	%	%	NOUN
ajlm-2394	90	16	)	)	PUNCT
ajlm-2394	90	17	.	.	PUNCT
ajlm-2394	91	1	acute	acute	ADJ
ajlm-2394	91	2	myelogenous	myelogenous	ADJ
ajlm-2394	91	3	leukaemia	leukaemia	NOUN
ajlm-2394	91	4	m5	m5	NOUN
ajlm-2394	91	5	-	-	PUNCT
ajlm-2394	91	6	like	like	ADJ
ajlm-2394	91	7	were	be	AUX
ajlm-2394	91	8	typified	typify	VERB
ajlm-2394	91	9	by	by	ADP
ajlm-2394	91	10	the	the	DET
ajlm-2394	91	11	demonstration	demonstration	NOUN
ajlm-2394	91	12	of	of	ADP
ajlm-2394	91	13	markers	marker	NOUN
ajlm-2394	91	14	of	of	ADP
ajlm-2394	91	15	mature	mature	NOUN
ajlm-2394	91	16	monocytes	monocyte	VERB
ajlm-2394	91	17	cd64	cd64	PROPN
ajlm-2394	91	18	and/or	and/or	CCONJ
ajlm-2394	91	19	cd14	cd14	PROPN
ajlm-2394	91	20	,	,	PUNCT
ajlm-2394	91	21	and	and	CCONJ
ajlm-2394	91	22	lack	lack	NOUN
ajlm-2394	91	23	of	of	ADP
ajlm-2394	91	24	immature	immature	ADJ
ajlm-2394	91	25	markers	marker	NOUN
ajlm-2394	91	26	.	.	PUNCT
ajlm-2394	92	1	acute	acute	ADJ
ajlm-2394	92	2	myelogenous	myelogenous	PROPN
ajlm-2394	92	3	leukaemia	leukaemia	PROPN
ajlm-2394	92	4	m4	m4	PROPN
ajlm-2394	92	5	-	-	PUNCT
ajlm-2394	92	6	like	like	NOUN
ajlm-2394	92	7	were	be	AUX
ajlm-2394	92	8	notable	notable	ADJ
ajlm-2394	92	9	for	for	ADP
ajlm-2394	92	10	the	the	DET
ajlm-2394	92	11	presence	presence	NOUN
ajlm-2394	92	12	of	of	ADP
ajlm-2394	92	13	two	two	NUM
ajlm-2394	92	14	distinct	distinct	ADJ
ajlm-2394	92	15	populations	population	NOUN
ajlm-2394	92	16	of	of	ADP
ajlm-2394	92	17	leukaemia	leukaemia	NOUN
ajlm-2394	92	18	with	with	ADP
ajlm-2394	92	19	differing	differ	VERB
ajlm-2394	92	20	densities	density	NOUN
ajlm-2394	92	21	of	of	ADP
ajlm-2394	92	22	cd45	cd45	PROPN
ajlm-2394	92	23	and	and	CCONJ
ajlm-2394	92	24	side	side	NOUN
ajlm-2394	92	25	scatter	scatter	NOUN
ajlm-2394	92	26	,	,	PUNCT
ajlm-2394	92	27	distinct	distinct	ADJ
ajlm-2394	92	28	from	from	ADP
ajlm-2394	92	29	each	each	DET
ajlm-2394	92	30	other	other	ADJ
ajlm-2394	92	31	and	and	CCONJ
ajlm-2394	92	32	from	from	ADP
ajlm-2394	92	33	normal	normal	ADJ
ajlm-2394	92	34	leukocytes	leukocyte	NOUN
ajlm-2394	92	35	,	,	PUNCT
ajlm-2394	92	36	with	with	ADP
ajlm-2394	92	37	one	one	NUM
ajlm-2394	92	38	subpopulation	subpopulation	NOUN
ajlm-2394	92	39	bearing	bear	VERB
ajlm-2394	92	40	immature	immature	ADJ
ajlm-2394	92	41	markers	marker	NOUN
ajlm-2394	92	42	(	(	PUNCT
ajlm-2394	92	43	cd34	cd34	PROPN
ajlm-2394	92	44	and	and	CCONJ
ajlm-2394	92	45	cd117	cd117	PROPN
ajlm-2394	92	46	)	)	PUNCT
ajlm-2394	92	47	,	,	PUNCT
ajlm-2394	92	48	and	and	CCONJ
ajlm-2394	92	49	the	the	DET
ajlm-2394	92	50	other	other	ADJ
ajlm-2394	92	51	monocyte	monocyte	NOUN
ajlm-2394	92	52	markers	marker	NOUN
ajlm-2394	92	53	cd14	cd14	PROPN
ajlm-2394	92	54	and/or	and/or	CCONJ
ajlm-2394	92	55	cd64	cd64	PROPN
ajlm-2394	92	56	.	.	PUNCT
ajlm-2394	93	1	acute	acute	PROPN
ajlm-2394	93	2	myelogenous	myelogenous	ADJ
ajlm-2394	93	3	leukaemia	leukaemia	NOUN
ajlm-2394	93	4	m3	m3	PROPN
ajlm-2394	93	5	-	-	PUNCT
ajlm-2394	93	6	like	like	ADJ
ajlm-2394	93	7	cells	cell	NOUN
ajlm-2394	93	8	were	be	AUX
ajlm-2394	93	9	those	those	PRON
ajlm-2394	93	10	intermediate	intermediate	ADJ
ajlm-2394	93	11	between	between	ADP
ajlm-2394	93	12	extremes	extreme	NOUN
ajlm-2394	93	13	of	of	ADP
ajlm-2394	93	14	m0	m0	PROPN
ajlm-2394	93	15	-	-	PUNCT
ajlm-2394	93	16	2	2	NUM
ajlm-2394	93	17	-	-	PUNCT
ajlm-2394	93	18	like	like	ADJ
ajlm-2394	93	19	and	and	CCONJ
ajlm-2394	93	20	m4	m4	NOUN
ajlm-2394	93	21	-	-	PUNCT
ajlm-2394	93	22	like	like	ADJ
ajlm-2394	93	23	or	or	CCONJ
ajlm-2394	93	24	m5	m5	NOUN
ajlm-2394	93	25	-	-	PUNCT
ajlm-2394	93	26	like	like	ADJ
ajlm-2394	93	27	.	.	PUNCT
ajlm-2394	94	1	these	these	PRON
ajlm-2394	94	2	were	be	AUX
ajlm-2394	94	3	typically	typically	ADV
ajlm-2394	94	4	cd117	cd117	PROPN
ajlm-2394	94	5	positive	positive	ADJ
ajlm-2394	94	6	and	and	CCONJ
ajlm-2394	94	7	hla	hla	PROPN
ajlm-2394	94	8	-	-	PUNCT
ajlm-2394	94	9	dr	dr	PROPN
ajlm-2394	94	10	negative	negative	ADJ
ajlm-2394	94	11	(	(	PUNCT
ajlm-2394	94	12	figure	figure	NOUN
ajlm-2394	94	13	1	1	NUM
ajlm-2394	94	14	)	)	PUNCT
ajlm-2394	94	15	.	.	PUNCT
ajlm-2394	95	1	among	among	ADP
ajlm-2394	95	2	aml	aml	PROPN
ajlm-2394	95	3	subtypes	subtype	NOUN
ajlm-2394	95	4	,	,	PUNCT
ajlm-2394	95	5	only	only	ADV
ajlm-2394	95	6	the	the	DET
ajlm-2394	95	7	aml	aml	PROPN
ajlm-2394	95	8	-	-	PUNCT
ajlm-2394	95	9	m0	m0	NOUN
ajlm-2394	95	10	-	-	PUNCT
ajlm-2394	95	11	m2	m2	NOUN
ajlm-2394	95	12	-	-	PUNCT
ajlm-2394	95	13	like	like	ADJ
ajlm-2394	95	14	subtype	subtype	NOUN
ajlm-2394	95	15	was	be	AUX
ajlm-2394	95	16	reported	report	VERB
ajlm-2394	95	17	in	in	ADP
ajlm-2394	95	18	adolescent	adolescent	ADJ
ajlm-2394	95	19	cases	case	NOUN
ajlm-2394	95	20	(	(	PUNCT
ajlm-2394	95	21	100	100	NUM
ajlm-2394	95	22	%	%	NOUN
ajlm-2394	96	1	[	[	X
ajlm-2394	96	2	5/5	5/5	NUM
ajlm-2394	96	3	]	]	PUNCT
ajlm-2394	96	4	)	)	PUNCT
ajlm-2394	96	5	,	,	PUNCT
ajlm-2394	96	6	whereas	whereas	SCONJ
ajlm-2394	96	7	all	all	DET
ajlm-2394	96	8	aml	aml	NOUN
ajlm-2394	96	9	-	-	PUNCT
ajlm-2394	96	10	like	like	ADJ
ajlm-2394	96	11	subtypes	subtype	NOUN
ajlm-2394	96	12	were	be	AUX
ajlm-2394	96	13	reported	report	VERB
ajlm-2394	96	14	in	in	ADP
ajlm-2394	96	15	adult	adult	NOUN
ajlm-2394	96	16	cases	case	NOUN
ajlm-2394	96	17	,	,	PUNCT
ajlm-2394	96	18	including	include	VERB
ajlm-2394	96	19	aml	aml	PROPN
ajlm-2394	96	20	-	-	PUNCT
ajlm-2394	96	21	m3	m3	NOUN
ajlm-2394	96	22	-	-	PUNCT
ajlm-2394	96	23	like	like	NOUN
ajlm-2394	96	24	,	,	PUNCT
ajlm-2394	96	25	aml	aml	PROPN
ajlm-2394	96	26	–	–	PUNCT
ajlm-2394	96	27	m4	m4	NOUN
ajlm-2394	96	28	-	-	PUNCT
ajlm-2394	96	29	like	like	ADJ
ajlm-2394	96	30	and	and	CCONJ
ajlm-2394	96	31	aml	aml	NOUN
ajlm-2394	96	32	-	-	PUNCT
ajlm-2394	96	33	m5	m5	NOUN
ajlm-2394	96	34	-	-	PUNCT
ajlm-2394	96	35	like	like	ADJ
ajlm-2394	96	36	(	(	PUNCT
ajlm-2394	96	37	table	table	NOUN
ajlm-2394	96	38	4	4	NUM
ajlm-2394	96	39	)	)	PUNCT
ajlm-2394	96	40	.	.	PUNCT
ajlm-2394	97	1	figure	figure	VERB
ajlm-2394	97	2	1	1	NUM
ajlm-2394	97	3	:	:	PUNCT
ajlm-2394	97	4	immunophenotypes	immunophenotype	NOUN
ajlm-2394	97	5	of	of	ADP
ajlm-2394	97	6	arbitrary	arbitrary	ADJ
ajlm-2394	97	7	acute	acute	ADJ
ajlm-2394	97	8	myelogenous	myelogenous	ADJ
ajlm-2394	97	9	leukaemia	leukaemia	NOUN
ajlm-2394	97	10	(	(	PUNCT
ajlm-2394	97	11	aml	aml	NOUN
ajlm-2394	97	12	)	)	PUNCT
ajlm-2394	97	13	subtypes	subtype	NOUN
ajlm-2394	97	14	among	among	ADP
ajlm-2394	97	15	acute	acute	ADJ
ajlm-2394	97	16	leukaemia	leukaemia	NOUN
ajlm-2394	97	17	cases	case	NOUN
ajlm-2394	97	18	at	at	ADP
ajlm-2394	97	19	tikur	tikur	PROPN
ajlm-2394	97	20	anbessa	anbessa	ADJ
ajlm-2394	97	21	specialised	specialised	ADJ
ajlm-2394	97	22	hospital	hospital	NOUN
ajlm-2394	97	23	,	,	PUNCT
ajlm-2394	97	24	addis	addis	PROPN
ajlm-2394	97	25	ababa	ababa	PROPN
ajlm-2394	97	26	,	,	PUNCT
ajlm-2394	97	27	ethiopia	ethiopia	PROPN
ajlm-2394	97	28	,	,	PUNCT
ajlm-2394	97	29	april	april	PROPN
ajlm-2394	97	30	2019	2019	NUM
ajlm-2394	97	31	to	to	ADP
ajlm-2394	97	32	june	june	PROPN
ajlm-2394	97	33	2021	2021	NUM
ajlm-2394	97	34	.	.	PUNCT
ajlm-2394	98	1	(	(	PUNCT
ajlm-2394	98	2	a	a	X
ajlm-2394	98	3	)	)	PUNCT
ajlm-2394	98	4	immunophenotypes	immunophenotype	NOUN
ajlm-2394	98	5	of	of	ADP
ajlm-2394	98	6	aml	aml	PROPN
ajlm-2394	98	7	-	-	PUNCT
ajlm-2394	98	8	m3	m3	NOUN
ajlm-2394	98	9	-	-	PUNCT
ajlm-2394	98	10	like	like	ADJ
ajlm-2394	98	11	(	(	PUNCT
ajlm-2394	98	12	n	n	NOUN
ajlm-2394	98	13	=	=	SYM
ajlm-2394	98	14	10	10	NUM
ajlm-2394	98	15	)	)	PUNCT
ajlm-2394	98	16	,	,	PUNCT
ajlm-2394	98	17	(	(	PUNCT
ajlm-2394	98	18	b	b	X
ajlm-2394	98	19	)	)	PUNCT
ajlm-2394	98	20	aml	aml	NOUN
ajlm-2394	98	21	-	-	PUNCT
ajlm-2394	98	22	m0	m0	NOUN
ajlm-2394	98	23	-	-	PUNCT
ajlm-2394	98	24	m2	m2	NOUN
ajlm-2394	98	25	-	-	PUNCT
ajlm-2394	98	26	like	like	ADJ
ajlm-2394	98	27	(	(	PUNCT
ajlm-2394	98	28	n	n	NOUN
ajlm-2394	98	29	=	=	SYM
ajlm-2394	98	30	46	46	NUM
ajlm-2394	98	31	)	)	PUNCT
ajlm-2394	98	32	,	,	PUNCT
ajlm-2394	98	33	(	(	PUNCT
ajlm-2394	98	34	c	c	X
ajlm-2394	98	35	)	)	PUNCT
ajlm-2394	98	36	aml	aml	PROPN
ajlm-2394	98	37	-	-	PUNCT
ajlm-2394	98	38	m4	m4	VERB
ajlm-2394	98	39	-	-	PUNCT
ajlm-2394	98	40	like	like	ADJ
ajlm-2394	98	41	(	(	PUNCT
ajlm-2394	98	42	n	n	NOUN
ajlm-2394	98	43	=	=	SYM
ajlm-2394	98	44	6	6	NUM
ajlm-2394	98	45	)	)	PUNCT
ajlm-2394	98	46	,	,	PUNCT
ajlm-2394	98	47	and	and	CCONJ
ajlm-2394	98	48	(	(	PUNCT
ajlm-2394	98	49	d	d	NOUN
ajlm-2394	98	50	)	)	PUNCT
ajlm-2394	98	51	aml	aml	NOUN
ajlm-2394	98	52	-	-	PUNCT
ajlm-2394	98	53	m5	m5	NOUN
ajlm-2394	98	54	-	-	PUNCT
ajlm-2394	98	55	like	like	ADJ
ajlm-2394	98	56	(	(	PUNCT
ajlm-2394	98	57	n	n	NOUN
ajlm-2394	98	58	=	=	SYM
ajlm-2394	98	59	3	3	NUM
ajlm-2394	98	60	)	)	PUNCT
ajlm-2394	98	61	leukaemia	leukaemia	NOUN
ajlm-2394	98	62	cases	case	NOUN
ajlm-2394	98	63	.	.	PUNCT
ajlm-2394	99	1	for	for	ADP
ajlm-2394	99	2	(	(	PUNCT
ajlm-2394	99	3	a	a	NOUN
ajlm-2394	99	4	)	)	PUNCT
ajlm-2394	99	5	,	,	PUNCT
ajlm-2394	99	6	(	(	PUNCT
ajlm-2394	99	7	b	b	NOUN
ajlm-2394	99	8	)	)	PUNCT
ajlm-2394	99	9	,	,	PUNCT
ajlm-2394	99	10	and	and	CCONJ
ajlm-2394	99	11	(	(	PUNCT
ajlm-2394	99	12	d	d	NOUN
ajlm-2394	99	13	)	)	PUNCT
ajlm-2394	99	14	,	,	PUNCT
ajlm-2394	99	15	markers	marker	NOUN
ajlm-2394	99	16	are	be	AUX
ajlm-2394	99	17	depicted	depict	VERB
ajlm-2394	99	18	either	either	CCONJ
ajlm-2394	99	19	as	as	ADP
ajlm-2394	99	20	percentage	percentage	NOUN
ajlm-2394	99	21	of	of	ADP
ajlm-2394	99	22	cases	case	NOUN
ajlm-2394	99	23	with	with	ADP
ajlm-2394	99	24	>	>	SYM
ajlm-2394	99	25	20	20	NUM
ajlm-2394	99	26	%	%	NOUN
ajlm-2394	99	27	leukaemic	leukaemic	ADJ
ajlm-2394	99	28	cells	cell	NOUN
ajlm-2394	99	29	(	(	PUNCT
ajlm-2394	99	30	vertical	vertical	ADJ
ajlm-2394	99	31	bars	bar	NOUN
ajlm-2394	99	32	)	)	PUNCT
ajlm-2394	99	33	or	or	CCONJ
ajlm-2394	99	34	percentage	percentage	NOUN
ajlm-2394	99	35	of	of	ADP
ajlm-2394	99	36	leukaemia	leukaemia	NOUN
ajlm-2394	99	37	cells	cell	NOUN
ajlm-2394	99	38	positive	positive	ADJ
ajlm-2394	99	39	across	across	ADP
ajlm-2394	99	40	all	all	DET
ajlm-2394	99	41	patients	patient	NOUN
ajlm-2394	99	42	(	(	PUNCT
ajlm-2394	99	43	indicated	indicate	VERB
ajlm-2394	99	44	at	at	ADP
ajlm-2394	99	45	the	the	DET
ajlm-2394	99	46	bottom	bottom	NOUN
ajlm-2394	99	47	row	row	NOUN
ajlm-2394	99	48	)	)	PUNCT
ajlm-2394	99	49	.	.	PUNCT
ajlm-2394	100	1	for	for	ADP
ajlm-2394	100	2	figure	figure	NOUN
ajlm-2394	100	3	(	(	PUNCT
ajlm-2394	100	4	c	c	NOUN
ajlm-2394	100	5	)	)	PUNCT
ajlm-2394	100	6	,	,	PUNCT
ajlm-2394	100	7	aml	aml	PROPN
ajlm-2394	100	8	-	-	PUNCT
ajlm-2394	100	9	m4	m4	VERB
ajlm-2394	100	10	-	-	PUNCT
ajlm-2394	100	11	like	like	ADJ
ajlm-2394	100	12	,	,	PUNCT
ajlm-2394	100	13	percentage	percentage	NOUN
ajlm-2394	100	14	of	of	ADP
ajlm-2394	100	15	leukaemia	leukaemia	NOUN
ajlm-2394	100	16	cells	cell	NOUN
ajlm-2394	100	17	positive	positive	ADJ
ajlm-2394	100	18	across	across	ADP
ajlm-2394	100	19	all	all	DET
ajlm-2394	100	20	patients	patient	NOUN
ajlm-2394	100	21	is	be	AUX
ajlm-2394	100	22	depicted	depict	VERB
ajlm-2394	100	23	for	for	ADP
ajlm-2394	100	24	each	each	PRON
ajlm-2394	100	25	of	of	ADP
ajlm-2394	100	26	two	two	NUM
ajlm-2394	100	27	separable	separable	ADJ
ajlm-2394	100	28	populations	population	NOUN
ajlm-2394	100	29	,	,	PUNCT
ajlm-2394	100	30	an	an	DET
ajlm-2394	100	31	immature	immature	ADJ
ajlm-2394	100	32	myeloblast	myeloblast	ADJ
ajlm-2394	100	33	-	-	PUNCT
ajlm-2394	100	34	like	like	ADJ
ajlm-2394	100	35	cell	cell	NOUN
ajlm-2394	100	36	,	,	PUNCT
ajlm-2394	100	37	and	and	CCONJ
ajlm-2394	100	38	a	a	DET
ajlm-2394	100	39	more	more	ADV
ajlm-2394	100	40	mature	mature	ADJ
ajlm-2394	100	41	monocyte	monocyte	ADJ
ajlm-2394	100	42	-	-	PUNCT
ajlm-2394	100	43	like	like	ADJ
ajlm-2394	100	44	cell	cell	NOUN
ajlm-2394	100	45	.	.	PUNCT
ajlm-2394	101	1	discussion	discussion	NOUN
ajlm-2394	101	2	we	we	PRON
ajlm-2394	101	3	observed	observe	VERB
ajlm-2394	101	4	a	a	DET
ajlm-2394	101	5	similar	similar	ADJ
ajlm-2394	101	6	distribution	distribution	NOUN
ajlm-2394	101	7	of	of	ADP
ajlm-2394	101	8	aml	aml	PROPN
ajlm-2394	101	9	,	,	PUNCT
ajlm-2394	101	10	b	b	X
ajlm-2394	101	11	-	-	PUNCT
ajlm-2394	101	12	all	all	PRON
ajlm-2394	101	13	,	,	PUNCT
ajlm-2394	101	14	t	t	PROPN
ajlm-2394	101	15	-	-	PUNCT
ajlm-2394	101	16	all	all	PRON
ajlm-2394	101	17	,	,	PUNCT
ajlm-2394	101	18	as	as	ADV
ajlm-2394	101	19	well	well	ADV
ajlm-2394	101	20	as	as	ADP
ajlm-2394	101	21	age	age	NOUN
ajlm-2394	101	22	associations	association	NOUN
ajlm-2394	101	23	,	,	PUNCT
ajlm-2394	101	24	to	to	ADP
ajlm-2394	101	25	our	our	PRON
ajlm-2394	101	26	previous	previous	ADJ
ajlm-2394	101	27	2017	2017	NUM
ajlm-2394	101	28	study7	study7	NOUN
ajlm-2394	101	29	and	and	CCONJ
ajlm-2394	101	30	another	another	DET
ajlm-2394	101	31	african	african	ADJ
ajlm-2394	101	32	study.14	study.14	PROPN
ajlm-2394	101	33	secondly	secondly	ADV
ajlm-2394	101	34	,	,	PUNCT
ajlm-2394	101	35	we	we	PRON
ajlm-2394	101	36	defined	define	VERB
ajlm-2394	101	37	frequencies	frequency	NOUN
ajlm-2394	101	38	of	of	ADP
ajlm-2394	101	39	subsets	subset	NOUN
ajlm-2394	101	40	of	of	ADP
ajlm-2394	101	41	b	b	X
ajlm-2394	101	42	-	-	PUNCT
ajlm-2394	101	43	all	all	PRON
ajlm-2394	101	44	based	base	VERB
ajlm-2394	101	45	on	on	ADP
ajlm-2394	101	46	flow	flow	NOUN
ajlm-2394	101	47	cytometric	cytometric	ADJ
ajlm-2394	101	48	phenotypes	phenotype	NOUN
ajlm-2394	101	49	having	have	VERB
ajlm-2394	101	50	known	know	VERB
ajlm-2394	101	51	associations	association	NOUN
ajlm-2394	101	52	with	with	ADP
ajlm-2394	101	53	cytogenetic	cytogenetic	ADJ
ajlm-2394	101	54	abnormalities	abnormality	NOUN
ajlm-2394	101	55	,	,	PUNCT
ajlm-2394	101	56	and	and	CCONJ
ajlm-2394	101	57	find	find	VERB
ajlm-2394	101	58	similarities	similarity	NOUN
ajlm-2394	101	59	consistent	consistent	ADJ
ajlm-2394	101	60	with	with	ADP
ajlm-2394	101	61	previously	previously	ADV
ajlm-2394	101	62	reported	report	VERB
ajlm-2394	101	63	prevalence	prevalence	NOUN
ajlm-2394	101	64	.	.	PUNCT
ajlm-2394	102	1	in	in	ADP
ajlm-2394	102	2	particular	particular	ADJ
ajlm-2394	102	3	,	,	PUNCT
ajlm-2394	102	4	we	we	PRON
ajlm-2394	102	5	observed	observe	VERB
ajlm-2394	102	6	a	a	DET
ajlm-2394	102	7	high	high	ADJ
ajlm-2394	102	8	prevalence	prevalence	NOUN
ajlm-2394	102	9	of	of	ADP
ajlm-2394	102	10	cd10+/cd34+/cd66	cd10+/cd34+/cd66	NOUN
ajlm-2394	102	11	+	+	CCONJ
ajlm-2394	102	12	b	b	X
ajlm-2394	102	13	-	-	PUNCT
ajlm-2394	102	14	all	all	ADV
ajlm-2394	102	15	likely	likely	ADJ
ajlm-2394	102	16	to	to	PART
ajlm-2394	102	17	be	be	AUX
ajlm-2394	102	18	associated	associate	VERB
ajlm-2394	102	19	with	with	ADP
ajlm-2394	102	20	t(9;22	t(9;22	PROPN
ajlm-2394	102	21	)	)	PUNCT
ajlm-2394	102	22	,	,	PUNCT
ajlm-2394	102	23	and	and	CCONJ
ajlm-2394	102	24	cd10+/cd34	cd10+/cd34	NUM
ajlm-2394	102	25	–	–	PUNCT
ajlm-2394	102	26	b	b	X
ajlm-2394	102	27	-	-	PUNCT
ajlm-2394	102	28	all	all	PRON
ajlm-2394	102	29	leukaemias	leukaemia	NOUN
ajlm-2394	102	30	,	,	PUNCT
ajlm-2394	102	31	at	at	ADP
ajlm-2394	102	32	least	least	ADJ
ajlm-2394	102	33	some	some	PRON
ajlm-2394	102	34	of	of	ADP
ajlm-2394	102	35	which	which	PRON
ajlm-2394	102	36	have	have	AUX
ajlm-2394	102	37	been	be	AUX
ajlm-2394	102	38	associated	associate	VERB
ajlm-2394	102	39	with	with	ADP
ajlm-2394	102	40	t(1:19	t(1:19	NOUN
ajlm-2394	102	41	)	)	PUNCT
ajlm-2394	102	42	translocations.15	translocations.15	NOUN
ajlm-2394	102	43	thirdly	thirdly	ADV
ajlm-2394	102	44	,	,	PUNCT
ajlm-2394	102	45	myeloid	myeloid	ADJ
ajlm-2394	102	46	markers	marker	NOUN
ajlm-2394	102	47	were	be	AUX
ajlm-2394	102	48	preferentially	preferentially	ADV
ajlm-2394	102	49	expressed	express	VERB
ajlm-2394	102	50	on	on	ADP
ajlm-2394	102	51	t	t	PROPN
ajlm-2394	102	52	-	-	PUNCT
ajlm-2394	102	53	all	all	PRON
ajlm-2394	102	54	leukaemias	leukaemias	AUX
ajlm-2394	102	55	with	with	ADP
ajlm-2394	102	56	the	the	DET
ajlm-2394	102	57	most	most	ADV
ajlm-2394	102	58	immature	immature	ADJ
ajlm-2394	102	59	phenotypes	phenotype	NOUN
ajlm-2394	102	60	.	.	PUNCT
ajlm-2394	103	1	fourthly	fourthly	ADV
ajlm-2394	103	2	,	,	PUNCT
ajlm-2394	103	3	we	we	PRON
ajlm-2394	103	4	report	report	VERB
ajlm-2394	103	5	arbitrary	arbitrary	ADJ
ajlm-2394	103	6	flow	flow	NOUN
ajlm-2394	103	7	cytometric	cytometric	ADJ
ajlm-2394	103	8	classification	classification	NOUN
ajlm-2394	103	9	of	of	ADP
ajlm-2394	103	10	subtypes	subtype	NOUN
ajlm-2394	103	11	of	of	ADP
ajlm-2394	103	12	aml	aml	PROPN
ajlm-2394	103	13	based	base	VERB
ajlm-2394	103	14	on	on	ADP
ajlm-2394	103	15	a	a	DET
ajlm-2394	103	16	review	review	NOUN
ajlm-2394	103	17	of	of	ADP
ajlm-2394	103	18	the	the	DET
ajlm-2394	103	19	study,16	study,16	NOUN
ajlm-2394	103	20	and	and	CCONJ
ajlm-2394	103	21	identify	identify	VERB
ajlm-2394	103	22	a	a	DET
ajlm-2394	103	23	subset	subset	NOUN
ajlm-2394	103	24	expressing	express	VERB
ajlm-2394	103	25	cd19	cd19	PROPN
ajlm-2394	103	26	and	and	CCONJ
ajlm-2394	103	27	cd56	cd56	PROPN
ajlm-2394	103	28	consistent	consistent	ADJ
ajlm-2394	103	29	with	with	ADP
ajlm-2394	103	30	the	the	DET
ajlm-2394	103	31	t(8;21	t(8;21	PROPN
ajlm-2394	103	32	)	)	PUNCT
ajlm-2394	103	33	translocation	translocation	NOUN
ajlm-2394	103	34	.	.	PUNCT
ajlm-2394	104	1	collectively	collectively	ADV
ajlm-2394	104	2	,	,	PUNCT
ajlm-2394	104	3	these	these	DET
ajlm-2394	104	4	findings	finding	NOUN
ajlm-2394	104	5	underscore	underscore	VERB
ajlm-2394	104	6	the	the	DET
ajlm-2394	104	7	importance	importance	NOUN
ajlm-2394	104	8	of	of	ADP
ajlm-2394	104	9	multi	multi	ADJ
ajlm-2394	104	10	-	-	ADJ
ajlm-2394	104	11	dimensional	dimensional	ADJ
ajlm-2394	104	12	approaches	approach	NOUN
ajlm-2394	104	13	for	for	ADP
ajlm-2394	104	14	leukaemia	leukaemia	NOUN
ajlm-2394	104	15	diagnosis	diagnosis	NOUN
ajlm-2394	104	16	and	and	CCONJ
ajlm-2394	104	17	prognosis	prognosis	NOUN
ajlm-2394	104	18	.	.	PUNCT
ajlm-2394	105	1	we	we	PRON
ajlm-2394	105	2	described	describe	VERB
ajlm-2394	105	3	subsets	subset	NOUN
ajlm-2394	105	4	of	of	ADP
ajlm-2394	105	5	b	b	X
ajlm-2394	105	6	-	-	PUNCT
ajlm-2394	105	7	all	all	PRON
ajlm-2394	105	8	,	,	PUNCT
ajlm-2394	105	9	using	use	VERB
ajlm-2394	105	10	cd34	cd34	PROPN
ajlm-2394	105	11	,	,	PUNCT
ajlm-2394	105	12	cd10	cd10	PROPN
ajlm-2394	105	13	and	and	CCONJ
ajlm-2394	105	14	,	,	PUNCT
ajlm-2394	105	15	for	for	ADP
ajlm-2394	105	16	some	some	DET
ajlm-2394	105	17	cases	case	NOUN
ajlm-2394	105	18	,	,	PUNCT
ajlm-2394	105	19	cd66c	cd66c	NOUN
ajlm-2394	105	20	,	,	PUNCT
ajlm-2394	105	21	because	because	SCONJ
ajlm-2394	105	22	these	these	PRON
ajlm-2394	105	23	are	be	AUX
ajlm-2394	105	24	commonly	commonly	ADV
ajlm-2394	105	25	used	use	VERB
ajlm-2394	105	26	markers	marker	NOUN
ajlm-2394	105	27	and	and	CCONJ
ajlm-2394	105	28	data	datum	NOUN
ajlm-2394	105	29	exist	exist	AUX
ajlm-2394	105	30	describing	describe	VERB
ajlm-2394	105	31	their	their	PRON
ajlm-2394	105	32	associations	association	NOUN
ajlm-2394	105	33	with	with	ADP
ajlm-2394	105	34	clinical	clinical	ADJ
ajlm-2394	105	35	outcomes17	outcomes17	NOUN
ajlm-2394	105	36	and	and	CCONJ
ajlm-2394	105	37	with	with	ADP
ajlm-2394	105	38	genetic	genetic	ADJ
ajlm-2394	105	39	aberrations.18	aberrations.18	NOUN
ajlm-2394	105	40	moreover	moreover	ADV
ajlm-2394	105	41	,	,	PUNCT
ajlm-2394	105	42	cd34	cd34	PROPN
ajlm-2394	105	43	and	and	CCONJ
ajlm-2394	105	44	cd10	cd10	PROPN
ajlm-2394	105	45	are	be	AUX
ajlm-2394	105	46	well	well	ADV
ajlm-2394	105	47	-	-	PUNCT
ajlm-2394	105	48	described	describe	VERB
ajlm-2394	105	49	markers	marker	NOUN
ajlm-2394	105	50	whose	whose	DET
ajlm-2394	105	51	expression	expression	NOUN
ajlm-2394	105	52	aids	aid	NOUN
ajlm-2394	105	53	in	in	ADP
ajlm-2394	105	54	delineating	delineate	VERB
ajlm-2394	105	55	steps	step	NOUN
ajlm-2394	105	56	in	in	ADP
ajlm-2394	105	57	early	early	ADJ
ajlm-2394	105	58	b	b	NOUN
ajlm-2394	105	59	-	-	PUNCT
ajlm-2394	105	60	cell	cell	NOUN
ajlm-2394	105	61	development.19,20	development.19,20	NOUN
ajlm-2394	105	62	thus	thus	ADV
ajlm-2394	105	63	,	,	PUNCT
ajlm-2394	105	64	cd34+/cd10	cd34+/cd10	PROPN
ajlm-2394	105	65	–	–	PUNCT
ajlm-2394	105	66	,	,	PUNCT
ajlm-2394	105	67	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	105	68	+	+	NUM
ajlm-2394	105	69	and	and	CCONJ
ajlm-2394	105	70	cd34–/cd10	cd34–/cd10	PROPN
ajlm-2394	105	71	+	+	PRON
ajlm-2394	105	72	represent	represent	VERB
ajlm-2394	105	73	successive	successive	ADJ
ajlm-2394	105	74	stages	stage	NOUN
ajlm-2394	105	75	of	of	ADP
ajlm-2394	105	76	immature	immature	ADJ
ajlm-2394	105	77	b	b	NOUN
ajlm-2394	105	78	-	-	PUNCT
ajlm-2394	105	79	cell	cell	NOUN
ajlm-2394	105	80	differentiation	differentiation	NOUN
ajlm-2394	105	81	from	from	ADP
ajlm-2394	105	82	pre	pre	ADJ
ajlm-2394	105	83	-	-	ADJ
ajlm-2394	105	84	pro19,20	pro19,20	ADJ
ajlm-2394	105	85	cells	cell	NOUN
ajlm-2394	105	86	to	to	PART
ajlm-2394	105	87	,	,	PUNCT
ajlm-2394	105	88	ultimately	ultimately	ADV
ajlm-2394	105	89	,	,	PUNCT
ajlm-2394	105	90	transitional	transitional	ADJ
ajlm-2394	105	91	b	b	NOUN
ajlm-2394	105	92	-	-	PUNCT
ajlm-2394	105	93	cells	cell	NOUN
ajlm-2394	105	94	,	,	PUNCT
ajlm-2394	105	95	although	although	SCONJ
ajlm-2394	105	96	reports	report	NOUN
ajlm-2394	105	97	differ	differ	VERB
ajlm-2394	105	98	on	on	ADP
ajlm-2394	105	99	the	the	DET
ajlm-2394	105	100	classification	classification	NOUN
ajlm-2394	105	101	of	of	ADP
ajlm-2394	105	102	intermediate	intermediate	ADJ
ajlm-2394	105	103	pro	pro	ADJ
ajlm-2394	105	104	-	-	ADJ
ajlm-2394	105	105	b	b	ADJ
ajlm-2394	105	106	and	and	CCONJ
ajlm-2394	105	107	pre	pre	ADJ
ajlm-2394	105	108	-	-	ADJ
ajlm-2394	105	109	b	b	ADJ
ajlm-2394	105	110	cells.19,20	cells.19,20	NOUN
ajlm-2394	105	111	of	of	ADP
ajlm-2394	105	112	note	note	NOUN
ajlm-2394	105	113	,	,	PUNCT
ajlm-2394	105	114	cd34+/cd10	cd34+/cd10	PROPN
ajlm-2394	105	115	+	+	NOUN
ajlm-2394	105	116	b	b	X
ajlm-2394	105	117	-	-	PUNCT
ajlm-2394	105	118	all	all	PRON
ajlm-2394	105	119	has	have	AUX
ajlm-2394	105	120	also	also	ADV
ajlm-2394	105	121	been	be	AUX
ajlm-2394	105	122	termed	term	VERB
ajlm-2394	105	123	common	common	ADJ
ajlm-2394	105	124	b	b	NOUN
ajlm-2394	105	125	-	-	PUNCT
ajlm-2394	105	126	all.21	all.21	VERB
ajlm-2394	105	127	these	these	DET
ajlm-2394	105	128	stages	stage	NOUN
ajlm-2394	105	129	also	also	ADV
ajlm-2394	105	130	appear	appear	VERB
ajlm-2394	105	131	to	to	PART
ajlm-2394	105	132	be	be	AUX
ajlm-2394	105	133	similar	similar	ADJ
ajlm-2394	105	134	to	to	ADP
ajlm-2394	105	135	the	the	DET
ajlm-2394	105	136	b1	b1	NOUN
ajlm-2394	105	137	,	,	PUNCT
ajlm-2394	105	138	b2	b2	NOUN
ajlm-2394	105	139	and	and	CCONJ
ajlm-2394	105	140	b3	b3	NOUN
ajlm-2394	105	141	subsets	subset	NOUN
ajlm-2394	105	142	of	of	ADP
ajlm-2394	105	143	b	b	X
ajlm-2394	105	144	-	-	PUNCT
ajlm-2394	105	145	all	all	PRON
ajlm-2394	105	146	defined	define	VERB
ajlm-2394	105	147	by	by	ADP
ajlm-2394	105	148	the	the	DET
ajlm-2394	105	149	european	european	PROPN
ajlm-2394	105	150	group	group	NOUN
ajlm-2394	105	151	for	for	ADP
ajlm-2394	105	152	the	the	DET
ajlm-2394	105	153	immunological	immunological	ADJ
ajlm-2394	105	154	characterization	characterization	NOUN
ajlm-2394	105	155	of	of	ADP
ajlm-2394	105	156	leukemias	leukemias	PROPN
ajlm-2394	105	157	classification,22	classification,22	NOUN
ajlm-2394	105	158	though	though	SCONJ
ajlm-2394	105	159	reports	report	NOUN
ajlm-2394	105	160	differ	differ	VERB
ajlm-2394	105	161	on	on	ADP
ajlm-2394	105	162	the	the	DET
ajlm-2394	105	163	classification	classification	NOUN
ajlm-2394	105	164	of	of	ADP
ajlm-2394	105	165	cd34	cd34	PROPN
ajlm-2394	105	166	+	+	CCONJ
ajlm-2394	105	167	positivity	positivity	NOUN
ajlm-2394	105	168	on	on	ADP
ajlm-2394	105	169	pre	pre	ADJ
ajlm-2394	105	170	-	-	PROPN
ajlm-2394	105	171	b	b	ADJ
ajlm-2394	105	172	cells.23	cells.23	PROPN
ajlm-2394	105	173	including	include	VERB
ajlm-2394	105	174	cd66c	cd66c	NOUN
ajlm-2394	105	175	in	in	ADP
ajlm-2394	105	176	the	the	DET
ajlm-2394	105	177	analysis	analysis	NOUN
ajlm-2394	105	178	allowed	allow	VERB
ajlm-2394	105	179	us	we	PRON
ajlm-2394	105	180	to	to	PART
ajlm-2394	105	181	identify	identify	VERB
ajlm-2394	105	182	four	four	NUM
ajlm-2394	105	183	subsets	subset	NOUN
ajlm-2394	105	184	of	of	ADP
ajlm-2394	105	185	b	b	NOUN
ajlm-2394	105	186	-	-	PUNCT
ajlm-2394	105	187	all	all	PRON
ajlm-2394	105	188	.	.	PUNCT
ajlm-2394	106	1	the	the	DET
ajlm-2394	106	2	cd34+/cd10+/cd66c+	cd34+/cd10+/cd66c+	NOUN
ajlm-2394	106	3	subset	subset	NOUN
ajlm-2394	106	4	was	be	AUX
ajlm-2394	106	5	common	common	ADJ
ajlm-2394	106	6	in	in	ADP
ajlm-2394	106	7	our	our	PRON
ajlm-2394	106	8	study	study	NOUN
ajlm-2394	106	9	.	.	PUNCT
ajlm-2394	107	1	a	a	DET
ajlm-2394	107	2	study	study	NOUN
ajlm-2394	107	3	in	in	ADP
ajlm-2394	107	4	saudi	saudi	PROPN
ajlm-2394	107	5	arabia	arabia	PROPN
ajlm-2394	107	6	reported	report	VERB
ajlm-2394	107	7	that	that	SCONJ
ajlm-2394	107	8	the	the	DET
ajlm-2394	107	9	cd66c	cd66c	NOUN
ajlm-2394	107	10	,	,	PUNCT
ajlm-2394	107	11	cd34	cd34	PROPN
ajlm-2394	107	12	and	and	CCONJ
ajlm-2394	107	13	cd10	cd10	PROPN
ajlm-2394	107	14	positivity	positivity	NOUN
ajlm-2394	107	15	phenotype	phenotype	NOUN
ajlm-2394	107	16	were	be	AUX
ajlm-2394	107	17	associated	associate	VERB
ajlm-2394	107	18	with	with	ADP
ajlm-2394	107	19	,	,	PUNCT
ajlm-2394	107	20	but	but	CCONJ
ajlm-2394	107	21	not	not	PART
ajlm-2394	107	22	perfectly	perfectly	ADV
ajlm-2394	107	23	predictive	predictive	ADJ
ajlm-2394	107	24	of	of	ADP
ajlm-2394	107	25	,	,	PUNCT
ajlm-2394	107	26	the	the	DET
ajlm-2394	107	27	t(9;22	t(9;22	NOUN
ajlm-2394	107	28	)	)	PUNCT
ajlm-2394	107	29	translocation	translocation	NOUN
ajlm-2394	107	30	,	,	PUNCT
ajlm-2394	107	31	which	which	PRON
ajlm-2394	107	32	is	be	AUX
ajlm-2394	107	33	common	common	ADJ
ajlm-2394	107	34	in	in	ADP
ajlm-2394	107	35	b	b	X
ajlm-2394	107	36	-	-	PUNCT
ajlm-2394	107	37	all	all	PRON
ajlm-2394	107	38	,	,	PUNCT
ajlm-2394	107	39	particularly	particularly	ADV
ajlm-2394	107	40	among	among	ADP
ajlm-2394	107	41	adults.8	adults.8	PROPN
ajlm-2394	107	42	of	of	ADP
ajlm-2394	107	43	note	note	NOUN
ajlm-2394	107	44	,	,	PUNCT
ajlm-2394	107	45	cd66c	cd66c	NOUN
ajlm-2394	107	46	positivity	positivity	NOUN
ajlm-2394	107	47	in	in	ADP
ajlm-2394	107	48	b	b	X
ajlm-2394	107	49	-	-	PUNCT
ajlm-2394	107	50	all	all	PRON
ajlm-2394	107	51	is	be	AUX
ajlm-2394	107	52	also	also	ADV
ajlm-2394	107	53	common	common	ADJ
ajlm-2394	107	54	in	in	ADP
ajlm-2394	107	55	cases	case	NOUN
ajlm-2394	107	56	with	with	ADP
ajlm-2394	107	57	hyperdiploidy.24,25	hyperdiploidy.24,25	NOUN
ajlm-2394	107	58	among	among	ADP
ajlm-2394	107	59	adults	adult	NOUN
ajlm-2394	107	60	,	,	PUNCT
ajlm-2394	107	61	it	it	PRON
ajlm-2394	107	62	has	have	VERB
ajlm-2394	107	63	a	a	DET
ajlm-2394	107	64	worse	bad	ADJ
ajlm-2394	107	65	prognosis,26	prognosis,26	NOUN
ajlm-2394	107	66	but	but	CCONJ
ajlm-2394	107	67	outcomes	outcome	NOUN
ajlm-2394	107	68	may	may	AUX
ajlm-2394	107	69	be	be	AUX
ajlm-2394	107	70	enhanced	enhance	VERB
ajlm-2394	107	71	with	with	ADP
ajlm-2394	107	72	the	the	DET
ajlm-2394	107	73	inclusion	inclusion	NOUN
ajlm-2394	107	74	of	of	ADP
ajlm-2394	107	75	tyrosine	tyrosine	PROPN
ajlm-2394	107	76	kinase	kinase	PROPN
ajlm-2394	107	77	inhibitors	inhibitor	NOUN
ajlm-2394	107	78	specific	specific	ADJ
ajlm-2394	107	79	for	for	ADP
ajlm-2394	107	80	the	the	DET
ajlm-2394	107	81	fusion	fusion	NOUN
ajlm-2394	107	82	gene	gene	NOUN
ajlm-2394	107	83	bcr	bcr	NOUN
ajlm-2394	107	84	-	-	ADJ
ajlm-2394	107	85	abl.27	abl.27	X
ajlm-2394	107	86	our	our	AUX
ajlm-2394	107	87	finding	find	VERB
ajlm-2394	107	88	that	that	SCONJ
ajlm-2394	107	89	40	40	NUM
ajlm-2394	107	90	%	%	NOUN
ajlm-2394	107	91	of	of	ADP
ajlm-2394	107	92	b	b	NOUN
ajlm-2394	107	93	-	-	PUNCT
ajlm-2394	107	94	all	all	PRON
ajlm-2394	107	95	in	in	ADP
ajlm-2394	107	96	this	this	DET
ajlm-2394	107	97	cohort	cohort	NOUN
ajlm-2394	107	98	had	have	VERB
ajlm-2394	107	99	the	the	DET
ajlm-2394	107	100	cd34+/cd10+/cd66c+	cd34+/cd10+/cd66c+	ADJ
ajlm-2394	107	101	phenotype	phenotype	NOUN
ajlm-2394	107	102	is	be	AUX
ajlm-2394	107	103	consistent	consistent	ADJ
ajlm-2394	107	104	with	with	ADP
ajlm-2394	107	105	another	another	DET
ajlm-2394	107	106	study.25	study.25	NOUN
ajlm-2394	107	107	a	a	DET
ajlm-2394	107	108	second	second	ADJ
ajlm-2394	107	109	common	common	ADJ
ajlm-2394	107	110	phenotype	phenotype	NOUN
ajlm-2394	107	111	in	in	ADP
ajlm-2394	107	112	our	our	PRON
ajlm-2394	107	113	study	study	NOUN
ajlm-2394	107	114	was	be	AUX
ajlm-2394	107	115	cd10+/cd34	cd10+/cd34	PROPN
ajlm-2394	107	116	–	–	PUNCT
ajlm-2394	107	117	,	,	PUNCT
ajlm-2394	107	118	consistent	consistent	ADJ
ajlm-2394	107	119	with	with	ADP
ajlm-2394	107	120	another	another	DET
ajlm-2394	107	121	study.9	study.9	PROPN
ajlm-2394	107	122	b	b	NOUN
ajlm-2394	107	123	-	-	PUNCT
ajlm-2394	107	124	cell	cell	NOUN
ajlm-2394	107	125	acute	acute	ADJ
ajlm-2394	107	126	lymphocytic	lymphocytic	ADJ
ajlm-2394	107	127	leukaemia	leukaemia	NOUN
ajlm-2394	107	128	with	with	ADP
ajlm-2394	107	129	the	the	DET
ajlm-2394	107	130	t(1;19	t(1;19	NOUN
ajlm-2394	107	131	)	)	PUNCT
ajlm-2394	107	132	translocation	translocation	NOUN
ajlm-2394	107	133	often	often	ADV
ajlm-2394	107	134	has	have	VERB
ajlm-2394	107	135	this	this	DET
ajlm-2394	107	136	phenotype	phenotype	NOUN
ajlm-2394	107	137	,	,	PUNCT
ajlm-2394	107	138	and	and	CCONJ
ajlm-2394	107	139	reportedly	reportedly	ADV
ajlm-2394	107	140	with	with	ADP
ajlm-2394	107	141	a	a	DET
ajlm-2394	107	142	favourable	favourable	ADJ
ajlm-2394	107	143	prognosis	prognosis	NOUN
ajlm-2394	107	144	with	with	ADP
ajlm-2394	107	145	intensive	intensive	ADJ
ajlm-2394	107	146	chemotherapy	chemotherapy	NOUN
ajlm-2394	107	147	regimens.28	regimens.28	NOUN
ajlm-2394	107	148	the	the	DET
ajlm-2394	107	149	prevalence	prevalence	NOUN
ajlm-2394	107	150	of	of	ADP
ajlm-2394	107	151	t(1;19	t(1;19	NOUN
ajlm-2394	107	152	)	)	PUNCT
ajlm-2394	107	153	has	have	AUX
ajlm-2394	107	154	been	be	AUX
ajlm-2394	107	155	observed	observe	VERB
ajlm-2394	107	156	to	to	PART
ajlm-2394	107	157	be	be	AUX
ajlm-2394	107	158	around	around	ADV
ajlm-2394	107	159	5	5	NUM
ajlm-2394	107	160	%	%	NOUN
ajlm-2394	107	161	e,28	e,28	NOUN
ajlm-2394	107	162	much	much	ADV
ajlm-2394	107	163	lower	low	ADJ
ajlm-2394	107	164	than	than	ADP
ajlm-2394	107	165	the	the	DET
ajlm-2394	107	166	associated	associated	ADJ
ajlm-2394	107	167	phenotype	phenotype	NOUN
ajlm-2394	107	168	that	that	PRON
ajlm-2394	107	169	we	we	PRON
ajlm-2394	107	170	report	report	VERB
ajlm-2394	107	171	here	here	ADV
ajlm-2394	107	172	.	.	PUNCT
ajlm-2394	108	1	if	if	SCONJ
ajlm-2394	108	2	the	the	DET
ajlm-2394	108	3	cd34	cd34	PROPN
ajlm-2394	108	4	–	–	PUNCT
ajlm-2394	108	5	cd10	cd10	PROPN
ajlm-2394	108	6	+	+	CCONJ
ajlm-2394	108	7	phenotype	phenotype	NOUN
ajlm-2394	108	8	is	be	AUX
ajlm-2394	108	9	strongly	strongly	ADV
ajlm-2394	108	10	predictive	predictive	ADJ
ajlm-2394	108	11	of	of	ADP
ajlm-2394	108	12	t(1;19	t(1;19	NOUN
ajlm-2394	108	13	)	)	PUNCT
ajlm-2394	108	14	aberrations	aberration	NOUN
ajlm-2394	108	15	,	,	PUNCT
ajlm-2394	108	16	this	this	PRON
ajlm-2394	108	17	implies	imply	VERB
ajlm-2394	108	18	that	that	SCONJ
ajlm-2394	108	19	such	such	ADJ
ajlm-2394	108	20	aberrancies	aberrancy	NOUN
ajlm-2394	108	21	are	be	AUX
ajlm-2394	108	22	exceptionally	exceptionally	ADV
ajlm-2394	108	23	high	high	ADJ
ajlm-2394	108	24	in	in	ADP
ajlm-2394	108	25	the	the	DET
ajlm-2394	108	26	ethiopian	ethiopian	ADJ
ajlm-2394	108	27	setting	setting	NOUN
ajlm-2394	108	28	.	.	PUNCT
ajlm-2394	109	1	however	however	ADV
ajlm-2394	109	2	,	,	PUNCT
ajlm-2394	109	3	we	we	PRON
ajlm-2394	109	4	favour	favour	VERB
ajlm-2394	109	5	the	the	DET
ajlm-2394	109	6	possibility	possibility	NOUN
ajlm-2394	109	7	that	that	SCONJ
ajlm-2394	109	8	whereas	whereas	SCONJ
ajlm-2394	109	9	most	most	ADJ
ajlm-2394	109	10	t(1;19	t(1;19	NOUN
ajlm-2394	109	11	)	)	PUNCT
ajlm-2394	109	12	may	may	AUX
ajlm-2394	109	13	be	be	AUX
ajlm-2394	109	14	cd10+cd34–,15	cd10+cd34–,15	VERB
ajlm-2394	109	15	the	the	DET
ajlm-2394	109	16	converse	converse	NOUN
ajlm-2394	109	17	is	be	AUX
ajlm-2394	109	18	not	not	PART
ajlm-2394	109	19	true	true	ADJ
ajlm-2394	109	20	,	,	PUNCT
ajlm-2394	109	21	and	and	CCONJ
ajlm-2394	109	22	there	there	PRON
ajlm-2394	109	23	may	may	AUX
ajlm-2394	109	24	be	be	AUX
ajlm-2394	109	25	many	many	ADJ
ajlm-2394	109	26	other	other	ADJ
ajlm-2394	109	27	rearrangements	rearrangement	NOUN
ajlm-2394	109	28	or	or	CCONJ
ajlm-2394	109	29	mutations	mutation	NOUN
ajlm-2394	109	30	present	present	ADJ
ajlm-2394	109	31	in	in	ADP
ajlm-2394	109	32	this	this	DET
ajlm-2394	109	33	subset	subset	NOUN
ajlm-2394	109	34	apart	apart	ADV
ajlm-2394	109	35	from	from	ADP
ajlm-2394	109	36	the	the	DET
ajlm-2394	109	37	t(1;19	t(1;19	NOUN
ajlm-2394	109	38	)	)	PUNCT
ajlm-2394	109	39	translocation	translocation	NOUN
ajlm-2394	109	40	.	.	PUNCT
ajlm-2394	110	1	further	far	ADV
ajlm-2394	110	2	molecular	molecular	ADJ
ajlm-2394	110	3	work	work	NOUN
ajlm-2394	110	4	will	will	AUX
ajlm-2394	110	5	be	be	AUX
ajlm-2394	110	6	required	require	VERB
ajlm-2394	110	7	to	to	PART
ajlm-2394	110	8	explore	explore	VERB
ajlm-2394	110	9	this	this	DET
ajlm-2394	110	10	possibility	possibility	NOUN
ajlm-2394	110	11	.	.	PUNCT
ajlm-2394	111	1	less	less	ADV
ajlm-2394	111	2	common	common	ADJ
ajlm-2394	111	3	in	in	ADP
ajlm-2394	111	4	this	this	DET
ajlm-2394	111	5	study	study	NOUN
ajlm-2394	111	6	were	be	AUX
ajlm-2394	111	7	two	two	NUM
ajlm-2394	111	8	additional	additional	ADJ
ajlm-2394	111	9	b	b	NOUN
ajlm-2394	111	10	-	-	PUNCT
ajlm-2394	111	11	all	all	PRON
ajlm-2394	111	12	phenotypes	phenotype	NOUN
ajlm-2394	111	13	,	,	PUNCT
ajlm-2394	111	14	the	the	DET
ajlm-2394	111	15	cd10+/cd34+/cd66c	cd10+/cd34+/cd66c	NOUN
ajlm-2394	111	16	–	–	PUNCT
ajlm-2394	111	17	phenotype	phenotype	NOUN
ajlm-2394	111	18	,	,	PUNCT
ajlm-2394	111	19	and	and	CCONJ
ajlm-2394	111	20	the	the	DET
ajlm-2394	111	21	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	111	22	–	–	PUNCT
ajlm-2394	111	23	subset	subset	NOUN
ajlm-2394	111	24	(	(	PUNCT
ajlm-2394	111	25	with	with	ADP
ajlm-2394	111	26	or	or	CCONJ
ajlm-2394	111	27	without	without	ADP
ajlm-2394	111	28	cd66c	cd66c	NOUN
ajlm-2394	111	29	)	)	PUNCT
ajlm-2394	111	30	.	.	PUNCT
ajlm-2394	112	1	the	the	DET
ajlm-2394	112	2	cd10+/cd34+/cd66c	cd10+/cd34+/cd66c	PROPN
ajlm-2394	112	3	–	–	PUNCT
ajlm-2394	112	4	b	b	X
ajlm-2394	112	5	-	-	PUNCT
ajlm-2394	112	6	all	all	DET
ajlm-2394	112	7	subtype	subtype	NOUN
ajlm-2394	112	8	has	have	AUX
ajlm-2394	112	9	been	be	AUX
ajlm-2394	112	10	shown	show	VERB
ajlm-2394	112	11	to	to	PART
ajlm-2394	112	12	be	be	AUX
ajlm-2394	112	13	correlated	correlate	VERB
ajlm-2394	112	14	with	with	ADP
ajlm-2394	112	15	the	the	DET
ajlm-2394	112	16	t(12;21	t(12;21	NOUN
ajlm-2394	112	17	)	)	PUNCT
ajlm-2394	112	18	translocation	translocation	NOUN
ajlm-2394	112	19	,	,	PUNCT
ajlm-2394	112	20	which	which	PRON
ajlm-2394	112	21	is	be	AUX
ajlm-2394	112	22	the	the	DET
ajlm-2394	112	23	most	most	ADV
ajlm-2394	112	24	common	common	ADJ
ajlm-2394	112	25	aberration	aberration	NOUN
ajlm-2394	112	26	in	in	ADP
ajlm-2394	112	27	paediatric	paediatric	ADJ
ajlm-2394	112	28	b	b	NOUN
ajlm-2394	112	29	-	-	PUNCT
ajlm-2394	112	30	all	all	PRON
ajlm-2394	112	31	,	,	PUNCT
ajlm-2394	112	32	and	and	CCONJ
ajlm-2394	112	33	which	which	PRON
ajlm-2394	112	34	carries	carry	VERB
ajlm-2394	112	35	a	a	DET
ajlm-2394	112	36	good	good	ADJ
ajlm-2394	112	37	prognosis.29	prognosis.29	NOUN
ajlm-2394	112	38	in	in	ADP
ajlm-2394	112	39	our	our	PRON
ajlm-2394	112	40	cohort	cohort	NOUN
ajlm-2394	112	41	,	,	PUNCT
ajlm-2394	112	42	the	the	DET
ajlm-2394	112	43	prevalence	prevalence	NOUN
ajlm-2394	112	44	of	of	ADP
ajlm-2394	112	45	this	this	DET
ajlm-2394	112	46	phenotype	phenotype	NOUN
ajlm-2394	112	47	was	be	AUX
ajlm-2394	112	48	low	low	ADJ
ajlm-2394	112	49	(	(	PUNCT
ajlm-2394	112	50	10	10	NUM
ajlm-2394	112	51	%	%	NOUN
ajlm-2394	112	52	)	)	PUNCT
ajlm-2394	112	53	,	,	PUNCT
ajlm-2394	112	54	but	but	CCONJ
ajlm-2394	112	55	our	our	PRON
ajlm-2394	112	56	cohort	cohort	NOUN
ajlm-2394	112	57	was	be	AUX
ajlm-2394	112	58	primarily	primarily	ADV
ajlm-2394	112	59	composed	compose	VERB
ajlm-2394	112	60	of	of	ADP
ajlm-2394	112	61	adult	adult	NOUN
ajlm-2394	112	62	and	and	CCONJ
ajlm-2394	112	63	adolescent	adolescent	ADJ
ajlm-2394	112	64	leukaemia	leukaemia	NOUN
ajlm-2394	112	65	cases	case	NOUN
ajlm-2394	112	66	,	,	PUNCT
ajlm-2394	112	67	so	so	SCONJ
ajlm-2394	112	68	this	this	DET
ajlm-2394	112	69	lower	low	ADJ
ajlm-2394	112	70	frequency	frequency	NOUN
ajlm-2394	112	71	would	would	AUX
ajlm-2394	112	72	be	be	AUX
ajlm-2394	112	73	expected.17	expected.17	PROPN
ajlm-2394	112	74	the	the	DET
ajlm-2394	112	75	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	112	76	–	–	PUNCT
ajlm-2394	112	77	subset	subset	NOUN
ajlm-2394	112	78	has	have	AUX
ajlm-2394	112	79	been	be	AUX
ajlm-2394	112	80	shown	show	VERB
ajlm-2394	112	81	to	to	PART
ajlm-2394	112	82	be	be	AUX
ajlm-2394	112	83	associated	associate	VERB
ajlm-2394	112	84	with	with	ADP
ajlm-2394	112	85	chromosome	chromosome	NOUN
ajlm-2394	112	86	11	11	NUM
ajlm-2394	112	87	mutations	mutation	NOUN
ajlm-2394	112	88	involving	involve	VERB
ajlm-2394	112	89	the	the	DET
ajlm-2394	112	90	mll	mll	PROPN
ajlm-2394	112	91	gene.30	gene.30	PROPN
ajlm-2394	112	92	the	the	DET
ajlm-2394	112	93	most	most	ADV
ajlm-2394	112	94	common	common	ADJ
ajlm-2394	112	95	of	of	ADP
ajlm-2394	112	96	these	these	DET
ajlm-2394	112	97	translocations	translocation	NOUN
ajlm-2394	112	98	is	be	AUX
ajlm-2394	112	99	t(4;11	t(4;11	PROPN
ajlm-2394	112	100	)	)	PUNCT
ajlm-2394	112	101	(	(	PUNCT
ajlm-2394	112	102	mll	mll	PROPN
ajlm-2394	112	103	-	-	PUNCT
ajlm-2394	112	104	af4	af4	PROPN
ajlm-2394	112	105	)	)	PUNCT
ajlm-2394	112	106	,	,	PUNCT
ajlm-2394	112	107	present	present	ADJ
ajlm-2394	112	108	in	in	ADP
ajlm-2394	112	109	5	5	NUM
ajlm-2394	112	110	%	%	NOUN
ajlm-2394	112	111	of	of	ADP
ajlm-2394	112	112	all.18	all.18	PROPN
ajlm-2394	112	113	our	our	PRON
ajlm-2394	112	114	finding	finding	NOUN
ajlm-2394	112	115	of	of	ADP
ajlm-2394	112	116	a	a	DET
ajlm-2394	112	117	6	6	NUM
ajlm-2394	112	118	%	%	NOUN
ajlm-2394	112	119	prevalence	prevalence	NOUN
ajlm-2394	112	120	of	of	ADP
ajlm-2394	112	121	the	the	DET
ajlm-2394	112	122	cd34+/cd10	cd34+/cd10	NOUN
ajlm-2394	112	123	–	–	PUNCT
ajlm-2394	112	124	phenotype	phenotype	NOUN
ajlm-2394	112	125	is	be	AUX
ajlm-2394	112	126	consistent	consistent	ADJ
ajlm-2394	112	127	with	with	ADP
ajlm-2394	112	128	this	this	PRON
ajlm-2394	112	129	.	.	PUNCT
ajlm-2394	113	1	we	we	PRON
ajlm-2394	113	2	defined	define	VERB
ajlm-2394	113	3	two	two	NUM
ajlm-2394	113	4	populations	population	NOUN
ajlm-2394	113	5	of	of	ADP
ajlm-2394	113	6	cytoplasmic	cytoplasmic	ADJ
ajlm-2394	113	7	cd3	cd3	NOUN
ajlm-2394	113	8	expressing	express	VERB
ajlm-2394	113	9	t	t	PROPN
ajlm-2394	113	10	-	-	PUNCT
ajlm-2394	113	11	all	all	PRON
ajlm-2394	113	12	,	,	PUNCT
ajlm-2394	113	13	those	those	PRON
ajlm-2394	113	14	without	without	ADP
ajlm-2394	113	15	and	and	CCONJ
ajlm-2394	113	16	those	those	PRON
ajlm-2394	113	17	with	with	ADP
ajlm-2394	113	18	detectable	detectable	ADJ
ajlm-2394	113	19	surface	surface	NOUN
ajlm-2394	113	20	cd3	cd3	PROPN
ajlm-2394	113	21	(	(	PUNCT
ajlm-2394	113	22	scd3	scd3	PROPN
ajlm-2394	113	23	)	)	PUNCT
ajlm-2394	113	24	.	.	PUNCT
ajlm-2394	114	1	according	accord	VERB
ajlm-2394	114	2	to	to	ADP
ajlm-2394	114	3	previous	previous	ADJ
ajlm-2394	114	4	european	european	ADJ
ajlm-2394	114	5	group	group	NOUN
ajlm-2394	114	6	for	for	ADP
ajlm-2394	114	7	the	the	DET
ajlm-2394	114	8	immunological	immunological	ADJ
ajlm-2394	114	9	characterization	characterization	NOUN
ajlm-2394	114	10	of	of	ADP
ajlm-2394	114	11	leukemias	leukemias	PROPN
ajlm-2394	114	12	classifications	classification	NOUN
ajlm-2394	114	13	,	,	PUNCT
ajlm-2394	114	14	the	the	DET
ajlm-2394	114	15	former	former	ADJ
ajlm-2394	114	16	would	would	AUX
ajlm-2394	114	17	likely	likely	ADV
ajlm-2394	114	18	comprise	comprise	VERB
ajlm-2394	114	19	the	the	DET
ajlm-2394	114	20	more	more	ADV
ajlm-2394	114	21	immature	immature	ADJ
ajlm-2394	114	22	t1	t1	NOUN
ajlm-2394	114	23	and	and	CCONJ
ajlm-2394	114	24	t2	t2	NOUN
ajlm-2394	114	25	,	,	PUNCT
ajlm-2394	114	26	and	and	CCONJ
ajlm-2394	114	27	the	the	DET
ajlm-2394	114	28	latter	latter	ADJ
ajlm-2394	114	29	the	the	DET
ajlm-2394	114	30	less	less	ADV
ajlm-2394	114	31	immature	immature	ADJ
ajlm-2394	114	32	t3	t3	NOUN
ajlm-2394	114	33	and	and	CCONJ
ajlm-2394	114	34	t4	t4	PROPN
ajlm-2394	114	35	phenotypes.31	phenotypes.31	PROPN
ajlm-2394	114	36	since	since	SCONJ
ajlm-2394	114	37	we	we	PRON
ajlm-2394	114	38	did	do	AUX
ajlm-2394	114	39	not	not	PART
ajlm-2394	114	40	evaluate	evaluate	VERB
ajlm-2394	114	41	cd1	cd1	NOUN
ajlm-2394	114	42	expression	expression	NOUN
ajlm-2394	114	43	,	,	PUNCT
ajlm-2394	114	44	we	we	PRON
ajlm-2394	114	45	were	be	AUX
ajlm-2394	114	46	unable	unable	ADJ
ajlm-2394	114	47	to	to	PART
ajlm-2394	114	48	distinguish	distinguish	VERB
ajlm-2394	114	49	the	the	DET
ajlm-2394	114	50	cortical	cortical	ADJ
ajlm-2394	114	51	t3	t3	NOUN
ajlm-2394	114	52	from	from	ADP
ajlm-2394	114	53	the	the	DET
ajlm-2394	114	54	more	more	ADV
ajlm-2394	114	55	mature	mature	ADJ
ajlm-2394	114	56	t4	t4	PROPN
ajlm-2394	114	57	phenotype	phenotype	NOUN
ajlm-2394	114	58	.	.	PUNCT
ajlm-2394	115	1	in	in	ADP
ajlm-2394	115	2	our	our	PRON
ajlm-2394	115	3	t	t	NOUN
ajlm-2394	115	4	-	-	PUNCT
ajlm-2394	115	5	all	all	DET
ajlm-2394	115	6	cases	case	NOUN
ajlm-2394	115	7	,	,	PUNCT
ajlm-2394	115	8	scd3	scd3	ADJ
ajlm-2394	115	9	,	,	PUNCT
ajlm-2394	115	10	when	when	SCONJ
ajlm-2394	115	11	detectable	detectable	ADJ
ajlm-2394	115	12	,	,	PUNCT
ajlm-2394	115	13	was	be	AUX
ajlm-2394	115	14	variable	variable	ADJ
ajlm-2394	115	15	in	in	ADP
ajlm-2394	115	16	percentage	percentage	NOUN
ajlm-2394	115	17	,	,	PUNCT
ajlm-2394	115	18	and	and	CCONJ
ajlm-2394	115	19	typically	typically	ADV
ajlm-2394	115	20	of	of	ADP
ajlm-2394	115	21	reduced	reduced	ADJ
ajlm-2394	115	22	intensity	intensity	NOUN
ajlm-2394	115	23	compared	compare	VERB
ajlm-2394	115	24	with	with	ADP
ajlm-2394	115	25	peripheral	peripheral	ADJ
ajlm-2394	115	26	normal	normal	ADJ
ajlm-2394	115	27	t	t	NOUN
ajlm-2394	115	28	-	-	PUNCT
ajlm-2394	115	29	cells	cell	NOUN
ajlm-2394	115	30	.	.	PUNCT
ajlm-2394	116	1	a	a	DET
ajlm-2394	116	2	notable	notable	ADJ
ajlm-2394	116	3	difference	difference	NOUN
ajlm-2394	116	4	between	between	ADP
ajlm-2394	116	5	the	the	DET
ajlm-2394	116	6	scd3	scd3	ADJ
ajlm-2394	116	7	negative	negative	ADJ
ajlm-2394	116	8	and	and	CCONJ
ajlm-2394	116	9	positive	positive	ADJ
ajlm-2394	116	10	subsets	subset	NOUN
ajlm-2394	116	11	was	be	AUX
ajlm-2394	116	12	the	the	DET
ajlm-2394	116	13	greater	great	ADJ
ajlm-2394	116	14	expression	expression	NOUN
ajlm-2394	116	15	of	of	ADP
ajlm-2394	116	16	myeloid	myeloid	NOUN
ajlm-2394	116	17	markers	marker	NOUN
ajlm-2394	116	18	cd33	cd33	PROPN
ajlm-2394	116	19	,	,	PUNCT
ajlm-2394	116	20	cmpo	cmpo	NOUN
ajlm-2394	116	21	and	and	CCONJ
ajlm-2394	116	22	cd13	cd13	PROPN
ajlm-2394	116	23	,	,	PUNCT
ajlm-2394	116	24	among	among	ADP
ajlm-2394	116	25	the	the	DET
ajlm-2394	116	26	most	most	ADV
ajlm-2394	116	27	immature	immature	ADJ
ajlm-2394	116	28	t	t	NOUN
ajlm-2394	116	29	-	-	PUNCT
ajlm-2394	116	30	all	all	PRON
ajlm-2394	116	31	.	.	PUNCT
ajlm-2394	117	1	cmyeloperoxidase	cmyeloperoxidase	ADJ
ajlm-2394	117	2	expression	expression	NOUN
ajlm-2394	117	3	is	be	AUX
ajlm-2394	117	4	uncommon	uncommon	ADJ
ajlm-2394	117	5	among	among	ADP
ajlm-2394	117	6	t	t	PROPN
ajlm-2394	117	7	-	-	PUNCT
ajlm-2394	117	8	all	all	PRON
ajlm-2394	117	9	,	,	PUNCT
ajlm-2394	117	10	although	although	SCONJ
ajlm-2394	117	11	it	it	PRON
ajlm-2394	117	12	has	have	AUX
ajlm-2394	117	13	been	be	AUX
ajlm-2394	117	14	described	describe	VERB
ajlm-2394	117	15	previously.32	previously.32	NOUN
ajlm-2394	117	16	we	we	PRON
ajlm-2394	117	17	observed	observe	VERB
ajlm-2394	117	18	expression	expression	NOUN
ajlm-2394	117	19	of	of	ADP
ajlm-2394	117	20	myeloid	myeloid	ADJ
ajlm-2394	117	21	antigens	antigen	NOUN
ajlm-2394	117	22	in	in	ADP
ajlm-2394	117	23	b	b	NOUN
ajlm-2394	117	24	-	-	PUNCT
ajlm-2394	117	25	all	all	PRON
ajlm-2394	117	26	as	as	ADV
ajlm-2394	117	27	well	well	ADV
ajlm-2394	117	28	,	,	PUNCT
ajlm-2394	117	29	confirming	confirm	VERB
ajlm-2394	117	30	an	an	DET
ajlm-2394	117	31	other	other	ADJ
ajlm-2394	117	32	study.33	study.33	NOUN
ajlm-2394	117	33	it	it	PRON
ajlm-2394	117	34	is	be	AUX
ajlm-2394	117	35	possible	possible	ADJ
ajlm-2394	117	36	that	that	SCONJ
ajlm-2394	117	37	some	some	PRON
ajlm-2394	117	38	of	of	ADP
ajlm-2394	117	39	the	the	DET
ajlm-2394	117	40	t	t	PROPN
ajlm-2394	117	41	-	-	PUNCT
ajlm-2394	117	42	all	all	PRON
ajlm-2394	117	43	and	and	CCONJ
ajlm-2394	117	44	b	b	X
ajlm-2394	117	45	-	-	PUNCT
ajlm-2394	117	46	all	all	PRON
ajlm-2394	117	47	described	describe	VERB
ajlm-2394	117	48	here	here	ADV
ajlm-2394	117	49	may	may	AUX
ajlm-2394	117	50	better	well	ADV
ajlm-2394	117	51	fit	fit	VERB
ajlm-2394	117	52	the	the	DET
ajlm-2394	117	53	diagnosis	diagnosis	NOUN
ajlm-2394	117	54	of	of	ADP
ajlm-2394	117	55	mixed	mixed	ADJ
ajlm-2394	117	56	phenotype	phenotype	NOUN
ajlm-2394	117	57	acute	acute	NOUN
ajlm-2394	117	58	leukaemia	leukaemia	NOUN
ajlm-2394	117	59	.	.	PUNCT
ajlm-2394	118	1	this	this	PRON
ajlm-2394	118	2	would	would	AUX
ajlm-2394	118	3	imply	imply	VERB
ajlm-2394	118	4	a	a	DET
ajlm-2394	118	5	much	much	ADV
ajlm-2394	118	6	higher	high	ADJ
ajlm-2394	118	7	prevalence	prevalence	NOUN
ajlm-2394	118	8	of	of	ADP
ajlm-2394	118	9	this	this	DET
ajlm-2394	118	10	subtype	subtype	NOUN
ajlm-2394	118	11	in	in	ADP
ajlm-2394	118	12	the	the	DET
ajlm-2394	118	13	ethiopian	ethiopian	ADJ
ajlm-2394	118	14	setting	setting	NOUN
ajlm-2394	118	15	.	.	PUNCT
ajlm-2394	119	1	however	however	ADV
ajlm-2394	119	2	,	,	PUNCT
ajlm-2394	119	3	weak	weak	ADJ
ajlm-2394	119	4	expression	expression	NOUN
ajlm-2394	119	5	of	of	ADP
ajlm-2394	119	6	cmpo	cmpo	NOUN
ajlm-2394	119	7	in	in	ADP
ajlm-2394	119	8	particular	particular	ADJ
ajlm-2394	119	9	is	be	AUX
ajlm-2394	119	10	permitted	permit	VERB
ajlm-2394	119	11	within	within	ADP
ajlm-2394	119	12	the	the	DET
ajlm-2394	119	13	classification	classification	NOUN
ajlm-2394	119	14	criteria	criterion	NOUN
ajlm-2394	119	15	of	of	ADP
ajlm-2394	119	16	associazone	associazone	PROPN
ajlm-2394	119	17	italiana	italiana	PROPN
ajlm-2394	119	18	ematologia	ematologia	PROPN
ajlm-2394	119	19	oncologia	oncologia	PROPN
ajlm-2394	119	20	pediatrica	pediatrica	PROPN
ajlm-2394	119	21	-	-	PUNCT
ajlm-2394	119	22	berlin	berlin	PROPN
ajlm-2394	119	23	-	-	PUNCT
ajlm-2394	119	24	frankfurt	frankfurt	NOUN
ajlm-2394	119	25	-	-	PUNCT
ajlm-2394	119	26	münster11	münster11	NOUN
ajlm-2394	119	27	for	for	ADP
ajlm-2394	119	28	t	t	PROPN
ajlm-2394	119	29	-	-	PUNCT
ajlm-2394	119	30	all	all	PRON
ajlm-2394	119	31	,	,	PUNCT
ajlm-2394	119	32	and	and	CCONJ
ajlm-2394	119	33	we	we	PRON
ajlm-2394	119	34	observed	observe	VERB
ajlm-2394	119	35	on	on	ADP
ajlm-2394	119	36	average	average	ADJ
ajlm-2394	119	37	at	at	ADV
ajlm-2394	119	38	least	least	ADJ
ajlm-2394	119	39	4	4	NUM
ajlm-2394	119	40	-	-	ADJ
ajlm-2394	119	41	fold	fold	VERB
ajlm-2394	119	42	lower	low	ADJ
ajlm-2394	119	43	levels	level	NOUN
ajlm-2394	119	44	of	of	ADP
ajlm-2394	119	45	cmpo	cmpo	NOUN
ajlm-2394	119	46	on	on	ADP
ajlm-2394	119	47	those	those	DET
ajlm-2394	119	48	leukaemias	leukaemia	NOUN
ajlm-2394	119	49	we	we	PRON
ajlm-2394	119	50	classified	classify	VERB
ajlm-2394	119	51	as	as	ADP
ajlm-2394	119	52	t	t	PROPN
ajlm-2394	119	53	-	-	PUNCT
ajlm-2394	119	54	all	all	PRON
ajlm-2394	119	55	.	.	PUNCT
ajlm-2394	120	1	from	from	ADP
ajlm-2394	120	2	a	a	DET
ajlm-2394	120	3	mechanistic	mechanistic	ADJ
ajlm-2394	120	4	perspective	perspective	NOUN
ajlm-2394	120	5	,	,	PUNCT
ajlm-2394	120	6	given	give	VERB
ajlm-2394	120	7	that	that	DET
ajlm-2394	120	8	small	small	ADJ
ajlm-2394	120	9	fractions	fraction	NOUN
ajlm-2394	120	10	of	of	ADP
ajlm-2394	120	11	early	early	ADJ
ajlm-2394	120	12	t	t	PROPN
ajlm-2394	120	13	-	-	PUNCT
ajlm-2394	120	14	progenitor	progenitor	NOUN
ajlm-2394	120	15	cells	cell	NOUN
ajlm-2394	120	16	in	in	ADP
ajlm-2394	120	17	normal	normal	ADJ
ajlm-2394	120	18	individuals	individual	NOUN
ajlm-2394	120	19	can	can	AUX
ajlm-2394	120	20	express	express	VERB
ajlm-2394	120	21	some	some	DET
ajlm-2394	120	22	myeloid	myeloid	ADJ
ajlm-2394	120	23	markers,16,34	markers,16,34	NOUN
ajlm-2394	120	24	these	these	PRON
ajlm-2394	120	25	leukaemias	leukaemia	VERB
ajlm-2394	120	26	might	might	AUX
ajlm-2394	120	27	persistently	persistently	ADV
ajlm-2394	120	28	express	express	VERB
ajlm-2394	120	29	incompletely	incompletely	ADV
ajlm-2394	120	30	repressed	repress	VERB
ajlm-2394	120	31	myeloid	myeloid	ADJ
ajlm-2394	120	32	genes	gene	NOUN
ajlm-2394	120	33	,	,	PUNCT
ajlm-2394	120	34	as	as	SCONJ
ajlm-2394	120	35	suggested	suggest	VERB
ajlm-2394	120	36	for	for	ADP
ajlm-2394	120	37	b	b	NOUN
ajlm-2394	120	38	-	-	PUNCT
ajlm-2394	120	39	all.33	all.33	NOUN
ajlm-2394	120	40	further	further	ADJ
ajlm-2394	120	41	characterisation	characterisation	NOUN
ajlm-2394	120	42	will	will	AUX
ajlm-2394	120	43	be	be	AUX
ajlm-2394	120	44	necessary	necessary	ADJ
ajlm-2394	120	45	to	to	PART
ajlm-2394	120	46	distinguish	distinguish	VERB
ajlm-2394	120	47	between	between	ADP
ajlm-2394	120	48	these	these	DET
ajlm-2394	120	49	possibilities	possibility	NOUN
ajlm-2394	120	50	.	.	PUNCT
ajlm-2394	121	1	there	there	PRON
ajlm-2394	121	2	are	be	VERB
ajlm-2394	121	3	no	no	DET
ajlm-2394	121	4	generally	generally	ADV
ajlm-2394	121	5	accepted	accept	VERB
ajlm-2394	121	6	guidelines	guideline	NOUN
ajlm-2394	121	7	for	for	ADP
ajlm-2394	121	8	the	the	DET
ajlm-2394	121	9	sub	sub	NOUN
ajlm-2394	121	10	-	-	NOUN
ajlm-2394	121	11	classification	classification	NOUN
ajlm-2394	121	12	of	of	ADP
ajlm-2394	121	13	aml	aml	NOUN
ajlm-2394	121	14	by	by	ADP
ajlm-2394	121	15	flow	flow	NOUN
ajlm-2394	121	16	cytometry	cytometry	NOUN
ajlm-2394	121	17	.	.	PUNCT
ajlm-2394	122	1	originally	originally	ADV
ajlm-2394	122	2	,	,	PUNCT
ajlm-2394	122	3	the	the	DET
ajlm-2394	122	4	french	french	ADJ
ajlm-2394	122	5	-	-	PUNCT
ajlm-2394	122	6	american	american	ADJ
ajlm-2394	122	7	-	-	PUNCT
ajlm-2394	122	8	british	british	ADJ
ajlm-2394	122	9	classifications	classification	NOUN
ajlm-2394	122	10	defined	define	VERB
ajlm-2394	122	11	subgroups	subgroup	NOUN
ajlm-2394	122	12	of	of	ADP
ajlm-2394	122	13	aml	aml	NOUN
ajlm-2394	122	14	-	-	PUNCT
ajlm-2394	122	15	m0	m0	NOUN
ajlm-2394	122	16	,	,	PUNCT
ajlm-2394	122	17	-m1	-m1	INTJ
ajlm-2394	122	18	,	,	PUNCT
ajlm-2394	122	19	-m2	-m2	PROPN
ajlm-2394	122	20	,	,	PUNCT
ajlm-2394	122	21	-m3	-m3	ADV
ajlm-2394	122	22	,	,	PUNCT
ajlm-2394	122	23	-m4	-m4	NOUN
ajlm-2394	122	24	,	,	PUNCT
ajlm-2394	122	25	-m5	-m5	PROPN
ajlm-2394	122	26	,	,	PUNCT
ajlm-2394	122	27	-m6	-m6	PROPN
ajlm-2394	122	28	and	and	CCONJ
ajlm-2394	122	29	-m7	-m7	PROPN
ajlm-2394	122	30	,	,	PUNCT
ajlm-2394	122	31	which	which	PRON
ajlm-2394	122	32	represented	represent	VERB
ajlm-2394	122	33	,	,	PUNCT
ajlm-2394	122	34	respectively	respectively	ADV
ajlm-2394	122	35	,	,	PUNCT
ajlm-2394	122	36	aml	aml	NOUN
ajlm-2394	122	37	with	with	ADP
ajlm-2394	122	38	minimally	minimally	ADV
ajlm-2394	122	39	differentiated	differentiated	ADJ
ajlm-2394	122	40	,	,	PUNCT
ajlm-2394	122	41	aml	aml	NOUN
ajlm-2394	122	42	without	without	ADP
ajlm-2394	122	43	maturation	maturation	NOUN
ajlm-2394	122	44	,	,	PUNCT
ajlm-2394	122	45	aml	aml	NOUN
ajlm-2394	122	46	with	with	ADP
ajlm-2394	122	47	maturation	maturation	NOUN
ajlm-2394	122	48	,	,	PUNCT
ajlm-2394	122	49	acute	acute	ADJ
ajlm-2394	122	50	promyelocytic	promyelocytic	ADJ
ajlm-2394	122	51	leukaemia	leukaemia	NOUN
ajlm-2394	122	52	,	,	PUNCT
ajlm-2394	122	53	acute	acute	ADJ
ajlm-2394	122	54	myelomonocytic	myelomonocytic	ADJ
ajlm-2394	122	55	leukaemia	leukaemia	NOUN
ajlm-2394	122	56	,	,	PUNCT
ajlm-2394	122	57	acute	acute	ADJ
ajlm-2394	122	58	monocytic	monocytic	ADJ
ajlm-2394	122	59	leukaemia	leukaemia	NOUN
ajlm-2394	122	60	,	,	PUNCT
ajlm-2394	122	61	acute	acute	ADJ
ajlm-2394	122	62	erythroid	erythroid	ADJ
ajlm-2394	122	63	leukaemia	leukaemia	PROPN
ajlm-2394	122	64	and	and	CCONJ
ajlm-2394	122	65	acute	acute	ADJ
ajlm-2394	122	66	megakaryocytic	megakaryocytic	ADJ
ajlm-2394	122	67	leukaemia	leukaemia	NOUN
ajlm-2394	122	68	.	.	PUNCT
ajlm-2394	123	1	the	the	DET
ajlm-2394	123	2	newer	new	ADJ
ajlm-2394	123	3	who	who	PRON
ajlm-2394	123	4	classifications10	classifications10	NOUN
ajlm-2394	123	5	comprise	comprise	NOUN
ajlm-2394	123	6	mostly	mostly	ADV
ajlm-2394	123	7	recurrent	recurrent	ADJ
ajlm-2394	123	8	cytogenetic	cytogenetic	ADJ
ajlm-2394	123	9	translocations	translocation	NOUN
ajlm-2394	123	10	in	in	ADP
ajlm-2394	123	11	aml	aml	NOUN
ajlm-2394	123	12	,	,	PUNCT
ajlm-2394	123	13	and	and	CCONJ
ajlm-2394	123	14	aml	aml	PROPN
ajlm-2394	123	15	not	not	PART
ajlm-2394	123	16	otherwise	otherwise	ADV
ajlm-2394	123	17	categorised	categorise	VERB
ajlm-2394	123	18	.	.	PUNCT
ajlm-2394	124	1	the	the	DET
ajlm-2394	124	2	former	former	ADJ
ajlm-2394	124	3	category	category	NOUN
ajlm-2394	124	4	includes	include	VERB
ajlm-2394	124	5	aml	aml	NOUN
ajlm-2394	124	6	with	with	ADP
ajlm-2394	124	7	t(8;21	t(8;21	PROPN
ajlm-2394	124	8	)	)	PUNCT
ajlm-2394	124	9	,	,	PUNCT
ajlm-2394	124	10	aml	aml	NOUN
ajlm-2394	124	11	with	with	ADP
ajlm-2394	124	12	t(16;16	t(16;16	PROPN
ajlm-2394	124	13	)	)	PUNCT
ajlm-2394	124	14	,	,	PUNCT
ajlm-2394	124	15	aml	aml	NOUN
ajlm-2394	124	16	with	with	ADP
ajlm-2394	124	17	t(15;17	t(15;17	PROPN
ajlm-2394	124	18	)	)	PUNCT
ajlm-2394	124	19	,	,	PUNCT
ajlm-2394	124	20	as	as	ADV
ajlm-2394	124	21	well	well	ADV
ajlm-2394	124	22	as	as	ADP
ajlm-2394	124	23	several	several	ADJ
ajlm-2394	124	24	other	other	ADJ
ajlm-2394	124	25	translocations	translocation	NOUN
ajlm-2394	124	26	and	and	CCONJ
ajlm-2394	124	27	genetic	genetic	ADJ
ajlm-2394	124	28	anomalies	anomaly	NOUN
ajlm-2394	124	29	or	or	CCONJ
ajlm-2394	124	30	mutations	mutation	NOUN
ajlm-2394	124	31	which	which	PRON
ajlm-2394	124	32	are	be	AUX
ajlm-2394	124	33	less	less	ADV
ajlm-2394	124	34	common	common	ADJ
ajlm-2394	124	35	.	.	PUNCT
ajlm-2394	125	1	the	the	DET
ajlm-2394	125	2	t(8;21	t(8;21	PROPN
ajlm-2394	125	3	)	)	PUNCT
ajlm-2394	125	4	translocation	translocation	NOUN
ajlm-2394	125	5	is	be	AUX
ajlm-2394	125	6	commonly	commonly	ADV
ajlm-2394	125	7	associated	associate	VERB
ajlm-2394	125	8	with	with	ADP
ajlm-2394	125	9	some	some	DET
ajlm-2394	125	10	aml	aml	PROPN
ajlm-2394	125	11	-	-	PUNCT
ajlm-2394	125	12	m2	m2	PROPN
ajlm-2394	125	13	,	,	PUNCT
ajlm-2394	125	14	the	the	DET
ajlm-2394	125	15	t(16;16	t(16;16	NOUN
ajlm-2394	125	16	)	)	PUNCT
ajlm-2394	125	17	with	with	ADP
ajlm-2394	125	18	some	some	DET
ajlm-2394	125	19	aml	aml	NOUN
ajlm-2394	125	20	-	-	PUNCT
ajlm-2394	125	21	m4	m4	PROPN
ajlm-2394	125	22	,	,	PUNCT
ajlm-2394	125	23	and	and	CCONJ
ajlm-2394	125	24	the	the	DET
ajlm-2394	125	25	t(15;17	t(15;17	NOUN
ajlm-2394	125	26	)	)	PUNCT
ajlm-2394	125	27	with	with	ADP
ajlm-2394	125	28	some	some	DET
ajlm-2394	125	29	aml	aml	PROPN
ajlm-2394	125	30	-	-	PUNCT
ajlm-2394	125	31	m3	m3	PROPN
ajlm-2394	125	32	.	.	PUNCT
ajlm-2394	126	1	however	however	ADV
ajlm-2394	126	2	,	,	PUNCT
ajlm-2394	126	3	many	many	ADJ
ajlm-2394	126	4	genetic	genetic	ADJ
ajlm-2394	126	5	anomalies	anomaly	NOUN
ajlm-2394	126	6	do	do	AUX
ajlm-2394	126	7	not	not	PART
ajlm-2394	126	8	neatly	neatly	ADV
ajlm-2394	126	9	map	map	VERB
ajlm-2394	126	10	to	to	ADP
ajlm-2394	126	11	old	old	ADJ
ajlm-2394	126	12	fab	fab	NOUN
ajlm-2394	126	13	categories	category	NOUN
ajlm-2394	126	14	,	,	PUNCT
ajlm-2394	126	15	and	and	CCONJ
ajlm-2394	126	16	,	,	PUNCT
ajlm-2394	126	17	conversely	conversely	ADV
ajlm-2394	126	18	,	,	PUNCT
ajlm-2394	126	19	many	many	ADJ
ajlm-2394	126	20	aml	aml	NOUN
ajlm-2394	126	21	do	do	AUX
ajlm-2394	126	22	not	not	PART
ajlm-2394	126	23	have	have	AUX
ajlm-2394	126	24	defined	define	VERB
ajlm-2394	126	25	cytogenetic	cytogenetic	ADJ
ajlm-2394	126	26	anomalies	anomaly	NOUN
ajlm-2394	126	27	.	.	PUNCT
ajlm-2394	127	1	the	the	DET
ajlm-2394	127	2	new	new	ADJ
ajlm-2394	127	3	who	who	PRON
ajlm-2394	127	4	general	general	ADJ
ajlm-2394	127	5	category	category	NOUN
ajlm-2394	127	6	of	of	ADP
ajlm-2394	127	7	aml	aml	PROPN
ajlm-2394	127	8	not	not	PART
ajlm-2394	127	9	otherwise	otherwise	ADV
ajlm-2394	127	10	categorised	categorise	VERB
ajlm-2394	127	11	thus	thus	ADV
ajlm-2394	127	12	includes	include	VERB
ajlm-2394	127	13	subcategories	subcategorie	NOUN
ajlm-2394	127	14	which	which	PRON
ajlm-2394	127	15	align	align	VERB
ajlm-2394	127	16	with	with	ADP
ajlm-2394	127	17	the	the	DET
ajlm-2394	127	18	previous	previous	ADJ
ajlm-2394	127	19	fab	fab	NOUN
ajlm-2394	127	20	system.10	system.10	ADV
ajlm-2394	127	21	because	because	SCONJ
ajlm-2394	127	22	we	we	PRON
ajlm-2394	127	23	were	be	AUX
ajlm-2394	127	24	neither	neither	CCONJ
ajlm-2394	127	25	able	able	ADJ
ajlm-2394	127	26	to	to	PART
ajlm-2394	127	27	obtain	obtain	VERB
ajlm-2394	127	28	cytogenetics	cytogenetic	NOUN
ajlm-2394	127	29	for	for	ADP
ajlm-2394	127	30	our	our	PRON
ajlm-2394	127	31	samples	sample	NOUN
ajlm-2394	127	32	,	,	PUNCT
ajlm-2394	127	33	nor	nor	CCONJ
ajlm-2394	127	34	able	able	ADJ
ajlm-2394	127	35	to	to	PART
ajlm-2394	127	36	obtain	obtain	VERB
ajlm-2394	127	37	fab	fab	ADJ
ajlm-2394	127	38	subtypes	subtype	NOUN
ajlm-2394	127	39	by	by	ADP
ajlm-2394	127	40	morphology	morphology	NOUN
ajlm-2394	127	41	on	on	ADP
ajlm-2394	127	42	most	most	ADJ
ajlm-2394	127	43	of	of	ADP
ajlm-2394	127	44	the	the	DET
ajlm-2394	127	45	samples	sample	NOUN
ajlm-2394	127	46	,	,	PUNCT
ajlm-2394	127	47	we	we	PRON
ajlm-2394	127	48	opted	opt	VERB
ajlm-2394	127	49	for	for	ADP
ajlm-2394	127	50	an	an	DET
ajlm-2394	127	51	ad	ad	NOUN
ajlm-2394	127	52	hoc	hoc	X
ajlm-2394	127	53	flow	flow	NOUN
ajlm-2394	127	54	cytometric	cytometric	ADJ
ajlm-2394	127	55	classification	classification	NOUN
ajlm-2394	127	56	based	base	VERB
ajlm-2394	127	57	on	on	ADP
ajlm-2394	127	58	published	publish	VERB
ajlm-2394	127	59	literature.35	literature.35	NOUN
ajlm-2394	127	60	there	there	PRON
ajlm-2394	127	61	are	be	VERB
ajlm-2394	127	62	extensive	extensive	ADJ
ajlm-2394	127	63	published	publish	VERB
ajlm-2394	127	64	data	datum	NOUN
ajlm-2394	127	65	available	available	ADJ
ajlm-2394	127	66	,	,	PUNCT
ajlm-2394	127	67	both	both	CCONJ
ajlm-2394	127	68	in	in	ADP
ajlm-2394	127	69	relation	relation	NOUN
ajlm-2394	127	70	to	to	ADP
ajlm-2394	127	71	fab	fab	NOUN
ajlm-2394	127	72	types	type	NOUN
ajlm-2394	127	73	as	as	ADV
ajlm-2394	127	74	well	well	ADV
ajlm-2394	127	75	as	as	ADP
ajlm-2394	127	76	in	in	ADP
ajlm-2394	127	77	relation	relation	NOUN
ajlm-2394	127	78	to	to	PART
ajlm-2394	127	79	abnormalities.35	abnormalities.35	VERB
ajlm-2394	127	80	in	in	ADP
ajlm-2394	127	81	the	the	DET
ajlm-2394	127	82	present	present	ADJ
ajlm-2394	127	83	study	study	NOUN
ajlm-2394	127	84	,	,	PUNCT
ajlm-2394	127	85	we	we	PRON
ajlm-2394	127	86	made	make	VERB
ajlm-2394	127	87	arbitrary	arbitrary	ADJ
ajlm-2394	127	88	classifications	classification	NOUN
ajlm-2394	127	89	based	base	VERB
ajlm-2394	127	90	on	on	ADP
ajlm-2394	127	91	these	these	DET
ajlm-2394	127	92	published	publish	VERB
ajlm-2394	127	93	data	datum	NOUN
ajlm-2394	127	94	.	.	PUNCT
ajlm-2394	128	1	with	with	ADP
ajlm-2394	128	2	regard	regard	NOUN
ajlm-2394	128	3	to	to	ADP
ajlm-2394	128	4	aml	aml	NOUN
ajlm-2394	128	5	-	-	PUNCT
ajlm-2394	128	6	m0	m0	NOUN
ajlm-2394	128	7	,	,	PUNCT
ajlm-2394	128	8	-m1	-m1	PUNCT
ajlm-2394	128	9	and	and	CCONJ
ajlm-2394	128	10	-m2	-m2	PROPN
ajlm-2394	128	11	,	,	PUNCT
ajlm-2394	128	12	we	we	PRON
ajlm-2394	128	13	made	make	VERB
ajlm-2394	128	14	no	no	DET
ajlm-2394	128	15	attempt	attempt	NOUN
ajlm-2394	128	16	to	to	PART
ajlm-2394	128	17	differentiate	differentiate	VERB
ajlm-2394	128	18	between	between	ADP
ajlm-2394	128	19	these	these	DET
ajlm-2394	128	20	types	type	NOUN
ajlm-2394	128	21	using	use	VERB
ajlm-2394	128	22	flow	flow	NOUN
ajlm-2394	128	23	cytometry	cytometry	NOUN
ajlm-2394	128	24	.	.	PUNCT
ajlm-2394	129	1	we	we	PRON
ajlm-2394	129	2	further	far	ADV
ajlm-2394	129	3	subdivided	subdivide	VERB
ajlm-2394	129	4	aml	aml	PROPN
ajlm-2394	129	5	into	into	ADP
ajlm-2394	129	6	m3	m3	PROPN
ajlm-2394	129	7	-	-	PUNCT
ajlm-2394	129	8	like	like	ADJ
ajlm-2394	129	9	,	,	PUNCT
ajlm-2394	129	10	m4	m4	PROPN
ajlm-2394	129	11	-	-	PUNCT
ajlm-2394	129	12	like	like	ADJ
ajlm-2394	129	13	,	,	PUNCT
ajlm-2394	129	14	m5	m5	NOUN
ajlm-2394	129	15	-	-	PUNCT
ajlm-2394	129	16	like	like	ADJ
ajlm-2394	129	17	categories	category	NOUN
ajlm-2394	129	18	.	.	PUNCT
ajlm-2394	130	1	in	in	ADP
ajlm-2394	130	2	comparing	compare	VERB
ajlm-2394	130	3	our	our	PRON
ajlm-2394	130	4	distributions	distribution	NOUN
ajlm-2394	130	5	of	of	ADP
ajlm-2394	130	6	aml	aml	PROPN
ajlm-2394	130	7	subtypes	subtype	NOUN
ajlm-2394	130	8	with	with	ADP
ajlm-2394	130	9	the	the	DET
ajlm-2394	130	10	reported	report	VERB
ajlm-2394	130	11	literature	literature	NOUN
ajlm-2394	130	12	our	our	PRON
ajlm-2394	130	13	prevalence	prevalence	NOUN
ajlm-2394	130	14	aml	aml	PROPN
ajlm-2394	130	15	m0	m0	PROPN
ajlm-2394	130	16	-	-	PUNCT
ajlm-2394	130	17	2	2	NUM
ajlm-2394	130	18	-	-	PUNCT
ajlm-2394	130	19	like	like	NOUN
ajlm-2394	130	20	was	be	AUX
ajlm-2394	130	21	higher	high	ADJ
ajlm-2394	130	22	than	than	ADP
ajlm-2394	130	23	what	what	PRON
ajlm-2394	130	24	would	would	AUX
ajlm-2394	130	25	be	be	AUX
ajlm-2394	130	26	predicted	predict	VERB
ajlm-2394	130	27	by	by	ADP
ajlm-2394	130	28	other	other	ADJ
ajlm-2394	130	29	reports	report	NOUN
ajlm-2394	130	30	in	in	ADP
ajlm-2394	130	31	the	the	DET
ajlm-2394	130	32	literature	literature	NOUN
ajlm-2394	130	33	,	,	PUNCT
ajlm-2394	130	34	and	and	CCONJ
ajlm-2394	130	35	our	our	PRON
ajlm-2394	130	36	estimated	estimate	VERB
ajlm-2394	130	37	prevalence	prevalence	NOUN
ajlm-2394	130	38	of	of	ADP
ajlm-2394	130	39	m4	m4	PROPN
ajlm-2394	130	40	-	-	PUNCT
ajlm-2394	130	41	like	like	ADJ
ajlm-2394	130	42	and	and	CCONJ
ajlm-2394	130	43	m5	m5	NOUN
ajlm-2394	130	44	-	-	PUNCT
ajlm-2394	130	45	like	like	ADJ
ajlm-2394	130	46	were	be	AUX
ajlm-2394	130	47	lower.36	lower.36	VERB
ajlm-2394	130	48	among	among	ADP
ajlm-2394	130	49	the	the	DET
ajlm-2394	130	50	four	four	NUM
ajlm-2394	130	51	aml	aml	NOUN
ajlm-2394	130	52	subtypes	subtype	NOUN
ajlm-2394	130	53	,	,	PUNCT
ajlm-2394	130	54	all	all	PRON
ajlm-2394	130	55	identified	identify	VERB
ajlm-2394	130	56	in	in	ADP
ajlm-2394	130	57	adults	adult	NOUN
ajlm-2394	130	58	and	and	CCONJ
ajlm-2394	130	59	aml	aml	NOUN
ajlm-2394	130	60	-	-	PUNCT
ajlm-2394	130	61	m0	m0	NOUN
ajlm-2394	130	62	-	-	PUNCT
ajlm-2394	130	63	m2	m2	NOUN
ajlm-2394	130	64	-	-	PUNCT
ajlm-2394	130	65	like	like	ADJ
ajlm-2394	130	66	subtypes	subtype	NOUN
ajlm-2394	130	67	were	be	AUX
ajlm-2394	130	68	more	more	ADV
ajlm-2394	130	69	identified	identify	VERB
ajlm-2394	130	70	in	in	ADP
ajlm-2394	130	71	adolescent	adolescent	ADJ
ajlm-2394	130	72	cases	case	NOUN
ajlm-2394	130	73	,	,	PUNCT
ajlm-2394	130	74	and	and	CCONJ
ajlm-2394	130	75	it	it	PRON
ajlm-2394	130	76	is	be	AUX
ajlm-2394	130	77	similar	similar	ADJ
ajlm-2394	130	78	with	with	ADP
ajlm-2394	130	79	a	a	DET
ajlm-2394	130	80	previous	previous	ADJ
ajlm-2394	130	81	study.37	study.37	NOUN
ajlm-2394	130	82	in	in	ADP
ajlm-2394	130	83	this	this	DET
ajlm-2394	130	84	study	study	NOUN
ajlm-2394	130	85	,	,	PUNCT
ajlm-2394	130	86	m0	m0	NOUN
ajlm-2394	130	87	-	-	PUNCT
ajlm-2394	130	88	2	2	NUM
ajlm-2394	130	89	-	-	PUNCT
ajlm-2394	130	90	like	like	NOUN
ajlm-2394	130	91	was	be	AUX
ajlm-2394	130	92	largely	largely	ADV
ajlm-2394	130	93	defined	define	VERB
ajlm-2394	130	94	on	on	ADP
ajlm-2394	130	95	the	the	DET
ajlm-2394	130	96	basis	basis	NOUN
ajlm-2394	130	97	of	of	ADP
ajlm-2394	130	98	the	the	DET
ajlm-2394	130	99	simultaneous	simultaneous	ADJ
ajlm-2394	130	100	expression	expression	NOUN
ajlm-2394	130	101	of	of	ADP
ajlm-2394	130	102	immature	immature	ADJ
ajlm-2394	130	103	markers	marker	NOUN
ajlm-2394	130	104	,	,	PUNCT
ajlm-2394	130	105	including	include	VERB
ajlm-2394	130	106	cd34	cd34	PROPN
ajlm-2394	130	107	,	,	PUNCT
ajlm-2394	130	108	cd117	cd117	PROPN
ajlm-2394	130	109	and	and	CCONJ
ajlm-2394	130	110	hla	hla	PROPN
ajlm-2394	130	111	-	-	PUNCT
ajlm-2394	130	112	dr	dr	PROPN
ajlm-2394	130	113	.	.	PUNCT
ajlm-2394	131	1	the	the	DET
ajlm-2394	131	2	majority	majority	NOUN
ajlm-2394	131	3	of	of	ADP
ajlm-2394	131	4	aml	aml	PROPN
ajlm-2394	131	5	were	be	AUX
ajlm-2394	131	6	of	of	ADP
ajlm-2394	131	7	this	this	DET
ajlm-2394	131	8	arbitrary	arbitrary	ADJ
ajlm-2394	131	9	classification	classification	NOUN
ajlm-2394	131	10	.	.	PUNCT
ajlm-2394	132	1	however	however	ADV
ajlm-2394	132	2	,	,	PUNCT
ajlm-2394	132	3	cd34	cd34	PROPN
ajlm-2394	132	4	and	and	CCONJ
ajlm-2394	132	5	cd117	cd117	PROPN
ajlm-2394	132	6	co	co	NOUN
ajlm-2394	132	7	-	-	NOUN
ajlm-2394	132	8	expression	expression	NOUN
ajlm-2394	132	9	is	be	AUX
ajlm-2394	132	10	not	not	PART
ajlm-2394	132	11	universal	universal	ADJ
ajlm-2394	132	12	in	in	ADP
ajlm-2394	132	13	aml	aml	PROPN
ajlm-2394	132	14	-	-	PUNCT
ajlm-2394	132	15	m0	m0	NOUN
ajlm-2394	132	16	,	,	PUNCT
ajlm-2394	132	17	-m1	-m1	INTJ
ajlm-2394	132	18	,	,	PUNCT
ajlm-2394	132	19	and/or	and/or	CCONJ
ajlm-2394	132	20	-m2.35	-m2.35	PROPN
ajlm-2394	132	21	thus	thus	ADV
ajlm-2394	132	22	,	,	PUNCT
ajlm-2394	132	23	this	this	PRON
ajlm-2394	132	24	may	may	AUX
ajlm-2394	132	25	be	be	AUX
ajlm-2394	132	26	a	a	DET
ajlm-2394	132	27	principal	principal	ADJ
ajlm-2394	132	28	explanation	explanation	NOUN
ajlm-2394	132	29	why	why	SCONJ
ajlm-2394	132	30	our	our	PRON
ajlm-2394	132	31	prevalence	prevalence	NOUN
ajlm-2394	132	32	estimates	estimate	NOUN
ajlm-2394	132	33	for	for	ADP
ajlm-2394	132	34	aml	aml	PROPN
ajlm-2394	132	35	subtypes	subtype	NOUN
ajlm-2394	132	36	differ	differ	VERB
ajlm-2394	132	37	from	from	ADP
ajlm-2394	132	38	other	other	ADJ
ajlm-2394	132	39	studies.38	studies.38	PROPN
ajlm-2394	132	40	a	a	DET
ajlm-2394	132	41	distinct	distinct	ADJ
ajlm-2394	132	42	subset	subset	NOUN
ajlm-2394	132	43	of	of	ADP
ajlm-2394	132	44	aml	aml	PROPN
ajlm-2394	132	45	-	-	PUNCT
ajlm-2394	132	46	m2	m2	PROPN
ajlm-2394	132	47	leukaemias	leukaemia	NOUN
ajlm-2394	132	48	include	include	VERB
ajlm-2394	132	49	those	those	PRON
ajlm-2394	132	50	with	with	ADP
ajlm-2394	132	51	the	the	DET
ajlm-2394	132	52	t(8;21	t(8;21	PROPN
ajlm-2394	132	53	)	)	PUNCT
ajlm-2394	132	54	translocation	translocation	NOUN
ajlm-2394	132	55	,	,	PUNCT
ajlm-2394	132	56	which	which	PRON
ajlm-2394	132	57	typically	typically	ADV
ajlm-2394	132	58	results	result	VERB
ajlm-2394	132	59	in	in	ADP
ajlm-2394	132	60	the	the	DET
ajlm-2394	132	61	aberrant	aberrant	ADJ
ajlm-2394	132	62	expression	expression	NOUN
ajlm-2394	132	63	of	of	ADP
ajlm-2394	132	64	cd19	cd19	PROPN
ajlm-2394	132	65	and	and	CCONJ
ajlm-2394	132	66	cd56	cd56	PROPN
ajlm-2394	132	67	,	,	PUNCT
ajlm-2394	132	68	a	a	DET
ajlm-2394	132	69	phenotype	phenotype	NOUN
ajlm-2394	132	70	which	which	PRON
ajlm-2394	132	71	has	have	AUX
ajlm-2394	132	72	been	be	AUX
ajlm-2394	132	73	reported	report	VERB
ajlm-2394	132	74	in	in	ADP
ajlm-2394	132	75	association	association	NOUN
ajlm-2394	132	76	with	with	ADP
ajlm-2394	132	77	the	the	DET
ajlm-2394	132	78	t(8;21	t(8;21	PROPN
ajlm-2394	132	79	)	)	PUNCT
ajlm-2394	132	80	translocation.39	translocation.39	NOUN
ajlm-2394	132	81	we	we	PRON
ajlm-2394	132	82	observed	observe	VERB
ajlm-2394	132	83	three	three	NUM
ajlm-2394	132	84	such	such	ADJ
ajlm-2394	132	85	cases	case	NOUN
ajlm-2394	132	86	in	in	ADP
ajlm-2394	132	87	this	this	DET
ajlm-2394	132	88	cohort	cohort	NOUN
ajlm-2394	132	89	within	within	ADP
ajlm-2394	132	90	our	our	PRON
ajlm-2394	132	91	‘	'	PUNCT
ajlm-2394	132	92	m0	m0	NOUN
ajlm-2394	132	93	-	-	PUNCT
ajlm-2394	132	94	2	2	NUM
ajlm-2394	132	95	-	-	PUNCT
ajlm-2394	132	96	like	like	ADJ
ajlm-2394	132	97	’	'	PUNCT
ajlm-2394	132	98	subtype	subtype	NOUN
ajlm-2394	132	99	,	,	PUNCT
ajlm-2394	132	100	numbers	number	NOUN
ajlm-2394	132	101	in	in	ADP
ajlm-2394	132	102	line	line	NOUN
ajlm-2394	132	103	with	with	ADP
ajlm-2394	132	104	predictions	prediction	NOUN
ajlm-2394	132	105	based	base	VERB
ajlm-2394	132	106	on	on	ADP
ajlm-2394	132	107	a	a	DET
ajlm-2394	132	108	study	study	NOUN
ajlm-2394	132	109	evaluating	evaluate	VERB
ajlm-2394	132	110	t(8;21).39	t(8;21).39	NOUN
ajlm-2394	132	111	notably	notably	ADV
ajlm-2394	132	112	,	,	PUNCT
ajlm-2394	132	113	these	these	DET
ajlm-2394	132	114	three	three	NUM
ajlm-2394	132	115	did	do	AUX
ajlm-2394	132	116	not	not	PART
ajlm-2394	132	117	express	express	VERB
ajlm-2394	132	118	other	other	ADJ
ajlm-2394	132	119	b	b	NOUN
ajlm-2394	132	120	-	-	PUNCT
ajlm-2394	132	121	cell	cell	NOUN
ajlm-2394	132	122	markers	marker	NOUN
ajlm-2394	132	123	making	make	VERB
ajlm-2394	132	124	a	a	DET
ajlm-2394	132	125	diagnosis	diagnosis	NOUN
ajlm-2394	132	126	of	of	ADP
ajlm-2394	132	127	mixed	mixed	ADJ
ajlm-2394	132	128	phenotype	phenotype	NOUN
ajlm-2394	132	129	or	or	CCONJ
ajlm-2394	132	130	bi	bi	ADJ
ajlm-2394	132	131	-	-	ADJ
ajlm-2394	132	132	lineage	lineage	NOUN
ajlm-2394	132	133	phenotype	phenotype	NOUN
ajlm-2394	132	134	unlikely.40	unlikely.40	NOUN
ajlm-2394	132	135	a	a	DET
ajlm-2394	132	136	previous	previous	ADJ
ajlm-2394	132	137	study	study	NOUN
ajlm-2394	132	138	described	describe	VERB
ajlm-2394	132	139	the	the	DET
ajlm-2394	132	140	t(8;21	t(8;21	PROPN
ajlm-2394	132	141	)	)	PUNCT
ajlm-2394	132	142	translocations	translocation	NOUN
ajlm-2394	132	143	with	with	ADP
ajlm-2394	132	144	lower	low	ADJ
ajlm-2394	132	145	density	density	NOUN
ajlm-2394	132	146	or	or	CCONJ
ajlm-2394	132	147	lower	low	ADJ
ajlm-2394	132	148	percentage	percentage	NOUN
ajlm-2394	132	149	of	of	ADP
ajlm-2394	132	150	positive	positive	ADJ
ajlm-2394	132	151	cells	cell	NOUN
ajlm-2394	132	152	expressing	express	VERB
ajlm-2394	132	153	these	these	DET
ajlm-2394	132	154	two	two	NUM
ajlm-2394	132	155	markers,41	markers,41	NOUN
ajlm-2394	132	156	and	and	CCONJ
ajlm-2394	132	157	we	we	PRON
ajlm-2394	132	158	did	do	AUX
ajlm-2394	132	159	observe	observe	VERB
ajlm-2394	132	160	other	other	ADJ
ajlm-2394	132	161	‘	'	PUNCT
ajlm-2394	132	162	m0	m0	NOUN
ajlm-2394	132	163	-	-	PUNCT
ajlm-2394	132	164	2	2	NUM
ajlm-2394	132	165	-	-	PUNCT
ajlm-2394	132	166	like	like	ADJ
ajlm-2394	132	167	’	'	PUNCT
ajlm-2394	132	168	with	with	ADP
ajlm-2394	132	169	similar	similar	ADJ
ajlm-2394	132	170	phenotypes	phenotype	NOUN
ajlm-2394	132	171	which	which	PRON
ajlm-2394	132	172	could	could	AUX
ajlm-2394	132	173	also	also	ADV
ajlm-2394	132	174	conceivably	conceivably	ADV
ajlm-2394	132	175	express	express	VERB
ajlm-2394	132	176	the	the	DET
ajlm-2394	132	177	t(8;21	t(8;21	PROPN
ajlm-2394	132	178	)	)	PUNCT
ajlm-2394	132	179	translocation	translocation	NOUN
ajlm-2394	132	180	.	.	PUNCT
ajlm-2394	133	1	further	further	ADJ
ajlm-2394	133	2	work	work	NOUN
ajlm-2394	133	3	will	will	AUX
ajlm-2394	133	4	be	be	AUX
ajlm-2394	133	5	required	require	VERB
ajlm-2394	133	6	to	to	PART
ajlm-2394	133	7	assess	assess	VERB
ajlm-2394	133	8	this	this	DET
ajlm-2394	133	9	possibility	possibility	NOUN
ajlm-2394	133	10	.	.	PUNCT
ajlm-2394	134	1	in	in	ADP
ajlm-2394	134	2	addition	addition	NOUN
ajlm-2394	134	3	,	,	PUNCT
ajlm-2394	134	4	we	we	PRON
ajlm-2394	134	5	observed	observe	VERB
ajlm-2394	134	6	that	that	SCONJ
ajlm-2394	134	7	among	among	ADP
ajlm-2394	134	8	the	the	DET
ajlm-2394	134	9	‘	'	PUNCT
ajlm-2394	134	10	m0	m0	NOUN
ajlm-2394	134	11	-	-	PUNCT
ajlm-2394	134	12	2	2	NUM
ajlm-2394	134	13	-	-	PUNCT
ajlm-2394	134	14	like	like	ADJ
ajlm-2394	134	15	’	'	PUNCT
ajlm-2394	134	16	leukaemias	leukaemia	VERB
ajlm-2394	134	17	,	,	PUNCT
ajlm-2394	134	18	a	a	DET
ajlm-2394	134	19	relatively	relatively	ADV
ajlm-2394	134	20	high	high	ADJ
ajlm-2394	134	21	fraction	fraction	NOUN
ajlm-2394	134	22	expressed	express	VERB
ajlm-2394	134	23	the	the	DET
ajlm-2394	134	24	cd7	cd7	PROPN
ajlm-2394	134	25	and	and	CCONJ
ajlm-2394	134	26	tdt	tdt	PROPN
ajlm-2394	134	27	markers	marker	NOUN
ajlm-2394	134	28	,	,	PUNCT
ajlm-2394	134	29	typically	typically	ADV
ajlm-2394	134	30	associated	associate	VERB
ajlm-2394	134	31	with	with	ADP
ajlm-2394	134	32	early	early	ADJ
ajlm-2394	134	33	lymphocyte	lymphocyte	ADJ
ajlm-2394	134	34	progenitors	progenitor	NOUN
ajlm-2394	134	35	and	and	CCONJ
ajlm-2394	134	36	cells	cell	NOUN
ajlm-2394	134	37	of	of	ADP
ajlm-2394	134	38	the	the	DET
ajlm-2394	134	39	t	t	NOUN
ajlm-2394	134	40	-	-	PUNCT
ajlm-2394	134	41	cell	cell	NOUN
ajlm-2394	134	42	lineage	lineage	NOUN
ajlm-2394	134	43	,	,	PUNCT
ajlm-2394	134	44	respectively	respectively	ADV
ajlm-2394	134	45	.	.	PUNCT
ajlm-2394	135	1	this	this	PRON
ajlm-2394	135	2	was	be	AUX
ajlm-2394	135	3	also	also	ADV
ajlm-2394	135	4	observed	observe	VERB
ajlm-2394	135	5	in	in	ADP
ajlm-2394	135	6	other	other	ADJ
ajlm-2394	135	7	subtypes	subtype	NOUN
ajlm-2394	135	8	of	of	ADP
ajlm-2394	135	9	aml	aml	PROPN
ajlm-2394	135	10	.	.	PUNCT
ajlm-2394	136	1	the	the	DET
ajlm-2394	136	2	observation	observation	NOUN
ajlm-2394	136	3	that	that	SCONJ
ajlm-2394	136	4	such	such	ADJ
ajlm-2394	136	5	markers	marker	NOUN
ajlm-2394	136	6	are	be	AUX
ajlm-2394	136	7	commonly	commonly	ADV
ajlm-2394	136	8	expressed	express	VERB
ajlm-2394	136	9	among	among	ADP
ajlm-2394	136	10	aml	aml	PROPN
ajlm-2394	136	11	leukaemia	leukaemia	NOUN
ajlm-2394	136	12	is	be	AUX
ajlm-2394	136	13	well	well	ADV
ajlm-2394	136	14	documented.42	documented.42	NOUN
ajlm-2394	136	15	acute	acute	ADJ
ajlm-2394	136	16	myelogenous	myelogenous	ADJ
ajlm-2394	136	17	‘	'	PUNCT
ajlm-2394	136	18	m4	m4	NOUN
ajlm-2394	136	19	-	-	PUNCT
ajlm-2394	136	20	like	like	ADJ
ajlm-2394	136	21	’	'	PUNCT
ajlm-2394	136	22	leukaemia	leukaemia	NOUN
ajlm-2394	136	23	was	be	AUX
ajlm-2394	136	24	easily	easily	ADV
ajlm-2394	136	25	visualised	visualise	VERB
ajlm-2394	136	26	through	through	ADP
ajlm-2394	136	27	the	the	DET
ajlm-2394	136	28	identification	identification	NOUN
ajlm-2394	136	29	of	of	ADP
ajlm-2394	136	30	immature	immature	ADJ
ajlm-2394	136	31	myeloblasts	myeloblast	NOUN
ajlm-2394	136	32	and	and	CCONJ
ajlm-2394	136	33	more	more	ADV
ajlm-2394	136	34	mature	mature	ADJ
ajlm-2394	136	35	monoblast-/monocyte	monoblast-/monocyte	NOUN
ajlm-2394	136	36	-	-	PUNCT
ajlm-2394	136	37	like	like	ADJ
ajlm-2394	136	38	populations.12	populations.12	NOUN
ajlm-2394	136	39	aml	aml	PROPN
ajlm-2394	136	40	-	-	PUNCT
ajlm-2394	136	41	m4	m4	PROPN
ajlm-2394	136	42	leukaemia	leukaemia	NOUN
ajlm-2394	136	43	is	be	AUX
ajlm-2394	136	44	associated	associate	VERB
ajlm-2394	136	45	with	with	ADP
ajlm-2394	136	46	the	the	DET
ajlm-2394	136	47	inv16	inv16	NOUN
ajlm-2394	136	48	chromosome	chromosome	NOUN
ajlm-2394	136	49	abnormality	abnormality	NOUN
ajlm-2394	136	50	and	and	CCONJ
ajlm-2394	136	51	also	also	ADV
ajlm-2394	136	52	with	with	ADP
ajlm-2394	136	53	bone	bone	NOUN
ajlm-2394	136	54	marrow	marrow	PROPN
ajlm-2394	136	55	eosinophilia	eosinophilia	PROPN
ajlm-2394	136	56	,	,	PUNCT
ajlm-2394	136	57	leading	lead	VERB
ajlm-2394	136	58	to	to	ADP
ajlm-2394	136	59	the	the	DET
ajlm-2394	136	60	unique	unique	ADJ
ajlm-2394	136	61	who	who	PRON
ajlm-2394	136	62	diagnostic	diagnostic	VERB
ajlm-2394	136	63	classification	classification	NOUN
ajlm-2394	136	64	.	.	PUNCT
ajlm-2394	137	1	however	however	ADV
ajlm-2394	137	2	,	,	PUNCT
ajlm-2394	137	3	not	not	PART
ajlm-2394	137	4	all	all	DET
ajlm-2394	137	5	forms	form	NOUN
ajlm-2394	137	6	of	of	ADP
ajlm-2394	137	7	aml	aml	PROPN
ajlm-2394	137	8	-	-	PUNCT
ajlm-2394	137	9	m4	m4	NOUN
ajlm-2394	137	10	express	express	VERB
ajlm-2394	137	11	this	this	DET
ajlm-2394	137	12	abnormality,43	abnormality,43	ADJ
ajlm-2394	137	13	and	and	CCONJ
ajlm-2394	137	14	other	other	ADJ
ajlm-2394	137	15	common	common	ADJ
ajlm-2394	137	16	abnormalities	abnormality	NOUN
ajlm-2394	137	17	include	include	VERB
ajlm-2394	137	18	ccaat	ccaat	NOUN
ajlm-2394	137	19	enhancer	enhancer	NOUN
ajlm-2394	137	20	binding	bind	VERB
ajlm-2394	137	21	protein	protein	NOUN
ajlm-2394	137	22	alpha	alpha	NOUN
ajlm-2394	137	23	(	(	PUNCT
ajlm-2394	137	24	cebpa	cebpa	NOUN
ajlm-2394	137	25	)	)	PUNCT
ajlm-2394	137	26	and	and	CCONJ
ajlm-2394	137	27	nmp1	nmp1	PROPN
ajlm-2394	137	28	mutations,44,45	mutations,44,45	NOUN
ajlm-2394	137	29	both	both	PRON
ajlm-2394	137	30	with	with	ADP
ajlm-2394	137	31	generally	generally	ADV
ajlm-2394	137	32	good	good	ADJ
ajlm-2394	137	33	prognosis.46	prognosis.46	PROPN
ajlm-2394	137	34	acute	acute	ADJ
ajlm-2394	137	35	myelogenous	myelogenous	ADJ
ajlm-2394	137	36	‘	'	PUNCT
ajlm-2394	137	37	m5	m5	NOUN
ajlm-2394	137	38	-	-	PUNCT
ajlm-2394	137	39	like	like	ADJ
ajlm-2394	137	40	’	'	PUNCT
ajlm-2394	137	41	leukaemia	leukaemia	NOUN
ajlm-2394	137	42	was	be	AUX
ajlm-2394	137	43	primarily	primarily	ADV
ajlm-2394	137	44	based	base	VERB
ajlm-2394	137	45	in	in	ADP
ajlm-2394	137	46	this	this	DET
ajlm-2394	137	47	study	study	NOUN
ajlm-2394	137	48	on	on	ADP
ajlm-2394	137	49	the	the	DET
ajlm-2394	137	50	detection	detection	NOUN
ajlm-2394	137	51	of	of	ADP
ajlm-2394	137	52	monocyte	monocyte	ADJ
ajlm-2394	137	53	-	-	PUNCT
ajlm-2394	137	54	like	like	ADJ
ajlm-2394	137	55	cell	cell	NOUN
ajlm-2394	137	56	subpopulations	subpopulation	NOUN
ajlm-2394	137	57	expressing	express	VERB
ajlm-2394	137	58	cd14	cd14	PROPN
ajlm-2394	137	59	and	and	CCONJ
ajlm-2394	137	60	cd64	cd64	PROPN
ajlm-2394	137	61	and	and	CCONJ
ajlm-2394	137	62	lack	lack	NOUN
ajlm-2394	137	63	of	of	ADP
ajlm-2394	137	64	immaturity	immaturity	NOUN
ajlm-2394	137	65	markers	marker	NOUN
ajlm-2394	137	66	such	such	ADJ
ajlm-2394	137	67	as	as	ADP
ajlm-2394	137	68	cd34	cd34	PROPN
ajlm-2394	137	69	and	and	CCONJ
ajlm-2394	137	70	cd117	cd117	PROPN
ajlm-2394	137	71	,	,	PUNCT
ajlm-2394	137	72	though	though	SCONJ
ajlm-2394	137	73	the	the	DET
ajlm-2394	137	74	latter	latter	ADJ
ajlm-2394	137	75	two	two	NUM
ajlm-2394	137	76	markers	marker	NOUN
ajlm-2394	137	77	among	among	ADP
ajlm-2394	137	78	m5	m5	NOUN
ajlm-2394	137	79	leukaemias	leukaemia	NOUN
ajlm-2394	137	80	have	have	AUX
ajlm-2394	137	81	been	be	AUX
ajlm-2394	137	82	cited	cite	VERB
ajlm-2394	137	83	in	in	ADP
ajlm-2394	137	84	the	the	DET
ajlm-2394	137	85	literature.40	literature.40	NOUN
ajlm-2394	137	86	a	a	DET
ajlm-2394	137	87	number	number	NOUN
ajlm-2394	137	88	of	of	ADP
ajlm-2394	137	89	mutations	mutation	NOUN
ajlm-2394	137	90	have	have	AUX
ajlm-2394	137	91	been	be	AUX
ajlm-2394	137	92	associated	associate	VERB
ajlm-2394	137	93	with	with	ADP
ajlm-2394	137	94	m5	m5	NOUN
ajlm-2394	137	95	,	,	PUNCT
ajlm-2394	137	96	notably	notably	ADV
ajlm-2394	137	97	the	the	DET
ajlm-2394	137	98	mll	mll	PROPN
ajlm-2394	137	99	containing	contain	VERB
ajlm-2394	137	100	t(9;11)47	t(9;11)47	PROPN
ajlm-2394	137	101	and	and	CCONJ
ajlm-2394	137	102	also	also	ADV
ajlm-2394	137	103	forms	form	VERB
ajlm-2394	137	104	with	with	ADP
ajlm-2394	137	105	npm1	npm1	NOUN
ajlm-2394	137	106	mutations,44	mutations,44	NOUN
ajlm-2394	137	107	although	although	SCONJ
ajlm-2394	137	108	both	both	DET
ajlm-2394	137	109	mutations	mutation	NOUN
ajlm-2394	137	110	are	be	AUX
ajlm-2394	137	111	also	also	ADV
ajlm-2394	137	112	seen	see	VERB
ajlm-2394	137	113	in	in	ADP
ajlm-2394	137	114	other	other	ADJ
ajlm-2394	137	115	aml	aml	NOUN
ajlm-2394	137	116	types.44	types.44	NOUN
ajlm-2394	137	117	the	the	DET
ajlm-2394	137	118	definition	definition	NOUN
ajlm-2394	137	119	we	we	PRON
ajlm-2394	137	120	used	use	VERB
ajlm-2394	137	121	for	for	ADP
ajlm-2394	137	122	aml	aml	PROPN
ajlm-2394	137	123	‘	'	PUNCT
ajlm-2394	137	124	m3	m3	PROPN
ajlm-2394	137	125	-	-	PUNCT
ajlm-2394	137	126	like	like	ADJ
ajlm-2394	137	127	’	'	PUNCT
ajlm-2394	137	128	leukaemias	leukaemia	VERB
ajlm-2394	137	129	represented	represent	VERB
ajlm-2394	137	130	those	those	PRON
ajlm-2394	137	131	with	with	ADP
ajlm-2394	137	132	phenotypes	phenotype	NOUN
ajlm-2394	137	133	more	more	ADV
ajlm-2394	137	134	intermediate	intermediate	ADJ
ajlm-2394	137	135	to	to	ADP
ajlm-2394	137	136	those	those	PRON
ajlm-2394	137	137	of	of	ADP
ajlm-2394	137	138	the	the	DET
ajlm-2394	137	139	immature	immature	ADJ
ajlm-2394	137	140	marker	marker	NOUN
ajlm-2394	137	141	expressing	express	VERB
ajlm-2394	137	142	aml	aml	PROPN
ajlm-2394	137	143	‘	'	PUNCT
ajlm-2394	137	144	m0	m0	NOUN
ajlm-2394	137	145	-	-	PUNCT
ajlm-2394	137	146	2	2	NUM
ajlm-2394	137	147	-	-	PUNCT
ajlm-2394	137	148	like	like	ADJ
ajlm-2394	137	149	’	'	PUNCT
ajlm-2394	137	150	and	and	CCONJ
ajlm-2394	137	151	those	those	PRON
ajlm-2394	137	152	expressing	express	VERB
ajlm-2394	137	153	monocyte	monocyte	NOUN
ajlm-2394	137	154	markers	marker	NOUN
ajlm-2394	137	155	.	.	PUNCT
ajlm-2394	138	1	of	of	ADP
ajlm-2394	138	2	note	note	NOUN
ajlm-2394	138	3	,	,	PUNCT
ajlm-2394	138	4	the	the	DET
ajlm-2394	138	5	majority	majority	NOUN
ajlm-2394	138	6	of	of	ADP
ajlm-2394	138	7	‘	'	PUNCT
ajlm-2394	138	8	m3	m3	PROPN
ajlm-2394	138	9	-	-	PUNCT
ajlm-2394	138	10	like	like	ADJ
ajlm-2394	138	11	’	'	PUNCT
ajlm-2394	138	12	leukaemias	leukaemia	VERB
ajlm-2394	138	13	in	in	ADP
ajlm-2394	138	14	this	this	DET
ajlm-2394	138	15	study	study	NOUN
ajlm-2394	138	16	were	be	AUX
ajlm-2394	138	17	cd34–/cd117	cd34–/cd117	NUM
ajlm-2394	138	18	+	+	SYM
ajlm-2394	138	19	and	and	CCONJ
ajlm-2394	138	20	hla	hla	PROPN
ajlm-2394	138	21	-	-	PUNCT
ajlm-2394	138	22	dr	dr	PROPN
ajlm-2394	138	23	–	–	PUNCT
ajlm-2394	138	24	,	,	PUNCT
ajlm-2394	138	25	a	a	DET
ajlm-2394	138	26	flow	flow	NOUN
ajlm-2394	138	27	cytometry	cytometry	NOUN
ajlm-2394	138	28	phenotype	phenotype	NOUN
ajlm-2394	138	29	often	often	ADV
ajlm-2394	138	30	described	describe	VERB
ajlm-2394	138	31	in	in	ADP
ajlm-2394	138	32	association	association	NOUN
ajlm-2394	138	33	with	with	ADP
ajlm-2394	138	34	aml	aml	PROPN
ajlm-2394	138	35	-	-	PUNCT
ajlm-2394	138	36	m3.48	m3.48	PROPN
ajlm-2394	138	37	importantly	importantly	ADV
ajlm-2394	138	38	the	the	DET
ajlm-2394	138	39	aml	aml	PROPN
ajlm-2394	138	40	-	-	PUNCT
ajlm-2394	138	41	m3	m3	PROPN
ajlm-2394	138	42	phenotype	phenotype	NOUN
ajlm-2394	138	43	is	be	AUX
ajlm-2394	138	44	mostly	mostly	ADV
ajlm-2394	138	45	associated	associate	VERB
ajlm-2394	138	46	with	with	ADP
ajlm-2394	138	47	the	the	DET
ajlm-2394	138	48	t(15;17	t(15;17	NOUN
ajlm-2394	138	49	)	)	PUNCT
ajlm-2394	138	50	rearrangement,12	rearrangement,12	NOUN
ajlm-2394	138	51	but	but	CCONJ
ajlm-2394	138	52	it	it	PRON
ajlm-2394	138	53	is	be	AUX
ajlm-2394	138	54	important	important	ADJ
ajlm-2394	138	55	to	to	PART
ajlm-2394	138	56	note	note	VERB
ajlm-2394	138	57	that	that	PRON
ajlm-2394	138	58	occasional	occasional	ADJ
ajlm-2394	138	59	t(15;17	t(15;17	NOUN
ajlm-2394	138	60	)	)	PUNCT
ajlm-2394	138	61	translocations	translocation	NOUN
ajlm-2394	138	62	exist	exist	VERB
ajlm-2394	138	63	which	which	PRON
ajlm-2394	138	64	are	be	AUX
ajlm-2394	138	65	associated	associate	VERB
ajlm-2394	138	66	with	with	ADP
ajlm-2394	138	67	other	other	ADJ
ajlm-2394	138	68	aml	aml	PROPN
ajlm-2394	138	69	subtypes,49	subtypes,49	PROPN
ajlm-2394	138	70	and	and	CCONJ
ajlm-2394	138	71	even	even	ADV
ajlm-2394	138	72	markers	marker	NOUN
ajlm-2394	138	73	such	such	ADJ
ajlm-2394	138	74	as	as	ADP
ajlm-2394	138	75	ccd3.50	ccd3.50	PROPN
ajlm-2394	138	76	recommendations	recommendation	NOUN
ajlm-2394	138	77	importantly	importantly	ADV
ajlm-2394	138	78	,	,	PUNCT
ajlm-2394	138	79	our	our	PRON
ajlm-2394	138	80	study	study	NOUN
ajlm-2394	138	81	underscores	underscore	VERB
ajlm-2394	138	82	the	the	DET
ajlm-2394	138	83	heterogeneity	heterogeneity	NOUN
ajlm-2394	138	84	of	of	ADP
ajlm-2394	138	85	leukaemia	leukaemia	NOUN
ajlm-2394	138	86	,	,	PUNCT
ajlm-2394	138	87	and	and	CCONJ
ajlm-2394	138	88	the	the	DET
ajlm-2394	138	89	need	need	NOUN
ajlm-2394	138	90	for	for	ADP
ajlm-2394	138	91	future	future	ADJ
ajlm-2394	138	92	use	use	NOUN
ajlm-2394	138	93	of	of	ADP
ajlm-2394	138	94	markers	marker	NOUN
ajlm-2394	138	95	of	of	ADP
ajlm-2394	138	96	molecular	molecular	ADJ
ajlm-2394	138	97	mutations	mutation	NOUN
ajlm-2394	138	98	or	or	CCONJ
ajlm-2394	138	99	chromosomal	chromosomal	ADJ
ajlm-2394	138	100	arrangements	arrangement	NOUN
ajlm-2394	138	101	,	,	PUNCT
ajlm-2394	138	102	as	as	ADV
ajlm-2394	138	103	well	well	ADV
ajlm-2394	138	104	as	as	ADP
ajlm-2394	138	105	evaluation	evaluation	NOUN
ajlm-2394	138	106	of	of	ADP
ajlm-2394	138	107	long	long	ADJ
ajlm-2394	138	108	-	-	PUNCT
ajlm-2394	138	109	term	term	NOUN
ajlm-2394	138	110	patient	patient	ADJ
ajlm-2394	138	111	outcomes	outcome	NOUN
ajlm-2394	138	112	.	.	PUNCT
ajlm-2394	139	1	these	these	PRON
ajlm-2394	139	2	are	be	AUX
ajlm-2394	139	3	planned	plan	VERB
ajlm-2394	139	4	for	for	ADP
ajlm-2394	139	5	future	future	ADJ
ajlm-2394	139	6	studies	study	NOUN
ajlm-2394	139	7	.	.	PUNCT
ajlm-2394	140	1	limitations	limitation	NOUN
ajlm-2394	140	2	our	our	PRON
ajlm-2394	140	3	study	study	NOUN
ajlm-2394	140	4	was	be	AUX
ajlm-2394	140	5	limited	limit	VERB
ajlm-2394	140	6	by	by	ADP
ajlm-2394	140	7	the	the	DET
ajlm-2394	140	8	numbers	number	NOUN
ajlm-2394	140	9	of	of	ADP
ajlm-2394	140	10	markers	marker	NOUN
ajlm-2394	140	11	we	we	PRON
ajlm-2394	140	12	utilised	utilise	VERB
ajlm-2394	140	13	.	.	PUNCT
ajlm-2394	141	1	in	in	ADP
ajlm-2394	141	2	particular	particular	ADJ
ajlm-2394	141	3	,	,	PUNCT
ajlm-2394	141	4	we	we	PRON
ajlm-2394	141	5	did	do	AUX
ajlm-2394	141	6	not	not	PART
ajlm-2394	141	7	look	look	VERB
ajlm-2394	141	8	for	for	ADP
ajlm-2394	141	9	subsets	subset	NOUN
ajlm-2394	141	10	of	of	ADP
ajlm-2394	141	11	aml	aml	NOUN
ajlm-2394	141	12	requiring	require	VERB
ajlm-2394	141	13	additional	additional	ADJ
ajlm-2394	141	14	markers	marker	NOUN
ajlm-2394	141	15	to	to	PART
ajlm-2394	141	16	define	define	VERB
ajlm-2394	141	17	erythroblastic	erythroblastic	ADJ
ajlm-2394	141	18	or	or	CCONJ
ajlm-2394	141	19	megakaryocyte	megakaryocyte	NOUN
ajlm-2394	141	20	leukaemia	leukaemia	NOUN
ajlm-2394	141	21	,	,	PUNCT
ajlm-2394	141	22	mast	mast	NOUN
ajlm-2394	141	23	,	,	PUNCT
ajlm-2394	141	24	natural	natural	ADJ
ajlm-2394	141	25	killer	killer	NOUN
ajlm-2394	141	26	,	,	PUNCT
ajlm-2394	141	27	basophil	basophil	NOUN
ajlm-2394	141	28	or	or	CCONJ
ajlm-2394	141	29	dendritic	dendritic	ADJ
ajlm-2394	141	30	cell	cell	NOUN
ajlm-2394	141	31	leukaemias	leukaemia	VERB
ajlm-2394	141	32	,	,	PUNCT
ajlm-2394	141	33	and	and	CCONJ
ajlm-2394	141	34	did	do	AUX
ajlm-2394	141	35	not	not	PART
ajlm-2394	141	36	characterise	characterise	VERB
ajlm-2394	141	37	mixed	mixed	ADJ
ajlm-2394	141	38	lineage	lineage	NOUN
ajlm-2394	141	39	or	or	CCONJ
ajlm-2394	141	40	phenotype	phenotype	NOUN
ajlm-2394	141	41	leukaemias	leukaemia	VERB
ajlm-2394	141	42	.	.	PUNCT
ajlm-2394	142	1	in	in	ADP
ajlm-2394	142	2	addition	addition	NOUN
ajlm-2394	142	3	,	,	PUNCT
ajlm-2394	142	4	since	since	SCONJ
ajlm-2394	142	5	morphology	morphology	NOUN
ajlm-2394	142	6	results	result	VERB
ajlm-2394	142	7	from	from	ADP
ajlm-2394	142	8	smears	smear	NOUN
ajlm-2394	142	9	can	can	AUX
ajlm-2394	142	10	only	only	ADV
ajlm-2394	142	11	clearly	clearly	ADV
ajlm-2394	142	12	distinguish	distinguish	VERB
ajlm-2394	142	13	between	between	ADP
ajlm-2394	142	14	myeloid	myeloid	NOUN
ajlm-2394	142	15	and	and	CCONJ
ajlm-2394	142	16	lymphoid	lymphoid	ADJ
ajlm-2394	142	17	lineages	lineage	NOUN
ajlm-2394	142	18	,	,	PUNCT
ajlm-2394	142	19	clear	clear	ADV
ajlm-2394	142	20	-	-	PUNCT
ajlm-2394	142	21	cut	cut	VERB
ajlm-2394	142	22	comparisons	comparison	NOUN
ajlm-2394	142	23	can	can	AUX
ajlm-2394	142	24	not	not	PART
ajlm-2394	142	25	be	be	AUX
ajlm-2394	142	26	made	make	VERB
ajlm-2394	142	27	between	between	ADP
ajlm-2394	142	28	morphology	morphology	NOUN
ajlm-2394	142	29	approaches	approach	NOUN
ajlm-2394	142	30	and	and	CCONJ
ajlm-2394	142	31	flow	flow	NOUN
ajlm-2394	142	32	cytometry	cytometry	NOUN
ajlm-2394	142	33	.	.	PUNCT
ajlm-2394	143	1	conclusion	conclusion	NOUN
ajlm-2394	143	2	acute	acute	NOUN
ajlm-2394	143	3	leukaemia	leukaemia	NOUN
ajlm-2394	143	4	diagnosis	diagnosis	NOUN
ajlm-2394	143	5	and	and	CCONJ
ajlm-2394	143	6	prognosis	prognosis	NOUN
ajlm-2394	143	7	represent	represent	VERB
ajlm-2394	143	8	a	a	DET
ajlm-2394	143	9	challenge	challenge	NOUN
ajlm-2394	143	10	in	in	ADP
ajlm-2394	143	11	resource	resource	NOUN
ajlm-2394	143	12	-	-	PUNCT
ajlm-2394	143	13	limited	limit	VERB
ajlm-2394	143	14	settings	setting	NOUN
ajlm-2394	143	15	.	.	PUNCT
ajlm-2394	144	1	most	most	ADJ
ajlm-2394	144	2	of	of	ADP
ajlm-2394	144	3	the	the	DET
ajlm-2394	144	4	more	more	ADV
ajlm-2394	144	5	advanced	advanced	ADJ
ajlm-2394	144	6	approaches	approach	NOUN
ajlm-2394	144	7	utilised	utilise	VERB
ajlm-2394	144	8	in	in	ADP
ajlm-2394	144	9	developed	develop	VERB
ajlm-2394	144	10	country	country	NOUN
ajlm-2394	144	11	settings	setting	NOUN
ajlm-2394	144	12	are	be	AUX
ajlm-2394	144	13	unavailable	unavailable	ADJ
ajlm-2394	144	14	;	;	PUNCT
ajlm-2394	144	15	moreover	moreover	ADV
ajlm-2394	144	16	,	,	PUNCT
ajlm-2394	144	17	no	no	DET
ajlm-2394	144	18	single	single	ADJ
ajlm-2394	144	19	approach	approach	NOUN
ajlm-2394	144	20	,	,	PUNCT
ajlm-2394	144	21	even	even	ADV
ajlm-2394	144	22	among	among	ADP
ajlm-2394	144	23	advanced	advanced	ADJ
ajlm-2394	144	24	methodologies	methodology	NOUN
ajlm-2394	144	25	,	,	PUNCT
ajlm-2394	144	26	is	be	AUX
ajlm-2394	144	27	alone	alone	ADJ
ajlm-2394	144	28	sufficient	sufficient	ADJ
ajlm-2394	144	29	for	for	ADP
ajlm-2394	144	30	diagnosis	diagnosis	NOUN
ajlm-2394	144	31	and	and	CCONJ
ajlm-2394	144	32	prognosis	prognosis	NOUN
ajlm-2394	144	33	according	accord	VERB
ajlm-2394	144	34	to	to	ADP
ajlm-2394	144	35	current	current	ADJ
ajlm-2394	144	36	who	who	PRON
ajlm-2394	144	37	guidelines	guideline	VERB
ajlm-2394	144	38	.	.	PUNCT
ajlm-2394	145	1	in	in	ADP
ajlm-2394	145	2	the	the	DET
ajlm-2394	145	3	present	present	ADJ
ajlm-2394	145	4	study	study	NOUN
ajlm-2394	145	5	we	we	PRON
ajlm-2394	145	6	have	have	AUX
ajlm-2394	145	7	attempted	attempt	VERB
ajlm-2394	145	8	to	to	PART
ajlm-2394	145	9	come	come	VERB
ajlm-2394	145	10	up	up	ADP
ajlm-2394	145	11	with	with	ADP
ajlm-2394	145	12	a	a	DET
ajlm-2394	145	13	compromise	compromise	NOUN
ajlm-2394	145	14	approach	approach	NOUN
ajlm-2394	145	15	,	,	PUNCT
ajlm-2394	145	16	utilising	utilise	VERB
ajlm-2394	145	17	more	more	ADJ
ajlm-2394	145	18	affordable	affordable	ADJ
ajlm-2394	145	19	four	four	NUM
ajlm-2394	145	20	-	-	PUNCT
ajlm-2394	145	21	colour	colour	NOUN
ajlm-2394	145	22	flow	flow	NOUN
ajlm-2394	145	23	cytometry	cytometry	NOUN
ajlm-2394	145	24	and	and	CCONJ
ajlm-2394	145	25	engaging	engage	VERB
ajlm-2394	145	26	in	in	ADP
ajlm-2394	145	27	more	more	ADV
ajlm-2394	145	28	detailed	detailed	ADJ
ajlm-2394	145	29	phenotypic	phenotypic	ADJ
ajlm-2394	145	30	characterisation	characterisation	NOUN
ajlm-2394	145	31	of	of	ADP
ajlm-2394	145	32	patient	patient	NOUN
ajlm-2394	145	33	and	and	CCONJ
ajlm-2394	145	34	leukaemia	leukaemia	NOUN
ajlm-2394	145	35	subtypes	subtype	NOUN
ajlm-2394	145	36	.	.	PUNCT
ajlm-2394	146	1	however	however	ADV
ajlm-2394	146	2	,	,	PUNCT
ajlm-2394	146	3	it	it	PRON
ajlm-2394	146	4	is	be	AUX
ajlm-2394	146	5	clear	clear	ADJ
ajlm-2394	146	6	that	that	SCONJ
ajlm-2394	146	7	this	this	DET
ajlm-2394	146	8	approach	approach	NOUN
ajlm-2394	146	9	,	,	PUNCT
ajlm-2394	146	10	while	while	SCONJ
ajlm-2394	146	11	promising	promise	VERB
ajlm-2394	146	12	,	,	PUNCT
ajlm-2394	146	13	will	will	AUX
ajlm-2394	146	14	require	require	VERB
ajlm-2394	146	15	considerably	considerably	ADV
ajlm-2394	146	16	more	more	ADJ
ajlm-2394	146	17	standardisation	standardisation	NOUN
ajlm-2394	146	18	and	and	CCONJ
ajlm-2394	146	19	validation	validation	NOUN
ajlm-2394	146	20	in	in	ADP
ajlm-2394	146	21	the	the	DET
ajlm-2394	146	22	context	context	NOUN
ajlm-2394	146	23	of	of	ADP
ajlm-2394	146	24	who	who	PRON
ajlm-2394	146	25	classification	classification	VERB
ajlm-2394	146	26	as	as	ADV
ajlm-2394	146	27	well	well	ADV
ajlm-2394	146	28	as	as	ADP
ajlm-2394	146	29	patient	patient	ADJ
ajlm-2394	146	30	outcomes	outcome	NOUN
ajlm-2394	146	31	.	.	PUNCT
ajlm-2394	147	1	acknowledgements	acknowledgement	NOUN
ajlm-2394	147	2	we	we	PRON
ajlm-2394	147	3	are	be	AUX
ajlm-2394	147	4	grateful	grateful	ADJ
ajlm-2394	147	5	to	to	ADP
ajlm-2394	147	6	addis	addis	PROPN
ajlm-2394	147	7	ababa	ababa	PROPN
ajlm-2394	147	8	university	university	PROPN
ajlm-2394	147	9	,	,	PUNCT
ajlm-2394	147	10	the	the	DET
ajlm-2394	147	11	armauer	armauer	PROPN
ajlm-2394	147	12	hansen	hansen	PROPN
ajlm-2394	147	13	research	research	PROPN
ajlm-2394	147	14	institute	institute	PROPN
ajlm-2394	147	15	,	,	PUNCT
ajlm-2394	147	16	tikur	tikur	PROPN
ajlm-2394	147	17	anbessa	anbessa	ADJ
ajlm-2394	147	18	specialised	specialised	ADJ
ajlm-2394	147	19	hospital	hospital	NOUN
ajlm-2394	147	20	,	,	PUNCT
ajlm-2394	147	21	the	the	DET
ajlm-2394	147	22	alert	alert	ADJ
ajlm-2394	147	23	hospital	hospital	NOUN
ajlm-2394	147	24	,	,	PUNCT
ajlm-2394	147	25	especially	especially	ADV
ajlm-2394	147	26	professionals	professional	NOUN
ajlm-2394	147	27	at	at	ADP
ajlm-2394	147	28	the	the	DET
ajlm-2394	147	29	medical	medical	PROPN
ajlm-2394	147	30	laboratory	laboratory	PROPN
ajlm-2394	147	31	department	department	PROPN
ajlm-2394	147	32	,	,	PUNCT
ajlm-2394	147	33	the	the	DET
ajlm-2394	147	34	international	international	ADJ
ajlm-2394	147	35	clinical	clinical	ADJ
ajlm-2394	147	36	laboratories	laboratory	NOUN
ajlm-2394	147	37	,	,	PUNCT
ajlm-2394	147	38	addis	addis	PROPN
ajlm-2394	147	39	ababa	ababa	PROPN
ajlm-2394	147	40	,	,	PUNCT
ajlm-2394	147	41	ethiopia	ethiopia	PROPN
ajlm-2394	147	42	,	,	PUNCT
ajlm-2394	147	43	for	for	ADP
ajlm-2394	147	44	their	their	PRON
ajlm-2394	147	45	technical	technical	ADJ
ajlm-2394	147	46	support	support	NOUN
ajlm-2394	147	47	during	during	ADP
ajlm-2394	147	48	the	the	DET
ajlm-2394	147	49	study	study	NOUN
ajlm-2394	147	50	,	,	PUNCT
ajlm-2394	147	51	and	and	CCONJ
ajlm-2394	147	52	to	to	ADP
ajlm-2394	147	53	all	all	DET
ajlm-2394	147	54	patients	patient	NOUN
ajlm-2394	147	55	who	who	PRON
ajlm-2394	147	56	voluntarily	voluntarily	ADV
ajlm-2394	147	57	participated	participate	VERB
ajlm-2394	147	58	in	in	ADP
ajlm-2394	147	59	this	this	DET
ajlm-2394	147	60	study	study	NOUN
ajlm-2394	147	61	.	.	PUNCT
ajlm-2394	148	1	this	this	DET
ajlm-2394	148	2	article	article	NOUN
ajlm-2394	148	3	is	be	AUX
ajlm-2394	148	4	partially	partially	ADV
ajlm-2394	148	5	based	base	VERB
ajlm-2394	148	6	on	on	ADP
ajlm-2394	148	7	j.a	j.a	PROPN
ajlm-2394	148	8	.	.	PROPN
ajlm-2394	148	9	’s	’s	PART
ajlm-2394	148	10	dissertation	dissertation	NOUN
ajlm-2394	148	11	entitled	entitle	VERB
ajlm-2394	148	12	‘	'	PUNCT
ajlm-2394	148	13	prevalence	prevalence	NOUN
ajlm-2394	148	14	of	of	ADP
ajlm-2394	148	15	viral	viral	ADJ
ajlm-2394	148	16	infections	infection	NOUN
ajlm-2394	148	17	and	and	CCONJ
ajlm-2394	148	18	flow	flow	VERB
ajlm-2394	148	19	cytometric	cytometric	ADJ
ajlm-2394	148	20	analysis	analysis	NOUN
ajlm-2394	148	21	among	among	ADP
ajlm-2394	148	22	acute	acute	ADJ
ajlm-2394	148	23	leukaemia	leukaemia	NOUN
ajlm-2394	148	24	patients	patient	NOUN
ajlm-2394	148	25	at	at	ADP
ajlm-2394	148	26	tikur	tikur	PROPN
ajlm-2394	148	27	anbessa	anbessa	ADJ
ajlm-2394	148	28	specialised	specialised	ADJ
ajlm-2394	148	29	hospital	hospital	NOUN
ajlm-2394	148	30	,	,	PUNCT
ajlm-2394	148	31	addis	addis	PROPN
ajlm-2394	148	32	ababa	ababa	PROPN
ajlm-2394	148	33	,	,	PUNCT
ajlm-2394	148	34	ethiopia	ethiopia	PROPN
ajlm-2394	148	35	’	'	PUNCT
ajlm-2394	148	36	towards	towards	ADP
ajlm-2394	148	37	the	the	DET
ajlm-2394	148	38	degree	degree	NOUN
ajlm-2394	148	39	of	of	ADP
ajlm-2394	148	40	phd	phd	NOUN
ajlm-2394	148	41	,	,	PUNCT
ajlm-2394	148	42	aklilu	aklilu	NOUN
ajlm-2394	148	43	lemma	lemma	PROPN
ajlm-2394	148	44	institute	institute	PROPN
ajlm-2394	148	45	of	of	ADP
ajlm-2394	148	46	pathobiology	pathobiology	NOUN
ajlm-2394	148	47	,	,	PUNCT
ajlm-2394	148	48	addis	addis	PROPN
ajlm-2394	148	49	ababa	ababa	PROPN
ajlm-2394	148	50	university	university	PROPN
ajlm-2394	148	51	,	,	PUNCT
ajlm-2394	148	52	ethiopia	ethiopia	PROPN
ajlm-2394	148	53	,	,	PUNCT
ajlm-2394	148	54	with	with	ADP
ajlm-2394	148	55	supervisors	supervisor	NOUN
ajlm-2394	148	56	prof	prof	PROPN
ajlm-2394	148	57	balako	balako	PROPN
ajlm-2394	148	58	gumi	gumi	PROPN
ajlm-2394	148	59	,	,	PUNCT
ajlm-2394	148	60	dr	dr	PROPN
ajlm-2394	148	61	rawleigh	rawleigh	PROPN
ajlm-2394	148	62	howe	howe	PROPN
ajlm-2394	148	63	,	,	PUNCT
ajlm-2394	148	64	prof	prof	NOUN
ajlm-2394	148	65	aster	aster	NOUN
ajlm-2394	148	66	tsegaye	tsegaye	NOUN
ajlm-2394	148	67	and	and	CCONJ
ajlm-2394	148	68	dr	dr	PROPN
ajlm-2394	148	69	amha	amha	PROPN
ajlm-2394	148	70	gebremedhin	gebremedhin	PROPN
ajlm-2394	148	71	.	.	PUNCT
ajlm-2394	149	1	competing	compete	VERB
ajlm-2394	149	2	interests	interest	NOUN
ajlm-2394	149	3	the	the	DET
ajlm-2394	149	4	author	author	NOUN
ajlm-2394	149	5	reported	report	VERB
ajlm-2394	149	6	that	that	SCONJ
ajlm-2394	149	7	they	they	PRON
ajlm-2394	149	8	received	receive	VERB
ajlm-2394	149	9	funding	funding	NOUN
ajlm-2394	149	10	from	from	ADP
ajlm-2394	149	11	addis	addis	PROPN
ajlm-2394	149	12	ababa	ababa	PROPN
ajlm-2394	149	13	university	university	PROPN
ajlm-2394	149	14	and	and	CCONJ
ajlm-2394	149	15	the	the	DET
ajlm-2394	149	16	armauer	armauer	PROPN
ajlm-2394	149	17	hansen	hansen	PROPN
ajlm-2394	149	18	research	research	PROPN
ajlm-2394	149	19	institute	institute	PROPN
ajlm-2394	149	20	,	,	PUNCT
ajlm-2394	149	21	addis	addis	PROPN
ajlm-2394	149	22	ababa	ababa	PROPN
ajlm-2394	149	23	,	,	PUNCT
ajlm-2394	149	24	ethiopia	ethiopia	PROPN
ajlm-2394	149	25	,	,	PUNCT
ajlm-2394	149	26	which	which	PRON
ajlm-2394	149	27	may	may	AUX
ajlm-2394	149	28	be	be	AUX
ajlm-2394	149	29	affected	affect	VERB
ajlm-2394	149	30	by	by	ADP
ajlm-2394	149	31	the	the	DET
ajlm-2394	149	32	research	research	NOUN
ajlm-2394	149	33	reported	report	VERB
ajlm-2394	149	34	in	in	ADP
ajlm-2394	149	35	the	the	DET
ajlm-2394	149	36	enclosed	enclose	VERB
ajlm-2394	149	37	publication	publication	NOUN
ajlm-2394	149	38	.	.	PUNCT
ajlm-2394	150	1	the	the	DET
ajlm-2394	150	2	author	author	NOUN
ajlm-2394	150	3	has	have	AUX
ajlm-2394	150	4	disclosed	disclose	VERB
ajlm-2394	150	5	those	those	DET
ajlm-2394	150	6	interests	interest	NOUN
ajlm-2394	150	7	fully	fully	ADV
ajlm-2394	150	8	and	and	CCONJ
ajlm-2394	150	9	has	have	AUX
ajlm-2394	150	10	implemented	implement	VERB
ajlm-2394	150	11	an	an	DET
ajlm-2394	150	12	approved	approve	VERB
ajlm-2394	150	13	plan	plan	NOUN
ajlm-2394	150	14	for	for	ADP
ajlm-2394	150	15	managing	manage	VERB
ajlm-2394	150	16	any	any	DET
ajlm-2394	150	17	potential	potential	ADJ
ajlm-2394	150	18	conflicts	conflict	NOUN
ajlm-2394	150	19	arising	arise	VERB
ajlm-2394	150	20	from	from	ADP
ajlm-2394	150	21	their	their	PRON
ajlm-2394	150	22	involvement	involvement	NOUN
ajlm-2394	150	23	.	.	PUNCT
ajlm-2394	151	1	the	the	DET
ajlm-2394	151	2	terms	term	NOUN
ajlm-2394	151	3	of	of	ADP
ajlm-2394	151	4	these	these	DET
ajlm-2394	151	5	funding	funding	NOUN
ajlm-2394	151	6	arrangements	arrangement	NOUN
ajlm-2394	151	7	have	have	AUX
ajlm-2394	151	8	been	be	AUX
ajlm-2394	151	9	reviewed	review	VERB
ajlm-2394	151	10	and	and	CCONJ
ajlm-2394	151	11	approved	approve	VERB
ajlm-2394	151	12	by	by	ADP
ajlm-2394	151	13	the	the	DET
ajlm-2394	151	14	affiliated	affiliated	ADJ
ajlm-2394	151	15	university	university	NOUN
ajlm-2394	151	16	in	in	ADP
ajlm-2394	151	17	accordance	accordance	NOUN
ajlm-2394	151	18	with	with	ADP
ajlm-2394	151	19	its	its	PRON
ajlm-2394	151	20	policy	policy	NOUN
ajlm-2394	151	21	on	on	ADP
ajlm-2394	151	22	objectivity	objectivity	NOUN
ajlm-2394	151	23	in	in	ADP
ajlm-2394	151	24	research	research	NOUN
ajlm-2394	151	25	.	.	PUNCT
ajlm-2394	152	1	authors	author	NOUN
ajlm-2394	152	2	’	'	PUNCT
ajlm-2394	152	3	contributions	contribution	NOUN
ajlm-2394	152	4	j.a	j.a	PROPN
ajlm-2394	152	5	.	.	PROPN
ajlm-2394	152	6	and	and	CCONJ
ajlm-2394	152	7	r.h	r.h	PROPN
ajlm-2394	152	8	.	.	PROPN
ajlm-2394	152	9	conceptualised	conceptualise	VERB
ajlm-2394	152	10	and	and	CCONJ
ajlm-2394	152	11	designed	design	VERB
ajlm-2394	152	12	the	the	DET
ajlm-2394	152	13	study	study	NOUN
ajlm-2394	152	14	,	,	PUNCT
ajlm-2394	152	15	collected	collect	VERB
ajlm-2394	152	16	laboratory	laboratory	NOUN
ajlm-2394	152	17	data	datum	NOUN
ajlm-2394	152	18	,	,	PUNCT
ajlm-2394	152	19	performed	perform	VERB
ajlm-2394	152	20	laboratory	laboratory	NOUN
ajlm-2394	152	21	testing	testing	NOUN
ajlm-2394	152	22	,	,	PUNCT
ajlm-2394	152	23	and	and	CCONJ
ajlm-2394	152	24	prepared	prepare	VERB
ajlm-2394	152	25	the	the	DET
ajlm-2394	152	26	article	article	NOUN
ajlm-2394	152	27	.	.	PUNCT
ajlm-2394	153	1	b.g	b.g	PROPN
ajlm-2394	153	2	.	.	PROPN
ajlm-2394	153	3	and	and	CCONJ
ajlm-2394	153	4	a.t	a.t	PROPN
ajlm-2394	153	5	.	.	PROPN
ajlm-2394	153	6	reviewed	review	VERB
ajlm-2394	153	7	and	and	CCONJ
ajlm-2394	153	8	analysed	analyse	VERB
ajlm-2394	153	9	the	the	DET
ajlm-2394	153	10	data	datum	NOUN
ajlm-2394	153	11	.	.	PUNCT
ajlm-2394	154	1	a.g	a.g	PROPN
ajlm-2394	154	2	.	.	PROPN
ajlm-2394	154	3	,	,	PUNCT
ajlm-2394	154	4	a.s	a.s	PROPN
ajlm-2394	154	5	.	.	PROPN
ajlm-2394	154	6	and	and	CCONJ
ajlm-2394	154	7	f.t	f.t	PROPN
ajlm-2394	154	8	.	.	PROPN
ajlm-2394	154	9	collected	collect	VERB
ajlm-2394	154	10	and	and	CCONJ
ajlm-2394	154	11	interpreted	interpret	VERB
ajlm-2394	154	12	the	the	DET
ajlm-2394	154	13	clinical	clinical	ADJ
ajlm-2394	154	14	data	datum	NOUN
ajlm-2394	154	15	.	.	PUNCT
ajlm-2394	155	1	r.h	r.h	PROPN
ajlm-2394	155	2	.	.	PROPN
ajlm-2394	155	3	,	,	PUNCT
ajlm-2394	155	4	a.t	a.t	PROPN
ajlm-2394	155	5	.	.	PROPN
ajlm-2394	155	6	,	,	PUNCT
ajlm-2394	155	7	a.s	a.s	PROPN
ajlm-2394	155	8	.	.	PROPN
ajlm-2394	155	9	and	and	CCONJ
ajlm-2394	155	10	a.g	a.g	PROPN
ajlm-2394	155	11	.	.	PROPN
ajlm-2394	155	12	revised	revise	VERB
ajlm-2394	155	13	the	the	DET
ajlm-2394	155	14	article	article	NOUN
ajlm-2394	155	15	and	and	CCONJ
ajlm-2394	155	16	supervised	supervise	VERB
ajlm-2394	155	17	the	the	DET
ajlm-2394	155	18	study	study	NOUN
ajlm-2394	155	19	.	.	PUNCT
ajlm-2394	156	1	j.a	j.a	PROPN
ajlm-2394	156	2	.	.	PROPN
ajlm-2394	156	3	,	,	PUNCT
ajlm-2394	156	4	b.g	b.g	PROPN
ajlm-2394	156	5	.	.	PROPN
ajlm-2394	156	6	,	,	PUNCT
ajlm-2394	156	7	a.t	a.t	PROPN
ajlm-2394	156	8	.	.	PROPN
ajlm-2394	156	9	,	,	PUNCT
ajlm-2394	156	10	a.s	a.s	PROPN
ajlm-2394	156	11	.	.	PROPN
ajlm-2394	156	12	,	,	PUNCT
ajlm-2394	156	13	f.t	f.t	PROPN
ajlm-2394	156	14	.	.	PROPN
ajlm-2394	156	15	,	,	PUNCT
ajlm-2394	156	16	a.g	a.g	PROPN
ajlm-2394	156	17	.	.	PROPN
ajlm-2394	156	18	,	,	PUNCT
ajlm-2394	156	19	and	and	CCONJ
ajlm-2394	156	20	r.h	r.h	PROPN
ajlm-2394	156	21	.	.	PROPN
ajlm-2394	156	22	approved	approve	VERB
ajlm-2394	156	23	the	the	DET
ajlm-2394	156	24	final	final	ADJ
ajlm-2394	156	25	article	article	NOUN
ajlm-2394	156	26	.	.	PUNCT
ajlm-2394	157	1	sources	source	NOUN
ajlm-2394	157	2	of	of	ADP
ajlm-2394	157	3	support	support	NOUN
ajlm-2394	157	4	our	our	PRON
ajlm-2394	157	5	study	study	NOUN
ajlm-2394	157	6	was	be	AUX
ajlm-2394	157	7	financially	financially	ADV
ajlm-2394	157	8	supported	support	VERB
ajlm-2394	157	9	by	by	ADP
ajlm-2394	157	10	addis	addis	PROPN
ajlm-2394	157	11	ababa	ababa	PROPN
ajlm-2394	157	12	university	university	PROPN
ajlm-2394	157	13	and	and	CCONJ
ajlm-2394	157	14	the	the	DET
ajlm-2394	157	15	armauer	armauer	PROPN
ajlm-2394	157	16	hansen	hansen	PROPN
ajlm-2394	157	17	research	research	PROPN
ajlm-2394	157	18	institute	institute	PROPN
ajlm-2394	157	19	,	,	PUNCT
ajlm-2394	157	20	addis	addis	PROPN
ajlm-2394	157	21	ababa	ababa	PROPN
ajlm-2394	157	22	,	,	PUNCT
ajlm-2394	157	23	ethiopia	ethiopia	PROPN
ajlm-2394	157	24	.	.	PUNCT
ajlm-2394	158	1	data	datum	NOUN
ajlm-2394	158	2	availability	availability	NOUN
ajlm-2394	158	3	the	the	DET
ajlm-2394	158	4	datasets	dataset	NOUN
ajlm-2394	158	5	analysed	analyse	VERB
ajlm-2394	158	6	and	and	CCONJ
ajlm-2394	158	7	presented	present	VERB
ajlm-2394	158	8	in	in	ADP
ajlm-2394	158	9	this	this	DET
ajlm-2394	158	10	study	study	NOUN
ajlm-2394	158	11	are	be	AUX
ajlm-2394	158	12	available	available	ADJ
ajlm-2394	158	13	from	from	ADP
ajlm-2394	158	14	the	the	DET
ajlm-2394	158	15	corresponding	corresponding	ADJ
ajlm-2394	158	16	author	author	NOUN
ajlm-2394	158	17	,	,	PUNCT
ajlm-2394	158	18	j.a	j.a	PROPN
ajlm-2394	158	19	.	.	PROPN
ajlm-2394	158	20	,	,	PUNCT
ajlm-2394	158	21	on	on	ADP
ajlm-2394	158	22	reasonable	reasonable	ADJ
ajlm-2394	158	23	request	request	NOUN
ajlm-2394	158	24	and	and	CCONJ
ajlm-2394	158	25	are	be	AUX
ajlm-2394	158	26	not	not	PART
ajlm-2394	158	27	publicly	publicly	ADV
ajlm-2394	158	28	available	available	ADJ
ajlm-2394	158	29	,	,	PUNCT
ajlm-2394	158	30	because	because	SCONJ
ajlm-2394	158	31	of	of	ADP
ajlm-2394	158	32	either	either	PRON
ajlm-2394	158	33	privacy	privacy	NOUN
ajlm-2394	158	34	or	or	CCONJ
ajlm-2394	158	35	ethical	ethical	ADJ
ajlm-2394	158	36	restrictions	restriction	NOUN
ajlm-2394	158	37	.	.	PUNCT
ajlm-2394	159	1	disclaimer	disclaimer	VERB
ajlm-2394	159	2	the	the	DET
ajlm-2394	159	3	views	view	NOUN
ajlm-2394	159	4	and	and	CCONJ
ajlm-2394	159	5	opinions	opinion	NOUN
ajlm-2394	159	6	expressed	express	VERB
ajlm-2394	159	7	in	in	ADP
ajlm-2394	159	8	this	this	DET
ajlm-2394	159	9	article	article	NOUN
ajlm-2394	159	10	are	be	AUX
ajlm-2394	159	11	those	those	PRON
ajlm-2394	159	12	of	of	ADP
ajlm-2394	159	13	the	the	DET
ajlm-2394	159	14	authors	author	NOUN
ajlm-2394	159	15	and	and	CCONJ
ajlm-2394	159	16	are	be	AUX
ajlm-2394	159	17	the	the	DET
ajlm-2394	159	18	product	product	NOUN
ajlm-2394	159	19	of	of	ADP
ajlm-2394	159	20	professional	professional	ADJ
ajlm-2394	159	21	research	research	NOUN
ajlm-2394	159	22	.	.	PUNCT
ajlm-2394	160	1	the	the	DET
ajlm-2394	160	2	article	article	NOUN
ajlm-2394	160	3	does	do	AUX
ajlm-2394	160	4	not	not	PART
ajlm-2394	160	5	necessarily	necessarily	ADV
ajlm-2394	160	6	reflect	reflect	VERB
ajlm-2394	160	7	the	the	DET
ajlm-2394	160	8	official	official	ADJ
ajlm-2394	160	9	policy	policy	NOUN
ajlm-2394	160	10	or	or	CCONJ
ajlm-2394	160	11	position	position	NOUN
ajlm-2394	160	12	of	of	ADP
ajlm-2394	160	13	any	any	DET
ajlm-2394	160	14	affiliated	affiliated	ADJ
ajlm-2394	160	15	institution	institution	NOUN
ajlm-2394	160	16	,	,	PUNCT
ajlm-2394	160	17	funder	funder	NOUN
ajlm-2394	160	18	,	,	PUNCT
ajlm-2394	160	19	agency	agency	NOUN
ajlm-2394	160	20	,	,	PUNCT
ajlm-2394	160	21	or	or	CCONJ
ajlm-2394	160	22	that	that	PRON
ajlm-2394	160	23	of	of	ADP
ajlm-2394	160	24	the	the	DET
ajlm-2394	160	25	publisher	publisher	NOUN
ajlm-2394	160	26	.	.	PUNCT
ajlm-2394	161	1	the	the	DET
ajlm-2394	161	2	authors	author	NOUN
ajlm-2394	161	3	are	be	AUX
ajlm-2394	161	4	responsible	responsible	ADJ
ajlm-2394	161	5	for	for	ADP
ajlm-2394	161	6	this	this	DET
ajlm-2394	161	7	article	article	NOUN
ajlm-2394	161	8	’s	’s	PART
ajlm-2394	161	9	results	result	NOUN
ajlm-2394	161	10	,	,	PUNCT
ajlm-2394	161	11	findings	finding	NOUN
ajlm-2394	161	12	,	,	PUNCT
ajlm-2394	161	13	and	and	CCONJ
ajlm-2394	161	14	content	content	NOUN
ajlm-2394	161	15	.	.	PUNCT
ajlm-2394	162	1	references	reference	NOUN
ajlm-2394	162	2	shipley	shipley	PROPN
ajlm-2394	162	3	jl	jl	PROPN
ajlm-2394	162	4	,	,	PUNCT
ajlm-2394	162	5	butera	butera	PROPN
ajlm-2394	162	6	jn	jn	PROPN
ajlm-2394	162	7	.	.	PROPN
ajlm-2394	162	8	acute	acute	PROPN
ajlm-2394	162	9	myelogenous	myelogenous	ADJ
ajlm-2394	162	10	leukemia	leukemia	NOUN
ajlm-2394	162	11	.	.	PUNCT
ajlm-2394	163	1	expert	expert	ADJ
ajlm-2394	163	2	hematol	hematol	NOUN
ajlm-2394	163	3	.	.	PUNCT
ajlm-2394	164	1	2009;37(6):649–658	2009;37(6):649–658	X
ajlm-2394	164	2	.	.	PUNCT
ajlm-2394	165	1	https://doi.org/10.1016/j.exphem.2009.04.002	https://doi.org/10.1016/j.exphem.2009.04.002	PROPN
ajlm-2394	165	2	tebbi	tebbi	VERB
ajlm-2394	165	3	ck	ck	PROPN
ajlm-2394	165	4	.	.	PUNCT
ajlm-2394	165	5	etiology	etiology	NOUN
ajlm-2394	165	6	of	of	ADP
ajlm-2394	165	7	acute	acute	ADJ
ajlm-2394	165	8	leukemia	leukemia	NOUN
ajlm-2394	165	9	:	:	PUNCT
ajlm-2394	165	10	a	a	DET
ajlm-2394	165	11	review	review	NOUN
ajlm-2394	165	12	.	.	PUNCT
ajlm-2394	166	1	cancers	cancer	NOUN
ajlm-2394	166	2	.	.	PUNCT
ajlm-2394	167	1	2021;13(9):2256	2021;13(9):2256	NUM
ajlm-2394	167	2	.	.	PUNCT
ajlm-2394	168	1	https://doi.org/10.3390/cancers13092256	https://doi.org/10.3390/cancers13092256	PROPN
ajlm-2394	168	2	lee	lee	PROPN
ajlm-2394	168	3	p	p	PROPN
ajlm-2394	168	4	-	-	PUNCT
ajlm-2394	168	5	s	s	PROPN
ajlm-2394	168	6	,	,	PUNCT
ajlm-2394	168	7	lin	lin	PROPN
ajlm-2394	168	8	c	c	PROPN
ajlm-2394	168	9	-	-	PUNCT
ajlm-2394	168	10	n	n	CCONJ
ajlm-2394	168	11	,	,	PUNCT
ajlm-2394	168	12	liu	liu	PROPN
ajlm-2394	168	13	c	c	PROPN
ajlm-2394	168	14	,	,	PUNCT
ajlm-2394	168	15	huang	huang	PROPN
ajlm-2394	168	16	c	c	PROPN
ajlm-2394	168	17	-	-	PUNCT
ajlm-2394	168	18	t	t	PROPN
ajlm-2394	168	19	,	,	PUNCT
ajlm-2394	168	20	hwang	hwang	PROPN
ajlm-2394	168	21	w	w	PROPN
ajlm-2394	168	22	-	-	PUNCT
ajlm-2394	168	23	s.	s.	PROPN
ajlm-2394	168	24	acute	acute	PROPN
ajlm-2394	168	25	leukemia	leukemia	PROPN
ajlm-2394	168	26	with	with	ADP
ajlm-2394	168	27	myeloid	myeloid	NOUN
ajlm-2394	168	28	,	,	PUNCT
ajlm-2394	168	29	b-	b-	X
ajlm-2394	168	30	,	,	PUNCT
ajlm-2394	168	31	and	and	CCONJ
ajlm-2394	168	32	natural	natural	ADJ
ajlm-2394	168	33	killer	killer	NOUN
ajlm-2394	168	34	cell	cell	NOUN
ajlm-2394	168	35	differentiation	differentiation	NOUN
ajlm-2394	168	36	:	:	PUNCT
ajlm-2394	168	37	a	a	DET
ajlm-2394	168	38	novel	novel	ADJ
ajlm-2394	168	39	form	form	NOUN
ajlm-2394	168	40	of	of	ADP
ajlm-2394	168	41	multilineage	multilineage	NOUN
ajlm-2394	168	42	leukemia	leukemia	NOUN
ajlm-2394	168	43	.	.	PUNCT
ajlm-2394	169	1	arch	arch	ADJ
ajlm-2394	169	2	pathol	pathol	NOUN
ajlm-2394	169	3	lab	lab	NOUN
ajlm-2394	169	4	med	me	VERB
ajlm-2394	169	5	.	.	PUNCT
ajlm-2394	170	1	2003;127(2):e93	2003;127(2):e93	ADJ
ajlm-2394	170	2	–	–	PUNCT
ajlm-2394	170	3	e95	e95	NOUN
ajlm-2394	170	4	.	.	PUNCT
ajlm-2394	171	1	https://doi.org/10.5858/2003-127-e93-alwman	https://doi.org/10.5858/2003-127-e93-alwman	PROPN
ajlm-2394	171	2	mason	mason	PROPN
ajlm-2394	171	3	j	j	PROPN
ajlm-2394	171	4	,	,	PUNCT
ajlm-2394	171	5	griffiths	griffiths	PROPN
ajlm-2394	171	6	m.	m.	PROPN
ajlm-2394	171	7	molecular	molecular	ADJ
ajlm-2394	171	8	diagnosis	diagnosis	NOUN
ajlm-2394	171	9	of	of	ADP
ajlm-2394	171	10	leukemia	leukemia	NOUN
ajlm-2394	171	11	.	.	PUNCT
ajlm-2394	172	1	expert	expert	NOUN
ajlm-2394	172	2	rev	rev	VERB
ajlm-2394	172	3	mol	mol	ADP
ajlm-2394	172	4	diagn	diagn	NOUN
ajlm-2394	172	5	.	.	PUNCT
ajlm-2394	173	1	2012;12(5):511–526	2012;12(5):511–526	X
ajlm-2394	173	2	.	.	PUNCT
ajlm-2394	173	3	https://doi.org/10.1586/erm.12.44	https://doi.org/10.1586/erm.12.44	PROPN
ajlm-2394	173	4	weir	weir	PROPN
ajlm-2394	173	5	eg	eg	PROPN
ajlm-2394	173	6	,	,	PUNCT
ajlm-2394	173	7	borowitz	borowitz	PROPN
ajlm-2394	173	8	mj	mj	PROPN
ajlm-2394	173	9	.	.	PROPN
ajlm-2394	173	10	flow	flow	NOUN
ajlm-2394	173	11	cytometry	cytometry	NOUN
ajlm-2394	173	12	in	in	ADP
ajlm-2394	173	13	the	the	DET
ajlm-2394	173	14	diagnosis	diagnosis	NOUN
ajlm-2394	173	15	of	of	ADP
ajlm-2394	173	16	acute	acute	ADJ
ajlm-2394	173	17	leukemia	leukemia	NOUN
ajlm-2394	173	18	.	.	PUNCT
ajlm-2394	174	1	seminars	seminar	NOUN
ajlm-2394	174	2	in	in	ADP
ajlm-2394	174	3	hematology	hematology	NOUN
ajlm-2394	174	4	.	.	PUNCT
ajlm-2394	175	1	2001;38(2):124–138	2001;38(2):124–138	NUM
ajlm-2394	175	2	.	.	PUNCT
ajlm-2394	175	3	https://doi.org/10.1016/s0037-1963(01)90046-0	https://doi.org/10.1016/s0037-1963(01)90046-0	PROPN
ajlm-2394	175	4	saxena	saxena	PROPN
ajlm-2394	175	5	r	r	PROPN
ajlm-2394	175	6	,	,	PUNCT
ajlm-2394	175	7	anand	anand	PROPN
ajlm-2394	175	8	h.	h.	PROPN
ajlm-2394	175	9	flow	flow	PROPN
ajlm-2394	175	10	cytometry	cytometry	PROPN
ajlm-2394	175	11	in	in	ADP
ajlm-2394	175	12	acute	acute	ADJ
ajlm-2394	175	13	leukemia	leukemia	NOUN
ajlm-2394	175	14	.	.	PUNCT
ajlm-2394	176	1	indian	indian	PROPN
ajlm-2394	176	2	j	j	PROPN
ajlm-2394	176	3	hematol	hematol	NOUN
ajlm-2394	176	4	blood	blood	NOUN
ajlm-2394	176	5	transf	transf	NOUN
ajlm-2394	176	6	.	.	PUNCT
ajlm-2394	177	1	2008;24:146–150	2008;24:146–150	NUM
ajlm-2394	177	2	.	.	PUNCT
ajlm-2394	178	1	https://doi.org/10.1007/s12288-008-0037-4	https://doi.org/10.1007/s12288-008-0037-4	NUM
ajlm-2394	178	2	tegegen	tegegen	PROPN
ajlm-2394	178	3	m	m	PROPN
ajlm-2394	178	4	,	,	PUNCT
ajlm-2394	178	5	hassen	hassen	PROPN
ajlm-2394	178	6	f	f	PROPN
ajlm-2394	178	7	,	,	PUNCT
ajlm-2394	178	8	abubeker	abubeker	NOUN
ajlm-2394	178	9	a	a	NOUN
ajlm-2394	178	10	,	,	PUNCT
ajlm-2394	178	11	et	et	PROPN
ajlm-2394	178	12	al	al	PROPN
ajlm-2394	178	13	.	.	PUNCT
ajlm-2394	179	1	diagnostic	diagnostic	ADJ
ajlm-2394	179	2	utility	utility	NOUN
ajlm-2394	179	3	of	of	ADP
ajlm-2394	179	4	immunophenotyping	immunophenotype	VERB
ajlm-2394	179	5	by	by	ADP
ajlm-2394	179	6	flow	flow	NOUN
ajlm-2394	179	7	cytometry	cytometry	NOUN
ajlm-2394	179	8	for	for	ADP
ajlm-2394	179	9	diagnosis	diagnosis	NOUN
ajlm-2394	179	10	and	and	CCONJ
ajlm-2394	179	11	classification	classification	NOUN
ajlm-2394	179	12	of	of	ADP
ajlm-2394	179	13	acute	acute	ADJ
ajlm-2394	179	14	leukemias	leukemia	NOUN
ajlm-2394	179	15	in	in	ADP
ajlm-2394	179	16	tikur	tikur	PROPN
ajlm-2394	179	17	anbessa	anbessa	ADJ
ajlm-2394	179	18	specialized	specialized	ADJ
ajlm-2394	179	19	hospital	hospital	NOUN
ajlm-2394	179	20	,	,	PUNCT
ajlm-2394	179	21	addis	addis	PROPN
ajlm-2394	179	22	ababa	ababa	PROPN
ajlm-2394	179	23	,	,	PUNCT
ajlm-2394	179	24	ethiopia	ethiopia	PROPN
ajlm-2394	179	25	.	.	PUNCT
ajlm-2394	180	1	indonesian	indonesian	PROPN
ajlm-2394	180	2	j	j	PROPN
ajlm-2394	180	3	cancer	cancer	NOUN
ajlm-2394	180	4	.	.	PUNCT
ajlm-2394	181	1	2021;15(3):129–137	2021;15(3):129–137	NUM
ajlm-2394	181	2	.	.	PUNCT
ajlm-2394	182	1	https://doi.org/10.33371/ijoc.v15i3.796	https://doi.org/10.33371/ijoc.v15i3.796	PROPN
ajlm-2394	182	2	owaidah	owaidah	PROPN
ajlm-2394	182	3	tm	tm	PROPN
ajlm-2394	182	4	,	,	PUNCT
ajlm-2394	182	5	rawas	rawa	VERB
ajlm-2394	182	6	fi	fi	NOUN
ajlm-2394	182	7	,	,	PUNCT
ajlm-2394	182	8	elkum	elkum	PROPN
ajlm-2394	182	9	nb	nb	PROPN
ajlm-2394	182	10	.	.	PUNCT
ajlm-2394	183	1	expression	expression	NOUN
ajlm-2394	183	2	of	of	ADP
ajlm-2394	183	3	cd66c	cd66c	NOUN
ajlm-2394	183	4	and	and	CCONJ
ajlm-2394	183	5	cd25	cd25	PROPN
ajlm-2394	183	6	in	in	ADP
ajlm-2394	183	7	acute	acute	ADJ
ajlm-2394	183	8	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	183	9	leukemia	leukemia	NOUN
ajlm-2394	183	10	as	as	ADP
ajlm-2394	183	11	a	a	DET
ajlm-2394	183	12	predictor	predictor	NOUN
ajlm-2394	183	13	of	of	ADP
ajlm-2394	183	14	the	the	DET
ajlm-2394	183	15	presence	presence	NOUN
ajlm-2394	183	16	of	of	ADP
ajlm-2394	183	17	bcr	bcr	PROPN
ajlm-2394	183	18	/	/	SYM
ajlm-2394	183	19	abl	abl	PROPN
ajlm-2394	183	20	rearrangement	rearrangement	NOUN
ajlm-2394	183	21	.	.	PUNCT
ajlm-2394	184	1	hematol	hematol	ADJ
ajlm-2394	184	2	oncol	oncol	ADJ
ajlm-2394	184	3	stem	stem	NOUN
ajlm-2394	184	4	cell	cell	NOUN
ajlm-2394	184	5	ther	ther	ADV
ajlm-2394	184	6	.	.	PUNCT
ajlm-2394	185	1	2008;1(1):34–37	2008;1(1):34–37	NOUN
ajlm-2394	185	2	.	.	PUNCT
ajlm-2394	186	1	https://doi.org/10.1016/s1658-3876(08)50058-6	https://doi.org/10.1016/s1658-3876(08)50058-6	PROPN
ajlm-2394	186	2	garg	garg	PROPN
ajlm-2394	186	3	n	n	CCONJ
ajlm-2394	186	4	,	,	PUNCT
ajlm-2394	186	5	gupta	gupta	PROPN
ajlm-2394	186	6	r	r	PROPN
ajlm-2394	186	7	,	,	PUNCT
ajlm-2394	186	8	kotru	kotru	PROPN
ajlm-2394	186	9	m.	m.	PROPN
ajlm-2394	186	10	cd34	cd34	PROPN
ajlm-2394	186	11	is	be	AUX
ajlm-2394	186	12	not	not	PART
ajlm-2394	186	13	expressed	express	VERB
ajlm-2394	186	14	by	by	ADP
ajlm-2394	186	15	blasts	blast	NOUN
ajlm-2394	186	16	in	in	ADP
ajlm-2394	186	17	a	a	DET
ajlm-2394	186	18	third	third	NOUN
ajlm-2394	186	19	of	of	ADP
ajlm-2394	186	20	b	b	NOUN
ajlm-2394	186	21	-	-	PUNCT
ajlm-2394	186	22	all	all	DET
ajlm-2394	186	23	patients	patient	NOUN
ajlm-2394	186	24	and	and	CCONJ
ajlm-2394	186	25	its	its	PRON
ajlm-2394	186	26	negativity	negativity	NOUN
ajlm-2394	186	27	is	be	AUX
ajlm-2394	186	28	associated	associate	VERB
ajlm-2394	186	29	with	with	ADP
ajlm-2394	186	30	aberrant	aberrant	ADJ
ajlm-2394	186	31	marker	marker	NOUN
ajlm-2394	186	32	expression	expression	NOUN
ajlm-2394	186	33	:	:	PUNCT
ajlm-2394	186	34	a	a	DET
ajlm-2394	186	35	retrospective	retrospective	ADJ
ajlm-2394	186	36	analysis	analysis	NOUN
ajlm-2394	186	37	.	.	PUNCT
ajlm-2394	187	1	asian	asian	PROPN
ajlm-2394	187	2	pacific	pacific	PROPN
ajlm-2394	187	3	j	j	PROPN
ajlm-2394	187	4	cancer	cancer	NOUN
ajlm-2394	187	5	prev	prev	X
ajlm-2394	187	6	.	.	PUNCT
ajlm-2394	188	1	2021;22(3):919–925	2021;22(3):919–925	X
ajlm-2394	188	2	.	.	PUNCT
ajlm-2394	189	1	https://doi.org/10.31557/apjcp.2021.22.3.919	https://doi.org/10.31557/apjcp.2021.22.3.919	PROPN
ajlm-2394	189	2	arber	arber	PROPN
ajlm-2394	189	3	da	da	PROPN
ajlm-2394	189	4	,	,	PUNCT
ajlm-2394	189	5	orazi	orazi	X
ajlm-2394	189	6	a	a	PRON
ajlm-2394	189	7	,	,	PUNCT
ajlm-2394	189	8	hasserjian	hasserjian	ADJ
ajlm-2394	189	9	r	r	NOUN
ajlm-2394	189	10	,	,	PUNCT
ajlm-2394	189	11	et	et	PROPN
ajlm-2394	189	12	al	al	PROPN
ajlm-2394	189	13	.	.	PUNCT
ajlm-2394	190	1	the	the	DET
ajlm-2394	190	2	2016	2016	NUM
ajlm-2394	190	3	revision	revision	NOUN
ajlm-2394	190	4	to	to	ADP
ajlm-2394	190	5	the	the	DET
ajlm-2394	190	6	world	world	PROPN
ajlm-2394	190	7	health	health	PROPN
ajlm-2394	190	8	organization	organization	PROPN
ajlm-2394	190	9	classification	classification	NOUN
ajlm-2394	190	10	of	of	ADP
ajlm-2394	190	11	myeloid	myeloid	ADJ
ajlm-2394	190	12	neoplasms	neoplasm	NOUN
ajlm-2394	190	13	and	and	CCONJ
ajlm-2394	190	14	acute	acute	ADJ
ajlm-2394	190	15	leukemia	leukemia	NOUN
ajlm-2394	190	16	.	.	PUNCT
ajlm-2394	191	1	blood	blood	NOUN
ajlm-2394	191	2	.	.	PUNCT
ajlm-2394	192	1	2016;127(20):2391–2405	2016;127(20):2391–2405	NUM
ajlm-2394	192	2	.	.	PUNCT
ajlm-2394	192	3	https://doi.org/10.1182/blood-2016-03-643544	https://doi.org/10.1182/blood-2016-03-643544	PROPN
ajlm-2394	192	4	dworzak	dworzak	PROPN
ajlm-2394	192	5	mn	mn	PROPN
ajlm-2394	192	6	,	,	PUNCT
ajlm-2394	192	7	buldini	buldini	PROPN
ajlm-2394	192	8	b	b	PROPN
ajlm-2394	192	9	,	,	PUNCT
ajlm-2394	192	10	gaipa	gaipa	ADJ
ajlm-2394	192	11	g	g	NOUN
ajlm-2394	192	12	,	,	PUNCT
ajlm-2394	192	13	et	et	PROPN
ajlm-2394	192	14	al	al	PROPN
ajlm-2394	192	15	.	.	PROPN
ajlm-2394	192	16	aieop	aieop	PROPN
ajlm-2394	192	17	-	-	PUNCT
ajlm-2394	192	18	bfm	bfm	PROPN
ajlm-2394	192	19	consensus	consensus	NOUN
ajlm-2394	192	20	guidelines	guideline	NOUN
ajlm-2394	192	21	2016	2016	NUM
ajlm-2394	192	22	for	for	ADP
ajlm-2394	192	23	flow	flow	NOUN
ajlm-2394	192	24	cytometric	cytometric	ADJ
ajlm-2394	192	25	immunophenotyping	immunophenotyping	NOUN
ajlm-2394	192	26	of	of	ADP
ajlm-2394	192	27	pediatric	pediatric	ADJ
ajlm-2394	192	28	acute	acute	ADJ
ajlm-2394	192	29	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	192	30	leukemia	leukemia	NOUN
ajlm-2394	192	31	.	.	PUNCT
ajlm-2394	193	1	cytomet	cytomet	PROPN
ajlm-2394	193	2	b	b	PROPN
ajlm-2394	193	3	clin	clin	PROPN
ajlm-2394	193	4	cytomet	cytomet	NOUN
ajlm-2394	193	5	.	.	PUNCT
ajlm-2394	194	1	2018;94(1):82–93	2018;94(1):82–93	X
ajlm-2394	194	2	.	.	PUNCT
ajlm-2394	194	3	https://doi.org/10.1002/cyto.b.21518	https://doi.org/10.1002/cyto.b.21518	X
ajlm-2394	194	4	ortolani	ortolani	PROPN
ajlm-2394	194	5	c.	c.	PROPN
ajlm-2394	194	6	flow	flow	NOUN
ajlm-2394	194	7	cytometry	cytometry	NOUN
ajlm-2394	194	8	of	of	ADP
ajlm-2394	194	9	hematological	hematological	ADJ
ajlm-2394	194	10	malignancies	malignancy	NOUN
ajlm-2394	194	11	.	.	PUNCT
ajlm-2394	195	1	1st	1st	ADJ
ajlm-2394	195	2	ed	ed	NOUN
ajlm-2394	195	3	.	.	PUNCT
ajlm-2394	196	1	chicester	chicester	PROPN
ajlm-2394	196	2	,	,	PUNCT
ajlm-2394	196	3	west	west	PROPN
ajlm-2394	196	4	sussex	sussex	PROPN
ajlm-2394	196	5	:	:	PUNCT
ajlm-2394	196	6	willey	willey	PROPN
ajlm-2394	196	7	:	:	PUNCT
ajlm-2394	196	8	blackwell	blackwell	PROPN
ajlm-2394	196	9	publishing	publishing	NOUN
ajlm-2394	196	10	;	;	PUNCT
ajlm-2394	196	11	2011	2011	NUM
ajlm-2394	196	12	,	,	PUNCT
ajlm-2394	197	1	168–174	168–174	NUM
ajlm-2394	197	2	p.	p.	NOUN
ajlm-2394	197	3	george	george	PROPN
ajlm-2394	197	4	bs	bs	PROPN
ajlm-2394	197	5	,	,	PUNCT
ajlm-2394	197	6	yohannan	yohannan	PROPN
ajlm-2394	197	7	b	b	PROPN
ajlm-2394	197	8	,	,	PUNCT
ajlm-2394	197	9	gonzalez	gonzalez	PROPN
ajlm-2394	197	10	a	a	PROPN
ajlm-2394	197	11	,	,	PUNCT
ajlm-2394	197	12	rios	rios	PROPN
ajlm-2394	197	13	a.	a.	PROPN
ajlm-2394	197	14	mixed	mix	VERB
ajlm-2394	197	15	-	-	PUNCT
ajlm-2394	197	16	phenotype	phenotype	NOUN
ajlm-2394	197	17	acute	acute	NOUN
ajlm-2394	197	18	leukemia	leukemia	NOUN
ajlm-2394	197	19	:	:	PUNCT
ajlm-2394	197	20	clinical	clinical	ADJ
ajlm-2394	197	21	diagnosis	diagnosis	NOUN
ajlm-2394	197	22	and	and	CCONJ
ajlm-2394	197	23	therapeutic	therapeutic	ADJ
ajlm-2394	197	24	strategies	strategy	NOUN
ajlm-2394	197	25	.	.	PUNCT
ajlm-2394	198	1	biomedicines	biomedicine	NOUN
ajlm-2394	198	2	.	.	PUNCT
ajlm-2394	199	1	2022;10(8):1974–1983	2022;10(8):1974–1983	NUM
ajlm-2394	199	2	.	.	PUNCT
ajlm-2394	200	1	https://doi.org/10.3390/biomedicines10081974	https://doi.org/10.3390/biomedicines10081974	PROPN
ajlm-2394	200	2	hamed	hamed	PROPN
ajlm-2394	200	3	eo	eo	PROPN
ajlm-2394	200	4	,	,	PUNCT
ajlm-2394	200	5	el	el	PROPN
ajlm-2394	200	6	-	-	PROPN
ajlm-2394	200	7	deen	deen	PROPN
ajlm-2394	200	8	af	af	PROPN
ajlm-2394	200	9	.	.	PROPN
ajlm-2394	200	10	flow	flow	VERB
ajlm-2394	200	11	cytometric	cytometric	ADJ
ajlm-2394	200	12	diagnosis	diagnosis	NOUN
ajlm-2394	200	13	of	of	ADP
ajlm-2394	200	14	acute	acute	ADJ
ajlm-2394	200	15	leukemia	leukemia	NOUN
ajlm-2394	200	16	and	and	CCONJ
ajlm-2394	200	17	aberrant	aberrant	ADJ
ajlm-2394	200	18	antigen	antigen	ADV
ajlm-2394	200	19	:	:	PUNCT
ajlm-2394	200	20	sohag	sohag	NOUN
ajlm-2394	200	21	university	university	NOUN
ajlm-2394	200	22	experience	experience	NOUN
ajlm-2394	200	23	.	.	PUNCT
ajlm-2394	201	1	open	open	ADJ
ajlm-2394	201	2	j	j	PROPN
ajlm-2394	201	3	blood	blood	NOUN
ajlm-2394	201	4	dis	dis	PROPN
ajlm-2394	201	5	.	.	PUNCT
ajlm-2394	202	1	2018;8(2):37–48	2018;8(2):37–48	X
ajlm-2394	202	2	.	.	PUNCT
ajlm-2394	203	1	https://doi.org/10.4236/ojbd.2018.82005	https://doi.org/10.4236/ojbd.2018.82005	PROPN
ajlm-2394	203	2	borowitz	borowitz	PROPN
ajlm-2394	203	3	mj	mj	PROPN
ajlm-2394	203	4	,	,	PUNCT
ajlm-2394	203	5	hunger	hunger	NOUN
ajlm-2394	203	6	sp	sp	NOUN
ajlm-2394	203	7	,	,	PUNCT
ajlm-2394	203	8	carroll	carroll	PROPN
ajlm-2394	203	9	aj	aj	PROPN
ajlm-2394	203	10	,	,	PUNCT
ajlm-2394	203	11	et	et	PROPN
ajlm-2394	203	12	al	al	PROPN
ajlm-2394	203	13	.	.	PROPN
ajlm-2394	203	14	predictability	predictability	NOUN
ajlm-2394	203	15	of	of	ADP
ajlm-2394	203	16	the	the	DET
ajlm-2394	203	17	t	t	NOUN
ajlm-2394	203	18	(	(	PUNCT
ajlm-2394	203	19	1	1	NUM
ajlm-2394	203	20	;	;	PUNCT
ajlm-2394	203	21	19)(q23	19)(q23	NUM
ajlm-2394	203	22	;	;	PUNCT
ajlm-2394	203	23	p13	p13	PROPN
ajlm-2394	203	24	)	)	PUNCT
ajlm-2394	203	25	from	from	ADP
ajlm-2394	203	26	surface	surface	NOUN
ajlm-2394	203	27	antigen	antigen	ADJ
ajlm-2394	203	28	phenotype	phenotype	NOUN
ajlm-2394	203	29	:	:	PUNCT
ajlm-2394	203	30	implications	implication	NOUN
ajlm-2394	203	31	for	for	ADP
ajlm-2394	203	32	screening	screen	VERB
ajlm-2394	203	33	cases	case	NOUN
ajlm-2394	203	34	of	of	ADP
ajlm-2394	203	35	childhood	childhood	NOUN
ajlm-2394	203	36	acute	acute	NOUN
ajlm-2394	203	37	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	203	38	leukemia	leukemia	NOUN
ajlm-2394	203	39	for	for	ADP
ajlm-2394	203	40	molecular	molecular	ADJ
ajlm-2394	203	41	analysis	analysis	NOUN
ajlm-2394	203	42	:	:	PUNCT
ajlm-2394	203	43	a	a	DET
ajlm-2394	203	44	pediatric	pediatric	ADJ
ajlm-2394	203	45	oncology	oncology	NOUN
ajlm-2394	203	46	group	group	NOUN
ajlm-2394	203	47	study	study	NOUN
ajlm-2394	203	48	.	.	PUNCT
ajlm-2394	204	1	blood	blood	NOUN
ajlm-2394	204	2	.	.	PUNCT
ajlm-2394	205	1	1993;82(4):1086–1091	1993;82(4):1086–1091	NUM
ajlm-2394	205	2	.	.	PUNCT
ajlm-2394	206	1	https://doi.org/10.1182/blood.v82.4.1086.1086	https://doi.org/10.1182/blood.v82.4.1086.1086	X
ajlm-2394	206	2	ortolani	ortolani	PROPN
ajlm-2394	206	3	c.	c.	PROPN
ajlm-2394	206	4	flow	flow	NOUN
ajlm-2394	206	5	cytometry	cytometry	NOUN
ajlm-2394	206	6	of	of	ADP
ajlm-2394	206	7	hematological	hematological	ADJ
ajlm-2394	206	8	malignancies	malignancy	NOUN
ajlm-2394	206	9	.	.	PUNCT
ajlm-2394	207	1	1st	1st	ADJ
ajlm-2394	207	2	ed	ed	NOUN
ajlm-2394	207	3	.	.	PUNCT
ajlm-2394	208	1	chicester	chicester	PROPN
ajlm-2394	208	2	,	,	PUNCT
ajlm-2394	208	3	west	west	PROPN
ajlm-2394	208	4	sussex	sussex	PROPN
ajlm-2394	208	5	:	:	PUNCT
ajlm-2394	208	6	willey-	willey-	ADJ
ajlm-2394	208	7	:	:	PUNCT
ajlm-2394	208	8	blackwell	blackwell	NOUN
ajlm-2394	208	9	publishing	publishing	NOUN
ajlm-2394	208	10	;	;	PUNCT
ajlm-2394	208	11	2011	2011	NUM
ajlm-2394	208	12	,	,	PUNCT
ajlm-2394	209	1	68–76	68–76	NUM
ajlm-2394	209	2	p.	p.	NOUN
ajlm-2394	209	3	shah	shah	PROPN
ajlm-2394	209	4	ma	ma	PROPN
ajlm-2394	209	5	,	,	PUNCT
ajlm-2394	209	6	ahmad	ahmad	PROPN
ajlm-2394	209	7	u	u	PROPN
ajlm-2394	209	8	,	,	PUNCT
ajlm-2394	209	9	mahmood	mahmood	PROPN
ajlm-2394	209	10	mt	mt	PROPN
ajlm-2394	209	11	,	,	PUNCT
ajlm-2394	209	12	ahmad	ahmad	PROPN
ajlm-2394	209	13	ah	ah	INTJ
ajlm-2394	209	14	,	,	PUNCT
ajlm-2394	209	15	bakar	bakar	PROPN
ajlm-2394	209	16	ma	ma	PROPN
ajlm-2394	209	17	,	,	PUNCT
ajlm-2394	209	18	mahmood	mahmood	PROPN
ajlm-2394	209	19	sr	sr	PROPN
ajlm-2394	209	20	mt	mt	PROPN
ajlm-2394	209	21	.	.	PROPN
ajlm-2394	209	22	frequency	frequency	PROPN
ajlm-2394	209	23	of	of	ADP
ajlm-2394	209	24	cd34	cd34	PROPN
ajlm-2394	209	25	and	and	CCONJ
ajlm-2394	209	26	cd10	cd10	PROPN
ajlm-2394	209	27	expression	expression	NOUN
ajlm-2394	209	28	in	in	ADP
ajlm-2394	209	29	adolescent	adolescent	ADJ
ajlm-2394	209	30	and	and	CCONJ
ajlm-2394	209	31	young	young	ADJ
ajlm-2394	209	32	adult	adult	NOUN
ajlm-2394	209	33	patients	patient	NOUN
ajlm-2394	209	34	having	have	VERB
ajlm-2394	209	35	precursor	precursor	NOUN
ajlm-2394	209	36	b	b	NOUN
ajlm-2394	209	37	-	-	PUNCT
ajlm-2394	209	38	cell	cell	NOUN
ajlm-2394	209	39	acute	acute	ADJ
ajlm-2394	209	40	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	209	41	leukemia	leukemia	NOUN
ajlm-2394	209	42	and	and	CCONJ
ajlm-2394	209	43	its	its	PRON
ajlm-2394	209	44	correlation	correlation	NOUN
ajlm-2394	209	45	with	with	ADP
ajlm-2394	209	46	clinical	clinical	ADJ
ajlm-2394	209	47	outcomes	outcome	NOUN
ajlm-2394	209	48	:	:	PUNCT
ajlm-2394	209	49	a	a	DET
ajlm-2394	209	50	single	single	ADJ
ajlm-2394	209	51	-	-	PUNCT
ajlm-2394	209	52	center	center	NOUN
ajlm-2394	209	53	study	study	NOUN
ajlm-2394	209	54	.	.	PUNCT
ajlm-2394	210	1	cureus	cureus	NOUN
ajlm-2394	210	2	.	.	PUNCT
ajlm-2394	211	1	2022;14(1):e21261	2022;14(1):e21261	NUM
ajlm-2394	211	2	.	.	PUNCT
ajlm-2394	211	3	gleissner	gleissner	PROPN
ajlm-2394	211	4	b	b	PROPN
ajlm-2394	211	5	,	,	PUNCT
ajlm-2394	211	6	goekbuget	goekbuget	PROPN
ajlm-2394	211	7	n	n	CCONJ
ajlm-2394	211	8	,	,	PUNCT
ajlm-2394	211	9	rieder	rieder	ADJ
ajlm-2394	211	10	h	h	NOUN
ajlm-2394	211	11	,	,	PUNCT
ajlm-2394	211	12	et	et	PROPN
ajlm-2394	211	13	al	al	PROPN
ajlm-2394	211	14	.	.	PUNCT
ajlm-2394	212	1	cd10	cd10	PROPN
ajlm-2394	212	2	-	-	PUNCT
ajlm-2394	212	3	pre	pre	PROPN
ajlm-2394	212	4	-	-	ADJ
ajlm-2394	212	5	b	b	ADJ
ajlm-2394	212	6	acute	acute	ADJ
ajlm-2394	212	7	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	212	8	leukemia	leukemia	NOUN
ajlm-2394	212	9	(	(	PUNCT
ajlm-2394	212	10	all	all	PRON
ajlm-2394	212	11	)	)	PUNCT
ajlm-2394	212	12	is	be	AUX
ajlm-2394	212	13	a	a	DET
ajlm-2394	212	14	distinct	distinct	ADJ
ajlm-2394	212	15	high	high	ADJ
ajlm-2394	212	16	-	-	PUNCT
ajlm-2394	212	17	risk	risk	NOUN
ajlm-2394	212	18	subgroup	subgroup	NOUN
ajlm-2394	212	19	of	of	ADP
ajlm-2394	212	20	adult	adult	NOUN
ajlm-2394	212	21	all	all	PRON
ajlm-2394	212	22	associated	associate	VERB
ajlm-2394	212	23	with	with	ADP
ajlm-2394	212	24	a	a	DET
ajlm-2394	212	25	high	high	ADJ
ajlm-2394	212	26	frequency	frequency	NOUN
ajlm-2394	212	27	of	of	ADP
ajlm-2394	212	28	mll	mll	PROPN
ajlm-2394	212	29	aberrations	aberration	NOUN
ajlm-2394	212	30	:	:	PUNCT
ajlm-2394	212	31	results	result	NOUN
ajlm-2394	212	32	of	of	ADP
ajlm-2394	212	33	the	the	DET
ajlm-2394	212	34	german	german	ADJ
ajlm-2394	212	35	multicenter	multicenter	NOUN
ajlm-2394	212	36	trials	trial	NOUN
ajlm-2394	212	37	for	for	ADP
ajlm-2394	212	38	adult	adult	NOUN
ajlm-2394	212	39	all	all	DET
ajlm-2394	212	40	(	(	PUNCT
ajlm-2394	212	41	gmall	gmall	NOUN
ajlm-2394	212	42	)	)	PUNCT
ajlm-2394	212	43	.	.	PUNCT
ajlm-2394	213	1	blood	blood	NOUN
ajlm-2394	213	2	.	.	PUNCT
ajlm-2394	214	1	2005;106(13):4054–4056	2005;106(13):4054–4056	NUM
ajlm-2394	214	2	.	.	PUNCT
ajlm-2394	215	1	https://doi.org/10.1182/blood-2005-05-1866	https://doi.org/10.1182/blood-2005-05-1866	PROPN
ajlm-2394	215	2	wentink	wentink	PROPN
ajlm-2394	215	3	mw	mw	PROPN
ajlm-2394	215	4	,	,	PUNCT
ajlm-2394	215	5	kalina	kalina	PROPN
ajlm-2394	215	6	t	t	PROPN
ajlm-2394	215	7	,	,	PUNCT
ajlm-2394	215	8	perez	perez	PROPN
ajlm-2394	215	9	-	-	PUNCT
ajlm-2394	215	10	andres	andres	PROPN
ajlm-2394	215	11	m	m	PROPN
ajlm-2394	215	12	,	,	PUNCT
ajlm-2394	215	13	et	et	PROPN
ajlm-2394	215	14	al	al	PROPN
ajlm-2394	215	15	.	.	PUNCT
ajlm-2394	215	16	delineating	delineate	VERB
ajlm-2394	215	17	human	human	ADJ
ajlm-2394	215	18	b	b	PROPN
ajlm-2394	215	19	cell	cell	NOUN
ajlm-2394	215	20	precursor	precursor	NOUN
ajlm-2394	215	21	development	development	NOUN
ajlm-2394	215	22	with	with	ADP
ajlm-2394	215	23	genetically	genetically	ADV
ajlm-2394	215	24	identified	identify	VERB
ajlm-2394	215	25	pid	pid	NOUN
ajlm-2394	215	26	cases	case	NOUN
ajlm-2394	215	27	as	as	ADP
ajlm-2394	215	28	a	a	DET
ajlm-2394	215	29	model	model	NOUN
ajlm-2394	215	30	.	.	PUNCT
ajlm-2394	216	1	front	front	ADJ
ajlm-2394	216	2	immunol	immunol	NOUN
ajlm-2394	216	3	.	.	PUNCT
ajlm-2394	217	1	2019;10:1–12	2019;10:1–12	NUM
ajlm-2394	217	2	.	.	PUNCT
ajlm-2394	218	1	https://doi.org/10.3389/fimmu.2019.02680	https://doi.org/10.3389/fimmu.2019.02680	PROPN
ajlm-2394	218	2	o’byrne	o’byrne	NUM
ajlm-2394	218	3	s	s	PROPN
ajlm-2394	218	4	,	,	PUNCT
ajlm-2394	218	5	elliott	elliott	PROPN
ajlm-2394	218	6	n	n	CCONJ
ajlm-2394	218	7	,	,	PUNCT
ajlm-2394	218	8	rice	rice	PROPN
ajlm-2394	218	9	s	s	PROPN
ajlm-2394	218	10	,	,	PUNCT
ajlm-2394	218	11	et	et	PROPN
ajlm-2394	218	12	al	al	PROPN
ajlm-2394	218	13	.	.	PROPN
ajlm-2394	218	14	discovery	discovery	PROPN
ajlm-2394	218	15	of	of	ADP
ajlm-2394	218	16	a	a	DET
ajlm-2394	218	17	cd10	cd10	PROPN
ajlm-2394	218	18	-	-	PUNCT
ajlm-2394	218	19	negative	negative	ADJ
ajlm-2394	218	20	b	b	NOUN
ajlm-2394	218	21	-	-	NOUN
ajlm-2394	218	22	progenitor	progenitor	NOUN
ajlm-2394	218	23	in	in	ADP
ajlm-2394	218	24	human	human	ADJ
ajlm-2394	218	25	fetal	fetal	ADJ
ajlm-2394	218	26	life	life	NOUN
ajlm-2394	218	27	identifies	identify	VERB
ajlm-2394	218	28	unique	unique	ADJ
ajlm-2394	218	29	ontogeny	ontogeny	NOUN
ajlm-2394	218	30	-	-	PUNCT
ajlm-2394	218	31	related	relate	VERB
ajlm-2394	218	32	developmental	developmental	ADJ
ajlm-2394	218	33	programs	program	NOUN
ajlm-2394	218	34	.	.	PUNCT
ajlm-2394	219	1	blood	blood	NOUN
ajlm-2394	219	2	j	j	PROPN
ajlm-2394	219	3	am	be	AUX
ajlm-2394	219	4	soc	soc	NOUN
ajlm-2394	219	5	hematol	hematol	NOUN
ajlm-2394	219	6	.	.	PUNCT
ajlm-2394	220	1	2019;134(13):1059–1071	2019;134(13):1059–1071	NUM
ajlm-2394	220	2	.	.	PUNCT
ajlm-2394	220	3	https://doi.org/10.1182/blood.2019001289	https://doi.org/10.1182/blood.2019001289	PROPN
ajlm-2394	221	1	sharma	sharma	PROPN
ajlm-2394	221	2	p	p	X
ajlm-2394	221	3	,	,	PUNCT
ajlm-2394	221	4	srinivasan	srinivasan	PROPN
ajlm-2394	221	5	t	t	PROPN
ajlm-2394	221	6	,	,	PUNCT
ajlm-2394	221	7	mallik	mallik	PROPN
ajlm-2394	221	8	n.	n.	PROPN
ajlm-2394	221	9	flow	flow	NOUN
ajlm-2394	221	10	cytometry	cytometry	NOUN
ajlm-2394	221	11	in	in	ADP
ajlm-2394	221	12	the	the	DET
ajlm-2394	221	13	diagnostic	diagnostic	ADJ
ajlm-2394	221	14	laboratory	laboratory	NOUN
ajlm-2394	221	15	workup	workup	NOUN
ajlm-2394	221	16	of	of	ADP
ajlm-2394	221	17	acute	acute	ADJ
ajlm-2394	221	18	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	221	19	leukemias	leukemia	NOUN
ajlm-2394	221	20	.	.	PUNCT
ajlm-2394	222	1	ind	ind	PROPN
ajlm-2394	222	2	j	j	PROPN
ajlm-2394	222	3	med	me	VERB
ajlm-2394	222	4	paediatr	paediatr	NOUN
ajlm-2394	222	5	oncol	oncol	ADJ
ajlm-2394	222	6	.	.	PUNCT
ajlm-2394	223	1	2023;44:474–481	2023;44:474–481	NOUN
ajlm-2394	223	2	.	.	PUNCT
ajlm-2394	224	1	https://doi.org/10.1055/s-0043-1772204	https://doi.org/10.1055/s-0043-1772204	PROPN
ajlm-2394	224	2	bene	bene	PROPN
ajlm-2394	224	3	m	m	PROPN
ajlm-2394	224	4	,	,	PUNCT
ajlm-2394	224	5	castoldi	castoldi	PROPN
ajlm-2394	224	6	g	g	PROPN
ajlm-2394	224	7	,	,	PUNCT
ajlm-2394	224	8	knapp	knapp	PROPN
ajlm-2394	224	9	w	w	PROPN
ajlm-2394	224	10	,	,	PUNCT
ajlm-2394	224	11	et	et	PROPN
ajlm-2394	224	12	al	al	PROPN
ajlm-2394	224	13	.	.	PUNCT
ajlm-2394	224	14	proposals	proposal	NOUN
ajlm-2394	224	15	for	for	ADP
ajlm-2394	224	16	the	the	DET
ajlm-2394	224	17	immunological	immunological	ADJ
ajlm-2394	224	18	classification	classification	NOUN
ajlm-2394	224	19	of	of	ADP
ajlm-2394	224	20	acute	acute	ADJ
ajlm-2394	224	21	leukemias	leukemia	NOUN
ajlm-2394	224	22	.	.	PUNCT
ajlm-2394	225	1	european	european	ADJ
ajlm-2394	225	2	group	group	NOUN
ajlm-2394	225	3	for	for	ADP
ajlm-2394	225	4	the	the	DET
ajlm-2394	225	5	immunological	immunological	ADJ
ajlm-2394	225	6	characterization	characterization	NOUN
ajlm-2394	225	7	of	of	ADP
ajlm-2394	225	8	leukemias	leukemias	PROPN
ajlm-2394	225	9	(	(	PUNCT
ajlm-2394	225	10	egil	egil	PROPN
ajlm-2394	225	11	)	)	PUNCT
ajlm-2394	225	12	.	.	PUNCT
ajlm-2394	226	1	leukemia	leukemia	NOUN
ajlm-2394	226	2	.	.	PUNCT
ajlm-2394	227	1	1995;9(10):1783–1786	1995;9(10):1783–1786	NOUN
ajlm-2394	227	2	.	.	PUNCT
ajlm-2394	228	1	pui	pui	PROPN
ajlm-2394	228	2	c	c	PROPN
ajlm-2394	228	3	-	-	PUNCT
ajlm-2394	228	4	h	h	PROPN
ajlm-2394	228	5	,	,	PUNCT
ajlm-2394	228	6	hancock	hancock	PROPN
ajlm-2394	228	7	ml	ml	PROPN
ajlm-2394	228	8	,	,	PUNCT
ajlm-2394	228	9	head	head	PROPN
ajlm-2394	228	10	dr	dr	PROPN
ajlm-2394	228	11	,	,	PUNCT
ajlm-2394	228	12	et	et	PROPN
ajlm-2394	228	13	al	al	PROPN
ajlm-2394	228	14	.	.	PROPN
ajlm-2394	229	1	clinical	clinical	ADJ
ajlm-2394	229	2	significance	significance	NOUN
ajlm-2394	229	3	of	of	ADP
ajlm-2394	229	4	cd34	cd34	PROPN
ajlm-2394	229	5	expression	expression	NOUN
ajlm-2394	229	6	in	in	ADP
ajlm-2394	229	7	childhood	childhood	NOUN
ajlm-2394	229	8	acute	acute	NOUN
ajlm-2394	229	9	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	229	10	leukemia	leukemia	NOUN
ajlm-2394	229	11	.	.	PUNCT
ajlm-2394	230	1	blood	blood	NOUN
ajlm-2394	230	2	.	.	PUNCT
ajlm-2394	231	1	1993;82(3):889–894	1993;82(3):889–894	NUM
ajlm-2394	231	2	.	.	PUNCT
ajlm-2394	231	3	https://doi.org/10.1182/blood.v82.3.889.889	https://doi.org/10.1182/blood.v82.3.889.889	PROPN
ajlm-2394	231	4	chen	chen	PROPN
ajlm-2394	231	5	z	z	PROPN
ajlm-2394	231	6	,	,	PUNCT
ajlm-2394	231	7	sun	sun	PROPN
ajlm-2394	231	8	y	y	PROPN
ajlm-2394	231	9	,	,	PUNCT
ajlm-2394	231	10	xie	xie	PROPN
ajlm-2394	231	11	w	w	PROPN
ajlm-2394	231	12	,	,	PUNCT
ajlm-2394	231	13	et	et	PROPN
ajlm-2394	231	14	al	al	PROPN
ajlm-2394	231	15	.	.	PROPN
ajlm-2394	231	16	is	be	AUX
ajlm-2394	231	17	hyperdiploidy	hyperdiploidy	VERB
ajlm-2394	231	18	a	a	DET
ajlm-2394	231	19	favorable	favorable	ADJ
ajlm-2394	231	20	cytogenetics	cytogenetic	NOUN
ajlm-2394	231	21	in	in	ADP
ajlm-2394	231	22	adults	adult	NOUN
ajlm-2394	231	23	with	with	ADP
ajlm-2394	231	24	b	b	NOUN
ajlm-2394	231	25	-	-	PUNCT
ajlm-2394	231	26	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	231	27	leukemia	leukemia	NOUN
ajlm-2394	231	28	?	?	PUNCT
ajlm-2394	232	1	cancer	cancer	NOUN
ajlm-2394	232	2	med	med	PROPN
ajlm-2394	232	3	.	.	PUNCT
ajlm-2394	233	1	2019;8(9):4093–4099	2019;8(9):4093–4099	X
ajlm-2394	233	2	.	.	PUNCT
ajlm-2394	233	3	https://doi.org/10.1002/cam4.2255	https://doi.org/10.1002/cam4.2255	PART
ajlm-2394	233	4	guillaume	guillaume	PROPN
ajlm-2394	233	5	n	n	CCONJ
ajlm-2394	233	6	,	,	PUNCT
ajlm-2394	233	7	penther	penther	NOUN
ajlm-2394	233	8	d	d	PROPN
ajlm-2394	233	9	,	,	PUNCT
ajlm-2394	233	10	vaida	vaida	PROPN
ajlm-2394	234	1	i	i	PRON
ajlm-2394	234	2	,	,	PUNCT
ajlm-2394	234	3	et	et	PROPN
ajlm-2394	234	4	al	al	PROPN
ajlm-2394	234	5	.	.	PROPN
ajlm-2394	234	6	cd66c	cd66c	NOUN
ajlm-2394	234	7	expression	expression	NOUN
ajlm-2394	234	8	in	in	ADP
ajlm-2394	234	9	b	b	NOUN
ajlm-2394	234	10	-	-	PUNCT
ajlm-2394	234	11	cell	cell	NOUN
ajlm-2394	234	12	acute	acute	ADJ
ajlm-2394	234	13	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	234	14	leukemia	leukemia	NOUN
ajlm-2394	234	15	:	:	PUNCT
ajlm-2394	234	16	strength	strength	NOUN
ajlm-2394	234	17	and	and	CCONJ
ajlm-2394	234	18	weakness	weakness	NOUN
ajlm-2394	234	19	.	.	PUNCT
ajlm-2394	235	1	int	int	NOUN
ajlm-2394	235	2	j	j	PROPN
ajlm-2394	235	3	lab	lab	NOUN
ajlm-2394	235	4	hematol	hematol	NOUN
ajlm-2394	235	5	.	.	PUNCT
ajlm-2394	236	1	2011;33(1):92–96	2011;33(1):92–96	X
ajlm-2394	236	2	.	.	PUNCT
ajlm-2394	237	1	https://doi.org/10.1111/j.1751-553x.2010.01254.x	https://doi.org/10.1111/j.1751-553x.2010.01254.x	PROPN
ajlm-2394	238	1	yilmaz	yilmaz	PROPN
ajlm-2394	238	2	m	m	PROPN
ajlm-2394	238	3	,	,	PUNCT
ajlm-2394	238	4	kantarjian	kantarjian	ADJ
ajlm-2394	238	5	h	h	NOUN
ajlm-2394	238	6	,	,	PUNCT
ajlm-2394	238	7	ravandi	ravandi	NOUN
ajlm-2394	238	8	-	-	PUNCT
ajlm-2394	238	9	kashani	kashani	ADJ
ajlm-2394	238	10	f	f	PROPN
ajlm-2394	238	11	,	,	PUNCT
ajlm-2394	238	12	short	short	PROPN
ajlm-2394	238	13	nj	nj	PROPN
ajlm-2394	238	14	,	,	PUNCT
ajlm-2394	238	15	jabbour	jabbour	PROPN
ajlm-2394	238	16	e.	e.	PROPN
ajlm-2394	238	17	philadelphia	philadelphia	PROPN
ajlm-2394	238	18	chromosome	chromosome	NOUN
ajlm-2394	238	19	-	-	PUNCT
ajlm-2394	238	20	positive	positive	ADJ
ajlm-2394	238	21	acute	acute	ADJ
ajlm-2394	238	22	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	238	23	leukemia	leukemia	NOUN
ajlm-2394	238	24	in	in	ADP
ajlm-2394	238	25	adults	adult	NOUN
ajlm-2394	238	26	:	:	PUNCT
ajlm-2394	238	27	current	current	ADJ
ajlm-2394	238	28	treatments	treatment	NOUN
ajlm-2394	238	29	and	and	CCONJ
ajlm-2394	238	30	future	future	ADJ
ajlm-2394	238	31	perspectives	perspective	NOUN
ajlm-2394	238	32	.	.	PUNCT
ajlm-2394	239	1	clin	clin	PROPN
ajlm-2394	239	2	adv	adv	PROPN
ajlm-2394	239	3	hematol	hematol	PROPN
ajlm-2394	239	4	oncol	oncol	ADJ
ajlm-2394	239	5	.	.	PUNCT
ajlm-2394	240	1	2018;16(3):216–223	2018;16(3):216–223	X
ajlm-2394	240	2	.	.	PUNCT
ajlm-2394	241	1	saleh	saleh	PROPN
ajlm-2394	241	2	k	k	PROPN
ajlm-2394	241	3	,	,	PUNCT
ajlm-2394	241	4	fernandez	fernandez	PROPN
ajlm-2394	241	5	a	a	PRON
ajlm-2394	241	6	,	,	PUNCT
ajlm-2394	241	7	pasquier	pasquier	PROPN
ajlm-2394	241	8	f.	f.	PROPN
ajlm-2394	241	9	treatment	treatment	PROPN
ajlm-2394	241	10	of	of	ADP
ajlm-2394	241	11	philadelphia	philadelphia	PROPN
ajlm-2394	241	12	chromosome	chromosome	NOUN
ajlm-2394	241	13	-	-	PUNCT
ajlm-2394	241	14	positive	positive	ADJ
ajlm-2394	241	15	acute	acute	ADJ
ajlm-2394	241	16	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	241	17	leukemia	leukemia	NOUN
ajlm-2394	241	18	in	in	ADP
ajlm-2394	241	19	adults	adult	NOUN
ajlm-2394	241	20	.	.	PUNCT
ajlm-2394	242	1	cancers	cancer	NOUN
ajlm-2394	242	2	.	.	PUNCT
ajlm-2394	243	1	2022;14(7):1805–1828	2022;14(7):1805–1828	NOUN
ajlm-2394	243	2	.	.	PUNCT
ajlm-2394	244	1	https://doi.org/10.3390/cancers14071805	https://doi.org/10.3390/cancers14071805	PROPN
ajlm-2394	244	2	yilmaz	yilmaz	PROPN
ajlm-2394	244	3	m	m	PROPN
ajlm-2394	244	4	,	,	PUNCT
ajlm-2394	244	5	kantarjian	kantarjian	ADJ
ajlm-2394	244	6	hm	hm	INTJ
ajlm-2394	244	7	,	,	PUNCT
ajlm-2394	244	8	toruner	toruner	NOUN
ajlm-2394	244	9	g	g	PROPN
ajlm-2394	244	10	,	,	PUNCT
ajlm-2394	244	11	et	et	PROPN
ajlm-2394	244	12	al	al	PROPN
ajlm-2394	244	13	.	.	PROPN
ajlm-2394	244	14	translocation	translocation	NOUN
ajlm-2394	244	15	t(1;19)(q23;p13	t(1;19)(q23;p13	NOUN
ajlm-2394	244	16	)	)	PUNCT
ajlm-2394	244	17	in	in	ADP
ajlm-2394	244	18	adult	adult	NOUN
ajlm-2394	244	19	acute	acute	NOUN
ajlm-2394	244	20	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	244	21	leukemia	leukemia	NOUN
ajlm-2394	244	22	–	–	PUNCT
ajlm-2394	244	23	a	a	DET
ajlm-2394	244	24	distinct	distinct	ADJ
ajlm-2394	244	25	subtype	subtype	NOUN
ajlm-2394	244	26	with	with	ADP
ajlm-2394	244	27	favorable	favorable	ADJ
ajlm-2394	244	28	prognosis	prognosis	NOUN
ajlm-2394	244	29	.	.	PUNCT
ajlm-2394	245	1	leukemia	leukemia	NOUN
ajlm-2394	245	2	lymphoma	lymphoma	NOUN
ajlm-2394	245	3	.	.	PUNCT
ajlm-2394	246	1	2021;62(1):224–228	2021;62(1):224–228	NUM
ajlm-2394	246	2	.	.	PUNCT
ajlm-2394	246	3	https://doi.org/10.1080/10428194.2020.1824071	https://doi.org/10.1080/10428194.2020.1824071	PROPN
ajlm-2394	246	4	shurtleff	shurtleff	VERB
ajlm-2394	246	5	s	s	PROPN
ajlm-2394	246	6	,	,	PUNCT
ajlm-2394	246	7	buijs	buijs	PROPN
ajlm-2394	246	8	a	a	PRON
ajlm-2394	246	9	,	,	PUNCT
ajlm-2394	246	10	behm	behm	NOUN
ajlm-2394	246	11	fg	fg	PROPN
ajlm-2394	246	12	,	,	PUNCT
ajlm-2394	246	13	et	et	PROPN
ajlm-2394	246	14	al	al	PROPN
ajlm-2394	246	15	.	.	PROPN
ajlm-2394	247	1	tel	tel	PROPN
ajlm-2394	247	2	/	/	SYM
ajlm-2394	247	3	aml1	aml1	PROPN
ajlm-2394	247	4	fusion	fusion	NOUN
ajlm-2394	247	5	resulting	result	VERB
ajlm-2394	247	6	from	from	ADP
ajlm-2394	247	7	a	a	DET
ajlm-2394	247	8	cryptic	cryptic	ADJ
ajlm-2394	247	9	t	t	NOUN
ajlm-2394	247	10	(	(	PUNCT
ajlm-2394	247	11	12	12	NUM
ajlm-2394	247	12	;	;	PUNCT
ajlm-2394	247	13	21	21	NUM
ajlm-2394	247	14	)	)	PUNCT
ajlm-2394	247	15	is	be	AUX
ajlm-2394	247	16	the	the	DET
ajlm-2394	247	17	most	most	ADV
ajlm-2394	247	18	common	common	ADJ
ajlm-2394	247	19	genetic	genetic	ADJ
ajlm-2394	247	20	lesion	lesion	NOUN
ajlm-2394	247	21	in	in	ADP
ajlm-2394	247	22	pediatric	pediatric	ADJ
ajlm-2394	247	23	all	all	PRON
ajlm-2394	247	24	and	and	CCONJ
ajlm-2394	247	25	defines	define	VERB
ajlm-2394	247	26	a	a	DET
ajlm-2394	247	27	subgroup	subgroup	NOUN
ajlm-2394	247	28	of	of	ADP
ajlm-2394	247	29	patients	patient	NOUN
ajlm-2394	247	30	with	with	ADP
ajlm-2394	247	31	an	an	DET
ajlm-2394	247	32	excellent	excellent	ADJ
ajlm-2394	247	33	prognosis	prognosis	NOUN
ajlm-2394	247	34	.	.	PUNCT
ajlm-2394	248	1	leukemia	leukemia	NOUN
ajlm-2394	248	2	.	.	PUNCT
ajlm-2394	249	1	1995;9(12):1985–1989	1995;9(12):1985–1989	PROPN
ajlm-2394	249	2	.	.	PUNCT
ajlm-2394	250	1	bertrand	bertrand	PROPN
ajlm-2394	250	2	fe	fe	PROPN
ajlm-2394	250	3	,	,	PUNCT
ajlm-2394	250	4	vogtenhuber	vogtenhuber	PROPN
ajlm-2394	250	5	c	c	PROPN
ajlm-2394	250	6	,	,	PUNCT
ajlm-2394	250	7	shah	shah	PROPN
ajlm-2394	250	8	n	n	CCONJ
ajlm-2394	250	9	,	,	PUNCT
ajlm-2394	250	10	lebien	lebien	ADJ
ajlm-2394	250	11	tw	tw	NOUN
ajlm-2394	250	12	.	.	PUNCT
ajlm-2394	250	13	pro	pro	ADJ
ajlm-2394	250	14	-	-	ADJ
ajlm-2394	250	15	b	b	NOUN
ajlm-2394	250	16	-	-	PUNCT
ajlm-2394	250	17	cell	cell	NOUN
ajlm-2394	250	18	to	to	ADP
ajlm-2394	250	19	pre	pre	ADJ
ajlm-2394	250	20	-	-	ADJ
ajlm-2394	250	21	b	b	ADJ
ajlm-2394	250	22	-	-	PUNCT
ajlm-2394	250	23	cell	cell	NOUN
ajlm-2394	250	24	development	development	NOUN
ajlm-2394	250	25	in	in	ADP
ajlm-2394	250	26	b	b	NOUN
ajlm-2394	250	27	-	-	PUNCT
ajlm-2394	250	28	lineage	lineage	NOUN
ajlm-2394	250	29	acute	acute	NOUN
ajlm-2394	250	30	lymphoblastic	lymphoblastic	ADJ
ajlm-2394	250	31	leukemia	leukemia	NOUN
ajlm-2394	250	32	expressing	express	VERB
ajlm-2394	250	33	the	the	DET
ajlm-2394	250	34	mll	mll	PROPN
ajlm-2394	250	35	/	/	SYM
ajlm-2394	250	36	af4	af4	PROPN
ajlm-2394	250	37	fusion	fusion	NOUN
ajlm-2394	250	38	protein	protein	NOUN
ajlm-2394	250	39	.	.	PUNCT
ajlm-2394	251	1	blood	blood	NOUN
ajlm-2394	251	2	j	j	PROPN
ajlm-2394	251	3	am	be	AUX
ajlm-2394	251	4	soc	soc	NOUN
ajlm-2394	251	5	hematol	hematol	NOUN
ajlm-2394	251	6	.	.	PUNCT
ajlm-2394	252	1	2001;98(12):3398–3405	2001;98(12):3398–3405	X
ajlm-2394	252	2	.	.	PUNCT
ajlm-2394	252	3	https://doi.org/10.1182/blood.v98.12.3398	https://doi.org/10.1182/blood.v98.12.3398	PROPN
ajlm-2394	252	4	szczepański	szczepański	PROPN
ajlm-2394	252	5	t	t	PROPN
ajlm-2394	252	6	,	,	PUNCT
ajlm-2394	252	7	van	van	PROPN
ajlm-2394	252	8	der	der	PROPN
ajlm-2394	252	9	velden	velden	PROPN
ajlm-2394	252	10	vh	vh	PROPN
ajlm-2394	252	11	,	,	PUNCT
ajlm-2394	252	12	van	van	PROPN
ajlm-2394	252	13	dongen	dongen	PROPN
ajlm-2394	252	14	jj	jj	PROPN
ajlm-2394	252	15	.	.	PUNCT
ajlm-2394	252	16	classification	classification	NOUN
ajlm-2394	252	17	systems	system	NOUN
ajlm-2394	252	18	for	for	ADP
ajlm-2394	252	19	acute	acute	ADJ
ajlm-2394	252	20	and	and	CCONJ
ajlm-2394	252	21	chronic	chronic	ADJ
ajlm-2394	252	22	leukaemias	leukaemia	NOUN
ajlm-2394	252	23	.	.	PUNCT
ajlm-2394	253	1	best	good	ADJ
ajlm-2394	253	2	pract	pract	PROPN
ajlm-2394	253	3	res	re	NOUN
ajlm-2394	253	4	clin	clin	PROPN
ajlm-2394	253	5	haematol	haematol	NOUN
ajlm-2394	253	6	.	.	PUNCT
ajlm-2394	254	1	2003;16(4):561–582	2003;16(4):561–582	X
ajlm-2394	254	2	.	.	PUNCT
ajlm-2394	254	3	https://doi.org/10.1016/s1521-6926(03)00086-0	https://doi.org/10.1016/s1521-6926(03)00086-0	PROPN
ajlm-2394	254	4	ortolani	ortolani	PROPN
ajlm-2394	254	5	c.	c.	PROPN
ajlm-2394	254	6	flow	flow	NOUN
ajlm-2394	254	7	cytometry	cytometry	NOUN
ajlm-2394	254	8	of	of	ADP
ajlm-2394	254	9	hematological	hematological	ADJ
ajlm-2394	254	10	malignancies	malignancy	NOUN
ajlm-2394	254	11	.	.	PUNCT
ajlm-2394	255	1	1st	1st	ADJ
ajlm-2394	255	2	ed	ed	NOUN
ajlm-2394	255	3	.	.	PUNCT
ajlm-2394	256	1	chicester	chicester	PROPN
ajlm-2394	256	2	,	,	PUNCT
ajlm-2394	256	3	west	west	PROPN
ajlm-2394	256	4	sussex	sussex	PROPN
ajlm-2394	256	5	:	:	PUNCT
ajlm-2394	256	6	willey-	willey-	ADJ
ajlm-2394	256	7	:	:	PUNCT
ajlm-2394	256	8	blackwell	blackwell	NOUN
ajlm-2394	256	9	publishing	publishing	NOUN
ajlm-2394	256	10	;	;	PUNCT
ajlm-2394	256	11	2011	2011	NUM
ajlm-2394	256	12	,	,	PUNCT
ajlm-2394	257	1	195–196	195–196	NUM
ajlm-2394	257	2	p.	p.	NOUN
ajlm-2394	257	3	alvarado	alvarado	PROPN
ajlm-2394	258	1	cs	cs	PROPN
ajlm-2394	258	2	,	,	PUNCT
ajlm-2394	258	3	austin	austin	PROPN
ajlm-2394	258	4	ge	ge	PROPN
ajlm-2394	258	5	,	,	PUNCT
ajlm-2394	258	6	borowitz	borowitz	PROPN
ajlm-2394	258	7	mj	mj	PROPN
ajlm-2394	258	8	,	,	PUNCT
ajlm-2394	258	9	et	et	PROPN
ajlm-2394	258	10	al	al	PROPN
ajlm-2394	258	11	.	.	PROPN
ajlm-2394	258	12	myeloperoxidase	myeloperoxidase	NOUN
ajlm-2394	258	13	gene	gene	NOUN
ajlm-2394	258	14	expression	expression	NOUN
ajlm-2394	258	15	in	in	ADP
ajlm-2394	258	16	infant	infant	NOUN
ajlm-2394	258	17	leukemia	leukemia	NOUN
ajlm-2394	258	18	:	:	PUNCT
ajlm-2394	258	19	a	a	DET
ajlm-2394	258	20	pediatric	pediatric	ADJ
ajlm-2394	258	21	oncology	oncology	NOUN
ajlm-2394	258	22	group	group	NOUN
ajlm-2394	258	23	study	study	NOUN
ajlm-2394	258	24	.	.	PUNCT
ajlm-2394	259	1	leukemia	leukemia	NOUN
ajlm-2394	259	2	lymphoma	lymphoma	NOUN
ajlm-2394	259	3	.	.	PUNCT
ajlm-2394	260	1	1998;29(1–2):145–160	1998;29(1–2):145–160	NUM
ajlm-2394	260	2	.	.	PUNCT
ajlm-2394	261	1	https://doi.org/10.3109/10428199809058390	https://doi.org/10.3109/10428199809058390	X
ajlm-2394	262	1	tjønnfjord	tjønnfjord	PROPN
ajlm-2394	262	2	ge	ge	PROPN
ajlm-2394	262	3	,	,	PUNCT
ajlm-2394	262	4	steen	steen	PROPN
ajlm-2394	262	5	r	r	PROPN
ajlm-2394	262	6	,	,	PUNCT
ajlm-2394	262	7	veiby	veiby	NOUN
ajlm-2394	262	8	op	op	NOUN
ajlm-2394	262	9	,	,	PUNCT
ajlm-2394	262	10	morkrid	morkrid	NOUN
ajlm-2394	262	11	l	l	NOUN
ajlm-2394	262	12	,	,	PUNCT
ajlm-2394	262	13	egeland	egeland	CCONJ
ajlm-2394	262	14	t.	t.	PROPN
ajlm-2394	262	15	haemopoietic	haemopoietic	ADJ
ajlm-2394	262	16	progenitor	progenitor	NOUN
ajlm-2394	262	17	cell	cell	NOUN
ajlm-2394	262	18	differentiation	differentiation	NOUN
ajlm-2394	262	19	:	:	PUNCT
ajlm-2394	263	1	flow	flow	VERB
ajlm-2394	263	2	cytometric	cytometric	ADJ
ajlm-2394	263	3	assessment	assessment	NOUN
ajlm-2394	263	4	in	in	ADP
ajlm-2394	263	5	bone	bone	NOUN
ajlm-2394	263	6	marrow	marrow	NOUN
ajlm-2394	263	7	and	and	CCONJ
ajlm-2394	263	8	thymus	thymus	VERB
ajlm-2394	263	9	.	.	PUNCT
ajlm-2394	264	1	br	br	PROPN
ajlm-2394	264	2	j	j	PROPN
ajlm-2394	264	3	haematol	haematol	NOUN
ajlm-2394	264	4	.	.	PUNCT
ajlm-2394	265	1	1995;91(4):1006–1016	1995;91(4):1006–1016	NUM
ajlm-2394	265	2	.	.	PUNCT
ajlm-2394	266	1	https://doi.org/10.1111/j.1365-2141.1995.tb05426.x	https://doi.org/10.1111/j.1365-2141.1995.tb05426.x	PROPN
ajlm-2394	266	2	ortolani	ortolani	PROPN
ajlm-2394	266	3	c.	c.	PROPN
ajlm-2394	266	4	flow	flow	NOUN
ajlm-2394	266	5	cytometry	cytometry	NOUN
ajlm-2394	266	6	of	of	ADP
ajlm-2394	266	7	hematological	hematological	ADJ
ajlm-2394	266	8	malignancies	malignancy	NOUN
ajlm-2394	266	9	.	.	PUNCT
ajlm-2394	267	1	1st	1st	ADJ
ajlm-2394	267	2	ed	ed	NOUN
ajlm-2394	267	3	.	.	PUNCT
ajlm-2394	268	1	chicester	chicester	PROPN
ajlm-2394	268	2	,	,	PUNCT
ajlm-2394	268	3	west	west	PROPN
ajlm-2394	268	4	sussex	sussex	PROPN
ajlm-2394	268	5	:	:	PUNCT
ajlm-2394	268	6	willey-	willey-	ADJ
ajlm-2394	268	7	:	:	PUNCT
ajlm-2394	268	8	blackwell	blackwell	NOUN
ajlm-2394	268	9	publishing	publishing	NOUN
ajlm-2394	268	10	;	;	PUNCT
ajlm-2394	268	11	2011	2011	NUM
ajlm-2394	268	12	,	,	PUNCT
ajlm-2394	268	13	169–170	169–170	NUM
ajlm-2394	268	14	p.	p.	NOUN
ajlm-2394	268	15	legrand	legrand	PROPN
ajlm-2394	269	1	o	o	PROPN
ajlm-2394	269	2	,	,	PUNCT
ajlm-2394	269	3	perrot	perrot	PROPN
ajlm-2394	269	4	j	j	PROPN
ajlm-2394	269	5	-	-	PROPN
ajlm-2394	269	6	y	y	PROPN
ajlm-2394	269	7	,	,	PUNCT
ajlm-2394	269	8	baudard	baudard	PROPN
ajlm-2394	269	9	m	m	PROPN
ajlm-2394	269	10	,	,	PUNCT
ajlm-2394	269	11	et	et	PROPN
ajlm-2394	269	12	al	al	PROPN
ajlm-2394	269	13	.	.	PUNCT
ajlm-2394	270	1	the	the	DET
ajlm-2394	270	2	immunophenotype	immunophenotype	NOUN
ajlm-2394	270	3	of	of	ADP
ajlm-2394	270	4	177	177	NUM
ajlm-2394	270	5	adults	adult	NOUN
ajlm-2394	270	6	with	with	ADP
ajlm-2394	270	7	acute	acute	ADJ
ajlm-2394	270	8	myeloid	myeloid	ADJ
ajlm-2394	270	9	leukemia	leukemia	NOUN
ajlm-2394	270	10	:	:	PUNCT
ajlm-2394	270	11	proposal	proposal	NOUN
ajlm-2394	270	12	of	of	ADP
ajlm-2394	270	13	a	a	DET
ajlm-2394	270	14	prognostic	prognostic	ADJ
ajlm-2394	270	15	score	score	NOUN
ajlm-2394	270	16	.	.	PUNCT
ajlm-2394	271	1	blood	blood	NOUN
ajlm-2394	271	2	.	.	PUNCT
ajlm-2394	272	1	2000;96(3):870–877	2000;96(3):870–877	X
ajlm-2394	272	2	.	.	PUNCT
ajlm-2394	273	1	https://doi.org/10.1182/blood.v96.3.870	https://doi.org/10.1182/blood.v96.3.870	PROPN
ajlm-2394	273	2	osman	osman	PROPN
ajlm-2394	274	1	i	i	PROPN
ajlm-2394	274	2	m	m	PROPN
ajlm-2394	274	3	,	,	PUNCT
ajlm-2394	274	4	humeida	humeida	PROPN
ajlm-2394	274	5	aa	aa	PROPN
ajlm-2394	274	6	,	,	PUNCT
ajlm-2394	274	7	eltayeb	eltayeb	PROPN
ajlm-2394	274	8	o	o	PROPN
ajlm-2394	274	9	,	,	PUNCT
ajlm-2394	274	10	abdelrhman	abdelrhman	NOUN
ajlm-2394	274	11	i	i	PROPN
ajlm-2394	274	12	,	,	PUNCT
ajlm-2394	274	13	elhadi	elhadi	PROPN
ajlm-2394	274	14	ta	ta	PROPN
ajlm-2394	274	15	.	.	PROPN
ajlm-2394	274	16	flowcytometric	flowcytometric	ADJ
ajlm-2394	274	17	immunophenotypic	immunophenotypic	ADJ
ajlm-2394	274	18	characterization	characterization	NOUN
ajlm-2394	274	19	of	of	ADP
ajlm-2394	274	20	acute	acute	ADJ
ajlm-2394	274	21	myeloid	myeloid	NOUN
ajlm-2394	274	22	leukemia	leukemia	NOUN
ajlm-2394	274	23	(	(	PUNCT
ajlm-2394	274	24	aml	aml	PROPN
ajlm-2394	274	25	)	)	PUNCT
ajlm-2394	274	26	in	in	ADP
ajlm-2394	274	27	sudan	sudan	PROPN
ajlm-2394	274	28	.	.	PUNCT
ajlm-2394	275	1	int	int	PROPN
ajlm-2394	275	2	j	j	PROPN
ajlm-2394	275	3	hematol	hematol	NOUN
ajlm-2394	275	4	blood	blood	NOUN
ajlm-2394	275	5	disord	disord	NOUN
ajlm-2394	275	6	.	.	PUNCT
ajlm-2394	276	1	2015;2(1):10–17	2015;2(1):10–17	X
ajlm-2394	276	2	.	.	PUNCT
ajlm-2394	277	1	cheng	cheng	PROPN
ajlm-2394	277	2	y	y	PROPN
ajlm-2394	277	3	,	,	PUNCT
ajlm-2394	277	4	wang	wang	PROPN
ajlm-2394	277	5	y	y	PROPN
ajlm-2394	277	6	,	,	PUNCT
ajlm-2394	277	7	wang	wang	PROPN
ajlm-2394	277	8	h	h	PROPN
ajlm-2394	277	9	,	,	PUNCT
ajlm-2394	277	10	et	et	PROPN
ajlm-2394	277	11	al	al	PROPN
ajlm-2394	277	12	.	.	PUNCT
ajlm-2394	278	1	cytogenetic	cytogenetic	ADJ
ajlm-2394	278	2	profile	profile	NOUN
ajlm-2394	278	3	of	of	ADP
ajlm-2394	278	4	de	de	X
ajlm-2394	278	5	novo	novo	PROPN
ajlm-2394	278	6	acute	acute	PROPN
ajlm-2394	278	7	myeloid	myeloid	PROPN
ajlm-2394	278	8	leukemia	leukemia	NOUN
ajlm-2394	278	9	:	:	PUNCT
ajlm-2394	278	10	a	a	DET
ajlm-2394	278	11	study	study	NOUN
ajlm-2394	278	12	based	base	VERB
ajlm-2394	278	13	on	on	ADP
ajlm-2394	278	14	1432	1432	NUM
ajlm-2394	278	15	patients	patient	NOUN
ajlm-2394	278	16	in	in	ADP
ajlm-2394	278	17	a	a	DET
ajlm-2394	278	18	single	single	ADJ
ajlm-2394	278	19	institution	institution	NOUN
ajlm-2394	278	20	of	of	ADP
ajlm-2394	278	21	china	china	PROPN
ajlm-2394	278	22	.	.	PUNCT
ajlm-2394	279	1	leukemia	leukemia	NOUN
ajlm-2394	279	2	.	.	PUNCT
ajlm-2394	280	1	2009;23(10):1801–1806	2009;23(10):1801–1806	X
ajlm-2394	280	2	.	.	PUNCT
ajlm-2394	281	1	https://doi.org/10.1038/leu.2009.107	https://doi.org/10.1038/leu.2009.107	PROPN
ajlm-2394	281	2	grimwade	grimwade	VERB
ajlm-2394	281	3	d	d	PROPN
ajlm-2394	281	4	,	,	PUNCT
ajlm-2394	281	5	hills	hills	PROPN
ajlm-2394	281	6	rk	rk	NOUN
ajlm-2394	281	7	,	,	PUNCT
ajlm-2394	281	8	moorman	moorman	NOUN
ajlm-2394	281	9	av	av	PROPN
ajlm-2394	281	10	,	,	PUNCT
ajlm-2394	282	1	et	et	PROPN
ajlm-2394	282	2	al	al	PROPN
ajlm-2394	282	3	.	.	PROPN
ajlm-2394	282	4	refinement	refinement	PROPN
ajlm-2394	282	5	of	of	ADP
ajlm-2394	282	6	cytogenetic	cytogenetic	ADJ
ajlm-2394	282	7	classification	classification	NOUN
ajlm-2394	282	8	in	in	ADP
ajlm-2394	282	9	acute	acute	ADJ
ajlm-2394	282	10	myeloid	myeloid	ADJ
ajlm-2394	282	11	leukemia	leukemia	NOUN
ajlm-2394	282	12	:	:	PUNCT
ajlm-2394	282	13	determination	determination	NOUN
ajlm-2394	282	14	of	of	ADP
ajlm-2394	282	15	prognostic	prognostic	ADJ
ajlm-2394	282	16	significance	significance	NOUN
ajlm-2394	282	17	of	of	ADP
ajlm-2394	282	18	rare	rare	ADJ
ajlm-2394	282	19	recurring	recur	VERB
ajlm-2394	282	20	chromosomal	chromosomal	ADJ
ajlm-2394	282	21	abnormalities	abnormality	NOUN
ajlm-2394	282	22	among	among	ADP
ajlm-2394	282	23	5876	5876	NUM
ajlm-2394	282	24	younger	young	ADJ
ajlm-2394	282	25	adult	adult	NOUN
ajlm-2394	282	26	patients	patient	NOUN
ajlm-2394	282	27	treated	treat	VERB
ajlm-2394	282	28	in	in	ADP
ajlm-2394	282	29	the	the	DET
ajlm-2394	282	30	united	united	PROPN
ajlm-2394	282	31	kingdom	kingdom	PROPN
ajlm-2394	282	32	medical	medical	PROPN
ajlm-2394	282	33	research	research	PROPN
ajlm-2394	282	34	council	council	PROPN
ajlm-2394	282	35	trials	trial	NOUN
ajlm-2394	282	36	.	.	PUNCT
ajlm-2394	283	1	blood	blood	NOUN
ajlm-2394	283	2	.	.	PUNCT
ajlm-2394	284	1	2010;116(3):354–365	2010;116(3):354–365	X
ajlm-2394	284	2	.	.	PUNCT
ajlm-2394	284	3	https://doi.org/10.1182/blood-2009-11-254441	https://doi.org/10.1182/blood-2009-11-254441	NUM
ajlm-2394	284	4	alexander	alexander	NOUN
ajlm-2394	284	5	tb	tb	PROPN
ajlm-2394	284	6	,	,	PUNCT
ajlm-2394	284	7	gu	gu	NOUN
ajlm-2394	284	8	z	z	PROPN
ajlm-2394	284	9	,	,	PUNCT
ajlm-2394	284	10	iacobucci	iacobucci	VERB
ajlm-2394	284	11	i	i	PRON
ajlm-2394	284	12	,	,	PUNCT
ajlm-2394	284	13	et	et	PROPN
ajlm-2394	284	14	al	al	PROPN
ajlm-2394	284	15	.	.	PUNCT
ajlm-2394	285	1	the	the	DET
ajlm-2394	285	2	genetic	genetic	ADJ
ajlm-2394	285	3	basis	basis	NOUN
ajlm-2394	285	4	and	and	CCONJ
ajlm-2394	285	5	cell	cell	NOUN
ajlm-2394	285	6	of	of	ADP
ajlm-2394	285	7	origin	origin	NOUN
ajlm-2394	285	8	of	of	ADP
ajlm-2394	285	9	mixed	mixed	ADJ
ajlm-2394	285	10	phenotype	phenotype	NOUN
ajlm-2394	285	11	acute	acute	NOUN
ajlm-2394	285	12	leukaemia	leukaemia	NOUN
ajlm-2394	285	13	.	.	PUNCT
ajlm-2394	286	1	nature	nature	NOUN
ajlm-2394	286	2	.	.	PUNCT
ajlm-2394	287	1	2018;562(7727):373–379	2018;562(7727):373–379	NUM
ajlm-2394	287	2	.	.	PUNCT
ajlm-2394	287	3	https://doi.org/10.1038/s41586-018-0436-0	https://doi.org/10.1038/s41586-018-0436-0	PROPN
ajlm-2394	287	4	kita	kita	PROPN
ajlm-2394	287	5	k	k	PROPN
ajlm-2394	287	6	,	,	PUNCT
ajlm-2394	287	7	nakase	nakase	PROPN
ajlm-2394	287	8	k	k	PROPN
ajlm-2394	287	9	,	,	PUNCT
ajlm-2394	287	10	miwa	miwa	PROPN
ajlm-2394	287	11	h	h	PROPN
ajlm-2394	287	12	,	,	PUNCT
ajlm-2394	287	13	et	et	PROPN
ajlm-2394	287	14	al	al	PROPN
ajlm-2394	287	15	.	.	PROPN
ajlm-2394	287	16	phenotypical	phenotypical	ADJ
ajlm-2394	287	17	characteristics	characteristic	NOUN
ajlm-2394	287	18	of	of	ADP
ajlm-2394	287	19	acute	acute	ADJ
ajlm-2394	287	20	myelocytic	myelocytic	ADJ
ajlm-2394	287	21	leukemia	leukemia	NOUN
ajlm-2394	287	22	associated	associate	VERB
ajlm-2394	287	23	with	with	ADP
ajlm-2394	287	24	the	the	DET
ajlm-2394	287	25	t	t	NOUN
ajlm-2394	287	26	(	(	PUNCT
ajlm-2394	287	27	8	8	NUM
ajlm-2394	287	28	;	;	PUNCT
ajlm-2394	287	29	21)(q22	21)(q22	NUM
ajlm-2394	287	30	;	;	PUNCT
ajlm-2394	287	31	q22	q22	NOUN
ajlm-2394	287	32	)	)	PUNCT
ajlm-2394	287	33	chromosomal	chromosomal	ADJ
ajlm-2394	287	34	abnormality	abnormality	NOUN
ajlm-2394	287	35	:	:	PUNCT
ajlm-2394	287	36	frequent	frequent	ADJ
ajlm-2394	287	37	expression	expression	NOUN
ajlm-2394	287	38	of	of	ADP
ajlm-2394	287	39	immature	immature	ADJ
ajlm-2394	287	40	b	b	NOUN
ajlm-2394	287	41	-	-	PUNCT
ajlm-2394	287	42	cell	cell	NOUN
ajlm-2394	287	43	antigen	antigen	NOUN
ajlm-2394	287	44	cd19	cd19	PROPN
ajlm-2394	287	45	together	together	ADV
ajlm-2394	287	46	with	with	ADP
ajlm-2394	287	47	stem	stem	NOUN
ajlm-2394	287	48	cell	cell	NOUN
ajlm-2394	287	49	antigen	antigen	ADP
ajlm-2394	287	50	cd34	cd34	PROPN
ajlm-2394	287	51	.	.	PUNCT
ajlm-2394	288	1	blood	blood	NOUN
ajlm-2394	288	2	.	.	PUNCT
ajlm-2394	289	1	1992;80(2):470–477	1992;80(2):470–477	X
ajlm-2394	289	2	.	.	PUNCT
ajlm-2394	289	3	https://doi.org/10.1182/blood.v80.2.470.470	https://doi.org/10.1182/blood.v80.2.470.470	PROPN
ajlm-2394	290	1	raza	raza	PROPN
ajlm-2394	290	2	h	h	PROPN
ajlm-2394	290	3	,	,	PUNCT
ajlm-2394	290	4	fatima	fatima	PROPN
ajlm-2394	290	5	m	m	PROPN
ajlm-2394	290	6	,	,	PUNCT
ajlm-2394	290	7	noor	noor	PROPN
ajlm-2394	290	8	t	t	PROPN
ajlm-2394	290	9	,	,	PUNCT
ajlm-2394	290	10	et	et	PROPN
ajlm-2394	290	11	al	al	PROPN
ajlm-2394	290	12	.	.	PUNCT
ajlm-2394	291	1	the	the	DET
ajlm-2394	291	2	frequency	frequency	NOUN
ajlm-2394	291	3	of	of	ADP
ajlm-2394	291	4	aberrant	aberrant	ADJ
ajlm-2394	291	5	cd7	cd7	PROPN
ajlm-2394	291	6	antigen	antigen	ADJ
ajlm-2394	291	7	expression	expression	NOUN
ajlm-2394	291	8	in	in	ADP
ajlm-2394	291	9	acute	acute	ADJ
ajlm-2394	291	10	myeloid	myeloid	ADJ
ajlm-2394	291	11	leukaemia	leukaemia	NOUN
ajlm-2394	291	12	patients	patient	NOUN
ajlm-2394	291	13	.	.	PUNCT
ajlm-2394	292	1	cureus	cureus	NOUN
ajlm-2394	292	2	.	.	PUNCT
ajlm-2394	293	1	2022;14(2):e22309	2022;14(2):e22309	NUM
ajlm-2394	293	2	.	.	PUNCT
ajlm-2394	294	1	https://doi.org/10.7759/cureus.22309	https://doi.org/10.7759/cureus.22309	PROPN
ajlm-2394	294	2	pulsoni	pulsoni	NOUN
ajlm-2394	294	3	a	a	PRON
ajlm-2394	294	4	,	,	PUNCT
ajlm-2394	294	5	iacobelli	iacobelli	PROPN
ajlm-2394	294	6	s	s	PROPN
ajlm-2394	294	7	,	,	PUNCT
ajlm-2394	294	8	bernardi	bernardi	PROPN
ajlm-2394	294	9	m	m	PROPN
ajlm-2394	294	10	,	,	PUNCT
ajlm-2394	294	11	et	et	PROPN
ajlm-2394	294	12	al	al	PROPN
ajlm-2394	294	13	.	.	PROPN
ajlm-2394	294	14	m4	m4	PROPN
ajlm-2394	294	15	acute	acute	PROPN
ajlm-2394	294	16	myeloid	myeloid	NOUN
ajlm-2394	294	17	leukemia	leukemia	NOUN
ajlm-2394	294	18	:	:	PUNCT
ajlm-2394	294	19	the	the	DET
ajlm-2394	294	20	role	role	NOUN
ajlm-2394	294	21	of	of	ADP
ajlm-2394	294	22	eosinophilia	eosinophilia	PROPN
ajlm-2394	294	23	and	and	CCONJ
ajlm-2394	294	24	cytogenetics	cytogenetic	NOUN
ajlm-2394	294	25	in	in	ADP
ajlm-2394	294	26	treatment	treatment	NOUN
ajlm-2394	294	27	response	response	NOUN
ajlm-2394	294	28	and	and	CCONJ
ajlm-2394	294	29	survival	survival	NOUN
ajlm-2394	294	30	.	.	PUNCT
ajlm-2394	295	1	the	the	DET
ajlm-2394	295	2	gimema	gimema	PROPN
ajlm-2394	295	3	experience	experience	NOUN
ajlm-2394	295	4	.	.	PUNCT
ajlm-2394	296	1	haematologica	haematologica	PROPN
ajlm-2394	296	2	.	.	PUNCT
ajlm-2394	297	1	2008;93(7):1025–1032	2008;93(7):1025–1032	NOUN
ajlm-2394	297	2	.	.	PUNCT
ajlm-2394	298	1	https://doi.org/10.3324/haematol.11889	https://doi.org/10.3324/haematol.11889	PROPN
ajlm-2394	298	2	mori	mori	PROPN
ajlm-2394	298	3	y	y	PROPN
ajlm-2394	298	4	,	,	PUNCT
ajlm-2394	298	5	yoshimoto	yoshimoto	PROPN
ajlm-2394	298	6	g	g	PROPN
ajlm-2394	298	7	,	,	PUNCT
ajlm-2394	298	8	kumano	kumano	PROPN
ajlm-2394	298	9	t	t	PROPN
ajlm-2394	298	10	,	,	PUNCT
ajlm-2394	298	11	et	et	PROPN
ajlm-2394	298	12	al	al	PROPN
ajlm-2394	298	13	.	.	PROPN
ajlm-2394	298	14	distinctive	distinctive	ADJ
ajlm-2394	298	15	expression	expression	NOUN
ajlm-2394	298	16	of	of	ADP
ajlm-2394	298	17	myelomonocytic	myelomonocytic	ADJ
ajlm-2394	298	18	markers	marker	NOUN
ajlm-2394	298	19	and	and	CCONJ
ajlm-2394	298	20	down	down	ADP
ajlm-2394	298	21	-	-	PUNCT
ajlm-2394	298	22	regulation	regulation	NOUN
ajlm-2394	298	23	of	of	ADP
ajlm-2394	298	24	cd34	cd34	PROPN
ajlm-2394	298	25	in	in	ADP
ajlm-2394	298	26	acute	acute	ADJ
ajlm-2394	298	27	myelogenous	myelogenous	ADJ
ajlm-2394	298	28	leukaemia	leukaemia	NOUN
ajlm-2394	298	29	with	with	ADP
ajlm-2394	298	30	flt3	flt3	PROPN
ajlm-2394	298	31	tandem	tandem	NOUN
ajlm-2394	298	32	duplication	duplication	NOUN
ajlm-2394	298	33	and	and	CCONJ
ajlm-2394	298	34	nucleophosmin	nucleophosmin	NOUN
ajlm-2394	298	35	mutation	mutation	NOUN
ajlm-2394	298	36	.	.	PUNCT
ajlm-2394	299	1	eur	eur	PROPN
ajlm-2394	299	2	j	j	PROPN
ajlm-2394	299	3	haematol	haematol	NOUN
ajlm-2394	299	4	.	.	PUNCT
ajlm-2394	300	1	2007;79(1):17–24	2007;79(1):17–24	X
ajlm-2394	300	2	.	.	PUNCT
ajlm-2394	301	1	https://doi.org/10.1111/j.1600-0609.2007.00866.x	https://doi.org/10.1111/j.1600-0609.2007.00866.x	PROPN
ajlm-2394	301	2	leroy	leroy	PROPN
ajlm-2394	301	3	h	h	PROPN
ajlm-2394	301	4	,	,	PUNCT
ajlm-2394	301	5	roumier	roumi	ADJ
ajlm-2394	301	6	c	c	NOUN
ajlm-2394	301	7	,	,	PUNCT
ajlm-2394	301	8	huyghe	huyghe	NOUN
ajlm-2394	301	9	p	p	NOUN
ajlm-2394	301	10	,	,	PUNCT
ajlm-2394	301	11	biggio	biggio	PROPN
ajlm-2394	301	12	v	v	NOUN
ajlm-2394	301	13	,	,	PUNCT
ajlm-2394	301	14	fenaux	fenaux	ADJ
ajlm-2394	301	15	p	p	NOUN
ajlm-2394	301	16	,	,	PUNCT
ajlm-2394	301	17	preudhomme	preudhomme	PROPN
ajlm-2394	301	18	c.	c.	PROPN
ajlm-2394	301	19	cebpa	cebpa	PROPN
ajlm-2394	301	20	point	point	VERB
ajlm-2394	301	21	mutations	mutation	NOUN
ajlm-2394	301	22	in	in	ADP
ajlm-2394	301	23	hematological	hematological	ADJ
ajlm-2394	301	24	malignancies	malignancy	NOUN
ajlm-2394	301	25	.	.	PUNCT
ajlm-2394	302	1	leukemia	leukemia	NOUN
ajlm-2394	302	2	.	.	PUNCT
ajlm-2394	303	1	2005;19(3):329–334	2005;19(3):329–334	X
ajlm-2394	303	2	.	.	PUNCT
ajlm-2394	303	3	https://doi.org/10.1038/sj.leu.2403614	https://doi.org/10.1038/sj.leu.2403614	PROPN
ajlm-2394	303	4	thiede	thiede	PROPN
ajlm-2394	303	5	c	c	PROPN
ajlm-2394	303	6	,	,	PUNCT
ajlm-2394	303	7	koch	koch	PROPN
ajlm-2394	303	8	s	s	PROPN
ajlm-2394	303	9	,	,	PUNCT
ajlm-2394	303	10	creutzig	creutzig	PROPN
ajlm-2394	303	11	e	e	PROPN
ajlm-2394	303	12	,	,	PUNCT
ajlm-2394	303	13	et	et	PROPN
ajlm-2394	303	14	al	al	PROPN
ajlm-2394	303	15	.	.	PUNCT
ajlm-2394	304	1	prevalence	prevalence	NOUN
ajlm-2394	304	2	and	and	CCONJ
ajlm-2394	304	3	prognostic	prognostic	ADJ
ajlm-2394	304	4	impact	impact	NOUN
ajlm-2394	304	5	of	of	ADP
ajlm-2394	304	6	npm1	npm1	NOUN
ajlm-2394	304	7	mutations	mutation	NOUN
ajlm-2394	304	8	in	in	ADP
ajlm-2394	304	9	1485	1485	NUM
ajlm-2394	304	10	adult	adult	NOUN
ajlm-2394	304	11	patients	patient	NOUN
ajlm-2394	304	12	with	with	ADP
ajlm-2394	304	13	acute	acute	ADJ
ajlm-2394	304	14	myeloid	myeloid	NOUN
ajlm-2394	304	15	leukemia	leukemia	NOUN
ajlm-2394	304	16	(	(	PUNCT
ajlm-2394	304	17	aml	aml	PROPN
ajlm-2394	304	18	)	)	PUNCT
ajlm-2394	304	19	.	.	PUNCT
ajlm-2394	305	1	blood	blood	NOUN
ajlm-2394	305	2	.	.	PUNCT
ajlm-2394	306	1	2006;107(10):4011–4020	2006;107(10):4011–4020	X
ajlm-2394	306	2	.	.	PUNCT
ajlm-2394	306	3	https://doi.org/10.1182/blood-2005-08-3167	https://doi.org/10.1182/blood-2005-08-3167	PROPN
ajlm-2394	306	4	rubnitz	rubnitz	PROPN
ajlm-2394	306	5	je	je	PROPN
ajlm-2394	306	6	,	,	PUNCT
ajlm-2394	306	7	raimondi	raimondi	PROPN
ajlm-2394	306	8	sc	sc	PROPN
ajlm-2394	306	9	,	,	PUNCT
ajlm-2394	306	10	tong	tong	PROPN
ajlm-2394	306	11	x	x	PROPN
ajlm-2394	306	12	,	,	PUNCT
ajlm-2394	306	13	et	et	PROPN
ajlm-2394	306	14	al	al	PROPN
ajlm-2394	306	15	.	.	PROPN
ajlm-2394	306	16	favorable	favorable	ADJ
ajlm-2394	306	17	impact	impact	NOUN
ajlm-2394	306	18	of	of	ADP
ajlm-2394	306	19	the	the	DET
ajlm-2394	306	20	t	t	NOUN
ajlm-2394	306	21	(	(	PUNCT
ajlm-2394	306	22	9	9	NUM
ajlm-2394	306	23	;	;	PUNCT
ajlm-2394	306	24	11	11	NUM
ajlm-2394	306	25	)	)	PUNCT
ajlm-2394	306	26	in	in	ADP
ajlm-2394	306	27	childhood	childhood	NOUN
ajlm-2394	306	28	acute	acute	NOUN
ajlm-2394	306	29	myeloid	myeloid	NOUN
ajlm-2394	306	30	leukemia	leukemia	NOUN
ajlm-2394	306	31	.	.	PUNCT
ajlm-2394	307	1	j	j	PROPN
ajlm-2394	307	2	clin	clin	PROPN
ajlm-2394	307	3	oncol	oncol	PROPN
ajlm-2394	307	4	.	.	PUNCT
ajlm-2394	308	1	2002;20(9):2302–2309	2002;20(9):2302–2309	NOUN
ajlm-2394	308	2	.	.	PUNCT
ajlm-2394	309	1	https://doi.org/10.1200/jco.2002.08.023	https://doi.org/10.1200/jco.2002.08.023	X
ajlm-2394	309	2	dong	dong	PROPN
ajlm-2394	309	3	hy	hy	PROPN
ajlm-2394	309	4	,	,	PUNCT
ajlm-2394	309	5	kung	kung	PROPN
ajlm-2394	309	6	jx	jx	PROPN
ajlm-2394	309	7	,	,	PUNCT
ajlm-2394	309	8	bhardwaj	bhardwaj	PROPN
ajlm-2394	309	9	v	v	PROPN
ajlm-2394	309	10	,	,	PUNCT
ajlm-2394	309	11	mcgill	mcgill	PROPN
ajlm-2394	309	12	j.	j.	PROPN
ajlm-2394	309	13	flow	flow	PROPN
ajlm-2394	309	14	cytometry	cytometry	PROPN
ajlm-2394	309	15	rapidly	rapidly	ADV
ajlm-2394	309	16	identifies	identify	VERB
ajlm-2394	309	17	all	all	DET
ajlm-2394	309	18	acute	acute	ADJ
ajlm-2394	309	19	promyelocytic	promyelocytic	ADJ
ajlm-2394	309	20	leukemias	leukemia	NOUN
ajlm-2394	309	21	with	with	ADP
ajlm-2394	309	22	high	high	ADJ
ajlm-2394	309	23	specificity	specificity	NOUN
ajlm-2394	309	24	independent	independent	ADJ
ajlm-2394	309	25	of	of	ADP
ajlm-2394	309	26	underlying	underlying	ADJ
ajlm-2394	309	27	cytogenetic	cytogenetic	ADJ
ajlm-2394	309	28	abnormalities	abnormality	NOUN
ajlm-2394	309	29	.	.	PUNCT
ajlm-2394	310	1	am	be	AUX
ajlm-2394	310	2	j	j	PROPN
ajlm-2394	310	3	clin	clin	PROPN
ajlm-2394	310	4	pathol	pathol	NOUN
ajlm-2394	310	5	.	.	PUNCT
ajlm-2394	311	1	2011;135(1):76–84	2011;135(1):76–84	NOUN
ajlm-2394	311	2	.	.	PUNCT
ajlm-2394	312	1	https://doi.org/10.1309/ajcpw9tslqnczavt	https://doi.org/10.1309/ajcpw9tslqnczavt	NOUN
ajlm-2394	312	2	allford	allford	PROPN
ajlm-2394	312	3	s	s	PROPN
ajlm-2394	312	4	,	,	PUNCT
ajlm-2394	312	5	grimwade	grimwade	ADJ
ajlm-2394	312	6	d	d	PROPN
ajlm-2394	312	7	,	,	PUNCT
ajlm-2394	312	8	langabeer	langabeer	PROPN
ajlm-2394	312	9	s	s	PROPN
ajlm-2394	312	10	,	,	PUNCT
ajlm-2394	312	11	et	et	PROPN
ajlm-2394	312	12	al	al	PROPN
ajlm-2394	312	13	.	.	PUNCT
ajlm-2394	313	1	identification	identification	NOUN
ajlm-2394	313	2	of	of	ADP
ajlm-2394	313	3	the	the	DET
ajlm-2394	313	4	t	t	NOUN
ajlm-2394	313	5	(	(	PUNCT
ajlm-2394	313	6	15	15	NUM
ajlm-2394	313	7	;	;	PUNCT
ajlm-2394	313	8	17	17	NUM
ajlm-2394	313	9	)	)	PUNCT
ajlm-2394	313	10	in	in	ADP
ajlm-2394	313	11	aml	aml	PROPN
ajlm-2394	313	12	fab	fab	PROPN
ajlm-2394	313	13	types	type	NOUN
ajlm-2394	313	14	other	other	ADJ
ajlm-2394	313	15	than	than	ADP
ajlm-2394	313	16	m3	m3	PROPN
ajlm-2394	313	17	:	:	PUNCT
ajlm-2394	313	18	evaluation	evaluation	NOUN
ajlm-2394	313	19	of	of	ADP
ajlm-2394	313	20	the	the	DET
ajlm-2394	313	21	role	role	NOUN
ajlm-2394	313	22	of	of	ADP
ajlm-2394	313	23	molecular	molecular	ADJ
ajlm-2394	313	24	screening	screening	NOUN
ajlm-2394	313	25	for	for	ADP
ajlm-2394	313	26	the	the	DET
ajlm-2394	313	27	pml	pml	PROPN
ajlm-2394	313	28	/	/	SYM
ajlm-2394	313	29	rarα	rarα	PROPN
ajlm-2394	313	30	rearrangement	rearrangement	NOUN
ajlm-2394	313	31	in	in	ADP
ajlm-2394	313	32	newly	newly	ADV
ajlm-2394	313	33	diagnosed	diagnose	VERB
ajlm-2394	313	34	aml	aml	NOUN
ajlm-2394	313	35	.	.	PUNCT
ajlm-2394	314	1	br	br	PROPN
ajlm-2394	314	2	j	j	PROPN
ajlm-2394	314	3	haematol	haematol	NOUN
ajlm-2394	314	4	.	.	PUNCT
ajlm-2394	315	1	1999;105(1):198–207	1999;105(1):198–207	NUM
ajlm-2394	315	2	.	.	PUNCT
ajlm-2394	316	1	https://doi.org/10.1111/j.1365-2141.1999.01312.x	https://doi.org/10.1111/j.1365-2141.1999.01312.x	PROPN
ajlm-2394	316	2	singh	singh	PROPN
ajlm-2394	316	3	zn	zn	PROPN
ajlm-2394	316	4	,	,	PUNCT
ajlm-2394	316	5	duong	duong	PROPN
ajlm-2394	316	6	vh	vh	PROPN
ajlm-2394	316	7	,	,	PUNCT
ajlm-2394	316	8	koka	koka	NOUN
ajlm-2394	316	9	r	r	PROPN
ajlm-2394	316	10	,	,	PUNCT
ajlm-2394	316	11	et	et	PROPN
ajlm-2394	316	12	al	al	PROPN
ajlm-2394	316	13	.	.	PROPN
ajlm-2394	316	14	high	high	ADJ
ajlm-2394	316	15	-	-	PUNCT
ajlm-2394	316	16	risk	risk	NOUN
ajlm-2394	316	17	acute	acute	NOUN
ajlm-2394	316	18	promyelocytic	promyelocytic	ADJ
ajlm-2394	316	19	leukemia	leukemia	NOUN
ajlm-2394	316	20	with	with	ADP
ajlm-2394	316	21	unusual	unusual	ADJ
ajlm-2394	316	22	t	t	NOUN
ajlm-2394	316	23	/	/	SYM
ajlm-2394	316	24	myeloid	myeloid	NOUN
ajlm-2394	316	25	immunophenotype	immunophenotype	NOUN
ajlm-2394	316	26	successfully	successfully	ADV
ajlm-2394	316	27	treated	treat	VERB
ajlm-2394	316	28	with	with	ADP
ajlm-2394	316	29	atra	atra	NOUN
ajlm-2394	316	30	and	and	CCONJ
ajlm-2394	316	31	arsenic	arsenic	ADJ
ajlm-2394	316	32	trioxide	trioxide	NOUN
ajlm-2394	316	33	-	-	PUNCT
ajlm-2394	316	34	based	base	VERB
ajlm-2394	316	35	regimen	regiman	NOUN
ajlm-2394	316	36	.	.	PUNCT
ajlm-2394	317	1	j	j	PROPN
ajlm-2394	317	2	hematopathol	hematopathol	NOUN
ajlm-2394	317	3	.	.	PUNCT
ajlm-2394	318	1	2018;11:67–74	2018;11:67–74	NUM
ajlm-2394	318	2	.	.	PUNCT
ajlm-2394	319	1	https://doi.org/10.1007/s12308-018-0329-z	https://doi.org/10.1007/s12308-018-0329-z	PROPN